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Abstract 
 
Up to a third of patients with mitochondrial disease exhibit epilepsy which is difficult to 
control with existing pharmacotherapies. Anti-epileptic drug development in this field 
has stalled due to a paucity of pre-clinical models. To address this, I developed a novel 
in vitro model of mitochondrial epilepsy. The main features of the model are respiratory 
chain complex I and IV inhibition as well as astrocytic aconitase inhibition using 
pharmacological agents. In this way, I observed epileptiform discharges in rodent and 
murine hippocampal brain slices. Using immunohistochemical techniques, I confirmed 
findings from human neuropathological studies in that epileptic slices showed a 
selective loss of GABAergic interneurons, sparing of pyramidal neurons, and profound 
astrogliosis. To demonstrate the models clinical relevancy, I illustrated the model’s 
predictive validity by observing that epileptic activity was unaffected by various 
antiepileptic drugs. These studies did reveal that there was an involvement of AMPA 
and GABAA receptors in the generation of the epileptiform discharges. Further 
experiments also implicated the astroglial glutamate-glutamine cycle in the process of 
epileptogenesis. Using metabolic tracing experiments, glutamine was observed to be 
depleted during the epileptic state. Glutamine supplementation sustained the synthesis 
of GABA in the epileptic tissue, presumably to restore metabolic homeostasis. Finally, 
aerobic respiration was inhibited alongside the upregulation of anaerobic glycolysis 
during the epileptic state. To dissect the role of glutamine in the modulation of 
mitochondrial respiration, I isolated neuronal and astrocytic populations and performed 
measurements of metabolic flux during the induction of seizure activity. Glutamine was 
able to rescue partial mitochondrial respiratory chain inhibition selectively in the 
astrocytes. Overall, I have developed an in vitro model of mitochondrial epilepsy and 
showed the interaction between astrocytes and neurons is prerequisite for seizure 
generation. Several pharmacological targets have emerged from these studies which 
may provide future novel therapeutic targets for this condition.  
 
 
 
 
 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
 
 
 
 
 
Dedicated to my mother, Lily Meliani Lauwensi, whose love and 
kindness have shaped me into the man and the scientist that I am. 
 
 
 
 
 
 
 
 
vi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
Acknowledgments 
 
First and foremost, I would like to thank my fantastic supervisory team that has 
given me excellent support throughout my Doctorate study. I am indebted to Professor 
Mark Cunningham, for whom I have developed a huge amount of respect for and for 
constantly pushing me to strive for the best scientific work possible. Equally, I would 
like to acknowledge Professor Sir Doug Turnbull, for being my role – model and mentor 
as a clinical academic who constantly challenge me with thought – provoking questions 
from the very first time I met him. Finally, I would like to thank Dr. Nichola Lax for being 
there for me every time I have a question and providing one of the best pastoral care 
that a graduate student can expect from their supervisory team.  
All the work presented in this thesis is my own, except for Figure 3.1 which uses 
images and data obtained from work conducted by Dr. Nichola Lax (used and 
reproduced with permission). Some Matlab scripts have also been written by various 
third parties that are used to analyse the data presented in this thesis. A copy of the 
Matlab script has been reproduced with permission and attached in Appendix 1. I would 
like to thank and acknowledge both Dr. Katherine Newling and Stacey Aston for the 
writing of this script. I would also like to thank Dede for the consultation and help in the 
graphical preparation of some of the figures in this thesis. The study presented in this 
thesis is also not possible without financial contributions from various sources. I would 
like to acknowledge the EPSRC Industrial CASE Award (EP/K50499X/1) studentship 
in collaboration with GlaxoSmithKline that primarily funds this study. I would also like 
to acknowledge HelloBio for the travel grant for attending the Society for Neuroscience 
Meeting to present this work and the Network of European Neuroscience Schools 
(NENS) Exchange Grant for funding the collaborative work done with University of 
Copenhagen. I would also like to acknowledge Eisai and The Wellcome Trust 
Biomedical Vacation Scholarships grant for the contribution towards the perampanel 
study.  
Throughout my PhD, all past and present members of the laboratory have 
assisted me in the completion of this study in various capacities. To that, I am forever 
grateful. I would like to acknowledge the past lab members; Dr Katherine Newling, Dr. 
Anais Thouin, Dr. Anna Simon, and Dr. Stephen Hall for largely training me in the 
wonderful world of neuroscience and tolerating the 18 – years old version of me starting 
out a doctorate study.  I am equally indebted to all current members of the laboratory; 
viii 
 
Dr. Georgia Rentesi, Dr. Tamara Modebadze, and (soon to be Dr) Anderson Brito da 
Silva for helping me grow and develop into the scientists that I am today. Thank you to 
Karen Parkin for checking up on me every morning. I also would like to acknowledge 
the Wellcome Trust Centre for Mitochondrial Research, members of which have largely 
also contributed towards the conception and development of this study. In particular, I 
would like to thank Dr. Nichola Lax and Dr. Monika Olahova for being my mentors and 
primary point of contact within the centre for any issues and questions that I have. I 
would also like to thank past and present members of the centre who have contributed 
to a dynamic discussion and study on mitochondrial research, particularly Alexia, Jono, 
and Craig (whom I started out with); Amy Reeve, Ollie, Pav, Lyndsey, Julie, Nishani, 
and Gavin F.  
I have also obtained advice and support from various other affiliated academics 
throughout this study. I would like to acknowledge my progress review panels; Dr. 
Fiona LeBeau and Professor Robert (Bob) Lightowlers for providing sound advice 
throughout my PhD and for helping me learn how to ‘be realistic’, ‘edit’, and ‘prioritize’. 
I would like to thank Professor Zofia-Chrzanowska Lightowlers for believing in me from 
when she was my personal tutor during my Masters and to date, still asking how I am 
holding up. Equally, I would like to thank Dr. Gavin Clowry, who was my first ever 
scientific mentor and has really played a major role in the realization of my academic 
career. I would also like to thank Dr. Michele Sweeney (particularly), Dr. Lindsey Ferrie, 
Dr. Vanessa Armstrong, and Dr. Martin Edwards for providing me with invaluable 
teaching experience that would be useful for my professional career development.  
Various clinicians affiliated with the Newcastle upon Tyne Hospitals NHS Foundation 
Trust have also provided constructive criticism and inputs in the development of this 
study. In particular, I would like to thank Dr. Mark Baker for the support and advice that 
he is always willing to give in the clinical applications of the study. I would also like to 
thank Dr. Anita Devlin for reigniting my interests in ketogenic diet research and 
providing me with the opportunity to observe her very professionally run epilepsy clinic.  
I have also worked closely with many talented undergraduate students who have 
helped with various aspects of this study. I would like to thank Heather Thompson for 
her hard work in helping optimize the Seahorse technique, Adam Skeen for his 
perseverance during the perampanel experiment, Angeline Kosim for her help with the 
oxidative stress assessment, Shuna Whyte for her assistance with 
ix 
 
immunohistochemistry and microscopy, and Elizabeth J. Tilley for her hard work in 
helping with the pharmacology experiments.  
As the study developed, I have also initiated active collaboration with various 
research institutions and groups in the use of novel approaches and techniques for in-
depth research of mitochondrial epilepsy. I would like to acknowledge NeuroMet in 
University of Copenhagen whom I have spent a few months working in and have truly 
welcomed me as part of the member of the NeuroMet family (officiated by singing the 
NeuroMet song). I would like to thank Professor Helle Waagepetersen for replying to 
a string of random emails that eventually developed into one of the best collaboration 
and fruitful moments that has come out of my PhD. Professor Waagepetersen has 
given me a unique approach to science and the nurturing of a familial collaborative 
research environment; for which I truly respect her. I would also like to thank Caroline 
Marie Voss for training me in everything (literally, everything), Blanca Irene Aldana 
Garcia for active assistance in any issues I have with the machines and techniques 
there (and the discussions on Mexican food), and Jens Valde Andersen for being a 
good friend whilst I was there (thank you for lending me the eraser).  
In Newcastle University, I would like to acknowledge Dr. Annette Meeson for 
kindly lending me the equipment and the bench space necessary to conduct the cell 
isolation described in this thesis. I would like to thank the members of her research 
group; Nani, Evie, and Kamilla; and Debra Jones, the technical manager, for 
welcoming me (a random stranger) into their workspace and helping me with any silly 
questions I might have. I would also like to thank Dr. Satomi Miwa for her expert advice 
on the Seahorse technique and Edward Fielder for being a good friend while I was 
working in the Centre for Aging and Vitality. 
The research that I have conducted would not have run as smoothly as it had, 
had it not been for the hard work of all the support team in the Institute of Neuroscience. 
I would like to acknowledge all the postgraduate support officers that have helped me 
throughout my postgraduate study in the Institute: Helen Stewart, Suzi Engelbright, 
Caroline Risacher, and (the rockstar) Beckie Hedley. I would like to thank Dr. Ann 
Fitchett for giving me the opportunity to develop my public engagement skills; which I 
now have a true passion for. I would like to thank Carole Ainsley and Glynis Mitchinson 
for always being there for whatever issue I might have (in P2P ordering or in life). I 
would also like to thank Kay Garrick and Samantha Cook for their prompt professional 
help whilst they were working in the Institute, Karen Curry for help whilst I am employed 
x 
 
as research assistant in the Institute, and Brian Claydon for ‘showing me the black 
magic’ of IT (and the new computer during the crucial time of thesis writing). 
I am also forever indebted to all my friends who are truly supportive in maintaining 
my sanity whilst I am doing my PhD. Truly, the experience of the weekly Forth Hotel 
pub quiz, courtesy of Helen Jones, is vital in this. As such, the quiz team members, 
past or present, have been such good friends to me for the past three years. To name 
a few; Clare, Grace, Gemma, Abi, Caroline, Chris T, Chris B, Conor G, Connor R, Joe 
C, Josh, and Carolyn are ‘core’ members of the team and my friendship group. I would 
also like to acknowledge all the postgraduate students of Institute of Neuroscience who 
have come to my quizzes and reignited my passion for extracurricular activities. I would 
also like to thank the other members of the office who have been such close friends to 
me; Sabine (and Tom), Yingdi, Jean, Myrto, Ruwaydah, and Nelson. My Indonesian 
friendship circle has also helped keep me grounded and rooted whilst I went through 
this emotional turmoil, for which I am thankful for. I would like to thank these lovely 
individuals: Vincent T, Sally, Angel K, Nora, Hans, Justine, Harata, Katherine S, Tiffany, 
Lusiana, Chris C, Victor T, Andre, Rio, Velasca, and Angel C for keeping up with all 
my antics. I would also like to thank ‘The Spice of Life’, particularly Liz and Michael; 
Trish from the Atrium, as well as ‘Happiness Inn’ for providing me with the necessary 
nourishment to keep me going through the long hours and late nights of writing a thesis.   
Finally, I would like to thank my family members for being there throughout this 
whole journey. I would like to thank my mother for always believing in me and my 
abilities even when no one would. For that, I am eternally grateful. I would also like to 
thank my father who has been patient and supportive with me throughout. I would also 
like to thank my aunt, Rosalinda, and her family for helping me get through the rough 
patches of the final stages of writing. My cousins, particularly Wenni, Checil, Eldo, and 
Eldmond, have also helped in many ways towards the completion of this thesis. Lastly, 
but not least, I would also like to acknowledge Mega and Steve Young for being 
wonderful ‘surrogate parents’ while I am here in the UK.  
 
 
 
 
xi 
 
Table of contents 
 
Abstract ...................................................................................................................... iii 
Acknowledgments ..................................................................................................... vii 
Table of contents ........................................................................................................ xi 
List of figures ............................................................................................................ xvi 
List of tables ............................................................................................................. xxi 
List of abbreviations .................................................................................................xxii 
Chapter 1 General introduction ................................................................................ 1 
1.1 Mitochondria ................................................................................................... 3 
1.2 Mitochondrial ATP production ........................................................................ 5 
1.3 Mitochondrial supercomplexes ....................................................................... 7 
1.4 Mitochondrial DNA ......................................................................................... 8 
1.5 Mitochondria, metabolism, and the brain: the blood-brain barrier ................ 10 
1.6 Neurons ........................................................................................................ 11 
1.6.1 Excitatory neurotransmission ................................................................. 13 
1.6.2 Inhibitory neurotransmission .................................................................. 18 
1.7 Astrocytes .................................................................................................... 23 
1.7.1 Astrogliosis ............................................................................................ 26 
1.7.2 Manipulation of astrocytic function ......................................................... 29 
1.8 Energy metabolism in the brain .................................................................... 31 
1.8.1 Overview of glucose metabolism ........................................................... 31 
1.8.2 Glycolysis .............................................................................................. 33 
1.8.3 TCA cycle (Krebs cycle) ........................................................................ 36 
1.8.4 Fatty acid metabolism ............................................................................ 37 
1.8.5 Ketogenesis ........................................................................................... 38 
1.8.6 Glutamate-glutamine cycle .................................................................... 41 
1.8.7 Astrocyte-neuron lactate shuttle hypothesis .......................................... 43 
1.9 Mitochondrial disease ................................................................................... 44 
1.10 Mitochondrial epilepsy............................................................................... 48 
1.11 Animal models of mitochondrial epilepsy .................................................. 50 
1.12 In vitro brain slice electrophysiology ......................................................... 51 
1.13 Temporal lobe and hippocampus in epilepsy ............................................ 55 
1.14 Pharmacological treatment of epilepsy ..................................................... 58 
1.15 Non-pharmacological treatment of epilepsy .............................................. 60 
1.15.1 Ketogenic diet ..................................................................................... 60 
xii 
 
1.15.2 Surgical intervention .......................................................................... 61 
1.15.3 Vitamin and supplements ................................................................... 62 
1.16 Working hypothesis to understand mitochondrial epilepsy ....................... 64 
1.17 Oxidative stress in epilepsy ...................................................................... 66 
1.18 Aims ......................................................................................................... 67 
Chapter 2 General methods ................................................................................... 69 
2.1 Animal provision .......................................................................................... 71 
2.2 Brain slice preparation ................................................................................. 71 
2.2.1 Solutions for brain slice preparation ...................................................... 71 
2.2.2 Slice Preparation (for in vitro electrophysiology) ................................... 72 
2.2.3 Slice Preparation (for metabolic studies) ............................................... 72 
2.3 Surgical human tissue collection and slice preparation ............................... 73 
2.4 Electrophysiological experiment setup ......................................................... 75 
2.5 Mitochondrial epileptic induction .................................................................. 75 
2.6 Data analysis ............................................................................................... 76 
2.7 Drugs ........................................................................................................... 76 
2.8 Immunohistochemistry ................................................................................. 78 
2.9 Microscopy, data acquisition, and data analysis .......................................... 81 
2.10 Measurement of carbonylated protein ...................................................... 81 
2.11 Brain slice incubation for metabolic mapping ........................................... 83 
2.12 Gas chromatography – mass spectrometry analysis ................................ 84 
2.13 High performance liquid chromatography analysis ................................... 89 
2.14 Magnetic-activated cell sorting ................................................................. 90 
2.15 Measurement of metabolic fluxes using Seahorse XF24 .......................... 91 
2.16 Post-hoc immunofluorescence ................................................................. 92 
Chapter 3 Developing an in vitro brain slice model of mitochondrial epilepsy ........ 95 
3.1 Introduction .................................................................................................. 97 
3.2 Methods ..................................................................................................... 100 
3.3 Results ....................................................................................................... 101 
3.3.1 Development of the brain slice model of mitochondrial epilepsy ......... 101 
3.3.2 Generalized energy failure is induced at higher concentration of 
respiratory chain inhibitors ............................................................................... 104 
3.3.3 Respiratory chain inhibitors are substitutable ...................................... 106 
3.3.4 The mitochondrial epilepsy induction is conserved across species ..... 108 
3.3.5 Quantification through automated burst detection demonstrates the 
stability of the epileptic activity ......................................................................... 110 
3.3.6 Neuronal population loss in the epileptic tissue................................... 112 
xiii 
 
3.3.7 There is no specific vulnerability of interneuron subtypes towards the 
mitochondrial epilepsy insult ............................................................................. 117 
3.3.8 Extensive astrogliosis is present in epileptic tissue .............................. 123 
3.4 Discussion .................................................................................................. 125 
3.4.1 Development of the in vitro model of mitochondrial epilepsy ............... 125 
3.4.2 Neuropathological findings .................................................................. 128 
3.5 Summary, strength, and weakness ............................................................ 133 
Chapter 4 Pharmacological characterization of mitochondrial epilepsy ................ 135 
4.1 Introduction ................................................................................................ 137 
4.2 Methods ..................................................................................................... 139 
4.3 Results ....................................................................................................... 140 
4.3.1 Pharmacological response towards application of vehicle ................... 140 
4.3.2 Characterization of receptor contributions in mitochondrial epilepsy ... 142 
4.3.3 Pharmacological responsiveness of mitochondrial epilepsy towards 
conventional antiepileptic drugs ........................................................................ 144 
4.3.4 Pharmacological responses towards substrates of the ketogenic diet . 155 
4.3.5 Pharmacological responses towards substrates of glycolysis ............. 160 
4.3.6 Pharmacological responses towards substrates of the glutamate-
glutamine cycle ................................................................................................. 166 
4.3.7 Synergism between benzodiazepine and GABA ................................. 170 
4.3.8 The use of mitochondrial – targeting compounds ................................ 172 
4.4 Discussion .................................................................................................. 175 
4.4.1 Execution of an in vitro pharmacological study .................................... 175 
4.4.2 Receptor contributions in mitochondrial epilepsy ................................. 176 
4.4.3 Use of antiepileptic drugs in mitochondrial epilepsy ............................ 178 
4.4.4 Ketogenic diet in mitochondrial epilepsy .............................................. 183 
4.4.5 Modulating glycolysis in mitochondrial epilepsy ................................... 186 
4.4.6 Application of substrates of glutamate – glutamine cycle in mitochondrial 
epilepsy ............................................................................................................. 188 
4.4.7 The use of mitochondrial – targeting compounds ................................ 189 
4.5 Summary, strength, and weakness ............................................................ 193 
Chapter 5 Probing the state of metabolism during mitochondrial epilepsy ........... 195 
5.1 Introduction ................................................................................................ 197 
5.2 Methods ..................................................................................................... 198 
5.3 Results ....................................................................................................... 199 
5.3.1 Glycolysis is significantly upregulated in epileptic tissue ..................... 199 
5.3.2 Krebs cycle activity is significantly downregulated in epileptic tissue ... 201 
xiv 
 
5.3.3 Aspartate labelling pattern indicates metabolic compartmentalization 207 
5.3.4 Glucose input into the glutamate – glutamine cycle is significantly altered 
in the mitochondrial epilepsy condition ............................................................. 208 
5.3.5 The amount of glutamine is significantly reduced in the epileptic tissue, 
despite the sustained amounts of glutamate and increased amount of GABA . 212 
5.3.6 The activity of the glutamate-glutamine cycle via the Krebs cycle is 
significantly reduced ......................................................................................... 214 
5.3.7 Glutamate can still enter the Krebs cycle despite inhibition of subsequent 
turns of the Krebs cycle .................................................................................... 217 
5.3.8 Aspartate formation is still reduced despite the addition of glutamate . 221 
5.3.9 Unlike glutamate, the addition of glutamine was able to sustain GABA 
synthesis within the glutamate – glutamine cycle ............................................. 223 
5.3.10 The entry of glutamine into the Krebs cycle is not impeded but 
subsequent turns of the Krebs cycle are inhibited ............................................ 227 
5.3.11 Addition of glutamine favours the breakdown of aspartate .............. 230 
5.3.12 Neither glutamine nor glutamate addition decreased glycolysis in the 
epileptic tissue. ................................................................................................. 232 
5.4 Discussion ................................................................................................. 233 
5.4.1 Glycolysis ............................................................................................ 233 
5.4.2 Krebs cycle .......................................................................................... 235 
5.4.3 Aspartate ............................................................................................. 236 
5.4.4 Glutamate – glutamine cycle ............................................................... 237 
5.4.5 Addition of glutamate .......................................................................... 239 
5.4.6 Addition of glutamine ........................................................................... 240 
5.5 Summary, strength, and weakness ............................................................ 242 
Chapter 6 Measuring metabolic fluxes in specific cellular population during 
mitochondrial epilepsy ............................................................................................ 245 
6.1 Introduction ................................................................................................ 247 
6.2 Methods ..................................................................................................... 248 
6.3 Results ....................................................................................................... 251 
6.3.1 Magnetic-activated cell sorting produced comparable yield and viability in 
astrocytes and neurons .................................................................................... 251 
6.3.2 Metabolic characterization of the isolated cellular compartments ....... 252 
6.3.3 Cell’s metabolic flux measurement is relatively stable over time ......... 257 
6.3.4 Measurement of cellular mitochondrial respiration following the induction 
of mitochondrial epilepsy .................................................................................. 258 
6.3.5 Glutamine may be able to rescue partial mitochondrial respiration 
inhibition, particularly in astrocytes ................................................................... 261 
xv 
 
6.3.6 There is significantly higher protein peroxidation in the epileptic tissue as 
compared against control tissue ....................................................................... 264 
6.4 Discussion .................................................................................................. 265 
6.4.1 Cell isolation ........................................................................................ 265 
6.4.2 Metabolic characterization of the cell isolates ...................................... 266 
6.4.3 Stability of metabolic flux measurement .............................................. 269 
6.4.4 Mitochondrial respiration during mitochondrial epilepsy ...................... 270 
6.4.5 Effects of glutamine ............................................................................. 272 
6.4.6 Oxidative stress during mitochondrial epilepsy .................................... 275 
6.5 Summary, strength, and weakness ............................................................ 276 
Chapter 7 Final discussion and future work .......................................................... 279 
7.1 Conceptualisation ....................................................................................... 281 
7.2 Mechanisms ............................................................................................... 283 
7.3 Therapeutic implications ............................................................................. 287 
7.3.1 AMPA-R ............................................................................................... 287 
7.3.2 GABAA-R ............................................................................................. 288 
7.3.3 Metabolic modulation ........................................................................... 290 
7.4 Future work ................................................................................................ 293 
Appendix 1. Matlab Script ....................................................................................... 295 
Appendix 2. Publications ......................................................................................... 296 
Bibliography ............................................................................................................. 307 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
List of figures 
 
Figure 1-1 Mitochondria anatomy. .............................................................................. 4 
Figure 1-2 Mitochondrial ATP production through oxidative phosphorylation. ............ 6 
Figure 1-3 Electron microscopic view of mitochondrial supercomplexes. ................... 8 
Figure 1-4 Human mitochondrial DNA. ....................................................................... 9 
Figure 1-5 Cellular components of the blood-brain barrier. ....................................... 11 
Figure 1-6 Basic structure of a neuron. ..................................................................... 12 
Figure 1-7 Generation of action potential. ................................................................. 14 
Figure 1-8 Schematic representation of the AMPA and NMDA receptors as well as 
the binding sites. ....................................................................................................... 17 
Figure 1-9 Interneuron morphology, connectivity, markers, and intrinsic properties. 19 
Figure 1-10 Schematic representation of the GABAA receptor and its binding sites. 22 
Figure 1-11 Astrocytes morphology in the context of neuronal population. .............. 23 
Figure 1-12 Astrocyte morphological variation in the human brain. .......................... 25 
Figure 1-13 Progression of astrogliosis..................................................................... 28 
Figure 1-14 Overview of glucose metabolism. .......................................................... 32 
Figure 1-15 Glycolysis and its branching points. ....................................................... 34 
Figure 1-16 The redox shuttle system in the brain. ................................................... 35 
Figure 1-17 The TCA cycle and its branching point. ................................................. 36 
Figure 1-18 Ketone bodies and their respective metabolic pathways. ...................... 39 
Figure 1-19 Utilization of fatty acids in the brain for ketone bodies metabolism. ....... 40 
Figure 1-20 Glutamate - glutamine cycle and GABA shunt as an astrocytic - neuronal 
metabolic cooperation. .............................................................................................. 42 
Figure 1-21 Astrocyte - neuron lactate shuttle hypothesis. ....................................... 44 
Figure 1-22 Overview of mitochondrial disease. ....................................................... 45 
Figure 1-23 Some examples of the common genotype - phenotype correlation in 
mitochondrial disease. .............................................................................................. 47 
Figure 1-24 A neuropharmacological framework to understanding 
electrophysiological correlate of mitochondrial dysfunction. ..................................... 53 
Figure 1-25 Macroanatomy of hippocampus. ............................................................ 56 
Figure 1-26 Hippocampus proper and the subdivisions. ........................................... 57 
Figure 1-27 Mechanism of action of conventional antiepileptic drugs. ...................... 58 
Figure 1-28 Current proposed working hypothesis for mechanisms underlying seizure 
generation in mitochondrial epilepsy. ........................................................................ 65 
xvii 
 
Figure 2-1 Flowchart of the standard immunohistochemistry protocol. ..................... 80 
Figure 2-2 An example of a gas chromatograph and mass spectrometry analysis. .. 85 
Figure 2-3 Incorporation of 13C into various metabolites following [U-13C]-glucose 
metabolism. ............................................................................................................... 87 
Figure 2-4 Incorporation of 13C into various metabolites following [U-13C]-glutamate or 
[U-13C]-glutamine metabolism. .................................................................................. 88 
Figure 2-5 An example of a chromatogram with amino acids of interest. .................. 90 
Figure 2-6 Seahorse plate layout and sites for image acquisition for cell counting. .. 93 
Figure 3-1 There is extensive astrogliosis and respiratory deficient astrocytes in the 
temporal cortex of patients with mitochondrial epilepsy. ........................................... 99 
Figure 3-2 The epileptic activity progression following the mitochondrial induction 
protocol. .................................................................................................................. 102 
Figure 3-3 There are two distinct form of epileptiform discharges in this model of 
mitochondrial epilepsy. ............................................................................................ 104 
Figure 3-4 At higher concentration of rotenone and potassium cyanide, spreading 
depression is induced instead. ................................................................................ 105 
Figure 3-5 Similar pattern of epileptiform discharges can be induced by substitution 
of the mitochondrial inhibitors used. ........................................................................ 107 
Figure 3-6 Mitochondrial epilepsy was able to be induced in both mice and human 
brain slices. ............................................................................................................. 109 
Figure 3-7 There is a period of stable frequency of epileptiform discharges after 2 
hour of application of rotenone and potassium cyanide. ......................................... 111 
Figure 3-8 There is a significant neuronal loss in the epileptic hippocampus CA3 
relative to control tissues. ........................................................................................ 113 
Figure 3-9 Excitatory cell population of the hippocampus CA3 is relatively spared in 
the epileptic tissue. .................................................................................................. 115 
Figure 3-10 There is a significant reduction in the inhibitory neuron population in the 
epileptic tissue. ........................................................................................................ 116 
Figure 3-11 There is a significant reduction in the parvalbumin - expressing 
interneurons in the epileptic hippocampus CA3. ..................................................... 118 
Figure 3-12 There is a significant reduction in the calbindin – expressing interneurons 
in the epileptic hippocampus CA3. .......................................................................... 120 
Figure 3-13 There is a significant reduction in the calretinin - expressing interneurons 
in the epileptic hippocampus CA3. .......................................................................... 122 
xviii 
 
Figure 3-14 There is extensive astrogliosis and glial scar formation in the epileptic 
tissue. ..................................................................................................................... 124 
Figure 4-1 Epileptic activity does not respond towards vehicle application. ............ 141 
Figure 4-2 Epileptic activity is dependent on the contribution of AMPA-R, but not 
NMDA-R. ................................................................................................................ 143 
Figure 4-3 Epileptic activity exhibited pharmacoresistance against sodium channel 
blockers. ................................................................................................................. 145 
Figure 4-4 Epileptic activity is resistant against levetiracetam application. ............. 147 
Figure 4-5 Epileptic activity is resistant against benzodiazepine application. ......... 148 
Figure 4-6 Epileptic activity is responsive to sodium pentobarbital application. ...... 149 
Figure 4-7 Epileptic activity is resistant against sodium valproate application. ....... 150 
Figure 4-8 There is a dose-dependent reduction in the frequency of the epileptiform 
discharges following perampanel addition. ............................................................. 152 
Figure 4-9 Summary of the response of the induced mitochondrial epileptiform 
discharges to the treatment with conventional antiepileptic agents. ....................... 154 
Figure 4-10 There is a dose-dependent reduction in epileptiform discharges following 
DL-β-hydroxybutyrate acute application. ................................................................ 156 
Figure 4-11 There is a dose-dependent reduction in the frequency of the epileptic 
activity following decanoic acid applications. .......................................................... 158 
Figure 4-12 There is a dose-dependent reduction in the frequency of the epileptic 
activity following octanoic acid application. ............................................................. 159 
Figure 4-13 There is a dose-dependent reduction in the frequency of epileptiform 
discharges following extra addition of glucose. ....................................................... 161 
Figure 4-14 There is a dose-dependent reduction in the frequency of epileptiform 
discharges following addition of pyruvate. .............................................................. 162 
Figure 4-15 Epileptiform discharge is only suppressed by the addition of very high 
concentration of lactate. .......................................................................................... 164 
Figure 4-16 There is a dose-dependent reduction in the frequency of the epileptiform 
discharges following the addition of stiripentol. ....................................................... 165 
Figure 4-17 Epileptic activity is not responsive towards L-glutamate application. ... 167 
Figure 4-18 Epileptic activity is responsive to the application of GABA. ................. 168 
Figure 4-19 Epileptic activity is responsive to L-glutamine addition. ....................... 169 
Figure 4-20 There is a synergistic effect with the co-application of the 
benzodiazepine lorazepam and GABA. .................................................................. 171 
Figure 4-21 Coenzyme Q10 did not exhibit any anticonvulsant property. ............... 173 
xix 
 
Figure 4-22 Bezafibrate exhibited an anticonvulsant property in the in vitro model of 
mitochondrial epilepsy. ............................................................................................ 174 
Figure 5-1 Glycolysis is significantly upregulated by the various components of the 
mitochondrial epilepsy protocol. .............................................................................. 200 
Figure 5-2 Krebs cycle activity is significantly decreased by the various components 
of the mitochondrial epilepsy protocol. .................................................................... 206 
Figure 5-3 Aspartate labelling is significantly modified by the rotenone and cyanide 
component of the mitochondrial epilepsy protocol. .................................................. 207 
Figure 5-4 The glutamate-glutamine cycle is significantly affected by the 
mitochondrial epilepsy protocol. .............................................................................. 210 
Figure 5-5 The amounts of the substrates of the glutamate-glutamine cycle are 
significantly altered in the mitochondrial epileptic condition. ................................... 213 
Figure 5-6 The immediate activity of the glutamate-glutamine cycle is sustained but 
recycling via the Krebs cycle is significantly reduced. ............................................. 216 
Figure 5-7 The addition of glutamate did not alter the metabolic profile of the epileptic 
tissue. ...................................................................................................................... 217 
Figure 5-8 Glutamate’s entry into the Krebs cycle is not affected but subsequent 
turns of Krebs cycle are inhibited by the mitochondrial epilepsy protocol. ............... 220 
Figure 5-9 Aspartate labelling and amount is significantly reduced in the epileptic 
tissue, even with the addition of glutamate. ............................................................. 222 
Figure 5-10 Glutamine addition did not rescue the recycling of the glutamate – 
glutamine cycle via the Krebs cycle but it did increase the synthesis of GABA. ...... 225 
Figure 5-11 The addition of glutamine significantly alter the metabolic profile of the 
epileptic tissue. ........................................................................................................ 226 
Figure 5-12 The entry of glutamine into the Krebs cycle is not affected but 
subsequent turns of Krebs cycle is inhibited by the mitochondrial epilepsy protocol.
 ................................................................................................................................ 230 
Figure 5-13 Glutamine addition favours the breakdown of aspartate. ..................... 231 
Figure 5-14. Lactate release from the media was not affected by treatment with either 
glutamate or glutamine. ........................................................................................... 232 
Figure 6-1 Cells isolated through MACS have comparable yield and viability. ........ 251 
Figure 6-2 Oxygen consumption rate of astrocytes and neurons in the absence or 
presence of glutamine shows a distinct metabolic profile. ....................................... 253 
Figure 6-3 ECAR is mostly attributable to CO2 generated from oxidative metabolism; 
yet still there exists a distinction between astrocytes and neurons. ......................... 256 
xx 
 
Figure 6-4 Oxygen consumption rate of astrocytes and neurons is relatively stable 
over time and unaffected by exposure to vehicle. ................................................... 257 
Figure 6-5 There is similar degree of inhibition of mitochondrial respiration by each 
components of mitochondrial respiration in astrocytes and neurons alike. ............. 260 
Figure 6-6 Glutamine may be able to rescue partial mitochondrial respiration 
inhibition, particularly in astrocytes. ........................................................................ 263 
Figure 6-7 There is a significantly higher carbonyl concentration in the epileptic tissue 
as compared against the control tissue................................................................... 264 
Figure 7-1 Proposed model for the understanding of the mechanisms behind 
mitochondrial epilepsy. ........................................................................................... 286 
Figure 7-2 Therapeutic target in mitochondrial epilepsy. ........................................ 292 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxi 
 
List of tables 
 
Table 1-1 Classification of glutamate receptor subtypes. .......................................... 15 
Table 1-2 Typical composition of mitochondrial treatment cocktail. ........................... 62 
Table 2-1 Summary of patient information. ............................................................... 74 
Table 2-2 List of drugs used for in vitro electrophysiology experiments. ................... 77 
Table 2-3 List of primary antibodies used in this thesis. ............................................ 78 
Table 2-4 List of secondary antibodies used in this thesis. ....................................... 79 
Table 2-5 List of isotopes used in this thesis. ............................................................ 83 
Table 3-1 Quantification of epileptic activity showed a period of stability (± 10%) at 
120 minute up to 180 minutes, as well as from 190 to 240 minutes after rotenone and 
cyanide application. ................................................................................................. 111 
Table 5-1 List of experimental conditions for metabolic mapping. ........................... 198 
Table 6-1 Composition of media used in the Seahorse experiments ...................... 248 
Table 6-2 Groups in the experimental setups .......................................................... 249 
Table 6-3 Cartridge setup in the experimental setups. ............................................ 249 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxii 
 
List of abbreviations 
 
2-DG 2-deoxyglucose 
ACSF Artificial cerebrospinal fluid 
AMPA-R α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor 
AMPK 5’ adenosine monophosphate-activated protein kinase 
ANLSH Astrocyte-neuron lactate shuttle hypothesis 
ANOVA Analysis of variance 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid assay 
BSA Bovine serum albumin 
C57BL/6 C57 black 6 
CA Ammon’s horn or Cornu Ammonis 
CaMKII calmodulin protein kinase type II 
cAMP Cyclic adenosine monophosphate 
CB Calbindin 
CoQ10 Coenzyme Q10 
CR Calretinin 
DAB 3,3’-diaminobenzidine 
D-AP5 D-(-)-2-amino-5-phosphonopentanoic acid 
dH2O Distilled water 
DMF N,N-dimethylformamide  
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNPH 2,4-dinitrophenylhydrazine 
DPX Distyrene, plasticiser, and xylene 
EAAT Excitatory amino acid transporter 
ECAR Extracellular acidification rate 
EDTA ethylenediaminetetraacetic acid  
EEG Electroencephalogram 
FAD Flavin adenine dinucleotide 
FBS Fetal bovine serum 
FCCP Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
GABA Gamma-aminobutyric acid 
xxiii 
 
GC-MS Gas chromatography – mass spectrometry 
GFAP Glial fibrillary acidic protein 
GHB Gamma hydroxybutyrate 
GLAST Glutamate aspartate transporter 
GSSG Glutathione disulphide 
HPLC High performance liquid chromatography 
HTn 4-hydroxy-trans-aconitate 
I.D Inner diameter 
IC50 Inhibitory concentration at 50% 
KA Kainate 
KCN Potassium cyanide 
LCFA Long chain fatty acids 
LFP Local field potential 
LHON Leber hereditary optic neuropathy 
MACS Magnetic activated cell sorting 
MCT Medium chain triglycerides 
MELAS Mitochondrial encephalopathy with lactic acidosis and stroke like 
episodes 
MERRF Myoclonic epilepsy with ragged red fibers  
MES 2-(N-morpholino)ethanesulfonic acid  
MIC Minimal inhibitory concentration 
MPP+ 1-methyl-4-phenylpyridinium 
MTBSTFA N-tert-butyldimethylsilyl-N-methyl-trifluoroacetamide  
MTC Maximal tolerable concentration 
nACSF Normal artificial cerebrospinal fluid 
NAD Nicotinamide adenine dinucleotide 
NADPH Nicotinamide adenine dinucleotide phosphate 
NBQX 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-
sulfonamide 
NeuN Neuronal nuclei 
NMDA-R N-methyl-D-aspartate receptor 
O.D Outer diameter 
OCR Oxygen consumption rate 
PBS Phosphate buffered saline 
xxiv 
 
PCP Phencyclidine 
PFA Paraformaldehyde acid 
Pfkfb3 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3 
PGC1-α Peroxisome proliferator-activated receptor gamma coactivator-1 
alpha 
PKC Protein kinase C 
PLC Phospholipase C 
PMSF phenylmethylsulfonyl fluoride  
POLG DNA polymerase gamma 
PPAR Peroxisome proliferator-activated receptor 
PPP Pentose phosphate pathway 
PSA-NCAM Polysialylated-neural cell adhesion molecule 
PTZ Pentylenetetrazol 
PV Parvalbumin 
sACSF Sucrose artificial cerebrospinal fluid 
SV2A Synaptic vesicle glycoprotein 2A 
TBS Tris-buffered saline 
TCA Tricarboxylic acid 
U-13C Universally labelled 13C 
VIP Vasoactive intestinal peptide 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 1 General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
1.1 Mitochondria 
 
Mitochondrion (plural-mitochondria) is one of the most primitive eukaryotic cell 
organelle, thought to originate from endosymbiotic relationship with the ancestral 
archaebacteria (Ettema, 2016). As one of the first cellular organelle to evolve, it clearly 
holds a vital role for eukaryotic cell evolution. Indeed, mitochondria are now understood 
to supply the majority of the eukaryotic cell’s energy requirement by generating ATP 
via oxidative phosphorylation (Hatefi, 1985).  
With advances in imaging technique, the structure of mitochondria is now very 
well described (Frey and Mannella, 2000). They are spherical in nature with two layers, 
the inner and outer mitochondrial membrane, separated by the intermembrane space. 
The inner membrane lines the matrix, which is highly folded with the cristae protruding 
in between (see Figure 1-1).  
Along with its main function as a cellular powerhouse, mitochondria are also 
involved in many other important cellular processes, including maintenance of calcium 
homeostasis (Gunter and Pfeiffer, 1990), generation of endogenous reactive oxygen 
species (Zorov et al., 2006), and regulation of apoptosis (Green and Reed, 1998). 
Mitochondria are also highly dynamic, meaning that they continuously undergo 
morphological change and cellular transport (Detmer and Chan, 2007). The two main 
processes that regulate mitochondrial morphology are fusion and fission (van der Bliek 
et al., 2013). If the balance between the two processes is even slightly perturbed, 
dramatic changes in the mitochondrial morphology can take place. In addition to the 
tight control of mitochondrial fusion and fission, mitochondria are transported along the 
cytoskeletal axis, either in an anterograde or retrograde direction, dependant on the 
cellular demands (Saxton and Hollenbeck, 2012).  
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Figure 1-1 Mitochondria anatomy.  Shown on (A) is a schematic representation of the mitochondrion with its corresponding 
structures and on (B) is an electron microscopy (EM) acquired image of a mitochondrion and its corresponding structures 
labelled. Image in (B) is reprinted from Trends in Biochemical Sciences, Volume 25, Issue 7, Frey TG and Mannella CA, The 
internal structure of mitochondria, Pages 319-324, Copyright (2000), with permission from Elsevier.  
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1.2 Mitochondrial ATP production 
 
The mitochondria produces the majority of a cell’s energy demand by generating 
ATP through a series of oxidation – reduction reactions, which are collectively called 
oxidative phosphorylation (Berg et al., 2012g). The process of oxidative 
phosphorylation depends on a series of electron transfer through four mitochondrial 
respiratory complexes (see Figure 1-2), namely the NADH-Q oxidoreductase (complex 
I), succinate-Q reductase (complex II), Q-cytochrome c oxidoreductase (complex III), 
and cytochrome c oxidase (complex IV). The driving forces of the oxidative 
phosphorylation process are the substrates NADH and FADH2, produced by the Krebs 
cycle (discussed further below in section 1.8.3). NADH enters the oxidative 
phosphorylation via complex I where it is oxidized and releases electrons, which are 
bound to the electron acceptors. This flow of electrons leads to the concomitant 
pumping of protons out of the mitochondrial matrix. FADH2 enters the oxidative 
phosphorylation via complex II and similarly to NADH, it transfers its electron onto the 
acceptor molecules but without pumping protons (unlike complex I). This unique 
distinction between complex I and complex II in its capability to pump protons causes 
FADH2 to generate less net total energy than NADH (Berg et al., 2012g). Both of these 
acceptor molecules then move through complex III and complex IV, creating a chain 
of electron transfer while also pumping protons out of the mitochondrial matrix. At 
complex IV, the final acceptor molecule, which is oxygen, is reduced to form 
dihydrogen oxide (H2O). This requirement of oxygen for the electron transfer chain 
reaction is what causes this process of mitochondrial ATP production to be described 
as an ‘aerobic’ process, specifically an aerobic respiration process (Berg et al., 2012g).  
A specific molecular assembly located in the inner mitochondrial membrane 
carries out the actual process of ATP synthesis, called the mitochondrial ATPase or 
ATP synthase or F1F0ATPase (complex V). Complex V utilizes the proton gradient 
created by the electron transfer chain and it is this proton-motive force that drives the 
catalytic unit to produce the energy providing molecule, adenosine triphosphate (ATP) 
(Elston et al., 1998). Therefore, the process of electron transfer chain and ATP 
synthesis are two biochemically separate systems, which are coupled through the 
proton-motive force (Berg et al., 2012g). This coupling is an important concept, as 
various molecules exist as a mitochondrial uncoupler, which could drive the electron 
transfer process without subsequently generating ATP (Terada, 1990). 
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Figure 1-2 Mitochondrial ATP production through oxidative phosphorylation. Shown in the image are the electron transfer chain process through complex I to IV and the coupling to the ATP synthesis 
via complex V by the proton motive force.  Shown in each complex as well is the subunit composition and the proportion of DNA encoding the subunits (mitochondrial or nuclear).
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1.3 Mitochondrial supercomplexes  
 
In recent studies, the mitochondrial respiratory complexes are found to interact 
and aggregate to form the supramolecular complexes, called the supercomplexes (see 
Figure 1-3). In mammalian mitochondria, for instance, a high proportion of the 
mitochondrial complex I is weaved with the mitochondrial complex III and together with 
a tetramer of complex IV constitute the ‘respirasomes’ (Schägger and Pfeiffer, 2000). 
These supercomplexes can form between any of the complexes (except for complex 
II), are known to be stable, and can be isolated from various organisms (Dudkina et al., 
2005). This assembly proves to be advantageous as it provides a dynamic and optimal 
electron flux, therefore increasing the efficiency of substrate utilization in aerobic 
respiration (Lapuente-Brun et al., 2013). This may prove to be important in discussing 
mitochondrial energetics, as dysfunction of this assembly has been proven to cause 
the failure of respiratory chain and lead to the development of various syndromes in 
humans, such as in Barth syndrome (McKenzie et al., 2006). Furthermore, each cell 
may have its own specific distribution of free-floating respiratory chain complex and 
supercomplexes. Neurons, for example, have been shown to have a higher proportion 
of complex I – III supercomplexes to the free-floating complex I, which is suggestive of 
a higher respiratory efficiency in neurons as compared to other cell types (Lopez-
Fabuel et al., 2016).   
The use of molecular oxygen as the final electron acceptor in the electron transfer 
chain naturally leads to the possibility of a partial reduction, causing the generation of 
the superoxide ion (O2-) instead (Berg et al., 2012g). These superoxide ions and their 
sister molecule, the peroxide ion (O22-), are both reactive oxygen species and can 
damage the cells, causing oxidative stress (discussed further below in section 1.17). 
One potentially important role of the assembly of supercomplexes comes from the 
finding that the destabilization of supercomplexes lead to the increased generation of 
reactive oxygen species (Maranzana et al., 2013). This suggests that the 
supercomplexes exist not only to increase the efficiency of mitochondrial respiration 
but also to limit the generation of reactive oxygen species. This limitation in the 
generation of reactive oxygen species may seem to appear beneficial, but in the case 
of neurons, they were found to be more vulnerable to the oxidative stress damage 
instead as their mitochondrial biology does not equip them with the necessary cellular 
machinery to combat reactive oxygen species production (Lopez-Fabuel et al., 2016).   
8 
 
 
 
Figure 1-3 Electron microscopic view of mitochondrial supercomplexes. Electron microscopic images are obtained through 
negative staining and shows the averaged side views of bovine mitochondrial complex I (A) and its supercomplexes (B-C). 
Positions of individual mitochondrial complexes within the complex I+III2+IV supercomplex or the more commonly referred to 
as ‘respirasome’ is illustrated in the schematic drawing in (D). Reprinted with modifications from Biochimica et Biophysica 
Acta, Volume 1797, Issues 6-7, Dudkina et al, Structure and function of mitochondrial supercomplexes, Pages 664-670, 
Copyright (2010), with permission from Elsevier. Also Springer special credit – ‘Reprinted from Journal of Bioenergetics and 
Biomembranes, Volume 40, Issue 5, Dudkina et al, The higher level of organization of the oxidative phosphorylation system : 
mitochondrial supercomplexes, Pages 419 – 424, Copyright (2008), with permission from Springer’.    
 
1.4 Mitochondrial DNA 
 
Mitochondria is unique to the other cellular organelles, in that it has its own unique 
genome, in the form of the circular mitochondrial DNA (mtDNA). This DNA is conserved 
across species and is very important in facilitating the process of evolution due to its 
high rate of mutation (Brown et al., 1979). Mitochondrial DNA is also different from 
nuclear DNA, in that it is exclusively maternally inherited (Giles et al., 1980).  
In humans, mitochondrial DNA is a compact double-stranded circular DNA, 
composed of 16,569 base pairs (Tuppen et al., 2010). The two strands are composed 
of the cytosine-rich light (L) strand and the guanine-rich heavy (H) strand (see Figure 
1-4). The complete sequence of the human mitochondrial DNA is well characterized 
and described (Andrews et al., 1999). The human mtDNA contains a total of only 37 
genes, all of which encode 13 polypeptides, all of which are core constituents of the 
mitochondrial respiratory chain complexes I, III, IV, and V, as well as the RNA 
necessary for the translation of the mitochondrial DNA (Tuppen et al., 2010). The 
remaining components of the mitochondrial respiratory complexes are encoded by the 
nuclear DNA (Scarpulla, 1997). There are no introns or intergenic noncoding 
nucleotides in the mitochondrial DNA genome, except for the 1.1 kb displacement loop 
9 
 
(D-loop), which contains the transcriptional promoters and the proposed origins of 
replication (OH) (Tuppen et al., 2010).      
 
 
Figure 1-4 Human mitochondrial DNA.  Shown is the schematic diagram of the human mitochondrial genome, with an 
enhanced view of the exceptional D-loop and transcription termination region. The two circles represents the double strand, 
with the outer circle being the heavy (H) strand and the inner circle being the light (L) strand. The human mitochondrial DNA 
encodes 2 mitochondrial-rRNAs (red), 22 mitochondrial-tRNAs (black bars), and 13 essential respiratory chain polypetides, 
including constituents of complex I (green), complex III (purple), complex IV (yellow), and complex V (blue). Reprinted from 
Biochimica et Biophysica Acta, Volume 1797, Issue 2, Tuppen et al, Mitochondrial DNA mutations and human disease, Pages 
113 – 128, Copyright (2010), with permission from Elsevier.   
 
In a normal cell, several hundreds or thousands of copies of the mitochondrial 
DNA are present at any one time. This unique property of mitochondrial DNA genetics 
allows for the presence of two or more variants of the mitochondrial genomes in a cell, 
a term also known as heteroplasmy, as opposed to homoplasmy when all the copies 
of a DNA within the cell are identical (Wallace and Chalkia, 2013). The finding that 
spontaneous de novo mutations in the mitochondrial DNA are suppressed in the 
female germ lines suggest the presence of a genetic bottleneck that is partly 
responsible for the presence of heteroplasmy (Stewart and Chinnery, 2015). 
Additionally, the phenotypic manifestation of these mutations depends on the presence 
of a specific proportion of the mutant mtDNA copies within a cell, a value that 
corresponds to the mitochondrial threshold effect (Rossignol et al., 2003).  
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1.5 Mitochondria, metabolism, and the brain: the blood-brain barrier 
 
The brain is a highly metabolically active organ. A human brain weighs only about 
2 % of the total body weight and yet it consumes 20 % of the total oxygen consumption 
(Quastel and Wheatley, 1932). Therefore, it is clear that the brain is heavily reliant on 
aerobic metabolism through oxidative phosphorylation in the mitochondria. 
Unsurprisingly, any dysfunction of the mitochondria in the brain could affect its function 
at both a cellular and global network level (Picard and McEwen, 2014).  
Any appreciation of metabolic rate in vivo, however, needs to consider various 
factors in addition to mitochondrial function and oxygen consumption. To sustain its 
function, the brain requires a continuous supply of oxygen and energy-yielding 
substrates. This high metabolic demand is tightly regulated by the functions of the 
blood-brain barrier (Paulson, 2002). The extremely high global cerebral oxygen 
consumption rate (~130μmol per 100 g per minute) is met by an equally very high rate 
of cerebral blood flow (~45 ml per 100 g per minute) (Jain et al., 2010). The blood-
brain barrier is composed of the highly impermeable tight junctions of the endothelial 
cells covered by the astrocytic end feet (see Figure 1-5) (Janzer and Raff, 1987). In 
addition to its tight regulation of cerebral blood flow, the blood-brain barrier has a 
unique distribution of transporters allowing for selective permeability to various 
substrates (McKenna et al., 2006). Therefore, the discussion on pharmacological 
studies should pay attention to the complexity of the blood – brain barrier as not all 
compounds developed by the pharmaceutical industry will readily cross the blood – 
brain barrier (Witt et al., 2001; Boonstra et al., 2015).  
Adding to the complexity of the brain’s metabolism; it is established that the 
metabolism in the brain is compartmentalized. Metabolic compartmentalisation is 
defined as the presence of more than one distinct pool of a given metabolite in a tissue 
(McKenna et al., 2006). The two major cells whereby the metabolism is highly 
compartmentalized are neurons, and glia (which includes astrocytes, oligodendrocytes, 
and microglia). Although all of these cell types have mitochondria, there exists a cell-
specific mitochondrial expression and function that contributes to the metabolic 
compartmentation. Therefore, when considering brain metabolism, it is imperative that 
in addition to discussing them at an in vivo level, that it is also discussed at a cellular 
level to account for this metabolic compartmentalisation.  
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Figure 1-5 Cellular components of the blood-brain barrier.  The blood-brain barrier is composed of capillary endothelial cells, 
wrapped by the astrocytic perivascular endfeet. The figure also shows other cellular components of the brain; neurons, 
pericytes, and microglia. Shown in (A) are the features of brain endothelial cells as observed in cell culture, complete with 
the transporters expression. Shown in (B) are the astroglial – endothelial interaction in the maintenance of the blood-brain 
barrier.  Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience (Abbott et al., 2006), 
copyright 2006.   
 
1.6 Neurons 
 
Neurons are the smallest functional unit of the nervous system. They are a 
specialised form of cells whose primary function is to communicate various bodily input 
and output via electrochemical network. Despite great variation in the size and 
morphological appearance, all neurons share the same basic structure (Young et al., 
2000) as shown below in Figure 1-6. All neurons have a large soma (or cell body) 
which contains the nucleus as well as the cells’ organelles such as the ever-important 
mitochondria. Unique to the neurons are the two processes that extend from the cell 
body; namely a single axon and either one or multiple dendrites. These processes form 
the basis of the network communication between neurons via the formation of the 
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synapses. The pre-synaptic axon terminal and the post – synaptic dendrites; along with 
the astrocytic processes; make up what is called the ‘tripartite synapse’ (Perea et al., 
2009).  
 
Figure 1-6 Basic structure of a neuron.  Shown in (A) is an example of a pyramidal neuron in adult rat brains as labelled using 
the biotinylated dextran amine (BDA) labelling techniques and in (B) are the corresponding illustrative drawing of the same 
neuron. The horizontal arrow indicates the axon of the neurons that project deep into the white matter but also sends branches 
horizontally, as indicated by the vertical arrows. The double arrows indicate an example of a dendrite, with spiny appendages 
(arrowheads) distributed along the labelled dendrite; as shown in the inset. The blue arrow indicates the soma of the neuron; 
which in this case is pyramidal – shaped. The camera lucida drawing of the labelled neurons shown in A further clarified all 
these labelled structures. Scale bar in A indicates 75µm, in B indicates 50µM, and in the inset in A 10µm. Reprinted with 
modifications from PLOS One, Volume 7, Edition 11, Ling et al, Resolving the Detailed Structure of Cortical and Thalamic 
Neurons in the Adult Rat Brain with Refined Biotinylated Dextran Amine Labelling, Copyright (2012) as an open – access article 
distributed under the terms of the Creative Commons Attribution License. 
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Neurons are intrinsically electrically active cells. The communication of 
information between neurons is an electrochemical signal transmission; through the 
coupling of the neurotransmitter release and the electrical changes in the membrane 
potential. Signal communication is continued through the postsynaptic neurons by the 
generation of action potentials (for mechanisms of generation, see Figure 1-7). Based 
on their choice of neurotransmitters and the response they induce, the neurons are 
largely classified as either excitatory or inhibitory neurons (Hof et al., 2014; Bear et al., 
2016b). The excitatory neurons release excitatory neurotransmitters (mostly glutamate, 
but also acetylcholine, norepinephrine, and other excitatory peptides) to induce 
depolarization in the synaptically connected post-synaptic neurons; therefore ‘exciting’ 
the neurons to increase action potential generation. Conversely, the inhibitory neurons 
release inhibitory neurotransmitters (mostly GABA, but also glycine) to induce 
hyperpolarization in synaptically connected post-synaptic neurons; therefore ‘inhibiting’ 
the neurons from generating action potential essentially silencing the postsynaptic 
communication. 
 
1.6.1 Excitatory neurotransmission 
 
As described above, excitatory neurons release excitatory neurotransmitters to 
induce depolarization in post – synaptic neurons. Of all the subtypes of the excitatory 
neurons, the most abundant are the pyramidal neurons (morphology as shown in 
Figure 1-6), which collectively make up approximately two-thirds of all the neurons in 
the mammalian cerebral cortex (Bekkers, 2011). The pyramidal neurons are named 
for their distinct morphological appearance: a pyramidal soma and a cluster of apical 
and basal dendrites (Spruston, 2008; Bekkers, 2011). These pyramidal neurons are 
primarily glutamatergic in nature; which means they release glutamate as their major 
excitatory neurotransmitter (Frotscher et al., 1986; Bekkers, 2011; Ling et al., 2012). 
Therefore, their neurotransmission is also dependent on the glutamate-gated channels 
(or glutamatergic receptors). The glutamate receptors are further subdivided into the 
fast excitatory ionotropic glutamate receptors and the slow excitatory metabotropic 
glutamate receptors (for further classification of the subtypes, see Table 1-1) (Bear et 
al., 2016b; Forman et al., 2017).  
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Figure 1-7 Generation of action potential.  In short, neurons typically have a resting membrane potential of approximately         
- 60mV. At resting state (1), both the sodium and potassium channel are closed. Following excitatory signal through glutamate 
binding, the glutamate – gated channel opens and allows influx of the Na+ ions into the cells, causing the membrane potential 
to be more positive or depolarized (2). Once it reaches the threshold value, the membrane potential reaches an all – or – none 
stage and recruits the voltage – gated sodium channel that rapidly depolarizes the potential until it reaches the peak value 
(3). The action potential is then fired and propagated. The inactivation gate of the voltage – gated sodium channel then closes 
to rapidly stops the sodium ion influx while the potassium channel activation gate opens to allow efflux of K+ ions out of the 
cells, causing the membrane potential to be more negative or hyperpolarized (4). The membrane potential continues to be 
hyperpolarized to a value more negative than the resting membrane potential (the undershoot value). It takes a short delay 
to return the neurone’s membrane potential to the resting state; which reflects the refractory period (5). This return to the 
resting state is facilitated through the closing of the activation gate of the voltage – gated sodium channel. Reprinted from 
Anaesthesia & Intensive Care Medicine, Volume 12, Issue 6, Fletcher A, Action potential : generation and propagation, Pages 
258-262, Copyright (2011), with permission from Elsevier. 
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Table 1-1 Classification of glutamate receptor subtypes. Table adapted from (Forman et al., 2017) 
Ionotropic glutamate receptor 
Subtype Subunits Agonists Actions 
AMPA GluR1 
GluR2 
GluR3 
GluR4 
Glutamate or 
AMPA. 
Increase Na+ and Ca2+ influx (except for 
receptor with GluR2). 
Increase K+ efflux. 
Kainate GluR5 
GluR6 
GluR7 
KA1 
KA2 
Glutamate or 
kainate. 
Increase Na+ influx. 
Increase K+ efflux. 
NMDA NR1 
NR2A 
NR2B 
NR2C 
NR2D 
NR3A 
NR3B 
Glutamate or 
NMDA and 
glycine 
Membrane 
depolarization 
Increase Na+ and Ca2+ influx. 
Increase K+ efflux.  
Metabotropic glutamate receptor 
I mGluR1 
mGluR5 
Glutamate Activates adenylyl cyclase to increase 
cAMP (mGluR1 only). 
Increases PLC activity to increase Ca2+ 
levels and stimulate PKC. 
Inhibits K+ channels. 
II mGluR2 
mGluR3 
Glutamate Inhibits adenylyl cyclase to decrease 
cAMP. 
Inhibits voltage – sensitive Ca2+ 
channels. 
Activate K+ channels. 
III mGluR4 
mGluR6 
mGluR7 
mGluR8 
Glutamate Inhibits adenylyl cyclase to decrease 
cAMP. 
Inhibits voltage – sensitive Ca2+ 
channels. 
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Of all the glutamate receptors, the ones that are relevant and discussed in this 
study are the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and the 
NMDA (N-methyl-D-aspartate) receptors (for schematic representation of these 
receptors, see Figure 1-8). Therefore, these receptors are discussed further below.  
The ionotropic receptors are membrane – bound protein complexes, which form 
an ion – permeable pore in the cell membrane (Waxham, 2014). The ionotropic 
receptors mediate fast synaptic responses, while the metabotropic receptors mediate 
slow synaptic responses (Forman et al., 2017). This is due to their difference in 
response to neurotransmitter binding. When a neurotransmitter binds to an ionotropic 
receptor, this binding directly results in the opening of the ion channels through an 
array of conformational changes. On the other hand, neurotransmitter binding to a 
metabotropic receptor mediates conformational changes as a G-protein coupled 
receptor via the cAMP-dependent protein kinase (Waxham, 2014). 
The AMPA receptors mediate the majority of the fast excitatory 
neurotransmission and are expressed in an activity – dependent manner (Rogawski, 
2013). Four subunits have been identified and it is believed that the AMPA receptor 
assembles as a tetrameric molecule (Kew and Kemp, 2005). Functional AMPA 
receptors have been identified not only in the hippocampal neurons, but also in the 
astrocytes (Martin et al., 1993; Hall and Soderling, 1997; Fan et al., 1999). Interestingly, 
the absence of the edited GluR2 subunit causes high calcium permeability 
(Vandenberghe et al., 2000; Isaac et al., 2007) and in the hippocampus, this is 
selectively expressed in the inhibitory interneurons (Kew and Kemp, 2005). This 
distinct AMPA-R expression has been shown to contribute towards the process of long 
– term potentiation (Wright and Vissel, 2012; Jia et al.); but may also be relevant in 
other neurological disorders such as the motor neuron disease  (Wright and Vissel, 
2012). The AMPA-R has a single binding site for its agonists (both glutamate and 
AMPA) but also has allosteric modulator site for barbiturate and alcohol (Forman et al., 
2017). The barbiturate allosteric binding is implicated in its antiepileptic and 
anaesthetic effect (Joo et al., 1999; Nardou et al., 2011); whereas the alcohol binding 
to AMPA-R is implicated in alcohol – craving behaviour and addiction (Cowen et al., 
2003; Möykkynen and Korpi, 2012; Cannady et al., 2013).  
 
 
17 
 
 
Figure 1-8 Schematic representation of the AMPA and NMDA receptors as well as the binding sites.  The ionotropic glutamate 
receptors have a general structure shown in (A). They are tetrameric complexes composed of either homomeric subunits or 
different heteromeric subunits. The zoomed – in structure on the right shows one such subunit, which spans the membrane 
three times and has a partially spanning hairpin turn. The bolded dark green spot on the glutamate receptor marks the 
glutamate binding site to one of the subunit of the receptor.  In (B) shown are major binding sites of the AMPA and NMDA 
receptors. The localization of these binding sites are schematically indicated in this diagram with precise location yet to be 
determined. Figure recreated and based from (Forman et al., 2017). 
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The NMDA receptors are constitutively expressed specifically in the neurons, 
unlike the AMPA receptors (Moriyoshi et al., 1991). The NMDA receptors are 
oligomeric transmembrane complexes composed of the NR1 in combination with one 
or more of the NR2 subunits or both the NR2 and NR3 subunits (Kew and Kemp, 2005). 
There are several unique properties of the NMDA receptors that distinguishes it from 
the other glutamatergic receptors. The activation of the NMDA receptors require the 
binding of two distinct agonists; glutamate (or NMDA) and glycine (Cummings and 
Popescu, 2015). In a resting condition, the channel pore of the NMDA receptor is 
blocked by the magnesium ion (Mg2+) (Nikolaev et al., 2012). A sufficient trains of 
postsynaptic action potentials or subsequent activation of AMPA or kainate (KA) 
receptors in close proximity to the receptor is therefore additionally required to create 
membrane depolarization that would unblock the receptor gating system (Arvanian and 
Mendell, 2001; Fleming and England, 2010) Therefore, the gating of NMDA receptor 
depends on more intense levels of presynaptic activity than that of AMPA or KA 
receptors (Forman et al., 2017). In addition to the agonist binding sites and the 
magnesium binding site, the NMDA receptor also has a binding site for the organic 
cation zinc (Zn2+) as well as an allosteric binding site for its inhibitor, phencyclidine. 
Similar to magnesium, zinc is also a potent inhibitor of the gating of the NMDA receptor 
(Amico-Ruvio et al., 2011; Sowa-Kućma et al., 2013). Meanwhile, phencyclidine (PCP) 
is an established non – competitive antagonist of the NMDA receptor and is frequently 
used to recapitulate the psychotic features of schizophrenia as an animal model of this 
psychiatric condition (Balla et al., 2001; Lee et al., 2006; Domino and Luby, 2012). 
 
1.6.2 Inhibitory neurotransmission 
 
Inhibitory neurons (or more commonly known as the inhibitory interneurons) 
releases the inhibitory neurotransmitter, mostly GABA (but also glycine), to induce 
hyperpolarization of the postsynaptic neurons. The use of the term interneuron dates 
back to the studies of Santiago Ramon y Cajal who found the distinction between the 
cells with a long axon (the projection neurons) and the cells with a short axon (the 
intrinsic neurons, eventually known as the interneurons) (Hof et al., 2014). These 
interneurons were found to be mostly GABA-ergic and constitute about 15 – 30 % of 
the total neuronal population (Jones, 2009).  
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Figure 1-9 Interneuron morphology, connectivity, markers, and intrinsic properties.  Shown are the variations in interneuron 
morphology, their respective connectivity, markers, and intrinsic properties. Highlighted are the properties of the fast – spiking 
cortical basket cells. Reprinted by permission and with slight modification from Macmillan Publishers Ltd: Nature (Kepecs and 
Fishell, 2014), copyright (2014).  
 
Studies on inhibitory interneurons initially focused on the examination of the 
diverse morphological features that they have (Mendenhall and Murphey, 1974). 
Eventually, their connectivity and electrophysiological properties was studied (Bartos 
and Elgueta, 2012). However, the biggest stride in interneuron studies, perhaps, is the 
use of calcium binding proteins as interneuron markers (Van Brederode et al., 1990; 
Demeulemeester et al., 1991; Wild et al., 2005; Zaitsev et al., 2005). The finding of the 
selective expression of these calcium binding proteins allow for the use of 
immunohistochemistry to further classify these interneurons into specific subtypes. 
Nowadays, the classification of interneurons can be made based on any of these four 
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distinctive features (Maccaferri and Lacaille, 2003) (see Figure 1-9); despite the shared 
features that these cells may have following the distinctive classification (summarized 
and reviewed elegantly in (Kepecs and Fishell, 2014) and (Markram et al., 2004)).  
Inhibitory interneurons are of interest in the study of neuroenergetics as recent 
studies have demonstrated that inhibitory interneurons have much higher energetic 
demand than the excitatory neurons (Kann et al., 2014). This has been shown in vitro 
in numerous studies in the context of gamma oscillations, a highly energetic 
physiological processes that depend on the temporal input of the fast – spiking 
inhibitory interneurons (Huchzermeyer et al., 2008; Kann et al., 2011; Whittaker et al., 
2011; Chan et al., 2016; Jessen et al., 2017). Furthermore, it was found that the 
inhibitory interneurons have higher expression of cytochrome c, a marker of 
mitochondrial respiration (Gulyás et al., 2006) as well as a higher expression of 
cyclophillin-D, the modulator of the mitochondrial transition pore (Hazelton et al., 2009). 
In post-mortem study of patients with mitochondrial disease, it was found that there 
was a dramatic loss of the inhibitory interneurons at the end-stage of the mitochondrial 
disease (Lax et al., 2016). Collectively, all these studies led to the development of the 
‘interneuron energy hypothesis’ (Kann, 2016), which postulates the importance of the 
inhibitory interneuron population at the core of various neurometabolic processes. 
As with excitatory cells, the inhibitory interneurons utilize the major inhibitory 
neurotransmitters, GABA, for their neurotransmission. GABA, like glutamate, also has 
two major classes of receptors; the ionotropic GABA receptors (GABAA and GABAC) 
and the metabotropic GABA receptors (GABAB). The most abundant GABA receptors 
in the brain is the ionotropic GABAA receptor (Forman et al., 2017); hence, this is 
further discussed below.  
The GABAA receptor is generally a pentameric protein, composed of heteromeric 
subunits (Sigel and Steinmann, 2012). Sixteen different subunits have been cloned 
thus far from the GABAA receptor and most frequently, it is made up of two α subunits, 
two β subunits, and another subunit (usually the γ subunit) (Miller and Aricescu, 2014). 
The functional GABAA receptors have high heterogeneity (Nutt, 2006), meaning it is 
virtually impossible to determine the precise subunit composition of each GABAA 
receptor. In addition to its endogenous agonist (GABA), various synthetic molecules 
have been found and synthesized as GABAA agonists (such as muscimol). The GABAA 
receptor has various binding sites; most notably the distinct barbiturate and 
benzodiazepine binding sites; as well as the neurosteroid, picrotoxin, flumanezil, 
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penicillin, and furosemide binding site (Forman et al., 2017). Both barbiturate and 
benzodiazepine are anticonvulsants that potentiate GABAA inhibitory 
neurotransmission but have been identified to have distinct binding sites (Eadie and 
Kwan, 2008; Schmidt and Wilensky, 2008; Greenfield Jr, 2013). Neurosteroids are 
endogenous steroids synthesized in the brain, adrenal glands, and the gonads; which 
exert a potent enhancement of the GABAA transmission (Lambert et al., 2003; Wang, 
2011). Finally, the remaining binding sites in the GABAA receptor pertains to 
antagonists of this receptor. Picrotoxin is perhaps the most classical of GABAA receptor 
antagonists. It is a potent non-competitive antagonist that works by disrupting the 
chloride (Cl-) ion flow through the ion channel (Olsen, 2006). Flumanezil is a unique 
pharmacological tool, as on its own, it potentiates the GABAA neurotransmission; but 
when co-applied with benzodiazepines, it inhibits the potentiating effect of the 
benzodiazepines (Weiss et al., 2002). Therefore, flumanezil is a potent inhibitor of the 
benzodiazepine binding site on the GABAA receptor. Penicillin, which is a member of 
the β-lactam antibiotic family, is known to be a weak GABAA receptor antagonist 
(Antoniadis et al., 1980). It is thought to non-competitively interfere with the ion flow 
across the channel in a similar manner to picrotoxin; but at a different binding site 
(Tsuda et al., 1994; Sugimoto et al., 2002; Rossokhin et al., 2014). Finally, furosemide 
is a well – characterized loop diuretic; which was found to have a unique inhibitory 
effect on the GABAA receptor. Its inhibitory effect seems to be region specific (restricted 
to the cerebellar cells), subtype specific, and acts as a sequential open channel blocker 
through inhibiting the dissociation of agonist while the channel is blocked (Korpi and 
Lüddens, 1997; Kolbaev et al., 2002).  
Hitherto, the basic principle underlying the excitatory and inhibitory 
neurotransmission has been discussed. The relevant receptors investigated within this 
study have also been described in detail. However, in reality, excitatory and inhibitory 
neurotransmission depends on various contributing factors and input. Therefore, the 
complexity of understanding these neurotransmissions should not be underestimated. 
Discussion on these contributing factors will be made as each experimental results 
described on these studies are examined and analysed in the context of the 
corresponding neurotransmission.  
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Figure 1-10 Schematic representation of the GABAA receptor and its binding sites.  The ionotropic GABAA receptor is the most 
abundant GABA receptor in the brain and their general structure is a pentameric complexes (as shown in (A)). Activation of 
the receptor requires simultaneous binding of two GABA molecules to the receptors at the site indicated as the bolded dark 
green spot on the subunit. Each subunit of the receptor has four membrane – spanning regions with a cysteine loop in the 
extracellular N – terminus (shown by the light green region). In (B), the major binding sites of these receptors are schematically 
indicated. As with the glutamatergic receptors, the exact location of these binding sites are unknown. (+) indicates agonist or 
allosteric modulator of the receptor whilst (-) indicates competitive or non-competitive antagonist. Figure recreated and based 
from (Forman et al., 2017). 
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1.7 Astrocytes 
 
The term neuroglia (or nerve glue) was first coined by Rudolph Virchow in 1859, 
who conceived these cells as the inactive ‘connecting tissue’ that holds neurons 
together in the central nervous system (Hof et al., 2014). The work of Ramon y Cajal, 
with his various staining techniques, advanced this description of the neuroglia cells to 
three distinct supporting cell types; which are oligodendrocytes, astrocytes, and 
microglia (García-Marín et al., 2007). Later, oligodendrocytes were found to be the 
myelinating cells of the central nervous system (Bradl and Lassmann, 2010); while the 
microglia was discovered to be the primary inflammatory cell of the central nervous 
system, acting as the resident macrophage of the brain (Prinz and Priller, 2014). 
Astrocytes, on the other hand, took centre stage as it was discovered that they closely 
associate with the neurons in the brain (see Figure 1-11) and are likely to participate 
in the process of neurotransmission (Olude et al., 2015).  
 
 
Figure 1-11 Astrocytes morphology in the context of neuronal population.  Shown are images obtained from neocortical slices 
from African giant rat that were stained using the Golgi silver impregnation method. In (A), a typical pyramidal neuron (red 
arrow) is seen to make association with the astrocytes (yellow arrows). In (B), the astrocytes were found to be in synaptic 
association (yellow circumscribed area) with the neurons. Scale bar 100µm. Reprinted with modifications from Frontiers in 
Neuroanatomy, Volume 9, Edition 67, Olude et al, Astrocyte morphology, heterogeneity, and density in the developing African 
giant rat (Cricetomys gambianus), Copyright (2015) as an open – access article distributed under the terms of the Creative 
Commons Attribution License. 
 
 
Astrocytes were named due to their star-shaped appearance under the 
microscope (García-Marín et al., 2007; Hof et al., 2014). They roughly constitute about 
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20 to 50 % of the volume of most brain areas occupied (Hof et al., 2014); therefore 
their importance in brain pathology should not be understated. Astrocytes have various 
distinct morphological variation in the human brain (described and discussed 
extensively in Figure 1-12). Two of these astrocytic morphological types, the 
interlaminar and the polarized astrocytes, are specific to the human brain (Oberheim 
et al., 2009). The other two subtypes, the fibrous and protoplasmic astrocytes, have 
been described in both humans and rodents; despite slight differences in the size of 
the soma between these two species (Matyash and Kettenmann, 2010). Furthermore, 
within species, there is also distinct functional and anatomical variation within the 
astrocytic population in different regions of the brain (Matyash and Kettenmann, 2010; 
Olude et al., 2015). One such example is the lack of expression of functional NMDA 
receptor in the astrocytes of the hippocampus in mice (Seifert and Steinhäuser, 1995). 
These subtle differences could contribute to different functional properties of the 
astrocytes depending on the region of interest. 
Subsequently, astrocytes were identified to serve many important functions in the 
maintenance of homeostasis in the central nervous system (reviewed elegantly in 
(Kimelberg and Nedergaard, 2010) and will be briefly discussed here). Due to the 
astrocytic expression of two potassium pumps (the ATP – dependent Na-K-ATPase 
and the Na-K-Cl cotransporter or NKCC pump) as well as the inward rectifying 
potassium channel (Kir), it is widely accepted that astrocytes play an important role in 
the buffering of extracellular K+ (Kofuji and Newman, 2004; Witthoft et al., 2013). The 
presence of various H+ and HCO3- transporting enzymes in astrocytes also allows for 
these cells to actively participate in the regulation of brain pH (Chesler, 2003; Hansen 
et al., 2015). Astrocytes also have various metabolic modulatory function such as the 
glutamate-glutamine cycle (Hertz, 2013) (discussed further below in section 1.8.6), the 
astrocyte-neuronal lactate shuttle (Chih and Roberts, 2003) (discussed further below 
in section 1.8.7), and the neurovascular coupling through the blood-brain barrier 
(Abbott et al., 2006) (as discussed above in section 1.5). Astrocytes are also involved 
in water transport due to the specific expression of aquaporin channels (Satoh et al., 
2007; Hubbard et al., 2015; Potokar et al., 2016). Finally, astrocytes also demonstrate 
a high expression level of key antioxidant enzymes; therefore they are thought to be 
an important source of endogenous defence against oxidative stress (Fernandez-
Fernandez et al., 2012; Baxter and Hardingham, 2016). 
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Figure 1-12 Astrocyte morphological variation in the human brain.  Morphological studies are based on immunostaining of 
the GFAP protein in the human cortex. There is a regional specific distribution of astrocytes subtypes in the human brain as 
shown in (A). Layer I is composed of the cell bodies of the interlaminar astrocytes, with their respective processes extending 
through to layer II – IV with their characteristic tortuous processes (as shown in (B)). The polarized astrocytes with varicose 
projections (shown in (C) and projections shown with the yellow arrows) are found only in humans and seen sparsely across 
layers V – VI. The protoplasmic astrocytes (shown in (D)), the most common form of astrocytes, occupy most of the grey matter, 
especially in layers II – VI. Finally, the fibrous astrocytes (shown in (E)) are primarly found in the white matter and 
characteristically contain numerous overlapping processes. Scale bar in (A) 150µm, (B) 10µm, (C) 50µm, (D) 20µM, and (E) 
10µm. Figure (A) and (F) is reprinted from Journal of Neuroscience, Volume 29, Edition 10, Oberheim et al, Uniquely Hominid 
Features of Adult Human Astrocytes, Page 3276 – 3287., Copyright (2009), with permission from the Society for Neuroscience. 
Figure (B), (C), (D), and (E) is reprinted from Brain Research Reviews, Volume 63, Issues 1 – 2, Matyash V and Kettenmann H, 
Heterogeneity in astrocyte morphology and physiology, Pages 2-10;, Copyright (2010), with permission from Elsevier. 
Permission also obtained from original images from (Oberheim, 2009) as with figure (A) and (F).  
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1.7.1 Astrogliosis 
 
Another important role of astrocytes is their classical response to neuronal injury 
called reactive astrogliosis. Reactive astrogliosis is a pathological increase in the 
number and size of the astrocytes due to upregulation of various gene expression and 
molecular markers following neuronal injury (Zamanian et al., 2012). One such marker 
of reactive astrogliosis is the glial fibrillary acidic protein (GFAP), which is known to be 
upregulated during astrogliosis but has eventually become used more extensively as 
an astrocytic marker due to its selective expression in the astrocytes (Hol and Pekny, 
2015). 
It is controversial whether reactive astrogliosis is largely beneficial or detrimental 
to the whole brain tissue in the context of neuronal injury (Sofroniew, 2009; Pekny and 
Pekna, 2014; Pekny et al., 2014). In various studies using a wide array of model, 
reactive astrogliosis has been shown to be a protective mechanism in limiting the 
extent of the brain injury and inflammation to the area of gliosis (Bush et al., 1999; Herx 
and Yong, 2001; Faulkner et al., 2004; Myer et al., 2006; Gadea et al., 2008; Voskuhl 
et al., 2009). On the other hand, in some models (particularly the spinal cord injury 
model), reactive astrogliosis has been demonstrated to be detrimental to 
neuroregeneration, especially in inhibiting new axonal growth following the neuronal 
injury (Liuzzi and Lasek, 1987; Snow et al., 1990; Cirillo and Papa, 2016). This 
detrimental response from the reactive astrogliosis is usually characterized as a 
maladaptive response of gliosis (Pekny et al., 2014). This distinction in the astrogliosis 
response to neuronal injury was also found to be model-specific and activates different 
gene expression pathways dependent on the injury types (Zamanian et al., 2012). 
Therefore, it supports the view that reactive astrogliosis should be considered within 
the context of each injury and model (Sofroniew, 2009; Zamanian et al., 2012; Pekny 
and Pekna, 2014).  
Structurally, reactive astrogliosis is characterized by a hypertrophic response that 
varies with the severity of each insult (Sofroniew and Vinters, 2010). In a healthy 
astrocyte, each cell occupies a discrete domain and there is no overlap in the 
processes. Following a mild to moderate injury, the astrocytic processes are extended 
and no longer occupy discrete domains. When the injury reaches the severe stage, a 
glial scar is formed in addition to the reactive astrocytes. The glial scar is composed of 
newly proliferated astrocytes along with some other cell types such as fibromeningeal 
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cells and other neuroglial cells (Sofroniew, 2009; Wanner et al., 2013; Silver, 2016). 
This glial scar forms a border around the extent of the injury and is usually very focal 
and well circumscribed. Therefore, the reactive astrogliosis can be graded in its 
response from a mild astrogliosis to a severe astrogliosis with glial scar formation (see 
Figure 1-13).  
In the context of neurotransmission, reactive astrogliosis has been very closely 
associated with the loss of inhibition. The selective induction of reactive astrogliosis 
acutely cause an erosion of inhibition, which was speculated to be due to the failure of 
the astrocytic glutamate-glutamine cycle (Ortinski et al., 2010). In a transgenic mice 
model of reactive astrogliosis, these animals were found to develop recurrent 
spontaneous seizure, which was thought to be due to alteration in the potassium 
channel expression (Yu et al., 2014; Robel et al., 2015). Indeed, reactive astrocytes 
and gliosis were found in various models of epilepsy and was associated with 
impairment in glutamatergic transmission (Represa et al., 1995; Aronica et al., 2000; 
Garzillo and Mello, 2002).  
Indeed, reactive astrogliosis is a well-characterized response to neuronal injury 
which may have a beneficial or detrimental effects, depending on the injury type and 
model. Whatever the mechanisms or the modulators, it should be borne in mind that 
astrogliosis should be considered and examined in the context of various neurological 
disorders.  
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Figure 1-13 Progression of astrogliosis. Shown in (A) are photographs of astrocytes in healthy tissue (a) and the different 
stages of reactive astrogliosis (b-c) and glial scar formation (c) following various tissue insults of different severity. Astrocytes 
are labelled through immunostaining of the glial fibrillary protein (GFAP). Scale bar 8µm. Shown in (B) are schematic 
representations of the mechanisms involved in the different gradations of these reactive astrogliosis. In (a), mild to moderate 
reactive astrogliosis constitutes the changes in molecular expression and functional properties of the astrocytes associated 
with cellular hypertrophy. These changes are temporary and can still resolve itself should the insult be removed. Severe 
reactive astrogliosis (b), on the other hand, occurs with persisting scar formation along the border to areas of tissue damage 
and inflammatory reactions. This glial scar formation is comprised of newly proliferated astrocytes (with red nuclei in figure) 
and other glial cell types (with gray nuclei). Mature glial scars persist for long periods of time and act as both a barrier to 
axonal regeneration and to the spread of intense inflammatory reaction from the damaged tissue. Reprinted from Trends in 
Neuroscience, Volume 32, Issue 12, Sofroniew M.V., Molecular dissection of reactive astrogliosis and glial scar formation, Page 
638-647., Copyright (2009), with permission from Elsevier.  
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1.7.2 Manipulation of astrocytic function 
 
Currently, there are not many methods available to study astrocyte functions 
specifically, in isolation from the neuronal compartments. Most of our current 
knowledge on astrocytic function have been based on studies using astrocytic culture 
or co-culture with neurons (Jones et al., 2012; Schildge et al., 2013). However, it can 
be argued that the culture conditions are extremely artificial and do not represent in 
vivo conditions accurately. In the use of animal models, certain transgenic animal 
models have been developed with regards to the manipulation of specific astrocytic 
function (Yu et al., 2014; Robel et al., 2015; Srinivasan et al., 2016). Whilst the use of 
genetically modified animals is certainly appealing due to its strength in the selective 
manipulation of astrocytic function, the generation of these animals tends to be 
expensive and time inefficient.  
In an in vitro study, the most time efficient, cost effective, and reproducible 
method of manipulating cellular function is using pharmacological tools. There are very 
few pharmacological compounds available to modulate astrocytic function specifically. 
One such compound (used in this thesis) is fluorocitrate. Fluorocitrate is a specific 
astrocyte aconitase inhibitor (Hassel et al., 1992). The specificity of this compound is 
reliant on the preferential uptake of citrate compounds into the astrocyte (Fonnum et 
al., 1997). After being taken up by the astrocytes, fluorocitrate undergoes conversion 
to fluoro-cis-aconitate and eventually forms the by-product, 4-hydroxy-trans-aconitate 
(HTn), which is shown to form a tight bond with the aconitase molecule (Lauble et al., 
1996).  
Metabolically, in addition to the inhibition of aconitase (a TCA cycle enzyme, TCA 
cycle to be discussed further below in section 1.8.3), fluorocitrate has been 
characterized to also cause many other metabolic changes. There is a significant 
decrease in glutamine production in the media of an astrocytic culture following 
fluorocitrate application (Hassel et al., 1992; Fonnum et al., 1997). Fluorocitrate has 
also been shown to significantly reduce cerebral oxidation of lactate and to a lesser 
extent, glucose (Ronald Zielke et al., 2007). In rat kidney mitochondria, fluorocitrate 
was demonstrated to inhibit pyruvate carboxylation (Mehlman, 1968). All these studies 
indicated that the use of fluorocitrate can potentially cause a large metabolic change 
in the exposed tissue in addition to its effect as an aconitase inhibitor.  
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Intracerebral injection of fluorocitrate in vivo has been shown to lead to the 
development of convulsive seizures (Hornfeldt and Larson, 1990; Willoughby et al., 
2003; Mirsattari et al., 2008). However, no single mechanisms has been ascribed to 
be responsible for this convulsive effect. In addition, another study using similar 
methods of delivery through intracerebral injection of fluorocitrate, albeit at a lower 
dose, did not find spontaneous seizure generation following the treatment (Lian and 
Stringer, 2004). Indeed, the selectivity of fluorocitrate inhibition towards the astrocytes 
has been shown to be dependent on concentration, time window, and method of 
delivery (Paulsen et al., 1987). In the study using the lower concentration of 
fluorocitrate (which would be more specific in inhibition of astrocyte function), it was 
found that fluorocitrate increased the tissue susceptibility to various pro-convulsants, 
such as kainic acid and pilocarpine (Lian and Stringer, 2004). This was reproduced in 
the context of spreading depression and it was concluded that in the presence of 
fluorocitrate, neurons were more vulnerable to a convulsive state and the generation 
of cortical spreading depression (Largo et al., 1997). Therefore, it seems more 
conclusive that fluorocitrate, as a modulator of astrocytic function, increased the 
neuronal vulnerability to a convulsive state; rather than acting as a direct pro-
convulsant.  
Interestingly, recent studies have shown that fluorocitrate may potentially 
modulate the function of other neuroglia cells, specifically the microglia in the context 
of understanding nociceptive pain transmission (Jiang et al., 2009; Sung et al., 2012; 
Xu et al., 2016). It is important to note that these studies are still preliminary findings 
and further studies are required to truly establish the effect of fluorocitrate on microglia 
metabolism. However, the presence of such studies should revitalize the interest in the 
use of fluorocitrate as a modulator of glial function.  
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1.8 Energy metabolism in the brain 
 
The main obligatory substrate for the brain is glucose (McKenna et al., 2006). In 
addition to its role as an energy-providing substrate, glucose is also the carbon source 
for the biosynthesis of various essential compounds in the brain, including 
neurotransmitters (Dienel, 2014). Therefore, across all cell types in the brain (for 
instance neurons and astrocytes); there is a common metabolic pathway in energy 
metabolism that utilizes glucose as a substrate. However, it is accepted that under 
certain conditions, other substrates can be utilized by the brain. During starvation, for 
example, the brain preferentially uses ketone bodies rather than glucose as a 
metabolic substrate (Owen, 2005). Therefore, lipid metabolism may also play an 
important role in the provision of energy for the brain. Furthermore, there are also 
metabolic pathways that require the contribution of the two major cellular 
compartments of the brain, neurons and astrocytes. Such pathways include the 
astrocytic-neuron lactate shuttle hypothesis and the glutamate-glutamine cycle as well 
as the GABA shunt. All of these metabolic pathways are to be discussed in detail below.  
 
1.8.1 Overview of glucose metabolism 
 
Glucose enters the cell through a glucose transporter and undergoes glycolysis 
in the cytoplasm. Each glucose molecule would generate two molecules of pyruvate 
and the net result of glycolysis also includes 2 ATP molecules and 2 NADH molecules 
per molecule of glucose. Each of the pyruvate molecule can enter the mitochondria to 
undergo decarboxylation to generate acetyl-CoA. This acetyl-CoA enters the TCA 
cycle and generate 3 NADH and 1 FADH2 as it undergoes the cycle. In addition, a 
molecule of GTP is generated and is readily converted to ATP per turn of the Krebs 
cycle. All these accumulated NADH and FADH2 then enters the oxidative 
phosphorylation (discussed above in section 1.2) to generate the majority of the ATP 
via glucose metabolism. After accounting for all the steps that require ATP as an 
intermediary, the net result of ATP generated per molecule of glucose following all 
these steps is 30 ATP per molecule (Berg et al., 2012g). It is important to note, however, 
that the metabolic processes in mitochondria are dependent on the presence of oxygen 
(see also above oxidative phosphorylation in section 1.2); hence making this complete 
glucose metabolism an ‘aerobic’ process (see Figure 1-14) (Berg et al., 2012g).  
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Figure 1-14 Overview of glucose metabolism.  Shown above is an overview of glucose metabolism and the important 
byproducts of the metabolism. The processes involved are coloured red and is placed at its respective locations; whether in 
the cytoplasm or the mitochondria. In green is the glucose transporter that allows the glucose to enter the cell.  
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1.8.2 Glycolysis 
 
Glycolysis is the first metabolic pathway, common to all tissues, in the metabolism 
of glucose (Berg et al., 2012f). It is a sequence of chemical reactions that metabolizes 
a molecule of glucose to two molecules of pyruvate. The net results of this reaction are 
two molecules of pyruvate, two molecules of ATP, and two molecules of NADH (see 
Figure 1-15). In the brain, glycolysis is relatively rapid and has many major branching 
points, where the carbon atoms are redirected from the glycolytic pathways to other 
metabolic pathways. One such branching point is following the rate-limiting step of 
glucose conversion to glucose-6-phosphate by the enzyme hexokinase (Berg et al., 
2012f). Glucose-6-phosphate can enter the pentose phosphate shunt pathway for the 
generation of NADPH and various nucleotide precursors (Berg et al., 2012b). NADPH 
is an important part of the endogenous oxidative defence system due to its strong 
reducing power (DeBerardinis et al., 2007). Additionally, glucose-6-phosphate can also 
be converted to glucose-1-phosphate, an important precursor to glycogen (Dienel, 
2014). In adult brain, glycogen is primarily stored in astrocytes and is usually the first 
fuel reserve utilized during an energy crisis (Brown and Ransom, 2007; Obel et al., 
2012). The next branching point in glycolysis is fructose-6-phosphate, which is a 
precursor to various glycoprotein components of the cell membrane (Dienel, 2014). 
Finally, 3-phosphoglycerate is also a branching point for the synthesis of various 
carbon compounds, such as the neurotransmitters, glycine and D-serine (Dienel, 2014).  
As a product of glycolysis, pyruvate itself has multiple fates. Under normal 
aerobic conditions, most pyruvate will be decarboxylated by the pyruvate 
dehydrogenase complex to generate acetyl-CoA that would enter the TCA cycle (Berg 
et al., 2012f). It can be transaminated to generate alanine by alanine transaminase 
(ALT) through a reaction coupled with the conversion of glutamate to alpha-
ketoglutarate (Bak et al., 2006). In the astrocytes, pyruvate is also an important source 
of anaplerosis and CO2 fixation through the action of the enzyme pyruvate carboxylase, 
which converts it to oxaloacetate (Shank et al., 1985). Finally, under anaerobic 
condition, pyruvate can also be reduced to form lactate by the enzyme lactate 
dehydrogenase, which is coupled to the oxidation of NADH to NAD+ (Berg et al., 2012f). 
This reaction is favourable under anaerobic condition as glycolysis requires NAD+ to 
continue and the regeneration through oxidative respiration is unavailable under such 
condition. 
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Figure 1-15 Glycolysis and its branching points.  Shown are the steps involved in glycolysis as well as the important byproducts 
of the reaction. In blue are all the branching points that could occur in normal aerobic condition, whereas in red is the 
branching point that could occur under anaerobic condition.  
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Another important concept to discuss at this point is the NAD+/NADH ratio, which 
acts as a good indicator of the redox status in the tissue (Dienel, 2014). NADH 
generated by glycolysis cannot directly cross the mitochondrial membrane to be 
oxidized via the electron transport chain. Therefore, to continue carrying on glycolysis, 
the tissue needs a pathway to replenish the NAD+ pool. Under aerobic conditions, this 
is mediated by the redox shuttle system and the major system in brain is the malate-
aspartate shuttle (see Figure 1-16) (Kane, 2014). Alternatively, pyruvate can also be 
reduced to lactate as mentioned above to regenerate the NAD+ pool under anaerobic 
conditions (Berg et al., 2012f). Under anaerobic conditions, NADH cannot be oxidized 
to NAD+, therefore the NAD+/NADH ratio would be less than 1 and indicates the failure 
of redox maintenance in the tissue. Therefore, the NAD+/NADH ratio is an important 
concept in understanding the redox status of the tissue following metabolic dysfunction.  
 
 
Figure 1-16 The redox shuttle system in the brain.  There are two major ways for the brain to replenish NAD+ content. Pyruvate 
can be reduced to lactate by the enzyme lactate dehydrogenase. Alternatively, a major redox shuttle system in the brain is the 
malate – aspartate shuttle, which involves various enzymes (such as malate dehydrogenase) and transporters (such as the 
malate – alpha ketoglutarate antiporter). Reprinted from Frontiers in Neuroscience, Volume 8, Edition 366, Kane D.A, Lactate 
oxidation at the mitochondria: a lactate – malate – aspartate shuttle, Copyright (2014) as an open – access article distributed 
under the terms of the Creative Commons Attribution License. 
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1.8.3 TCA cycle (Krebs cycle) 
 
Following glycolysis, the majority of the pyruvate generated is decarboxylated by 
the pyruvate dehydrogenase complex to generate acetyl-CoA (Berg et al., 2012f). 
Acetyl-CoA enters oxidative metabolism through the Krebs cycle (or the tricarboxylic 
acid cycle) (Berg et al., 2012d). The TCA cycle is unique as it represents the metabolic 
pathway where glucose, amino acids, and lipid metabolism converges (see Figure 1-17) 
(Dienel, 2014).  
 
Figure 1-17 The TCA cycle and its branching point.  Shown above is the TCA cycle or the Krebs cycle, its product, and its 
branching point. The step catalysed by the enzyme aconitase is highlighted as this is relevant to the study in this thesis. Blue 
represents the entry of amino acid metabolism and red represents the entry of lipid metabolism. Leu – leucine, Ileu – isoleucine, 
Tyr – tyrosine, Trp – tryptophan, Thr – threonine, Phe – phenylalanine, Glu – glutamate, Gln – glutamine, Arg – arginine, His 
– histidine, Pro – proline, Val – valine, Met – methionine, Asp – aspartate, Asn – asparagine.  
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The major products of the TCA cycle are the NADH and FADH2. As mentioned 
previously in section 1.2, NADH enters the mitochondrial respiratory chain at complex 
I. FADH2, in contrast, enters the mitochondrial respiratory chain directly from the TCA 
cycle without dissociating from the enzyme succinate dehydrogenase and forms 
complex II of the respiratory chain (Berg et al., 2012d). Together, the oxidation of 
NADH and FADH2 generated from the TCA cycle accounts for almost 90% of the 
energy requirement in human (Berg et al., 2012d), highlighting the importance of this 
cycle in the generation of high energy ATP molecules. Another important by-product 
of the TCA cycle is the production of carbon dioxide (CO2) and proton ions (H+). This 
carbon dioxide has been shown to be a major source of acidification in cellular 
respiration as it is readily converted to bicarbonate (HCO3-) and proton ion (H+) 
(Mookerjee et al., 2015).  
As shown in Figure 1-17, both amino acids and lipids enters energy-generating 
metabolism via the TCA cycle. Amino acids enter the TCA cycle through its 
intermediates. Glutamate, for example, enters the TCA cycle through the intermediate 
α-ketoglutarate following interconversion by the enzyme glutamate dehydrogenase 
(Bak et al., 2006). Lipid metabolism through mitochondrial β-oxidation enters the TCA 
cycle after its conversion to acetyl-CoA (Berg et al., 2012e) (to be discussed further 
below). Regardless, the TCA cycle represents an important converging metabolic 
pathway for the entry of various substrates to energy metabolism.  
 
1.8.4 Fatty acid metabolism 
 
Theoretically, fatty acids are the molecules with the highest efficiency in energy 
storage (Berg et al., 2012e). However, the brain is suboptimal in its use of the hydrogen 
– rich fatty acids as a form of metabolic fuel. This is a very puzzling observation but is 
explained by various experimental observations. Catabolism of the fatty acids is 
mediated by mitochondrial β-oxidation and demands more oxygen than glucose 
catabolism, therefore cells such as neurons could potentially be hypoxic should it be 
forced to rely on fatty acids as metabolic substrate (Schönfeld and Reiser, 2013).  
Furthermore, β-oxidation generates superoxide, a potent reactive oxygen species 
(ROS) (Rodrigues and Gomes, 2012; Schönfeld and Wojtczak, 2012), that when 
handled improperly can cause severe oxidative stress. The rate of β-oxidation is also 
thought to be slower than glucose oxidation, making it difficult to rely on β-oxidation to 
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sustain rapid neuronal activity (Schönfeld and Reiser, 2013). Collectively, this makes 
it unfavourable for neurons to use fatty acid as the preferred form of metabolic fuel.  
Regardless of all the disadvantages mentioned above, fatty acid metabolism still 
exists in brain tissue and is estimated to potentially account for up to 20% of the whole 
tissue metabolism (Panov et al., 2014). A recent school of thought has hypothesized 
that fatty acid metabolism is more suitable to astrocytes rather than neurons 
(Schönfeld and Reiser, 2013; Murphy, 2014; Panov et al., 2014). This is supported by 
various experimental evidence. For instance, astrocytes are better equipped with 
endogenous antioxidant systems to combat their natural reactive oxygen species 
formation due to their lack of mitochondrial supercomplexes organization (Lopez-
Fabuel et al., 2016). Astrocytes are therefore proposed to be a ‘metabolic cauldron’, 
without which, neuronal function would largely suffer (Panov et al., 2014).  
Another important cautionary note is that whilst most of the dietary long-chain 
fatty acids are metabolized through mitochondrial β-oxidation, some branched and 
very-long chain fatty acids are instead metabolized through the peroxisomal α- and β-
oxidation processes (Wanders et al., 2003). Therefore, the metabolism of each fatty 
acid should be considered in the context of its respective metabolic pathway. 
Furthermore, studies on fatty acid metabolism in the brain are relatively scarce and 
this area is still a growing field of study. Regardless, it proves worthwhile to investigate 
more on the exact roles that fatty acid play in energy metabolism of the brain.  
 
1.8.5 Ketogenesis 
 
As mentioned above, under starvation, the brain preferentially utilizes ketone 
bodies instead of glucose as metabolic fuel (Owen, 2005). Ketone bodies are collective 
groups of water-soluble molecules, comprised of β-hydroxybutyrate, acetoacetate, and 
acetone, that are generated from acetyl-CoA during starvation (see Figure 1-18) (Laffel, 
1999). This acetyl-coA can either be generated from pyruvate following glycolysis or 
from β-oxidation of fatty acids (Laffel, 1999). The ketone bodies are utilized in the brain 
through the TCA cycle following re-conversion to acetyl-coA through ketolysis (Laffel, 
1999) 
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Figure 1-18 Ketone bodies and their respective metabolic pathways.  Shown in (A) are the chemical structures of the three 
components of the ketone bodies, namely the β-hydroxybutyrate, acetoacetate, and acetone. The ketone bodies are 
generated through ketogenesis from acetyl-CoA, either obtained from glycolysis or β-oxidation, as shown in (B). Shown in (C) 
are the respective enzymes and transporters involved in ketogenesis. In (D), the use of ketone bodies or ketolysis is shown as 
it enters the TCA cycle to provide energy. HL – HMG CoA lyase, 3-KT – 3-ketothiolase, mHS – HMG CoA synthase, HBD – 3-HB 
dehydrogenase, SCOT – succinyl CoA-oxoacid transferase, and MAT – methylacetoacetyl CoA thiolase. Reprinted with slight 
modification from Diabetes Metabolism Research and Reviews, Volume 15, Issue 6, Laffel L, Ketone bodies: a review of 
physiology, pathophysiology and application of monitoring to diabetes, Page 412-426., Copyright (1999), with permission 
from John Wiley and Sons.  
 
In vivo, the major site of production of the ketone bodies is the liver (Berg et al., 
2012e). Out of the three ketone bodies, acetoacetate and β-hydroxybutyrate are the 
most abundant, whereas acetone is the least abundant and rarely detectable in the 
blood (Laffel, 1999). Acetoacetate accumulates during fatty acid metabolism under 
hypoglycemic conditions, whereas β-hydroxybutyrate is formed through the reduction 
of acetoacetate in the mitochondria. Therefore, similarly, the utilization of β-
hydroxybutyrate requires reconversion to acetoacetate, which is an energetically 
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favourable reaction as it yields NADH that is usable in oxidative phosphorylation (Berg 
et al., 2012e). Acetone is only generated by the spontaneous decarboxylation of 
acetoacetate (Laffel, 1999), hence why it is the least abundant of the three molecules.   
In the brain, it is thought that ketone body production is maintained through 
astrocytic fatty acid metabolism (Auestad et al., 1991; Romano et al., 2017). This 
astrocytic ketogenesis is tightly regulated by AMP-kinase (AMPK) and is upregulated 
in condition of energy crisis (Takahashi et al., 2014). Thus, these astrocytic-generated 
ketone bodies may represent an important neuronal substrate in such conditions (see 
Figure 1-19).  
 
 
Figure 1-19 Utilization of fatty acids in the brain for ketone bodies metabolism.  Recent evidence has shown that fatty acid 
metabolism in the brain may primarily be for ketone bodies production and utilization. The fatty acids mostly enter the brain 
as an albumin – bound form and is metabolized in the astrocytes through mitochondrial β-oxidation to generate ketone bodies. 
This ketone bodies are then taken up by the neurons and lysed in the mitochondria to generate acetyl-Co-A which would then 
supplement the TCA cycle in the neurons for ATP production. This ketone body production as well as glycolysis is shown to be 
modulated by the medium – chain fatty acids, octanoic acid (C8) and decanoic acid (C10). Reprinted  from The International 
Journal of Biochemistry & Cell Biology, Volume 84, Romano et al, Fats for thoughts: An update on brain fatty acid metabolism, 
Page 40-45, Copyright (2017), with permission from Elsevier.  
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1.8.6 Glutamate-glutamine cycle  
 
The glutamate-glutamine cycle is one of the many astrocytic mechanisms that 
directly modulate neurotransmission. The glutamate-glutamine cycle is an astrocytic 
metabolic pathway that is involved in the recycling of the neurotransmitters (Bak et al., 
2006). Together with the GABA shunt, these processes help maintain the excitatory 
and inhibitory neurotransmitter homeostasis by the degradation and production of 
glutamate and GABA (see Figure 1-20) (McKenna et al., 2006).  
Glutamine is the precursor to both glutamate and GABA (Dienel, 2014). However, 
the enzyme used to convert glutamate to glutamine, the ATP-dependent glutamine 
synthetase, is localized to astrocytes (Anlauf and Derouiche, 2013). Therefore, 
glutamine can only be synthesized by the astrocytes and in turn, astrocytes provide 
excitatory and inhibitory neurons with the precursors to glutamate and GABA 
respectively. The degradation of glutamate and GABA also occurs primarily in the 
astrocytic compartment. Glutamate readily enters the TCA cycle through 
interconversion to α-ketoglutarate, a reaction that is coupled with many other metabolic 
reactions (Berg et al., 2012a). On the other hand, GABA is taken up by the astrocytes 
and undergoes transamination by GABA transaminase to generate succinate 
semialdehyde. Succinate semialdehyde is readily oxidized to form succinate that would 
enter the TCA cycle. Since the flux from α-ketoglutarate to glutamate, glutamine, and 
eventually to GABA bypasses some of the TCA cycle steps, this pathway is termed the 
GABA shunt and is often considered in close relation with the glutamate-glutamine 
cycle (Dienel, 2014).  
This cycle is one example of how astrocytic metabolism complements and 
interacts with neuronal metabolism. The exact regulation and quantitative contributions 
of the different metabolic pathways towards this cycle are yet to be determined. 
However, the importance of this cycle in the brain homeostasis should not be 
undervalued.  
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Figure 1-20 Glutamate - glutamine cycle and GABA shunt as an astrocytic - neuronal metabolic cooperation.  Shown is a 
diagram representation of the glutamate – glutamine cycle and the GABA shunt that involves the neuronal and astrocytic 
compartment in the metabolic pathway.  
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1.8.7 Astrocyte-neuron lactate shuttle hypothesis 
 
The astrocyte-neuron lactate shuttle hypothesis (ANLSH) was originally 
conceived from the observation that glutamate increased astrocytic glycolysis rate and 
was postulated to release lactate, which was used by neurons as preferential metabolic 
fuel during period of intense neuronal activity (Pellerin and Magistretti, 1994). Briefly, 
glutamate is taken up by astrocytes by excitatory amino acid transporters (EAAT) and 
stimulates ATP – dependent Na+/K+ ATPase, causing sodium influx into the astrocytes. 
This sodium influx then causes upregulation of aerobic glycolysis, specifically causing 
the astrocytes to generate lactate. This lactate is said to be released by the astrocytes 
and taken up by neurons, which would subsequently convert it to pyruvate and use it 
for energy metabolism. Since its existence, the theory has taken a life of its own and 
has incorrectly evolved into the statement that neurons depend on astrocytic supply of 
lactate for energy metabolism. There is a very large body of evidence that directly 
supports (Pellerin and Magistretti, 1994; Mangia et al., 2009; Bélanger et al., 2011; 
Genc et al., 2011) or contradicts the ANLSH (Chih and Roberts, 2003; Ivanov et al., 
2013). Therefore, the true existence of this shuttle is yet to be determined. However, 
the original ANLSH has now been updated as to include only two components: the 
dependence of astrocytic glutamate uptake on glycolytic derived energy and the 
oxidation of lactate in neurons (Hertz, 2004). Even then, various evidence still arises 
to either support or question the existence of these two components (reviewed 
elegantly in (Hertz, 2004)). Regardless, the ANLSH represents an interesting 
mechanism whereby the astrocytic and neuronal metabolism might intersect. 
Therefore, its involvement in energy metabolism of the brain should be considered 
whenever the astrocytic and neuronal metabolism are perturbed.   
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Figure 1-21 Astrocyte - neuron lactate shuttle hypothesis.  There are now primarily two components to the shuttle, namely 
the upregulation of astrocyte aerobic glycolysis by glutamate uptake and the primary oxidation of lactate in neurons. GS – 
glutamine synthetase, GLS – glutaminase, LDH – lactate dehydrogenase, GLUT – glucose transporter, EAAT – excitatory 
amino acid transporters, and MCT – monocarboxylate transporters. Reprinted from Frontiers in Neuroscience, Allaman et al, 
Methylglyoxal, the dark side of glycolysis, Copyright (2015) as an open – access article distributed under the terms of the 
Creative Commons Attribution License. Also Elsevier special credit – ‘Reprinted from Cell Metabolism, Volume 14, Issue 6, 
Belanger et al, Brain energy metabolism: focus on astrocyte – neuron metabolic cooperation, Pages 724-738, Copyright 
(2011), with permission from Elsevier’.    
 
1.9 Mitochondrial disease 
 
As mentioned above, mitochondrial DNA has a very high rate of mutation (Brown 
et al., 1979). When mutation in the mitochondrial DNA is pathogenic, it causes 
impairment in the mitochondrial respiratory chain expression and typically leads to a 
severe multiorgan energy deficiency; collectively called mitochondrial disease (Tuppen 
et al., 2010). Over the past few years, more and more genetic mutations are 
characterized as the cause of mitochondrial disease and this extends to nuclear DNA 
that was found to be involved in the maintenance and expression of the mitochondrial 
respiratory chain subunits (Scaglia, 2012). Regardless of the origin of the mutation, the 
genetic mutation has to lead to the deficiency of mitochondrial respiratory chain 
expression for the phenotype to manifest as mitochondrial disease (see Figure 1-22).  
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Figure 1-22 Overview of mitochondrial disease.  Shown is the illustration of possible genetic mutations in the mitochondrial 
DNA or nuclear DNA which would subsequently affect the expression of the mitochondrial respiratory chain. This perturbed 
expression of the respiratory chain eventually leads to the manifestation of mitochondrial disease, which can have a range of 
clinical features across multiple organs. Reprinted from EMBO Molecular Medicine, Chinnery PF, Mitochondrial disease in 
adults: what’s old and what’s new?, Copyright (2015) as an open – access article distributed under the terms of the Creative 
Commons Attribution License. 
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Mitochondrial DNA mutation follows a unique pattern of inheritance, the maternal 
inheritance (Sato and Sato, 2013). However, the pathogenicity of these mutations also 
follows a unique principle due to heteroplasmy (Lightowlers et al., 1997). Depending 
on the total amount of mutated mitochondrial DNA within a single cell, a pathogenic 
mutation may either manifest phenotypically or not. This is also known as the ‘threshold 
effect’ and also account for the variation in the severity of the clinical manifestations 
(Tuppen et al., 2010). Furthermore, in mitochondrial disease, a phenotype is not 
associated strictly with a genotype. Instead, a majority of mutation at different sites 
within the mitochondrial or the nuclear DNA may lead to similar phenotypic 
manifestation (see Figure 1-23). In the North East of England, the most common 
pathogenic mutation is the m3243A>G mutation (Gorman et al., 2015) and this 
mutation has a broad spectrum of phenotypes but is the most common cause of 
MELAS (Nesbitt and McFarland, 2011; Mancuso et al., 2014).  
In total, mitochondrial disease is estimated to have a prevalence of about 1 in 
4,300 in the United Kingdom population and is therefore one of the most common adult 
forms of inherited neurological disorders (Gorman et al., 2015). The collective term, 
mitochondrial disease, encompasses a multitude of syndromes and clinical 
manifestations. Some of these phenotypic manifestations is single organ (such as the 
eye in Leber Hereditary Optic Neuropathy), whilst most of the time, it typically is 
multiorgan (Mattman et al., 2011). Typically, the brain, heart, and muscle are most 
severely affected, as these organs are classically the most metabolically active organs. 
Out of the multisystem manifestations, neurological manifestations are by far the 
most common manifestations encountered in a clinical setting, putting the neurologists 
at the forefront of care of patients with mitochondrial disease (McFarland et al., 2012). 
In a cohort study, the most common neurological manifestations are myopathy, chronic 
progressive external ophthalmoplegia, cerebellar ataxia, cognitive impairment, 
dysphagia, epilepsy, and stroke – like episode respectively (Ng et al., 2015). It is 
important as well to note that these neurological manifestations can either manifests 
acutely or chronically; but, regardless of the timing of its manifestation, these 
neurological manifestations are known to be progressive and results in 
neurodegenerative features in these patients over time (Ng and Turnbull, 2016; Lax et 
al., 2017).  
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Figure 1-23 Some examples of the common genotype - phenotype correlation in mitochondrial disease.  Shown is the 
mitochondrial DNA along with the common site of mutation and its associated clinical phenotypes. MELAS – Mitochondrial 
Encephalopathy with Lactic Acidosis and Stroke like episode, LS – Leigh Syndrome, LHON – Leber Hereditary Optic Neuropathy, 
CPEO – Chronic Progressive External Opthalmoplegia, MERRF – Myoclonic Epilepsy and Ragged Red Fibres, MILS – Maternally 
Inherited Leigh Syndrome, NARP – Neurogenic Weakness, Ataxia, and Retinitis Pigmentosa, and PS – Pearson Syndrome. 
Reprinted from Biochimica et Biophysica Acta, Volume 1797, Issue 2, Tuppen et al, Mitochondrial DNA mutations and human 
disease, Pages 113 – 128, Copyright (2010), with permission from Elsevier.   
 
Although the phenotypic manifestation of mitochondrial disease largely varies, 
therapeutic strategy for mitochondrial disease, in general, is still lacking and very much 
in its infancy (Parikh et al., 2009). Hitherto, treatment remains largely supportive and 
symptomatic and patients with mitochondrial disease tends to have poor prognosis 
(Avula et al., 2014).  
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1.10 Mitochondrial epilepsy 
 
The International League Against Epilepsy has proposed the diagnostic criteria 
of epilepsy as a neurological disease which has any of these conditions: (1) at least 
two unprovoked seizures occurring more than 24 hours apart; (2) one unprovoked 
seizure in addition to the risk of further seizures similar to the general recurrence risk 
after two unprovoked seizures (of at least 60 %), within the next 10 years; or (3) the 
diagnosis of an epilepsy syndrome (Fisher et al., 2014). Practically, this definition is 
summarized as such that epilepsy is a disease of the brain where there is increased 
risk of developing unprovoked seizures.  
Patients with mitochondrial disease are known to have a high risk of developing 
epilepsy. The most current epidemiological study places the overall prevalence of 
epilepsy in a cohort of patients with mitochondrial disease at 23.1% (Whittaker et al., 
2015). The development of epilepsy in patients with mitochondrial disease is fittingly 
termed ‘mitochondrial epilepsy’.  
The manifestation of mitochondrial epilepsy is highly dependent on the clinical 
phenotype of the patients with mitochondrial disease (Finsterer and Mahjoub, 2013). 
In the epidemiological study mentioned above, mitochondrial epilepsy is most 
frequently associated with the m.3243A>G mutation (Whittaker et al., 2015); which as 
mentioned above is most frequently associated with MELAS (Nesbitt and McFarland, 
2011; Mancuso et al., 2014). Epilepsy can also appear as the defining feature of the 
clinical phenotype of mitochondrial disease; such as in the case of MERRF (Myoclonus 
Epilepsy with Ragged Red Fiber), where myoclonus epilepsy is one of the 
characteristic symptoms of such patients (Bindoff and Engelsen, 2012).  
Virtually any seizure semiology and combinations can occur in the population of 
patients with mitochondrial epilepsy (Bindoff and Engelsen, 2012). In the 
epidemiological study, aside from myoclonus in patients with MERRF, the most 
common seizure types seen in the cohort as a whole were focal seizures, with or 
without progression to bilateral convulsive seizures (Whittaker et al., 2015). Indeed, a 
combination of different types of focal seizures, including motor seizures with or without 
loss of consciousness and awareness, is a typical observation in patients with 
mitochondrial epilepsy (Bindoff and Engelsen, 2012; Chevallier et al., 2014). In patients 
with MELAS, the most common seizure types were generalized tonic clonic seizure, 
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with generalized or focal epileptiform discharges in the electroencephalogram (EEG) 
(Chevallier et al., 2014). 
The EEG manifestation of epileptiform discharges in patients with mitochondrial 
epilepsy can also largely vary. An epidemiological study has reported that the most 
common findings in the EEG of these patients is a generalized slowing (60%) and the 
most common epileptiform discharges seen in the trace is multifocal (41%), followed 
closely by focal (39%) and generalized seizures (39%) (Chevallier et al., 2014). It 
therefore reaffirms that mitochondrial epilepsy is an umbrella term that encompasses 
a varying epileptic phenotype that can occur in patients with mitochondrial disease 
(Bindoff and Engelsen, 2012).  
The epileptic manifestation in this cohort of patients does not seem to contribute 
towards overall risk of mortality (Whittaker et al., 2015); however, when left 
uncontrolled, this severe epileptic phenotype can be extremely debilitating and lead to 
poor quality of life (Leppik, 2003; Lin and Thajeb, 2007). Mitochondrial epilepsy was 
reported with a varying degree of pharmacological response to conventional 
antiepileptics. In the adult population, antiepileptic use is generally well-tolerated and 
tends to provide early relief and seizure control (Bindoff and Engelsen, 2012; Finsterer 
and Mahjoub, 2013; Whittaker et al., 2015). In a study in the paediatric population, a 
larger proportion of the cohort (60%) was found to be pharmacoresistant to initial 
therapeutic regimen of antiepileptic agents (Khurana et al., 2008). All of these studies, 
however, agreed that response to antiepileptic drugs tend to deteriorate causing 
epileptic phenotypes to resurface and are frequently progressive (Leppik, 2003; 
Khurana et al., 2008; Bindoff and Engelsen, 2012; Finsterer and Mahjoub, 2013; 
Whittaker et al., 2015). 
Mitochondrial epilepsy is clearly a distinct epileptic syndrome that is unique to the 
other types of epilepsy. It is typically associated with a more severe manifestation of 
an epileptic phenotype with a degree of pharmacoresistance that is rarely seen in the 
other epileptic patients. Very few therapeutic recommendations were made for patients 
with mitochondrial epilepsy. The only clinical guideline that existed was produced in 
2010 by the Newcastle Mitochondrial Disease Guidelines and was largely based on 
clinical and anecdotal experiences (Schaefer et al., 2010). This clearly indicates a gap 
of knowledge in the understanding of mitochondrial epilepsy. This thesis aims to 
address this gap and provides a novel approach to understanding this distinctive 
epileptic syndrome. 
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1.11 Animal models of mitochondrial epilepsy 
 
 
Despite the bleak clinical picture of the patient population with mitochondrial 
epilepsy as described above in section 1.10, there has been very little progress in 
preclinical studies of mitochondrial epilepsy. One of the biggest aids in preclinical 
studies aimed at understanding any neurological disorder is the development of an 
animal model of such disease. To present, there have been a paucity of animal models 
truly developed for mitochondrial epilepsy and this has been a significant bottleneck in 
the study of mitochondrial epilepsy. 
The only animal model developed that claims to model mitochondrial epilepsy is 
the Sod2-/+ mice (Liang and Patel, 2004). This animal model was initially developed on 
the basis of the understanding of oxidative stress contribution towards epileptic seizure 
and was not based on any real clinical phenotype of patients with mitochondrial 
epilepsy. These mice had a partial deficiency of the mitochondrial superoxide 
dismutase that led them to develop increased incidence of spontaneous and handling-
induced seizures (Liang and Patel, 2004). This epileptic phenotype was found to be 
progressive and associated with mitochondrial aconitase inactivation (Liang and Patel, 
2004). Other studies using the same mice model had only mostly characterized the 
oxidative stress phenotype and had not reported any epileptic or neurological 
phenotypes (Williams et al., 1998; Van Remmen et al., 1999; Gyung and Pak, 2002; 
Gupta et al., 2015). Since there is only one study to date that demonstrated an epileptic 
phenotype in such mice and the modelling of the mice was not based on any clinical 
phenotype, it is hard to endorse this animal model as capturing mitochondrial epilepsy. 
In addition to the Sod2-/+ mice, various other small studies have reported epileptic 
phenotype in various animal models exposed to mitochondrial respiratory chain 
inhibitors. The mitochondrial complex II inhibitor, 3-nitropropionic acid, has been 
shown to evoke convulsions in a dose-dependent manner in mice (Haberek et al., 2000; 
Zuchora et al., 2001). However, the 3-nitropropionic acid model was much more 
relevant and accepted as a model of Huntington Disease, rather than that of 
mitochondrial epilepsy (Chan et al., 2016). One study has also reported that 
subcutaneous injection of potassium cyanide caused a dose-dependent tonic seizures 
in mice (Yamamoto and Tang, 1996). However, again, this model was only used in this 
single study and has not been replicated. Furthermore, similar to the Sod2-/+ mice, the 
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model was not based on the clinical phenotype of patients with mitochondrial epilepsy; 
thus, the model can largely be said to not reflect mitochondrial epilepsy. 
Conversely, a number of studies have focused on the involvement of 
mitochondria in other models of epilepsy, such as the kainic acid model (Liang et al., 
2000; Mohanan and Yamamoto, 2002; Yamamoto and Mohanan, 2003; Chuang et al., 
2004), the pilocarpine model (Kudin et al., 2002; Kudin et al., 2004; Gao et al., 2007; 
Olav et al., 2013), or the status epilepticus model (Cock et al., 2002; Sleven et al., 
2006). The major issue with such studies is that the currently available model of 
epilepsy tends to manipulate specific mechanisms that are virtually impossible to 
achieve in a clinical setting. Furthermore, each model was found to be specific to the 
mechanisms manipulated and would fail to identify potential novel antiepileptic agents 
that do not mediate anticonvulsant effects through the manipulated mechanisms 
(Löscher, 2011). Thus, whilst it is encouraging to know that mitochondrial dysfunction 
is intimately involved in these models of epilepsy, it does not progress our specific 
understanding of mitochondrial epilepsy.  
In order to combat this unfocused strategy in the modelling of neurological 
diseases particularly associated with mitochondrial dysfunction, a framework has been 
developed and proposed to prevent such shortcomings (Chan et al., 2016). Four main 
stages are identified, namely: (1) the extrapolation of findings from human 
neuropathological and/or electrophysiological studies, (2) a pilot study using in vitro 
brain slice electrophysiological study to recapitulate the findings extrapolated, (3) 
validation of the model using various techniques, and (4) further extrapolation (see 
Figure 1-24). The effort in modelling mitochondrial epilepsy described in this thesis will 
largely follow such proposed framework to avoid any pitfalls in the process of in vitro 
modelling.  
 
1.12 In vitro brain slice electrophysiology 
 
 
The framework, as proposed above, has recommended the use of in vitro brain 
slice electrophysiology as a pilot study for the understanding of the electrophysiological 
correlate of mitochondrial dysfunction. The use of a brain slice as an in vitro model was 
pioneered by Henry McIllwain, who was first and foremost a neurochemist 
(Collingridge, 1995). Therefore, there is already such a rich historical precedence in 
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the use of a brain slice model in neurometabolic study. In addition, current 
neuroscientists have adapted the brain slice model as the gold standard for in vitro 
electrophysiological study aimed at the understanding of cellular and molecular 
processes underlying such electrophysiological process (Ting et al., 2014). Originally 
conceived to be a model strictly for use in animals, the brain slice model has evolved 
even further and it is now possible to ethically obtain electrically active human brain 
slices from patients undergoing elective neurosurgical procedures (Jones et al., 2016). 
Furthermore, it is now possible to maintain the brain slices in a culture setting in a 
technique called the ‘organotypic brain slice culture’ (Humpel, 2015). 
From an electrophysiological standpoint, the basic approach used in a brain slice 
is extracellular local field potential recording, which shows the electrical network 
potential generated by the summation of the electrical currents flowing from a 
population of cells around the recording electrode (Sharott, 2013). A further step is the 
recording of individual cellular electrophysiological activity through the use of either 
patch clamp or sharp electrodes (Li et al., 2004). Such an approach is useful in 
dissecting the functional property of specific cellular population during an 
electrophysiological phenomenon, but should always be paired with local field potential 
recordings so that such correlation can be made. Technological advances have also 
led to the development of the multielectrode array, that allows simultaneous 
electrophysiological recordings from multiple channels and allow temporal and spatial 
analysis of such electrophysiological phenomenon (Ferrea et al., 2012). Finally, recent 
techniques have started to incorporate optogenetics, a genetic manipulation that would 
allow modulation and control of specific cellular population using light, in 
electrophysiological recordings from brain slices and opened up a whole new avenue 
in the understanding of cellular mechanisms underlying an electrophysiological system 
(Ting et al., 2014). 
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Figure 1-24 A neuropharmacological framework to understanding electrophysiological correlate of mitochondrial dysfunction.  This framework was originally developed within the context of neuronal 
oscillation as a physiological correlate for mitochondrial dysfunction, but is readily applicable to the modelling of mitochondrial epilepsy. Reprinted with slight modification from Neuropharmacology, 
Volume 102, Chan et al, Neuronal oscillations: A physiological correlate for targeting mitochondrial dysfunction in neurodegenerative diseases?, Pages 48-58, Copyright (2016), with permission from 
Elsevier.   
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In addition to the wide variety of electrophysiological techniques that are 
employable in a brain slice setting, many other techniques are also useful and feasible 
to conduct in acute brain slice preparations. Live cell imaging allows the examination 
of various dynamic cell processes (such as the Ca2+ imaging) on a real-time setting 
(Dailey et al., 2011). The use of various biosensors (such as the oxygen-sensitive 
microelectrodes) also allows for real-time imaging of biochemical processes in the slice 
as it incubates in various experimental conditions (Huchzermeyer et al., 2008). The 
preservation of the brain slices in fixative following various experiments also allows for 
post-hoc examination of the cellular population using specific antibody-mediated 
immunohistochemistry or immunofluorescence (Park and Cunningham, 2007). The 
possibility of techniques that are usable in a brain slice setting, therefore, is endless 
and with continuous advancement of technology and knowledge, more advanced and 
delicate probing would even be possible in such a crude preparation. 
Although the brain slice is a powerful platform for the understanding of cellular 
and molecular mechanisms underlying a neurological process, it is far from perfect and 
does have its own drawbacks and pitfalls as well. The largest criticism in the use of 
brain slice is its isolation of the studied structure from the overall neuronal network and 
connections that would have been present in vivo. The absence of wider networks and 
large scale connections could alter the functional profile of the structure studied and 
thus may undermine the relevance of the results found when translating the findings 
to an in vivo setting. Furthermore, the viability of the cells and tissue are highly 
susceptible to the brain slice preparation process and although this has been 
combatted in recent studies with the introduction of various ‘neuroprotective’ artificial 
cerebrospinal fluid media, one cannot ignore that the use of such ‘neuroprotective’ 
media may also alter the profile of such tissue from the actual in vivo setting (Buskila 
et al., 2014; Ting et al., 2014). Hence, whilst the use of acute in vitro slice preparation 
is favourable in its wide array of feasible techniques, the results from such a study 
should be critically analysed and be extrapolated to in vivo studies whenever possible 
(refer back to the framework described in Figure 1-24).  
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1.13 Temporal lobe and hippocampus in epilepsy 
 
In epilepsy study, it is well known that the origin of a large proportion of the  
epileptiform discharges (estimated at about 60%) is from the temporal lobe (Téllez-
Zenteno and Hernández-Ronquillo, 2012). It is such a large proportion that such cluster 
of epileptic manifestation is aptly referred to as ‘temporal lobe epilepsy’ (Engel Jr, 
1996). Therefore, epilepsy study and modelling has largely focused on the 
development of a model using the temporal lobe as a focused area of interest.  
Out of all the structures in the temporal lobe, the hippocampus has received 
significant coverage. This has originated from the finding that a large proportion of 
patients with temporal lobe epilepsy have a sclerotic hippocampus (Thom, 2014) and 
the removal of such sclerotic hippocampi led to the development of the epileptic 
surgical treatment for patients with temporal lobe epilepsy (Feindel et al., 2009). These 
findings have solidified the place of hippocampus as a generator of epileptiform 
discharges in such patients (Avoli, 2007).  
In addition to the reasons mentioned above, the structure of hippocampus, both 
in humans and rodents, have been extensively studied and characterized (Seress, 
2007). Therefore, from a modelling standpoint, it provides advantages in that the 
cellular populations and functional profile of the underlying connections have been 
largely identified in previous studies.  
The hippocampal anatomy will now be briefly reviewed below (Bear et al., 2016a). 
The hippocampus is a subcortical structure located deep in the temporal lobe and is 
surrounded by the parahippocampal cortices (see Figure 1-25). The hippocampus 
comprises of two thin sheets of neurons that are folded onto each other; namely the 
dentate gyrus and the Ammon’s horn. The Ammon’s horn is further subdivided into 
four divisions: the CA1, CA2, CA3, and CA4 (CA stands for Cornu Ammonis, the Latin 
for Ammon’s horn). This CA subfield is further subdivided into multiple layers (or strata); 
namely the stratum oriens, stratum pyramidale, stratum lucidum, stratum radiatum, 
stratum lacunosum, and stratum moleculare (see Figure 1-26). This stratum 
suborganization is important in the anatomical distribution of the cells of the 
hippocampus but the most important and by far, the most visible to the naked eye, is 
the stratum pyramidale. Stratum pyramidale is a distinct layer that is visible due to its 
dense organization of the cell bodies of the pyramidal cells and to a lesser degree, the 
interneurons of the hippocampus (Freund and Buzsaki, 1996).  
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Figure 1-25 Macroanatomy of hippocampus.  Shown in (A) is an illustration of the exposed hippocampus of the rat in situ. In 
(B) is a photograph of a rat brain with one side intact and the other side with the hippocampus exposed. In (C) is the illustration 
with anatomical labels corresponding to the structures of the hippocampus and the surrounding parahippocampal structures. 
DG – dentate gyrus, ENTO – entorhinal cortex, FIM – fibrria, PERI – perirhinal cortex, SUBIC – subiculum. Reprinted from Brain 
Research Bulletin, Volume 12, Issue 6, Teyler TJ and Discenna P, The topological anatomy of the hippocampus: A clue to its 
function, Pages 711-719, Copyright (1984), with permission from Elsevier.  
 
From a neuroenergetic standpoint, the hippocampus has been shown to have a 
strong association between the neuroenergetic profile and the cognitive state that it is 
largely responsible for in physiological conditions (Rowe et al., 2007; Kann et al., 2011). 
Specifically, the CA3 seems to be the most energy-demanding region of the 
hippocampus and is tightly correlated with the higher power of neuronal gamma 
oscillation as compared to the CA1 (Kann et al., 2011). This was further supported by 
the finding that some of the interneurons in the hippocampus CA3 have a higher 
expression of mitochondrial cytochrome c, as compared to the same population of 
interneurons in the dentate gyrus (Gulyás et al., 2006). 
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Figure 1-26 Hippocampus proper and the subdivisions.  Shown in (A) is the illustrated diagram of the hippocampus proper 
after isolated and sliced. The CA1, CA3, and DG subfields are illustrated in the diagram. Shown in (B) is a photograph of a 
typical hippocampal brain slices that have been immunostained for NeuN to label the whole neuronal population in the slice. 
Zoomed in is the hippocampus proper and the respective subdivisions labelled. The CA3 is magnified further to showcase the 
layers (or strata) of the hippocampal CA subfield. In white is the stratum pyramidale, that is clearly different from the other 
layers of the hippocampal CA and is dense with neuronal cell bodies. DG – dentate gyrus, alv – alveus, SO – stratum oriens, SP 
– stratum pyramidale, SL – stratum lacunosum, SR – stratum radiatum, SL/SM – stratum lacunosum and stratum moleculare. 
Figure (A) is reprinted from Brain Research Bulletin, Volume 12, Issue 6, Teyler TJ and Discenna P, The topological anatomy of 
the hippocampus: A clue to its function, Pages 711-719, Copyright (1984), with permission from Elsevier. Scale bar 100µm. 
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1.14 Pharmacological treatment of epilepsy 
 
The first-line treatment for epilepsy is the use of a pharmacological group of drugs, 
the antiepileptics, to try and achieve seizure control (or more significantly, seizure 
freedom). It is important to acknowledge that the conventionally available antiepileptic 
regimen is largely symptomatic, in that it controls seizure effectively. Neither effective 
prophylaxis nor disease-modifying treatment is currently available for epilepsy 
(McNamara, 2011).  
The mechanism of action of an antiepileptic largely falls into three major 
categories: (1) the limitation of sustained, repetitive firing of neurons; (2) the 
potentiation of GABA-mediated synaptic inhibition; and (3) inhibition of voltage-
activated Ca2+ channels, a mechanism specific to that of absence seizure (McNamara, 
2011) (see Figure 1-27). Within this diverse category of antiepileptic mechanism of 
actions, there is further subdivision of mechanisms that further classify these drugs into 
their respective families (such as sodium channel blockers or benzodiazepines).  
 
Figure 1-27 Mechanism of action of conventional antiepileptic drugs.  Shown are the conventional antiepileptic drugs and the 
proposed main mechanism of actions. Largely, the antiepileptic drugs either exert its anticonvulsant activity through the 
taming of excitatory input or the potentiation of inhibitory input. Reprinted from Muller Journal of Medical Sciences and 
Research, Volume5, Issue 2, Singh SK and Brashier DBS, Perampanel: New drug for treatment of refractory partial onset 
seizures, Copyright (2014) as an open – access article distributed under the terms of the Creative Commons Attribution License. 
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There are currently about 28 antiepileptic drugs licensed for use in the United 
Kingdom (Sills, 2014). Even with this large choice of antiepileptic drugs, a significant 
proportion of the epileptic patients remains pharmacoresistant and could not achieve 
seizure freedom with conventional antiepileptics. In a population study in France, this 
number was placed at 15 % (Picot et al., 2008); however, in the United Kingdom, this 
number was slightly higher and ranges from between 30 to 60 % (Kwan and Brodie, 
2000; Tidman et al., 2003). A proportion of these pharmacoresistant epilepsy patients 
can be attributed to mitochondrial epilepsy (Bindoff and Engelsen, 2012).  
It is unclear what leads to this dichotomy in pharmacological response to 
antiepileptics. Clinically, there are predictors for negative response towards 
antiepileptic regimen, such as a higher pre-treatment seizure frequency (Hitiris et al., 
2007). The advent in pharmacogenomics has also suggested some potential genetic 
properties, such as the polymorphism in cytochrome P450, that can lead to this 
difference in pharmacological response (Glauser, 2011). Finally, interestingly, it was 
suggested that mitochondrial dysfunction in epilepsy may contribute towards 
pharmacoresistance (Yuen and Sander, 2011).  
Despite the varying response of epileptic patients towards the antiepileptics, it 
should be acknowledged that there is still a large proportion of patients that do respond 
to these pharmacological treatments. Therefore, following the development of a new 
model of any form of epilepsy, pharmacological screening should be employed for 
these conventional antiepileptics. This will help provide an evidence-based therapeutic 
recommendation for the epileptic syndromes studied. Clinically, however, it should 
always be remembered that therapeutic regimen should be specifically tailored 
towards each patient’s responses and form the basis of personalized medicine (Walker 
et al., 2015).  
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1.15 Non-pharmacological treatment of epilepsy 
 
1.15.1 Ketogenic diet 
 
The ketogenic diet is by far, the most well-known and well-studied non-
pharmacological intervention in epilepsy. It is a dietary intervention with the aim of 
increasing ketone bodies production; that surprisingly was found to have a capacity to 
control intractable seizure (Branco et al., 2016). The diet has been in use since 1921 
and is still in use in present days due to its time-tested efficacy, safety, and tolerability 
profile (Nordli and De Vivo, 1997). The classical ketogenic diet regime is highly 
restrictive, with ratios of fat to protein and carbohydrate combined of 3-4:1 with 
moderate energy restriction (Miranda et al., 2012). Since then, the regime has evolved 
to a more lax regimen such as the medium chain triglycerides (MCT) diet with 30 to 
60% of the energy obtained from MCT (Huttenlocher et al., 1971), the modified Atkins 
diet (Kossoff et al., 2006), and the low glycaemic index diet (Muzykewicz et al., 2009). 
Across the classical and the alternative diets, the efficacy is largely promising and 
supports the use of any of these diets in treatment of intractable epilepsy (Miranda et 
al., 2012). 
The ketogenic diet is traditionally used in childhood (Neal et al., 2008), although 
evidence has existed of efficacy in adults (Sirven et al., 1999). In patients with 
mitochondrial epilepsy, ketogenic diet was also reported to have efficacy. In a small 
study of paediatric population with mitochondrial epilepsy, 50 % of the patients were 
able to achieve seizure freedom with the diet (Kang et al., 2007). Furthermore, various 
case studies have reported on the success of seizure control in patients with 
mitochondrial epilepsy using the ketogenic diet (Martikainen et al., 2012; Steriade et 
al., 2014). These findings warrant further investigation into the efficacy of ketogenic 
diet as treatment of mitochondrial epilepsy.  
Despite the large clinical evidence on the efficacy of the ketogenic diet, the 
mechanisms whereby the diet exerts its anticonvulsant effects is largely unknown and 
controversial (reviewed elegantly in (Nylen et al., 2009) and (de Lima et al., 2014)). 
The mechanisms that will be largely discussed in this study arises from the findings 
that the medium chain fatty acid, decanoic acid, was able to inhibit epileptiform 
discharges acutely due to inhibition of the AMPA-R (Chang et al., 2015). This fatty acid 
was also found to modulate mitochondrial function by increasing mitochondrial 
complex I activity (Hughes et al., 2014). Furthermore, decanoic acid and also octanoic 
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acid were found to modulate astrocyte ketogenesis (Thevenet et al., 2016). Although 
all these findings are exciting, it should be recognized that many other hypothesis have 
been proposed for the mechanisms of ketogenic diet; such as the pH hypothesis, the 
metabolic hypothesis, the GABA shunt hypothesis, and the ketone hypothesis (Nylen 
et al., 2009).  
 
1.15.2 Surgical intervention 
 
As briefly mentioned above, surgical treatments do exist for patients with 
intractable epilepsy and these typically represent last-line treatment options for such 
patients (Engel, 2003). Surgical treatments in epilepsy have a promising degree of 
success with a randomized clinical trial reporting 70% of patients with early surgical 
intervention able to achieve seizure freedom (Engel et al., 2012). However, these 
surgical treatments largely depend on accurate localization of the seizure foci and may 
not be possible in patients where such foci are in the eloquent cortex. Furthermore, 
significant cognitive deterioration has been reported in some proportion of patients with 
epileptic surgery, even when such surgery afforded them seizure freedom (Baxendale, 
2008). The increasing use of advanced imaging techniques (Raybaud et al., 2006), 
brain stimulation (Jobst, 2010), and comprehensive pre-surgical 
electroencephalographic mapping (Zijlmans et al., 2007) have somewhat 
circumvented these issues but the surgical regime currently available is far from perfect 
and is not suitable for just any patients with epilepsy. 
No studies have been done on evaluating the use of surgical intervention for 
seizure control in patients with mitochondrial epilepsy. This is partly due to the difficulty 
in offering such option to these subset of patients as neurosurgical procedure requires 
general fitness and patients with mitochondrial disease tend to have multiorgan 
involvement. This would deem them an unsuitable patient group for surgical 
consideration.  
The use of surgical intervention in patients with neurological disorders (such as 
epilepsy and tumour) has provided neuroscientists with the potential of obtaining acute 
human brain samples removed from these surgeries. This has led to the development 
of an array of human brain slice electrophysiology studies (Jones et al., 2016), which 
provide strength in its direct examination of mechanisms specific to human.  
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1.15.3 Vitamin and supplements 
 
In patients with mitochondrial epilepsy, physicians tended to treat the epileptic 
syndrome as a holistic approach towards therapy for mitochondrial disease and in their 
therapeutic regimens, they may have resorted to the use of various nutritional 
supplements and vitamins (elegantly reviewed in (Parikh et al., 2009) and (Avula et al., 
2014)). These treatments are often referred to as ‘mitochondrial treatment cocktail’ and 
the most common starting composition are a combination of CoQ10 and a B vitamin 
(see Table 1-2) (Parikh et al., 2009). These vitamins and supplements have not been 
assessed for efficacy and safety in a rigorous controlled clinical trial.  The success in 
the use of these supplements, therefore, has largely been based on anecdotal 
evidence (Chinnery and Turnbull, 2001). Some have claimed that these supplements 
do not make a significant difference in patients with mitochondrial disease (Matthews 
et al., 1993); whereas others have praised its benefits and efficacy (Hargreaves, 2014). 
Regardless, until proper clinical guidance based on pre-clinical and clinical evidence 
is produced, physicians are going to continue treatment for their patients with the only 
treatment option that they can offer, which is a personalized mitochondrial treatment 
cocktail.  
Table 1-2 Typical composition of mitochondrial treatment cocktail.  Table adapted from (Parikh et al., 2009). 
Medication  Dosage 
(adult) 
Monitoring Adverse 
effects 
Comments 
CoQ10 as 
ubiquinol 
(preferred) 
50-600 mg po 
daily 
Pretherapy 
level and 
monitor 
CoQ1 level 
in 
leukocytes 
or plasma 
Wakefulness, 
disruption of 
sleep, may 
interfere with 
warfarin 
concentration 
Solubilized 
bioavailable 
formulation 
preferred. 
Absorption may 
improve when 
taken with meals 
CoQ10 as 
ubiquinone 
300-2400 mg 
po daily, 2-3x a 
day 
Pretherapy 
level and 
monitor 
CoQ1 level 
in 
Wakefulness, 
disruption of 
sleep, may 
interfere with 
warfarin 
concentration 
Solubilized 
bioavailable 
formulation 
preferred. 
Absorption may 
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leukocytes 
or plasma 
improve when 
taken with meals 
Riboflavin 
(B2) 
50-400 mg po 
daily 
Not usually 
done 
High doses 
may lead to 
anorexia and 
nausea 
Change urine color 
and smell; less 
effects by bedtime 
administration 
L-creatine 5 g po daily 1-
2x a day 
Renal 
function 
Gastrointestinal 
upset 
Primarily for 
myopathy patients 
L-arginine Acute stroke: 
500mg/kg IV 
per day for 1- 3 
days 
Maintenance: 
150-300mg/kg 
PO or IV daily 
2-3x a day 
Plasma 
arginine 
Hypotension 
(due to IV 
loading), 
hyponatremia, 
headache, 
nausea, 
diarrhea, 
myelinolysis 
(high dose) 
Used with 
metabolic strokes, 
particularly in 
MELAS or those 
with low-normal 
plasma arginine; 
citrulline is used as 
alternative in urea 
cycle defects 
L-carnitine 100-1000mg 
per dose, IV or 
po 2-3x a day 
Pretherapy 
free and total 
plasma 
carnitine  
GI upset, fishy 
odor, cardiac 
rhythm 
disturbances 
(in LCFA 
defects) 
Only 10-20% 
absorbed. Acetyl-
carnitine is an 
alternative 
B50 or 
B100  
1 tab po 1-2x a 
day 
Not done Toxic 
neuropathy 
(chronic large 
dose) 
Poor palatability 
Vitamin E 100-200 IU po 
daily 
Not done Possible 
cardiac risks 
at >400 IU/day 
Absorption may 
improve when 
taken with meals 
Vitamin C 50-200mg po 
daily 
Not done Increases iron 
absorption; 
high doses may 
Easily absorbed 
water-soluble 
vitamin 
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cause renal 
insufficiency 
Alpha-lipoic 
acid 
50-200mg/d Not done Not known None 
Folinic acid 
as 
leucovorin 
2.5-25mg po 
daily 1-2x a 
day 
Spinal fluid 
folate and 
plasma / 
urine 
pipecolic 
acid 
Rash and 
pruritus 
Cerebral folate can 
be replenished with 
L-leucovorin or 5-
methyl 
tetrahydrofolate.  
 
1.16 Working hypothesis to understand mitochondrial epilepsy 
 
Section 1.10 has outlined in detail the clinical features of mitochondrial epilepsy 
and subsequently, section 1.11 has reviewed currently available animal models for 
mitochondrial epilepsy. Whilst the clinical characteristics of mitochondrial epilepsy are 
relatively well studied, there is clearly a lack of animal models for mitochondrial 
epilepsy. This, in turn, leads to a lack of studies exploring the mechanisms behind the 
generation of mitochondrial epilepsy. Several reviews have attempted to address this 
by proposing various working hypothesis for the mechanisms underlying seizure 
generation in mitochondrial epilepsy (see one of the working hypothesis in Figure 1-28 
and for the reviews, refer to (Zsurka and Kunz, 2015) and (Rahman, 2015))). However, 
all the mechanisms proposed in these reviews are based on inferences and theoretical 
postulation of possible underlying defects in neurotransmission caused by the primary 
mitochondrial deficiency.  Very few experimental evidences have been provided to 
clearly support the mechanisms proposed. Therefore, more work needs to be done 
before such hypothesis on the pathophysiological mechanisms of mitochondrial 
epilepsy can be confidently used.  
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Figure 1-28 Current proposed working hypothesis for mechanisms underlying seizure generation in mitochondrial epilepsy.  
Reprinted from The Lancet Neurology, Volume 14, No 9, Zsurka G and Kunz WS, Mitochondrial dysfunction and seizures: the 
neuronal energy crisis, Pages 956-966, Copyright (2015), with permission from Elsevier.  
 
There are, however, several mechanisms that are agreed upon by both reviews 
on seizure generation in mitochondrial epilepsy. Both reviews agreed that there must 
be some form of energy deficiency in the brain following the primary mitochondrial 
defects (Rahman, 2015; Zsurka and Kunz, 2015). Furthermore, both reviews also 
alluded to oxidative stress as the primary source of disruption in neurotransmission 
that would lead to seizure generation (Rahman, 2015; Zsurka and Kunz, 2015). It is 
proposed that due to the sensitivity of inhibitory interneurons and the astroglial and 
neuronal glutamate transporters to oxidative stress; that this is a very likely scenario in 
patients with primary mitochondrial defects (Zsurka and Kunz, 2015). Again, however, 
experimental evidence has not arisen to support this mechanism and as such, to this 
present time, this working hypothesis is still a putative pathophysiological mechanism.  
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1.17 Oxidative stress in epilepsy 
 
As mentioned above, one of the mechanisms that is largely promising and agreed 
upon to be an important mechanism in seizure generation in mitochondrial epilepsy is 
oxidative stress (Rahman, 2012; Zsurka and Kunz, 2015). Oxidative stress is defined 
as the homeostatic imbalance where the production of reactive oxygen species (free 
radicals) could not be balanced with the antioxidant defence system (Betteridge, 2000). 
The major endogenous source of the reactive oxygen species is mitochondria, 
especially in those lacking the supercomplex organization (Ott et al., 2007; Maranzana 
et al., 2013).  
In the brain, under oxygen saturation, about 1% of the respiratory chain electron 
flow is redirected towards production of reactive oxygen species in the form of 
superoxide and this can largely be attributed to complex I – mediated respiration (Kudin 
et al., 2008). This is confirmed in a study using in situ mitochondria and further 
extended the finding to the TCA cycle α-ketoglutarate dehydrogenase as a potential 
source of reactive oxygen species that furthers the vicious cycle of oxidative stress  
(Adam-Vizi, 2005). Within the cellular population of the brain, mitochondrial 
supercomplexes of complex I is more frequently associated with neurons and so very 
few reactive oxygen species is produced by neuronal mitochondrial respiration (Lopez-
Fabuel et al., 2016). This is in direct contrast with astrocytes, where the predominating 
form of complex I is the free form, therefore, their mitochondrial respiration significantly 
generates reactive oxygen species (Lopez-Fabuel et al., 2016). However, this is 
balanced by the strong antioxidant defence mechanism in astrocytes, mediated by the 
Nrf2-regulated pathway (Baxter and Hardingham, 2016).   
Oxidative stress has been implicated in various neurological disorders, including 
epilepsy (Popa-Wagner et al., 2013). In epilepsy, oxidative stress has been implicated 
in various models of epilepsy and the quenching of oxidative stress was repeatedly 
reported in various antiepileptic mechanisms of action (Devi et al., 2008; Waldbaum 
and Patel, 2010; Shin et al., 2011). However, there remains no clear consensus on 
how oxidative stress can contribute towards seizure generation. Seizure-induced 
oxidative stress has been reported to damage almost every macromolecule in the brain, 
from proteins, lipids, mitochondria (and mitochondrial DNA), and antioxidant 
mechanisms (Waldbaum and Patel, 2010).  Therefore, the effect of oxidative stress 
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should probably be considered in the context of the individual model or characteristics 
of epilepsy in question. 
With regards to mitochondrial epilepsy, the only experimental evidence available 
to support the involvement of oxidative stress is the Sod2-/+ mice (Liang and Patel, 
2004). Their spontaneous epileptic phenotype was associated by the authors with 
mitochondrial aconitase inactivation due to superoxide damage (Liang and Patel, 
2004). Whilst this seems promising, this is a single study and a single evidence in an 
animal model that is not based on any clinical conditions. Therefore, very little can be 
said to confidently support that oxidative stress is indeed involved in mitochondrial 
epilepsy. However, this finding certainly provides promising evidence that oxidative 
stress may be associated with mitochondrial epilepsy.  
 
1.18 Aims  
 
The aims of this study are briefly summarized as follow: 
1. To develop a novel in vitro brain slice model of mitochondrial epilepsy based on 
the neuropharmacological framework as proposed in Figure 1-24. 
2. To examine the mechanisms underlying seizure generation in the model of 
mitochondrial epilepsy; utilizing various approaches such as 
electrophysiological, histopathological, and biochemical approach.  
3. To conduct extensive pharmacological study and screening using the 
developed novel in vitro brain slice model of mitochondrial epilepsy. 
 
These aims largely conform to the three overarching theme of this thesis on the 
understanding of the mitochondrial epilepsy: (1) the conceptualization of a new in 
vitro model of mitochondrial epilepsy, (2) the understanding of the mechanisms 
involved in seizure generation in mitochondrial epilepsy, and (3) the conduct of 
pharmacological study and screening to provide direct evidence-based 
recommendations and therapeutic implications.  
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Chapter 2 General methods 
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2.1 Animal provision 
 
Adult male Wistar rats aged 10-12 weeks were obtained from Charles River 
Laboratories Inc. and housed in the Centre for Comparative Biology at Newcastle 
University under standard housing conditions. For some experiments in this thesis, I 
have used adult male C57 Black 6 mice (C57BL/6) aged 8-10 weeks, obtained from 
the same supplier.  
Works presented in Chapter 5 were conducted at the University of Copenhagen. 
Adult male Wistar rats aged 10 weeks old were obtained from Charles River 
Laboratories Inc. and housed in the animal housing facility under standard housing 
conditions.  
 
2.2 Brain slice preparation 
 
All experimental and surgical procedures were carried out in accordance to the 
UK Animals (Scientific Procedures) Act 1986 with the approval of the Newcastle 
University Ethical Review Committee. All procedures were conducted under the 
following personal and project licenses granted by the UK Government Home Office: 
 Felix Chan : PIL no 1886FA8EB  
 Mark Cunningham : PPL no 60/4455 
 
For works conducted at the University of Copenhagen, all experimental 
procedures were in accordance with the Danish National Ethics Committee and the 
European Convention ETS 123 of 1986.  
 
2.2.1 Solutions for brain slice preparation 
 
Normal-artificial cerebrospinal fluid (nACSF) contained 126mM NaCl, 3mM KCl, 
1.25mM NaH2PO4, 1mM MgSO4, 1.2mM CaCl2, 24mM NaHCO3, and 10mM glucose. 
Sucrose-artificial cerebrospinal fluid (sACSF) had the same composition, except for 
2mM MgSO4 and 2mM CaCl2, and the substitution of equimolar 252mM sucrose for 
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the 126mM NaCl. All the salts used for the ACSF were obtained from VWR or Sigma 
Aldrich. 
 
2.2.2 Slice Preparation (for in vitro electrophysiology) 
 
Animals were given the inhaled anaethetic isoflurane (IsoFlo® - Abbott 
Laboratories Ltd UK). Following loss of consciousness, animals were injected 
intramuscularly with a mixture of ketamine (0.3 ml) (Narketan® 100mg/ml – Vetoquinol,  
UK) and xylazine (0.3 ml) (Xylacare® 20mg/ml – Animalcare, UK). Various reflexes 
were then assessed to measure depth of anaesthesia, including pedal withdrawal, tail 
pinch, and eye blink. Once reflexes disappeared, a midline incision was made across 
the abdomen. The diaphragm was sectioned to expose the heart. A catheter was 
inserted into the left ventricle and a small cut was made on the right atrium. 
Transcardial perfusion with ice-cold oxygenated (95% O2/ 5% CO2) sACSF was then 
conducted. The rat was then decapitated and the brain was extracted carefully and 
rapidly. The cerebellum was removed and the brain was sliced to 450μm thick slices 
along the horizontal axis using the 5100mz Vibratome (Campden Instruments, UK). 
Slices were then collected and trimmed down leaving behind the hippocampus and 
parahippocampal cortices. Slices were then transferred into a holding chamber and 
maintained at an interface between the nACSF and carbogen gas at room temperature 
for one hour to equilibrate.  
 
2.2.3 Slice Preparation (for metabolic studies) 
 
Animals were euthanized through decapitation using the guillotine. The head 
was immediately submerged in slushed sACSF saturated with carbogen gas (95% O2/ 
5% CO2). The brain was then extracted carefully and rapidly. The hippocampi were 
separated from the cortices through gentle manual dissociation using the spatula. The 
hippocampi were then dissected and sliced along the coronal axis into 350μm thick 
slices using a McIlwain tissue chopper (The Vibratome Company, USA). Slices were 
then separated under a dissecting microscope and four hippocampal slices were 
placed in each chamber (for details on the incubation system, see section 2.11). Slices 
were allowed to recover from slicing by incubation in nACSF for 30 minutes at 370C 
before any experimental manipulation.  
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2.3 Surgical human tissue collection and slice preparation 
 
For some experiments, I have used human cortical slices obtained from routine 
neurosurgical procedures using protocols as described previously (Roopun et al., 2010; 
Cunningham et al., 2012; Simon et al., 2014). Data from human slice studies presented 
in this thesis were obtained from 6 patients (two males; four females; mean age, 34.00 
± 4.50 years; range, 23-53 years; median 32.5 years); four of whom had medically 
intractable epilepsy and two of whom had peritumoural epilepsy; undergoing elective 
neurosurgical tissue resection. All patients had given their written informed consent, 
prior to the surgery, for use of the resected brain tissue. The study was approved by 
the County Durham and Tees Valley 1 Local Research Ethics Committee 
(06/Q1003/51; date of review 3 July 2006), and had clinical governance approved by 
the Newcastle upon Tyne Hospitals NHS Trust (CM/PB/3707). All aspects of the study 
conformed with The Code of Ethics of the World Medical Association (Declaration of 
Helsinki) as printed in the British Medical Journal (18 July 1964). Details on these 6 
patients are summarised in Table 2-1. 
 Human slices were obtained from material removed as part of the elective 
neurosurgical treatment of the various conditions as described. Anaesthesia induction 
was conducted with intravenous remifentanil with or without alfentanil (0.2-0.4 and 
1mg/kg respectively). Following the induction, a bolus dose of propofol (1-2 mg/kg) 
was administered intravenously. The patient also received the muscle relaxant, 
vecuronium (0.1mg/kg). After anaesthesia was established, it was maintained with 
remifentanil, oxygen, and desflurane at a minimum alveolar concentration volume of 
0.5-1.0. Resected tissue was immediately transferred to oxygenated ice-cold sACSF 
and transported to the laboratory with transport time of under 5 minutes. Neocortical 
slices were cut into 450μm thick slices using the Microm HM 650V vibratome (Thermo 
Fisher Scientific, UK). They were then incubated in the holding chamber containing 
nACSF at room temperature for an hour prior to any experimentation.  
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Table 2-1 Summary of patient information. 
No Age at 
surgery 
(years) 
Gender Seizure semiology Pathology Type of 
surgery* 
Brain region Surgical outcome Antiepileptic 
medication** 
1 25  F Complex partial 
seizures 
Mesial temporal 
sclerosis 
SAH Right temporal 
lobe 
Seizure-free with 
post-op 
nystagmus 
CBZ 
2 38 M Complex partial 
seizures 
Hippocampal 
sclerosis 
SAH Left temporal 
lobe 
Seizure-free VPA/ECBZ/LEV 
3 23 F Complex partial 
seizures 
Mesial temporal 
sclerosis 
SAH Left temporal 
lobe 
Seizure-free LEV 
4 29 F Complex partial 
seizures 
Mesial temporal 
sclerosis 
SAH Right temporal 
lobe 
Seizure-free LEV/LTG 
5 36 M Focal onset seizures Grade III anaplastic 
astrocytoma 
AL Left temporal 
lobe 
No reduction in 
seizure 
CBZ 
6 53 F Generalised 
seizures 
Glioblastoma 
multiforme 
FC Left frontal lobe Seizure-free PHT/CBZ 
 
* SAH – selective amygdalohippocampectomy, AL – anterior lobectomy, FC – frontal craniotomy. 
** CBZ – carbamazepine, VPA – valproate, ECBZ – eslicarbazepine, LEV – levetiracetam, LTG – lamotrigine, PHT – phenytoin
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2.4 Electrophysiological experiment setup 
 
Slices were placed in an interface recording chamber and maintained at 30-330C 
at the interface between nACSF and humidified carbogen gas. nACSF was circulated 
using a SciQ 400 series pump (Watson Marlow, UK) at a rate of 1-1.2 mls/min. Slices 
were allowed to adjust to the chamber condition for 30 minutes before any form of 
experiments were initiated.  
Extracellular electrodes were prepared by pulling micropipettes from a thin walled 
borosilicate glass pipette (1.2mm O.D. x 0.94 mm I.D. – Harvard Apparatus Ltd, UK) 
with a PP-83 puller (Narishige, Japan). Electrodes were filled with nACSF and placed 
in the stratum pyramidale layer of the CA3 subregion of the hippocampus (see section 
1.13) on the brain slice. Local field potentials (LFP) were recorded by the extracellular 
electrodes connected to a pre-amplifier EXT-10/2F headstage (npi electronic, 
Germany). The LFP was then band pass filtered between 10 Hz and 100 Hz by the AI-
2130 differential amplifier (Axon Instrument, Molecular Devices, USA). The mains 
electrical noise was eliminated from the recorded LFP by the Hum-Bug noise eliminator 
(Quest Scientific Instruments, Canada). The obtained analog signal was digitized at 5 
kHz by the ITC-16 multi-channel data acquisition interface (Digitimer, UK). The 
extracellular LFP was then recorded using the AxoGraph X software (Axograph 
Scientific, USA) recorded on a Macbook Pro computer (Apple, UK).  
 
2.5 Mitochondrial epileptic induction 
 
Following the 30 minute recovery period, 0.1mM fluorocitrate was applied to the 
circulating nACSF for one hour. Slices were then challenged via the circulating nACSF 
with 500nM rotenone (Sigma Aldrich, R8875) and 10μM potassium cyanide (Sigma 
Aldrich, 60178). Slices were monitored continuously for the presence of any epileptic 
activity using extracellular local field potential recordings.  
Fluorocitrate was prepared as described in previous publication (Paulsen et al., 
1987).  Briefly, 8mg of the fluorocitric acid barium salt (Sigma Aldrich, F9634) was 
weighed out and dissolved in 1ml of 0.1M hydrochloric acid (Sigma Aldrich, UK). A few 
drops of 0.1M sodium sulphate (Sigma Aldrich, UK) were added to precipitate the 
barium. 2ml of 0.1M Na2HPO4 (VWR UK) was added and they were then centrifuged 
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at 1000 x g for 5 minutes. The supernatant was then taken and the pH was adjusted 
to 7.4 before the volume was made up in 0.9% NaCl to 10ml. This created a 2mM stock 
solution of fluorocitrate. The stock solution was stored at 40C and used within a week 
of stock preparation.  
 
2.6 Data analysis 
 
Data were analysed off-line with Microsoft Excel (Microsoft Inc., USA), Matlab 
2010a (MathWorks, USA), and Prism 7.0 (GraphPad Software, USA). An automated 
script was written in Matlab (courtesy of Dr. Katherine Newling, see Appendix 1. Matlab 
Script) to automatically detect burst discharges by setting a threshold against which 
the software detects the discharges. A 10-minute portion of the recording was used in 
any one time and the value of burst frequency were expressed as the amount of 
discharges per minute. These values were then arranged in a tabular format and 
appropriate statistical analysis were conducted using Prism 7.0. Normality of the data 
was tested with the Shapiro-Wilk normality test. For experimental treatment with just 
two conditions, a paired t-test was performed for parametric data or Wilcoxon matched-
pairs signed rank test for non-parametric equivalent. When there are more than two 
conditions, a repeated-measure one-way analysis of variance (ANOVA) was 
performed for parametric data or Friedman test for non-parametric equivalent. If there 
is statistical significance, a post-hoc Sidak’s multiple comparison test was then 
performed. A p-value of <0.05 was taken as significant.  
 
2.7 Drugs 
 
The following table lists the drugs used in this thesis for the in vitro 
electrophysiology experiments (see Table 2-2). Whenever possible, stock solutions of 
all drugs were prepared by dissolving in distilled H2O. Otherwise, drugs were dissolved 
in DMSO (Sigma Aldrich UK) with a final concentration of <1% v/v. Stock solutions 
were either kept at 40C or frozen at -200C in aliquots as per instructions from the 
supplier. 
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Table 2-2 List of drugs used for in vitro electrophysiology experiments. 
Drug Name Supplier Supplier Product Code 
Fluorocitric acid barium salt Sigma Aldrich F9634 
Rotenone Sigma Aldrich R8875 
Potassium cyanide Sigma Aldrich 60178 
MPP+-iodide Sigma Aldrich D048 
Sodium azide Sigma Aldrich 52002 
NBQX Abcam AB120045 
DAP-V Abcam AB120003 
Gabazine HelloBio HB0901 
Carbamazepine Tocris 4098 
Lamotrigine Sigma Aldrich L3791 
Levetiracetam Sigma Aldrich L8668 
Valproate acid Sigma Aldrich P4543 
Diphenylhydantoin  Sigma Aldrich D4505 
Midazolam Tocris 2832 
Lorazepam Sigma Aldrich L1764 
Sodium pentobarbital Sigma Aldrich P3761 
Perampanel Eisai A gift from Eisai 
Decanoic acid Sigma Aldrich C1875 
Nonanoic acid Sigma Aldrich N29902 
Octanoic acid Sigma Aldrich O3907 
GABA Tocris 0344 
L-glutamine Sigma Aldrich G3126 
L-glutamic acid Sigma Aldrich G1251 
Αlpha-ketoglutaric acid Sigma Aldrich K1128 
DL-β-hydroxybutyrate Sigma Aldrich H6501 
Glucose VWR  10117HV 
Sodium pyruvate Acros Organics A0327931 
D-Lactate Sigma Aldrich 71716 
Coenzyme Q10 Abcam AB143173 
Bezafibrate Sigma Aldrich B7273 
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2.8 Immunohistochemistry 
 
Slices that had been used for electrophysiological recordings were fixed in 4% 
paraformaldehyde (PFA) in 0.1M phosphate buffered saline (PBS) at the end of the 
recordings and stored at 40C. Control slices that had been incubating in the holding 
chamber for the same duration of time were also fixed. These slices were used for 
post-hoc immunohistochemistry (see Figure 2-1) to examine the cellular population in 
the tissue following electrophysiological experiments.  
A day prior to use, slices were removed from the PFA and placed in a 30% 
sucrose in Tris-buffered saline (TBS) solution for cryoprotection overnight. Slices were 
then resectioned to 40μm thick sections using a freezing stage microtome (Shandon 
Life Sciences International, UK). Slices were placed in a 24 well-plate in TBS in a 
sequential order (5 wells for each slice). This allows an equal distribution of the dorsal 
and ventral portion of the slices in each well. Antigen retrieval was conducted by two 
5-minute incubations in microwave-boiled 50mM sodium-citrate solution at pH 6.0. This 
was then followed by 3xTBS washes. Endogenous peroxidase activity was quenched 
by an hour incubation in 0.3% hydrogen peroxide (H2O2) in 70% methanol in TBS 
solution at room temperature. After another 3xTBS washes, sections were incubated 
in a 1% casein (FisherScientific, UK) in TBS solution for an hour for a non-specific 
binding block. This was then followed by 3xTBS washes and sections were then 
permeabilized by incubation in 0.05% Tween in TBS solution for 10 minutes. Following 
this, sections were then incubated in the primary antibody diluted in TBS with 5% 
normal serum (Vector Laboratories, UK) and 0.05% Tween. The choice of the serum 
depends on the secondary antibody used to detect the primary antibody binding and 
can either be normal goat, horse, or rabbit serum. The primary antibody was diluted 
according to the appropriate dilution factor as described in Table 2-3. 
Table 2-3 List of primary antibodies used in this thesis. 
Target protein Supplier Product code Host species Dilution 
NeuN Merck Millipore ABN90P Guinea pig 1:1000 
GABA Sigma Aldrich A0310 Mouse 1:1000 
CaMKII Abcam AB52476 Rabbit 1:1000 
GFAP Merck Millipore AB5804 Rabbit 1:1000 
PV Sigma Aldrich P3088 Mouse 1:1000 
CB Swant CB38 Rabbit 1:10,000 
CR Swant CG1 Goat 1:1000 
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 Following the overnight incubation, sections were then incubated for 2 hours at 
room temperature on a rocking platform. Sections were then washed with 3x TBS 
washes and incubated in the appropriate secondary antibodies (see Table 2-4) diluted 
to 1:200 in 0.05% Tween in TBS solution for 2 hours at room temperature. Sections 
were then, again, washed with 3x TBS washes and incubated in horseradish 
peroxidase (Ready-To-Use Streptavidin Horseradish Peroxidase, VectorLabs, UK) for 
2 hours at room temperature. Following yet another 3x TBS washes, the chromogenic 
reaction was then developed using DAB (SigmaFast® DAB tablets, Sigma Aldrich, UK) 
for 5 minutes before being washed with 3x TBS washes. Sections were then mounted 
onto gelatine-subbed glass slides (FisherScientific, UK). After air-drying overnight, 
slides were washed in distilled water and sections were then dehydrated by incubation 
in sequential ethanol concentration gradients; starting from 70%, 95%, and 100%; 
each for 5 minutes each, with a further 5 minutes in another 100% ethanol gradient. 
Sections were then bathed in Histoclear (National Diagnostics, USA) for 5 minutes 
twice before being coverslipped using DPX Mounting Media (FisherScientific, UK).  
Table 2-4 List of secondary antibodies used in this thesis. 
Antibody Supplier Product code 
Biotinylated goat-anti rabbit IgG antibody Vector 
Laboratories 
BA-1000 
Biotinylated horse-anti mouse IgG antibody Vector 
Laboratories 
BA-2000 
Biotinylated goat-anti guinea pig IgG antibody Vector 
Laboratories 
BA-4000 
 
 Unless otherwise mentioned, all the reagents used here were obtained from 
Sigma Aldrich, UK. Tris-buffered saline (TBS) contains 0.06% Trizma® base and 0.85% 
NaCl and is pH adjusted to 7.4.  
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Figure 2-1 Flowchart of the standard immunohistochemistry protocol. 
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2.9 Microscopy, data acquisition, and data analysis 
 
Microscope slides were visualized under stereology light microscope Olympus 
BX51 (Olympus Corporation, UK). The software Stereo Investigator (MBF Bioscience, 
USA) was used to analyse and perform the cell count. An outline was drawn at 2.5x 
magnification around the hippocampus CA3 and the area of the region was calculated. 
A meander scan was then performed at 20x magnification that allowed sequential 
scanning and counting of each portion of the region until the whole region was counted. 
The entire cell population was sampled according to the criteria of a clear and visible 
nuclear and cytoplasmic profile. This cell count was then divided by the area of count 
to generate the cell density (cells/mm2). Statistical analysis was then conducted using 
Prism 7.0. Normality of the data was tested with the Shapiro-Wilk normality test. For 
experimental treatment with just two conditions, an unpaired t-test was performed for 
parametric data or Mann-Whitney test for non-parametric equivalent. When there are 
more than two conditions, a one-way analysis of variance (ANOVA) was performed for 
parametric data or Kruskal-Wallis test for non-parametric equivalent. A p-value of 
<0.05 was taken as significant.  
 All of the images presented in this thesis were taken using a camera attached to 
the microscope (Nikon Instruments, Japan) and using the software Picture Frame 
(Softonic, Spain). When necessary, for aesthetic purposes, images were processed 
using Adobe Photoshop CC 2014 (Adobe, USA).  
 
2.10 Measurement of carbonylated protein 
 
Protein carbonylation is a process of protein oxidation that is promoted by the 
process of oxidative stress, and hence, it can be indicative of oxidative damage in the 
tissue (Suzuki et al., 2010). Carbonylated proteins can be derivatised by 2,4-
dinitrophenylhydrazine (DNPH) to form hydrazones that are detected using a 
colorimetric assay (Levine et al., 1994).  
Following electrophysiological recording in which epileptic activity was induced, 
brain slices were homogenized using a T-18 digital Ultra-Turrax® blender (IKA 
Labortechnik, Germany) through a 3 x 15 seconds blending on ice, with 30 seconds 
break between each blend. To obtain an adequate protein yield, four brain slices were 
pooled together and homogenized in 1ml of ice-cold MES buffer, containing 50mM 2-
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(N-morpholino)ethanesulfonic acid (MES), 1mM ethylenediaminetetraacetic acid 
(EDTA), 1% Tween-20, 1mM phenylmethylsulfonyl fluoride (PMSF), and 1x protease 
inhibitor cocktail. All reagents for the buffer were obtained from Sigma Aldrich, UK. 
Homogenate was then centrifuged at 10,000 x g for 10 minutes at 40C and the 
supernatant was taken. To remove the nucleic acids that may interfere with the assay, 
1% streptomycin sulphate (Sigma Aldrich, UK) was added and the mixture was 
incubated at room temperature for 15 minutes. Samples were then centrifuged at 6,000 
x g for 10 minutes at 40C. The supernatant was taken, snap-frozen in liquid nitrogen, 
and stored in -800C until processed.  
On the day of processing, samples were thawed and 200μl of the samples were 
transferred to two tubes: the sample (S) and control (C) tubes. Into the sample tubes, 
800μl of DNPH (Sigma Aldrich, UK) was added and into the control tubes, the same 
amount of 97% phosphoric acid (Sigma Aldrich, UK) was added. Both tubes were 
incubated in the dark for an hour and vortexed every 15 seconds to allow the 
derivatisation of the DNPH onto the carbonylated side chains. Into both tubes, 1 ml of 
20% trichloroacetic acid (Sigma Aldrich, UK) was then added and incubated on ice for 
5 minutes. Following centrifugation at 10,000 x g for 10 minutes at 40C; the supernatant 
was discarded and the pellet was resuspended in 1 ml of 10% trichloroacetic acid. 
Again, the tubes were incubated on ice for 5 minutes, centrifuged at 10,000 x g for 10 
minutes at 40C, and the supernatant was discarded. Then, the pellets underwent 3 x 
wash using a 1:1 ethanol / ethyl acetate mixture. Each wash involved resuspending 
pellets in 1 ml of the mixture, a vortex, and centrifugation at 10,000 x g for 10 minutes 
at 40C. After the final wash, pellets were resuspended in 500μl of 6M guanidine 
hydrochloride (Sigma Aldrich UK). Tubes were then centrifuged at 10,000 x g for 10 
minutes at 40C and 220μl of the supernatant was then put onto a 96-microwell plate to 
have their absorbance read at 360-385nm using the SpectraMax M3 plate reader 
(Molecular Devices, USA). The absorbance was then corrected by subtracting the 
control absorbance from the sample absorbance for each sample. Using the following 
equation, the value of the protein carbonyl was calculated.  
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑎𝑟𝑏𝑜𝑛𝑦𝑙 (
𝑛𝑚𝑜𝑙
𝑚𝑙
) = [
(𝐶𝐴)
0.011 𝜇𝑀−1
] (
500 𝜇𝑙
200 𝜇𝑙
) 
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The value for each sample was then normalized against the protein concentration. 
This was measured using a standard protein assay with the Bio-Rad Protein Assay Kit 
(Bio-Rad, USA). The values were tabulated and statistical analysis was performed as 
described in section 2.9.  
 
2.11 Brain slice incubation for metabolic mapping 
 
Following the brain slice preparation as described in section 2.2.3, slices were 
incubated in a specialized incubation system according to McNair et al (McNair et al., 
2016). The incubation system contains 9 incubation chambers, which holds a basket 
each whereon four hippocampal slices were placed. The baskets were placed at the 
interface of 10 ml nACSF which was pre-heated to 370C and equilibrated with 
humidified carbogen gas (5%CO2/95%O2). Following that, 0.1mM fluorocitrate was 
added to the nACSF and incubated for 30 minutes. Afterwards, 500nM rotenone and 
10μM potassium cyanide was added to the nACSF and further incubated for another 
30 minutes. This pre-incubation resembled the protocol described in section 2.5 and 
so, the slices were considered to be ‘epileptic’ at this stage of the incubation. ‘Control’ 
slices were exposed to vehicles instead of the epileptogenic compounds.  
Slices were then gently rinsed with glucose-free nACSF before they were 
transferred to the incubation medium and left to incubate for one hour. Incubation 
medium consisted of nACSF containing the 13C-labelled substrates (see Table 2-5) in 
addition to either the vehicles or the epileptogenic cocktail mixture, depending on the 
condition. In the case of conditions with the 13C-glucose, the unlabelled glucose in the 
nACSF was replaced with the labelled glucose. Incubations were terminated after one 
hour by removing the basket, gently rinsing with ice-cold glucose-free nACSF, and 
submerging them in 5 ml of ice-cold 70% ethanol.  
Table 2-5 List of isotopes used in this thesis. 
13C substrates Supplier Product code Concentration 
D-glucose (U-13C6, 99%) Cambridge Isotope 
Laboratories 
CLM-1396 10mM 
L-glutamic acid (U-13C6, 
99%)  
Cambridge Isotope 
Laboratories 
CLM-1800 0.5mM 
L-glutamine                                 
(U-13C6, 99%) 
Cambridge Isotope 
Laboratories 
CLM-1822 2.5mM 
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 The slices were removed from the basket and homogenized in the ethanol using 
the VibraCellTM ultrasonicator (400W model, Sonic & Materials Inc, USA). 
Subsequently, the samples were centrifuged at 20,000 x g for 20 minutes at 40C to 
separate the denatured protein. The supernatant was taken as the extract sample and 
stored at -800C until freeze drying was performed. The pellets were dried at room 
temperature overnight, reconstituted in 500µl 1M KOH for at least 8 hours, and 
subjected to protein determination using the Pierce BCA Protein assay-kit (Thermo 
Fisher Scientific, USA) as per the supplier’s instruction. Lactate release from the slices 
was measured in the incubation media using a lactate assay-kit (R-Biopharm AG, 
Germany) as per the supplier’s instruction.  
 
2.12 Gas chromatography – mass spectrometry analysis  
 
Gas chromatography – mass spectrometry (GC-MS) is used to detect the 
incorporation of 13C-labelling in various metabolites, including amino acids, lactate and 
alanine, and TCA cycle intermediates using an established protocol (Walls et al., 2014; 
McNair et al., 2016). Briefly, the extracts were freeze-dried and reconstituted in distilled 
water. An aliquot was taken and acidified using hydrochloric acid to pH 1-2 and dried 
under nitrogen gas flow. Metabolites then underwent extraction into 200µl of an organic 
phase consisting of 96% ethanol twice. 200µl of benzene was added to the combined 
organic phases before subsequent drying under nitrogen gas flow. Extracts were then 
reconstituted in N,N-dimethylformamide (DMF) (Sigma-Aldrich, USA) and N-tert-
butyldimethylsilyl-N-methyl-trifluoroacetamide (MTBSTFA) (Sigma Aldrich, USA) was 
utilized to derivatise the metabolites. The analyses were conducted on an Agilent 
Technologies 7820A chromatograph, J&W GC column HP-5MS, parts no. 19091S-433 
coupled to a mass spectrometer (Agilent Technologies 5977E, USA). Gas 
chromatography separates the metabolites by their boiling point and once each 
metabolite is isolated, they go through mass spectrometry to measure the mass of the 
metabolites as an indication of the 13C-labelling incorporation (see Figure 2-2).  
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Figure 2-2 An example of a gas chromatograph and mass spectrometry analysis. Shown in (A) is an example of a gas 
chromatogram and the site within the trace that corresponds with the retention time of characterized metabolites. In (B), an 
example of a mass spectrum of an isolated metabolite is shown (left) and the m/z ratio was calculated to show the distribution 
of the relative abundance of the 13C labelling (middle and right). In this example, 260.0 corresponds to the mass of the 
unlabelled molecule (M),  261.0 suggests incorporation of one carbon of the 13C-labelled substrates in the metabolite (M+1), 
262.0 has two (M+2), and 263.0 has three (M+3). Modified with permission from (Walls et al., 2014) 
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 The most abundant isotope of carbon in nature has an atomic mass of 12. 
Carbon-13, on the other hand, only constitutes 1.1% of the naturally occurring carbon. 
13C-labelled substrates have had one or more of the carbon atom modified so that they 
have an extra mass of 13. In uniformly labelled ([U-13C])-substrates, all the carbon 
atoms within that molecule are 13C atoms. Therefore, for [U-13C]-glucose, for instance, 
all six carbon atoms in the glucose are 13C atoms. Following metabolism of the labelled 
substrates, these 13C atoms can be incorporated into various metabolites (see Figure 
2-3 and Figure 2-4) and hence, they can be tracked by measuring the mass of the 
metabolites in the sample. Each metabolite can theoretically be labelled by none or 
any number of the 13C carbon atom. A non-labelled metabolite is the molecular ion (M) 
in the mass spectrum with its actual molecular mass. Each additional 13C carbon-atom 
incorporation gives rise to an increase in mass by 1 as compared to the molecular ion 
(M+1, M+2, M+3, etc). These are collectively called the isotopologues of the given 
metabolite. 13C-labelling data were corrected for natural abundance of 13C (1.1%) by 
subtracting the mass distribution of a non-labelled standard containing the relevant 
metabolites. The percentage of the 13C labelling was then calculated as described in a 
previous publication (Walls et al., 2014).  
These percentage values were then arranged in a tabular format and appropriate 
statistical analysis were conducted using GraphPad Prism 7.0. Normality of the data 
was tested with the Shapiro-Wilk normality test. For experimental treatment with two 
conditions, multiple unpaired t-test was performed with Holm-Sidak correction for 
parametric data or Mann-Whitney test for non-parametric equivalent. In the case of 
more than two conditions, a one-way analysis of variance (ANOVA) was performed for 
parametric data or Kruskal-Wallis test for non-parametric equivalent. If there is 
statistical significance, a post-hoc Sidak’s multiple comparison test was then 
performed. A p-value of <0.05 was taken as significant. 
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Figure 2-3 Incorporation of 13C into various metabolites following [U-13C]-glucose metabolism.  Each circle represents a carbon 
atom. White circles represent 12C and coloured circles represent 13C. In particular, red circles represent the carbon atom from 
the metabolism of [U-13C]-glucose and green circles represent carbon atoms from labelled acetyl-CoA introduced on the second 
turn of the TCA cycle. 1-T are molecules that could come about from the first turn of the TCA cycle and 2-T are molecules that 
could come about from the second turn of the TCA cycle. For example, on the first turn of the TCA cycle, one can only anticipate 
M+2 glutamate, whereas on the second turn, one can anticipate either M+3 or M+4 glutamate. This allows accurate dissection 
of the labelling from the first or second turn of the TCA cycle. 
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Figure 2-4 Incorporation of 13C into various metabolites following [U-13C]-glutamate or [U-13C]-glutamine metabolism. Each 
circle represents a carbon atom. White circles represent 12C and coloured circles represent 13C. Patterned red circles represent 
molecules that enter the second turn of the TCA cycle via GABA.  1-T are molecules that could come about from the first turn 
of the TCA cycle and 2-T are molecules that could come about from the second turn of the TCA cycle. Circle with the TCA label 
represents entry into the TCA cycle in the neuronal compartment.  
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2.13 High performance liquid chromatography analysis 
 
To quantify the pool of amino acids, reversed-phase high performance liquid 
chromatography (HPLC) was performed to separate the amino acids by polarity using 
an Agilent ZORBAX Eclipse plus C18 column (4.6 x 150mm, particle size 3.5µm; 
959963-902, Agilent Technologies, USA). The HPLC included pre-column online o-
phthaldialdehyde derivatization and fluorescence detection (338nm, 10nm bandwidth, 
and reference wave-length 390, 20nm bandwidth) using an Agilent 1260 Infinity system 
coupled to a 1260 Infinity fluorescence detector (McNair et al., 2016).  
 A mobile phase gradient that consisted of a mixture of mobile phase A (10mM 
Na2HPO4; 10mM Na2B4O7, pH 8.2; 5mM NaN3) and mobile phase B [45% acetonitrile : 
45% methanol : 10% water (v:v:v)] was utilized. The percentage of mobile phase B 
was increased linearly from 2 to 57% within 30 minutes, and from 57 to 100% in 6 
seconds and returned again to 2% in 3.5 minutes; giving a total run time of 35 minutes. 
The flow of the mixed mobile phases was continuously maintained at 1.5 ml/minute. 
The separation of the amino acid was conducted according to the method supplied by 
the Agilent application note (Henderson and Brooks, 2010) and modified accordingly 
to separate the amino acids of interest (see example chromatogram in Figure 2-5). The 
amount of the amino acids was quantified by comparing the measured value against a 
standard curve generated by parallel injection of a mixture of amino acids of interest 
at increasing known concentrations.  
Again, the data was tabulated and statistical analysis was conducted using 
GraphPad Prism 7.0 as described in section 2.9. 
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Figure 2-5 An example of a chromatogram with amino acids of interest.  Amino acids are separated by polarity and by 
comparing the retention time in the trace against the standard, the locations of the amino acids are determined.  
  
2.14 Magnetic-activated cell sorting 
 
In order to probe the metabolism of specific cellular compartments, a novel 
method was devised utilizing magnetic-activated cell sorting (MACS) technology to 
acutely isolate specific cellular populations from the hippocampus. Since the 
mitochondrial epilepsy induction depends on the specific inhibition of astrocytic 
aconitase, it is imperative to assess the state of mitochondrial respiration in neurons 
and astrocytes separately. To isolate the neurons, the anti-PSA-NCAM microbeads 
(Miltenyi Biotec, Germany, 130-092-966) was used and for the astrocytes, the anti-
GLAST (ACSA-1) microbeads (Miltenyi Biotec, Germany, 130-095-826) was used. 
Animals were sacrificed through transcardial perfusion as described in section 
2.2.2 and after the brain was removed from the skull, the two hippocampi were gently 
dissociated from the cortices using a spatula and the net weight of the tissue was 
determined. A net wet weight of circa 180-250mg of tissue was obtained per animal 
preparation from the two hippocampi. To dissociate the tissue, I used the Neural Tissue 
Dissociation Kit - Trypsin (Miltenyi Biotec, Germany, 130-093-231) and the 
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gentleMACS dissociator (Miltenyi Biotec, Germany, 130-093-235). Dissociation was 
performed as per the instruction on the kit.  
After obtaining the cell lysate, the neuronal compartment was separated first. The 
process involved the use of the miniMACS separator (Miltenyi Biotec, Germany, 130-
042-102) and the corresponding MS column (Miltenyi Biotec, Germany, 130-042-201) 
to separate the cells. Briefly, the cells were centrifuged at 300 x g for 10 minutes at 
40C and resuspended in the MACS buffer (0.1M PBS (Sigma Aldrich, UK) with 0.5% 
bovine serum albumin (BSA) (Sigma Aldrich, UK), pH 7.2). After incubating for 10 
minutes at 40C, the cells were labelled with the anti-PSA-NCAM Microbeads and 
incubated for 15 minutes at 40C. The cells were then washed with MACS buffer and 
centrifuged at 300 x g for 10 minutes. The supernatants were removed and the pellets 
were resuspended in MACS buffer before being passed through the column that has 
been placed in a magnetic field. The flow-through was collected as the negative 
fraction and then, the cells were then eluted from the column as the neuronal fraction. 
The negative fraction was then reprocessed to separate the astrocytes from the 
fraction. The cells were first labelled with the anti-GLAST (ACSA-1) -biotin microbeads 
as above and then, using the secondary anti-biotin microbeads. The incubation, wash, 
and separation process were similar to the neuronal process, as described above. The 
cells eluted from this column were then collected as the astrocytic fraction.  
 
2.15 Measurement of metabolic fluxes using Seahorse XF24 
 
The neurons and astrocytes isolated by the process outlined in section 2.14 were 
used for metabolic flux measurement using Seahorse XF24 Analyzer (Agilent 
Technologies, USA). Firstly, the Seahorse XF24 Cell Culture Microplates (Agilent 
Technologies, USA) were coated with 22.4µg/ml Cell-Tak (Corning, USA) made up in 
sterile 0.1M NaHCO3 (Sigma Aldrich, UK) and alkalinized with 1M NaOH. The plates 
were incubated for 30 minute at room temperature and the plates were washed in 
distilled H2O to remove the bicarbonate. The cell fraction was centrifuged at 10,000 x 
g for 30 seconds at 40C and resuspended in the 370C Seahorse media. Seahorse 
media consisted of Dulbecco’s Modified Eagle’s Medium (Sigma Aldrich, UK) 
resuspended according to the manufacturer’s instructions and supplemented with 
10mM D-glucose (Sigma Aldrich, UK) and 5mM pyruvate (Acros Organics, UK). Cell 
viability was determined using the tryptan blue cell viability assay and counted using 
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the automated cell counter Cellometer® Auto1000 (Nexcelom Biosciences, UK). The 
cells were then seeded at 300,000-400,000 cells/well. The plate was then centrifuged 
at   200 x g for 1 minute with zero deceleration. The plate was then incubated at 370C, 
0% CO2, for 30 minutes.  
The Seahorse media was then supplemented with 3% fetal bovine serum (FBS) 
(Sigma Aldrich, UK) to create the experimental media. The elimination of FBS in the 
original seeding media was due to the interference from FBS in the cell adherence to 
the Cell-Tak coated surfaces. The experimental media was then supplemented with 
experimental treatments as necessary. With each experiment, around 10 wells of each 
cell population can be obtained. Two treatment conditions are then usually tested per 
each cell population. Each experiment also involve a cartridge which can hold four 
pharmacological treatments (Port A, B, C, and D) which would be injected into the 
media consecutively according to the protocol (see Chapter 6 for more details). Once 
the run has finished, the media was aspirated and the cells were fixed in 4% PFA for 
30 minutes. Plates were washed with 0.1M PBS and stored at 40C until processing.  
 
2.16 Post-hoc immunofluorescence 
 
To visualize the cells that had undergone measurement of metabolic fluxes using 
Seahorse XF24, all of the wells on the plates were stained using a Hoechst stain 
bisbenzimide 2.5μg/ml in TBS (H33258, Sigma Aldrich, UK) for 30 minutes. The cells 
were then washed with TBS and visualized immediately under the inverted microscope 
Axiovert 200M (Zeiss, UK) with a fluorescent bulb HBO100 (Zeiss, UK) at excitation 
wavelength of 346nm and emission at 460nm.  Images were taken at 4x magnification 
at four pre-determined sites in each well (see Figure 2-6).  
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Figure 2-6 Seahorse plate layout and sites for image acquisition for cell counting.  Shown on top left corner is a typical layout 
of a Seahorse XF24 well plate and four sites were chosen for image acquisition as shown on the zoomed-in diagram of the well 
on the top left corner. Images 1 to 4 corresponds to an example of images taken from the four sites of a well of the XF24 plate. 
Scale bar 10μm.  
  
A Matlab script (courtesy of Stacey Aston, see Appendix 1. Matlab Script) was 
written to perform an automated cell count using threshold detection analysis on these 
images. An average was calculated for each well and using the ratio of the area of the 
visual field against the area of each well, the value was extrapolated to provide an 
estimate of the cell count in the whole well. Using the viability data from the tryptan 
blue assay, a viable cell count was obtained for each well (assuming that viability is 
equal across all wells with the same sample). The value for the Seahorse recording as 
conducted in section 2.15 was then normalized against the viable cell count.  
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Chapter 3 Developing an in vitro brain slice model of mitochondrial 
epilepsy 
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3.1 Introduction 
 
About a quarter of the patient population with mitochondrial disease develop 
epilepsy (Whittaker et al., 2015). Their epilepsy can virtually manifest in any seizure 
semiology and combinations; although classical absence seizures appear very rarely 
(Bindoff and Engelsen, 2012). Epilepsy can also be seen across multiple genotypes 
and phenotypes; with the most common syndromes associated with epilepsy reported 
to be the myoclonus epilepsy with ragged red fibres (MERRF) syndrome and the 
mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) 
syndrome (Bindoff and Engelsen, 2012; Whittaker et al., 2015). Furthermore, this 
epilepsy; the mitochondrial epilepsy; almost always never respond to traditional 
antiepileptic drugs and patients tend to deteriorate very rapidly with poor prognosis 
(Bindoff and Engelsen, 2012). Despite the severity of mitochondrial disease, very few 
animal models have been developed for the disease and the few models that were 
developed never phenotypically manifest as epilepsy (Tyynismaa and Suomalainen, 
2009; Dunn et al., 2012; Farrar et al., 2013); reflecting the poor representation of 
mitochondrial disease phenotypes in these animal models.  
Clearly, a fresh approach is required in developing a model of mitochondrial 
disease; particularly of mitochondrial epilepsy. A recent post-mortem 
neuropathological study on the investigation of neocortices of patients with 
mitochondrial epilepsy has shown profound interneuron loss as well as the extreme 
global loss of expression of mitochondrial complex I subunits and to a lesser degree, 
complex IV (Lax et al., 2016). The author of this study further extended this finding to 
the demonstration of profound astrogliosis in the neocortex of these patients as well 
as a similar degree of complex I and complex IV loss in the astrocytes (Lax et al., 
unpublished data; see Figure 3-1). Astrogliosis was indeed seen in some population 
of patients with mitochondrial disease (Sandbank and Lerman, 1972; Navarro-Sastre 
et al., 2011); although it has not been previously investigated in the context of 
mitochondrial epilepsy.  
This neuropathological finding, for the first time, implicated both the astrocytic 
and the neuronal compartment, in mitochondrial epilepsy. It is well demonstrated that 
the addition of high concentrations of complex I or complex IV inhibitors in acute brain 
slices alone did not cause epileptiform discharges in the hippocampal network 
recordings; despite a severe reduction in the interneuron firing rate and subsequent 
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disinhibition in the neuronal network (Kann et al., 2011; Whittaker et al., 2011). This 
indicates that the mere inhibition of mitochondrial complex I and IV using 
pharmacological tools is insufficient to modify the network into an epileptic state. 
Perhaps, an additional manipulation of astrocytic mitochondrial function is necessary 
for the generation of epileptiform discharges.  
With that in mind, there are very few pharmacological tools that specifically 
modulate astrocytic function. One of the few pharmacological tools that existed is the 
Krebs cycle inhibitor, fluorocitrate. Fluorocitrate is a well-characterized selective 
inhibitor of the astrocytic aconitase, an enzyme involved in the Krebs cycle in the 
conversion of citrate to isocitrate (Hassel et al., 1992; Swanson and Graham, 1994). It 
owes its selectivity to the preferential uptake of fluorocitrate by the glial cells (Fonnum 
et al., 1997).  
Taking all this into consideration, I combined the acute application of the 
astrocytic aconitase inhibitor, fluorocitrate, with the mitochondrial respiratory chain 
complex I and IV inhibitors, rotenone and potassium cyanide respectively, onto 
hippocampal brain slices to examine if this combination would generate epileptiform 
discharges. To validate the findings, all the exposed tissues were fixed in 
paraformaldehyde following the termination of the experiments and pathological 
studies are conducted to examine and compare the neuropathological results with the 
respective human neuropathological findings.  
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Figure 3-1 There is extensive astrogliosis and respiratory deficient astrocytes in the temporal cortex of patients with 
mitochondrial epilepsy.  Shown in (A) is the immunostaining for glial fibrillary acidic protein (GFAP) in temporal cortex of a 
patient with mitochondrial epilepsy. The pattern of staining showed extensive reactive astrogliosis. In (B), a quadruple 
immunofluorescence assay was performed to evaluate the complex I and complex IV subunit expression within the 
mitochondria of the astrocytes. There was severe complex I deficiency and a subtler complex IV deficiency in the astrocytes of 
patients with mitochondrial epilepsy phenotype. Scale bar in (A) indicates 100µm. Image courtesy of Nichola Lax, unpublished 
data from an ongoing study. 
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3.2 Methods 
 
Acute hippocampal slices were prepared from adult male Wistar rats and 
maintained as described extensively in Chapter 2. The combination of the three 
pharmacological agents (fluorocitrate, rotenone, and potassium cyanide) at the specific 
pro-convulsant concentration make up what was eventually known and described in 
the remainder of this thesis as the mitochondrial induction protocol (see section 2.5). 
For validation of the model, the concentration of these inhibitors was titrated higher to 
examine the impact of complete mitochondrial respiratory chain inhibition on the 
epileptic phenotype. Furthermore, to see if the protocol is specific to the respiratory 
chain inhibitors; an experiment substituting each of the respiratory chain inhibitors 
(rotenone and potassium cyanide) with their respective substitutes (MPP+ and sodium 
azide respectively) was performed. The protocol was also applied to mice brain slices 
and human brain slices as will be discussed below. Quantification was conducted as 
detailed in section 2.6.  
Subsequent to the termination of the electrophysiological experiments, these 
slices were fixed in 4% paraformaldehyde and post-hoc immunohistochemistry was 
performed as described in section 2.8. Slices were stained for various neuronal 
markers, including the excitatory and inhibitory neuronal markers, as well as the 
astroglial marker. For all the immunohistochemistry results presented here, the slices 
were recorded for up to 2 hours after application of rotenone and potassium cyanide 
before they were fixed in the 4% paraformaldehyde. Sections were imaged and 
analysis was conducted as described in section 2.9.  
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3.3 Results  
 
3.3.1 Development of the brain slice model of mitochondrial epilepsy 
 
As mentioned above, I attempted to model mitochondrial epilepsy based on 
recapitulating the findings from the post-mortem neuropathological studies showing a 
severe complex I and complex IV deficiency as well as an extensive astrogliosis. To 
replicate this dysfunction, I have chosen three pharmacological agents: rotenone 
(complex I inhibitor), potassium cyanide (complex IV inhibitor), and fluorocitrate 
(astrocytic aconitase inhibitor). The concentrations chosen for fluorocitrate was 0.1mM, 
which was the previously reported concentration whereby it is selectively inhibiting the 
astrocytic Krebs cycle (O'Dowd et al., 1994). Initially, I used the concentrations used 
in previously published study for rotenone and potassium cyanide where at the 
concentrations used, the interneuron’s firing rate was significantly reduced (Whittaker 
et al., 2011); however, upon testing, it was apparent that these concentrations were 
too high and created generalized energy failure instead (to be discussed further below 
in section 3.3.2). Therefore, I titrated the concentrations of these respiratory chain 
inhibitors to the optimal concentrations as used below, 500nM for rotenone and 10µM 
for potassium cyanide.  
Since the inhibitory effect of fluorocitrate relies on the uptake of the citric 
compound into the astrocytes, I chose to pre-incubate the tissue in 0.1mM fluorocitrate 
for an hour prior to the challenge with the mitochondrial respiratory chain inhibitors. 
During this pre-incubation, no epileptiform discharges were observed in the 
extracellular local field potential recordings (n=8). Subsequent to the pre-incubation 
with fluorocitrate, the slices were exposed to the concomitant application of the 
mitochondrial respiratory chain inhibitors; 500nM rotenone and 10µM potassium 
cyanide. Following this application, epileptiform discharges were robustly induced in 
the hippocampus CA3 (see Figure 3-2 for an example progression of activity following 
the mitochondrial epilepsy protocol). The mean onset of epileptic activity following this 
concomitant application is 26.32 minutes ± 3.98 minutes (data not shown on graph, 
n=8).  
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Figure 3-2 The epileptic activity progression following the mitochondrial induction protocol.  Shown are the 
electrophysiological recordings following each steps of the mitochondrial induction protocol. Each recording is a 10 minute 
recording shown for the respective time period as shown on the label. Scale bar indicates 0.05mV and 30 seconds. *Since the 
control and the fluorocitrate recording shows no epileptiform activity throughout the 30 minute control incubation and the 60 
minute fluorocitrate incubation, only a representative 10 minute recording is shown for each of the incubation conditions; 
rather than the whole incubation conditions.  
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The epileptiform discharges induced appear in two distinct form of activity: the 
interictal discharges and the ictal discharges (see Figure 3-3). Typically, following the 
onset of the seizure, the activity manifested as interictal discharges that gradually 
increase in amplitude and frequency (see Figure 3-2, time point 10-30 minutes after 
rotenone and KCN). These interictal discharges would eventually transform into a 
longer duration ictal discharges; which would then be followed by a period of silent 
network activity termed the post-ictal silencing (see Figure 3-2, time point 30-40 
minutes after rotenone and KCN and also Figure 3-3 for the morphological feature of 
the interictal and ictal discharges). This silencing lasts for approximately 5 – 10 minutes 
before the interictal discharges re-manifested in a similar cycle as previously described. 
This interictal – ictal cycle lasted for the first 2 hours of the mitochondrial epilepsy 
induction. After 2 hours, the network shifted towards chronic continuous interictal 
discharges without any ictal discharges. This profile resembled the progression seen 
in the zero-magnesium model where the early tonic-clonic seizure-like activity 
progressed into the late recurrent discharges (Reddy and Kuruba, 2013). I have found 
that these late interictal discharges can last for a significant period of time after its 
establishment and have recorded the viability of these discharges up to five hours after 
the application of rotenone and KCN. Furthermore, there is no morphological 
distinction between the early interictal discharges and the late recurrent discharges, 
making it difficult to pinpoint exactly when the transition occurred. The only obvious 
change in the network activity after 2 hours of rotenone and cyanide application seems 
to be the absence of ictal discharges.  
This induction of epileptiform discharges is dependent on the presence of all three 
components of the mitochondrial epilepsy induction protocol. The application of 
fluorocitrate on its own (n=6) or rotenone and cyanide on its own (n=6) did not induce 
epileptiform discharges in the hippocampus CA3; even up to three hours of incubation 
with these agents. Additionally, neither the combination of fluorocitrate and rotenone 
(n=6) nor the combination of fluorocitrate and potassium cyanide (n=6) was able to 
induce epileptiform discharges in the hippocampus CA3. Hence, there must be a 
synergistic effect between the three pharmacological components of the mitochondrial 
epilepsy induction protocol.  
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Figure 3-3 There are two distinct form of epileptiform discharges in this model of mitochondrial epilepsy.  Shown is an 
example of an electrophysiological recording obtained from exposure to the mitochondrial induction protocol. On top is an 
example of a 10-minute recording with both the interictal and ictal activity. Boxed up in red and zoomed in are examples of 
an interictal activity (on the left) and an ictal activity (on the right). Scale bar on the top indicates 1mV and 1 minute. Scale 
bar on the interictal and ictal activity indicates 0.5mV and 5 seconds.  
 
3.3.2 Generalized energy failure is induced at higher concentration of 
respiratory chain inhibitors 
 
I initially started by using the concentrations utilized in previously published study 
from our group that showed that these concentrations of the mitochondrial respiratory 
chain inhibitors were able to reduce the firing rate of the inhibitory interneurons 
significantly (Whittaker et al., 2011). These concentrations are 1µM for rotenone and 
100µM for potassium cyanide. However, I found that when using these concentrations, 
instead of generating epileptiform discharges as shown in Figure 3-2, I was able to 
induce a generalized spreading depression in the hippocampus CA3 within 5-10 
minutes of the joint application of these inhibitors (n=8, see Figure 3-4).  
105 
 
 
Figure 3-4 At higher concentration of rotenone and potassium cyanide, spreading depression is induced instead.  Shown is 
an example of a 10 minutes electrophysiological recordings obtained from the hippocampus CA3 following exposure to 
0.1mM for an hour followed by co-application of 1µM of rotenone and 100µM of potassium cyanide. Scale bar indicates 
0.1mV and 30 seconds.  
 
Following the spreading depression, there was no detectable network activity and 
this persisted even after washout of these inhibitors. This is very consistent with the 
cortical spreading depression pattern; an electroencephalogram feature where a giant 
wave of neuronal and glial depolarization occurs and is followed by a long lasting 
period of electrical silence across the entire cerebral cortex (Mayevsky et al., 1996; 
Fabricius et al., 2008). Classically, cortical spreading depression is associated with 
migraine and aura (Lauritzen; Noseda and Burstein, 2013). However, recent studies 
have implicated cortical spreading depression in conditions of high metabolic stress 
such as in hypoxic-ischemic injury (Fabricius et al., 2006; Takano et al., 2007). In 
studies of patients with mitochondrial disease, cortical spreading depression was found 
to be associated with stroke-like episodes in patients with the MELAS phenotype 
(Ohno et al., 1997; Yonemura et al., 2001). Therefore, I postulate that this activity is 
associated with a generalized energy failure in neuronal microcircuits and represents 
the progression from epileptiform discharges to a ‘more severe 
electroencephalographic manifestation’. The concentration of these inhibitors were 
then titrated down to their optimal concentrations for epileptic activity induction as 
discussed extensively in section 3.3.1.  
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3.3.3 Respiratory chain inhibitors are substitutable 
 
In order to ascertain if the mitochondrial epilepsy protocol is dependent on the 
specific use of rotenone and potassium cyanide as the mitochondrial complex I and IV 
inhibitor respectively, I devised a set of experiments whereby one component of the 
protocol is substituted with another characterized mitochondrial inhibitor. In one 
experiment, rotenone was substituted with MPP+-iodide at the same concentration 
used for rotenone (500nM). In another series of experiments, potassium cyanide was 
substituted with sodium azide at the same concentration used for cyanide (10µM). Both 
MPP+-iodide and sodium azide have been well described as a potent mitochondrial 
complex I and complex IV inhibitor respectively (Schapira, 2010; Lin et al., 2012).  
Both the substitution of 500nM rotenone with 500nM of MPP+ iodide (n=8) and 
the substitution of 10µM potassium cyanide with 10µM sodium azide (n=6) were able 
to induce epileptiform discharges in the hippocampus CA3 respectively (see Figure 
3-5). These epileptic activities are comparable to those induced by the components of 
the mitochondrial epilepsy protocol. Furthermore, both types of the discharges can be 
induced in the early stage of the epileptic induction using both these substitution 
protocols; the interictal and the ictal discharges. This indicates that the mitochondrial 
epilepsy protocol is not reliant on the specific use of rotenone and potassium cyanide. 
Rather, it requires a combination of a mitochondrial complex I and complex IV inhibitor 
with the astrocytic aconitase inhibitor to induce epileptiform discharges in the 
hippocampus CA3.  
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Figure 3-5 Similar pattern of epileptiform discharges can be induced by substitution of the mitochondrial inhibitors used.  
Shown in (A) is an example of electrophysiological recording obtained from the substitution of rotenone with MPP+-iodide in 
the mitochondrial epilepsy protocol and in (B) from the substitution of potassium cyanide with sodium azide. Shown as 
example are the zoomed-in examples of the interictal activity (on the left) and the ictal activity (on the right). Scale bar in (A) 
in the whole trace indicates 1mV and 1 minute, interictal activity 0.5mV and 1 second, and ictal activity 0.2mV and 3 second. 
Scale bar in (B) the whole trace indicates 2mV and 1 minute, interictal activity 1mV and 1 second, and ictal activity 2mV and 
3 seconds.  
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3.3.4 The mitochondrial epilepsy induction is conserved across species 
 
To validate this model further, I wanted to demonstrate that the mitochondrial 
epilepsy induction is not restricted to acutely prepared rat brain slices. Therefore, I 
chose to conduct this mitochondrial epilepsy induction using similar protocol in acute 
brain slices prepared from another commonly used laboratory murine, the C57BL/6 
mice. I have used male mice (similar gender to the male rat) and 8-10 weeks old mice 
(age equivalent to the 10-12 weeks old rat used). Slice preparation was conducted in 
the same manner to rat brain slice preparation and experimental setup was consistent.  
In addition to validation in mice, I also managed to use the mitochondrial epilepsy 
protocol in surgically resected human brain tissue obtained from patients undergoing 
neurosurgical procedures. Patients information from which brain slices were obtained 
are summarized in Table 2-1. Slice preparation was conducted as described in section 
2.3 and experimental setup was kept consistent with the experiments using murine and 
rodent brain slices.  
Epileptiform discharges were induced using the mitochondrial induction protocol 
in both C57BL/6 mice (n=10) and human (n=6) brain slices (see Figure 3-6). Both 
interictal and ictal discharges were observed following induction in both species. 
Overall, the pattern of induction in mice brain slices resembled the rat brain slices very 
closely. In human brain slices, however, onset of the epileptiform discharges vary quite 
considerably within the 2 hour of application of rotenone and cyanide. Furthermore, in 
some cases (as is shown in Figure 3-6), the intensity and the severity of the 
epileptiform discharges can vary quite significantly as well. In the particular case shown 
in Figure 3-6, two ictal discharges can be seen in a 10-minute recording, which is 
unseen of in rodent brain slices. Regardless, the pattern of activity is still the same in 
that interictal discharges are followed by ictal discharges, which then resulted in a post-
ictal silencing before re-manifesting as interictal discharges. This subtle variety in the 
onset, intensity, and severity of the epileptiform discharges probably reflects the 
genetic and clinical variety of the human patients from which the brain slices were 
obtained from.  
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Figure 3-6 Mitochondrial epilepsy was able to be induced in both mice and human brain slices.  Shown in (A) and (B) is an 
example of electrophysiological recordings obtained from C57BL/6 mice and human brain slices respectively. Shown as 
example are the zoomed-in examples of the interictal activity (on the left) and the ictal activity (on the right). Scale bar in (A) 
in the whole trace indicates 1mV and 1 minute, interictal activity 0.5mV and 2 seconds, and ictal activity 1mV and 10 seconds. 
Scale bar in (B) in the whole trace indicates 1mV and 1 minute, interictal activity 0.5mV and 0.5 second, and ictal activity 1mV 
and 1 second.  
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3.3.5 Quantification through automated burst detection demonstrates the 
stability of the epileptic activity 
 
Hitherto, this model has shown that it can robustly produce epileptiform 
discharges in hippocampus CA3 in vitro and the epileptic activity induction is 
conserved across multiple species. In order to use this model for pharmacological 
studies (results discussed in Chapter 4), a method of quantification needs to be 
developed that can accurately and consistently detect the epileptiform discharges and 
quantify them. To address this, a Matlab script was written (courtesy of Dr. Katherine 
Newling, see Appendix 1) to automate the burst detection procedure. The script is 
based on automated burst detection by threshold analysis. Various parameters can be 
measured through the automated burst detection; including the frequency, amplitude, 
and duration of the epileptiform discharges. Since the planned pharmacological studies 
were to provide recommendations for therapeutic planning in patients with 
mitochondrial epilepsy, a clinically relevant parameter is required. The frequency of the 
epileptiform discharges has been shown to be the most clinically relevant quantifiable 
parameter as it is a predictor of the pharmacological response of the epileptiform 
activity (Hitiris et al., 2007). Clinically, the response of an antiepileptic therapeutic 
intervention is usually measured by a 50% reduction in seizure frequency or the 
attainment of seizure freedom (Birbeck et al., 2002). Whilst, scientifically, a reduction 
in amplitude and duration of an epileptiform discharges might represent an interesting 
phenomenon by a therapeutic intervention; it may not provide a meaningful insight into 
the potential clinical efficacy of the intervention. Therefore, I decided to quantify only 
the frequency of the epileptiform discharges and assessed whether there is a period 
of stability of the burst frequency to provide a platform for pharmacological screening 
(n=5, see Table 3-1 and Figure 3-7). 
For 120 minutes following the application of rotenone and cyanide, the 
epileptiform activity gradually increased in terms of frequency with the onset of the first 
epileptiform discharges occurring after 30 minutes (although one slice did have a rapid 
onset at 10 minute after rotenone and cyanide application). There was an observable 
period of stability (± 10%) in frequency of epileptiform discharges at 120 to 180 minutes 
following rotenone and cyanide application. This corresponds very well to the 
previously discussed transition to the late recurrent interictal discharges. After 180 
minutes, there was a slight reduction in the frequency of the epileptiform discharges. 
However, for the next 60 minutes, this epileptic activity was again relatively stable (± 
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10%). Therefore, despite the slight reduction in the frequency of the epileptic activity, 
it can be argued that the epileptiform discharges are relatively stable from 120 to 240 
minutes after rotenone and cyanide application. This represents a window of stability 
for pharmacological studies to be conducted. 
 
Table 3-1 Quantification of epileptic activity showed a period of stability (± 10%) at 120 minute up to 180 minutes, as well as 
from 190 to 240 minutes after rotenone and cyanide application.  
Time (min) Burst count (mean ± SEM) 
in burst/min 
Time (min) Burst count (mean ± SEM) 
in burst/min 
10 1.80 ± 1.80 130 10.30 ± 1.97 
20 3.10 ± 3.10 140 10.30 ± 1.95 
30 6.22 ± 3.92 150 10.18 ± 1.96 
40 5.83 ± 4.32 160 10.12 ± 1.86 
50 9.29 ± 3.99 170 10.32 ± 2.16 
60 10.81 ± 1.77 180 9.22 ± 1.60 
70 11.04 ± 2.70 190 8.46 ± 1.33 
80 11.16 ± 2.59 200 8.18 ± 1.12 
90 12.36 ± 2.53 210 8.10 ± 1.02 
100 10.86 ± 3.19 220 7.70 ± 1.07 
110 11.18 ± 2.63 230 7.42 ± 0.40 
120 9.82 ± 1.86 240 7.54 ± 0.84 
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Figure 3-7 There is a period of stable frequency of epileptiform discharges after 2 hour of application of rotenone and 
potassium cyanide.  This time period corresponds to the observation of when the activity transitions to the late recurrent 
interictal discharges.  
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3.3.6 Neuronal population loss in the epileptic tissue 
 
It has long been recognized that severe and chronic epilepsy models (usually 
associated with status epilepticus) is associated with neuronal cell death (Dam, 1980; 
Meldrum, 1993; Dingledine et al., 2014). Neuropathological findings in patients with 
mitochondrial epilepsy also showed a severe loss of neuronal population in the 
neocortex, particularly those of the GABAergic interneurons (Lax et al., 2016). Since 
this model is based on the recapitulation of these neuropathological findings, it is 
unsurprising to expect a degree of neuronal loss in the hippocampus following the 
induction of the epileptiform activity. To examine this, post-hoc immunohistochemistry 
has been conducted on the pan-neuronal marker NeuN, a nuclear protein expressed 
exclusively in mature post-mitotic neuronal cells (Gusel’nikova and Korzhevskiy, 2015).  
There is a global loss of neurons in both the neocortex and the hippocampus of 
the epileptic brain slices (see Figure 3-8). Prominent thinning of the pyramidal layer of 
the hippocampus was observed in the epileptic tissue. Quantification in the CA3 
subfield of the hippocampus confirmed that there is a significant reduction (p<0.05) of 
the NeuN-positive cells in the epileptic tissue (344.10 ± 18.56 cells/mm2, n=9) as 
compared against control tissue (487.60 ± 33.39 cells/mm2, n=17). This indicates that 
there is a loss of neuronal population following the mitochondrial epilepsy induction 
protocol. To further characterize if there is a specific neuronal population that is more 
vulnerable to the epileptic induction, I have chosen to test against a panel of commonly 
used neuronal markers to confirm this finding.  
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Figure 3-8 There is a significant neuronal loss in the epileptic hippocampus CA3 relative to control tissues.  Shown is an example 
of control and epileptic slices stained for the NeuN protein. Insert showcases the higher magnification of the hippocampus 
CA3, where quantification was done. The bar chart shows the cell density measurements from the hippocampus CA3 in the 
control and epileptic slices respectively. Asterisk indicates significance at p< 0.05. Scale bar in both the whole brain image and 
the insert indicates 100µm.  
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3.3.6.1 Excitatory neurons 
 
Pyramidal neurons are the most prominent member of the excitatory neuron 
grouping and make up about two-thirds of all the neurons in the mammalian cerebral 
cortex (Bekkers, 2011), placing them centre-stage for many important brain processes. 
One marker that is commonly used to detect excitatory pyramidal cells is the 
calmodulin protein kinase type II (CaMKII). It has comprehensively been demonstrated 
that GABA-ergic inhibitory cells lack the expression of CaMKII and thus, the protein is 
an excellent surrogate marker of the excitatory neuronal population (Benson et al., 
1992; Liu and Murray, 2012; Wang et al., 2013).  
There was no observable difference in the expression of CaMKII between control 
and epileptic brain slices (see Figure 3-9). Quantification confirmed this and showed 
that there is no significant difference (p>0.05) between the control tissue (97.48 ± 12.35 
cells/mm2, n=11) and the epileptic tissue (81.05 ± 8.25 cells/mm2, n=7). This suggests 
that the excitatory pyramidal neurons are relatively spared by the mitochondrial 
epilepsy induction protocol.  
 
3.3.6.2 Inhibitory neurons 
 
Inhibitory interneurons contribute to only 20-30% of the neuronal population and 
yet are responsible for the inhibitory tone of the whole brain (Markram et al., 2004). 
There is growing evidence that inhibitory interneurons, unlike the excitatory pyramidal 
neurons, have a heavy metabolic demand and hence, relatively higher mitochondrial 
function (Gulyás et al., 2006; Hazelton et al., 2009; Lin-Hendel et al., 2016). This is 
confirmed in the neuropathological study of the patients with mitochondrial disease 
demonstrating significant loss of interneurons in those patients with epileptic 
phenotype (Lax et al., 2016). Unsurprisingly, I chose to stain for GABA as a marker for 
inhibitory interneuron population in the hippocampus. 
There is a considerable loss of expression of GABA in the epileptic tissue, as 
compared against control (see Figure 3-10). Quantification in the CA3 of hippocampus 
showed that there is indeed a significant reduction (p<0.05) of GABA-ergic cells in the 
epileptic tissue (89.80 ± 8.80 cells/mm2, n=6) when compared against the control 
tissue (168.20 ± 23.39 cells/mm2, n=6). This reduction in inhibitory interneuron 
population is reflective of alterations observed in human neuropathological studies.     
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Figure 3-9 Excitatory cell population of the hippocampus CA3 is relatively spared in the epileptic tissue.  Shown is an example 
of control and epileptic slices stained for the CaMKII protein. Insert showcases the higher magnification of the hippocampus 
CA3, where quantification was done. The bar chart shows the cell density measurements from the hippocampus CA3 in the 
control and epileptic slices respectively.  Scale bar in both the whole brain image and the insert indicates 100µm.  
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Figure 3-10 There is a significant reduction in the inhibitory neuron population in the epileptic tissue.  Shown is an example of 
control and epileptic slices stained for the GABA protein. Insert showcases the higher magnification of the hippocampus CA3, 
where quantification was done. The bar chart shows the cell density measurements from the hippocampus CA3 in the control 
and epileptic slices respectively. Asterisk indicates significance at p< 0.05. Scale bar in both the whole brain image and the 
insert indicates 100µm.  
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3.3.7 There is no specific vulnerability of interneuron subtypes towards the 
mitochondrial epilepsy insult 
 
Using GABA as a marker, I have observed a reduction in the number of inhibitory 
interneurons in epileptic tissue. However, there are many different types of 
interneurons with various distinct morphological and functional properties, such as the 
somadendritic – targeting basket cells or the dendritic – targeting Martinotti cells; which 
together make up more than 50% of the interneuron population in the cortex (Markram 
et al., 2004). These interneurons can be defined through the differential labelling of the 
various calcium binding proteins that they express (Van Brederode et al., 1990; 
Demeulemeester et al., 1991; Wild et al., 2005; Zaitsev et al., 2005). Functionally, it 
has been demonstrated that these interneurons are also distinct in their mitochondrial 
and metabolic capacity. For instance, parvalbumin-expressing interneurons in the 
hippocampus have a strong co-localization with the mitochondrial enzyme, cytochrome 
c, but not the calretinin-expressing interneurons (Gulyás et al., 2006). Therefore, I 
hypothesized that there could be selective vulnerability of specific interneuron 
subtypes towards the mitochondrial epilepsy induction protocol. As an initial screen, I 
have chosen three of the most commonly used calcium-binding proteins (parvalbumin, 
calbindin, and calretinin) to examine these specific interneuron populations.  
 
3.3.7.1 Parvalbumin-expressing interneurons 
 
Parvalbumin-expressing interneurons make up about 40% of the total interneuron 
populations, making them the most prominent subtypes of the inhibitory interneuron 
(Kelsom and Lu, 2013). There are two morphological types of interneurons that make 
up the parvalbumin-expressing interneuron population: the basket cell and the 
chandelier cell (Markram et al., 2004; Kelsom and Lu, 2013). These parvalbumin-
expressing interneurons are distinct in that they are rapidly recruited by excitatory 
synaptic input to generate high-frequency trains of action potentials that provide a rapid, 
stable, phase-locked, and timed inhibitory output (Bartos and Elgueta, 2012). It is due 
to this highly sophisticated and complex inhibitory output that the parvalbumin-
expressing interneurons are thought to require the highly co-localized mitochondrial 
enzyme, cytochrome c (Gulyás et al., 2006). Therefore, I examined the population of 
parvalbumin – expressing interneurons in the epileptic tissue, expecting a significant 
loss of this particular subtype of interneuron. 
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Figure 3-11 There is a significant reduction in the parvalbumin - expressing interneurons in the epileptic hippocampus CA3.  
Shown is an example of control and epileptic slices stained for the parvalbumin protein. Insert showcases the higher 
magnification of the hippocampus CA3, where quantification was done. The bar chart shows the cell density measurements 
from the hippocampus CA3 in the control and epileptic slices respectively. Asterisk indicates significance at p< 0.05. Scale bar 
in both the whole brain image and the insert indicates 100µm.  
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There was a significant reduction in the number of parvalbumin – expressing 
interneuron population in the epileptic tissue (see Figure 3-11). Furthermore, there is 
also a significant loss of the extensive dendritic arborisation in the stratum radiatum 
and lacunosum that is typically labelled by the parvalbumin antibody in the control 
hippocampus. When quantified, it was confirmed that there was a significant reduction 
(p<0.05) in the parvalbumin-expressing cell density in the epileptic tissue (6.51 ± 1.15 
cells/mm2, n=6) when compared against the control tissue (17.40 ± 2.81 cells/mm2, 
n=6).        
 
3.3.7.2 Calbindin-expressing interneurons 
 
Another subtype of the interneuron family is the calbindin-expressing 
interneurons. These interneurons were found to have region-specific mitochondrial 
expression with those in the hippocampus CA3 strongly co-localizing with 
mitochondrial cytochrome c; whereas in the dentate gyrus this co-localization was not 
present (Gulyás et al., 2006). Although calbindin is also expressed in the pyramidal 
cells in the hippocampus CA1, its expression in the CA3 is restricted to interneurons 
and they exhibit stellate-like appearance in all layers of this region (Freund and Buzsaki, 
1996). I, therefore, examined the population of calbindin-expressing interneurons in 
the CA3 region of the hippocampus.  
There was a generalized change in the calbindin expression in the epileptic slice 
(see Figure 3-12). The neocortex was very significantly affected in the epileptic slices, 
particularly in the deeper layers (cortical layer III-VI). The calbindin-expressing 
pyramidal cells of stratum pyramidale in CA1 were to a large degree well – preserved 
in the epileptic slice. In CA3, however, there was a significant loss of the calbindin – 
expressing interneurons typically found in stratum radiatum and lacunosum. 
Quantification of these cells confirmed that there was a significant loss (p<0.05) of the 
calbindin-expressing interneurons in the hippocampus CA3 of the epileptic tissue 
(15.70 ± 1.48 cells/mm2, n=7) as compared against control (22.40 ± 1.82 cells/mm2, 
n=5).  
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Figure 3-12 There is a significant reduction in the calbindin – expressing interneurons in the epileptic hippocampus CA3.  Shown 
is an example of control and epileptic slices stained for the calbindin protein. Insert showcases the higher magnification of the 
hippocampus CA3, where quantification was done. The bar chart shows the cell density measurements from the hippocampus 
CA3 in the control and epileptic slices respectively. Asterisk indicates significance at p< 0.05. Scale bar in both the whole brain 
image and the insert indicates 100µm.  
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3.3.7.3 Calretinin-expressing interneurons 
 
Calretinin-expressing interneurons are distributed across all layers and subfields 
of the hippocampus and the dentate gyrus (Freund and Buzsaki, 1996). The 
expression of mitochondrial cytochrome c is unique in that it weakly co-localizes with 
calretinin, unlike the parvalbumin and calbindin  expressing interneurons (Gulyás et al., 
2006). With that in mind, it is possible that calretinin-expressing interneurons might not 
be as susceptible to the mitochondrial epilepsy induction protocol as the parvalbumin 
and calbindin-expressing interneurons appear to be.  
Upon microscopic examination of the epileptic tissue, I found that there also 
appears to be a generalized change in the calretinin expression following the 
mitochondrial epilepsy induction (see Figure 3-13). There was a loss of calretinin-
expressing cells across all layers of the neocortex. There also appeared to be a 
thinning of the calretinin-expressing cells in the stratum pyramidale of the hippocampus, 
across the CA1 and the CA3 subfields. This was also seen in the dentate gyrus, albeit 
less pronounced as the CA subfields. Quantification in CA3 revealed that there was 
indeed a significant reduction in the density of calretinin – expressing cells in the 
epileptic tissue (105.90 ± 10.21 cells/mm2, n=9) as compared against the control tissue 
(145.20 ± 11.26 cells/mm2, n=11).  
Having now conducted the initial screen for the interneuron subtypes using three 
cellular markers; parvalbumin, calbindin, and calretinin; I have found that there was no 
specific vulnerability of a subtype of inhibitory interneurons in this model of 
mitochondrial epilepsy. However, there are other major subtypes of interneurons that 
were yet to be investigated, such as the somatostatin-expressing interneurons, the 
vasoactive intestinal peptide (VIP)-expressing interneurons, and the cholecystokinin-
expressing interneurons. The vulnerability of a specific subtype of interneuron cannot 
therefore be confidently excluded without the complete assessment of all the subtypes 
of inhibitory interneurons observable in the hippocampus.  
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Figure 3-13 There is a significant reduction in the calretinin - expressing interneurons in the epileptic hippocampus CA3.  Shown 
is an example of control and epileptic slices stained for the calretinin protein. Insert showcases the higher magnification of the 
hippocampus CA3, where quantification was done. The bar chart shows the cell density measurements from the hippocampus 
CA3 in the control and epileptic slices respectively. Asterisk indicates significance at p< 0.05. Scale bar in both the whole brain 
image and the insert indicates 100µm.  
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3.3.8 Extensive astrogliosis is present in epileptic tissue 
 
Hitherto, the discussion of the neuropathological changes in this brain slice model 
of mitochondrial epilepsy has been limited to the neuronal compartment. However, the 
neuropathological study mentioned previously has clearly outlined that there is also an 
extensive involvement of the astrocytic compartment in the post-mortem brain tissue 
of patients with mitochondrial epilepsy. Profound astrogliosis was observed in the 
neocortex and the remaining astrocytes were found to have mitochondrial respiratory 
complex I and IV deficiency (see Figure 3-1). Therefore, it is important to consider the 
astrocytic compartment as well in the observation of the neuropathological changes in 
this model of mitochondrial epilepsy. To do this, I have stained for the glial fibrillary 
acidic protein (GFAP), a protein expressed exclusively in the astrocytes and found to 
be upregulated following astrogliosis (Hol and Pekny, 2015).  
Following immunostaining, I found that expression of GFAP was significantly 
altered in the epileptic tissue (see Figure 3-14). In the control tissue, astrocytes were 
found across all layers in an organized and laminar labelling pattern. In the epileptic 
tissue, however, prominent glial scar was found in both the neocortex and the 
hippocampus. The glial scar is well-defined and encapsulated. At the core of each glial 
scar, no viable astrocytes were observed. The remaining astrocytes, either at the 
periphery of the glial scar or at the unscarred area, exhibited atypical dysmorphic 
morphology; indicative of reactive astrogliosis. Astrogliosis tends to follow a pattern of 
progression (Sofroniew; Sofroniew and Vinters, 2010) and in this model, it seems to 
have reached the end-stage of severe reactive astrogliosis followed by glial scar 
formation. Quantification was performed by delineating the area of reactive astrogliosis 
across the whole brain slice and calculating the proportion of the astrogliotic area 
against the area of the whole slice. Using this calculation, I found that there was 
significantly higher astrogliotic area in the epileptic tissue (32.77 ± 6.00 %, n=8) as 
compared against control (4.32 ± 1.95 %, n=11). This confirms that astrocytes are 
severely affected in this model of mitochondrial epilepsy to the end-stage of 
astrogliosis: severe reactive astrogliosis with glial scar formation.  
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Figure 3-14 There is extensive astrogliosis and glial scar formation in the epileptic tissue.  Shown is an example of control 
and epileptic slices stained for the glial fibrillary acidic protein. There appears to be extensive astrogliosis and glial scar 
formation in the epileptic tissue. Insert in the control tissue showcases normal astroglial labelling pattern in the 
hippocampus CA3 whereas insert in the epileptic tissue showcases higher magnification of the glial scar found in both the 
neocortex and the hippocampus. The bar chart shows quantification of the percentage of gliotic area in the control and 
epileptic slices respectively. Asterisk indicates significance at p<0.05. Scale bar in both the whole brain image and the insert 
indicates 100µm.  
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3.4 Discussion 
 
3.4.1 Development of the in vitro model of mitochondrial epilepsy 
 
This in vitro brain slice model of mitochondrial epilepsy is based on the principle 
of recapitulating the neuropathological findings from post-mortem studies on the 
neocortex of patients with mitochondrial epilepsy (Lax et al., 2016). It has been argued 
that this approach of back translation from human studies to animal models may be 
the most effective approach in in vitro modelling of human diseases (Chan et al., 2016). 
In previously published study, it was established that there is a severe interneuron loss 
in the cerebral cortex of patients with mitochondrial epilepsy and the deficiency of 
mitochondrial complex I and IV subunit expression in the remaining surviving 
interneurons (Lax et al., 2016). The author further extended this neuropathological 
finding and described similar deficiency of mitochondrial complex I and IV subunit 
expression in astrocytes as well as a prominent pattern of reactive astrogliosis (Lax et 
al., unpublished data; see Figure 3-1).  
This neuropathological study implicated that in addition to the neuronal 
compartment, the astrocytic compartment seems to be affected equally in patients with 
mitochondrial epilepsy. As a proof of concept, I conducted an experiment using acutely 
prepared rodent brain slices where I washed in mitochondrial complex I inhibitor 
(rotenone), complex IV inhibitor (potassium cyanide), and an astrocytic mitochondrial 
inhibitor (fluorocitrate). This combination of pharmacological agents at a specific 
concentration (discussed extensively in section 3.3.1) was able to induce epileptiform 
discharges robustly in the hippocampus CA3. This was the first study to describe an 
acute induction of epileptic activity through the manipulation of mitochondrial function. 
Interestingly, all three components of the induction protocol are required for induction 
of epileptiform discharges. The application of either one or two of the components 
alone cannot induce epileptiform discharges. This suggests a synergistic mechanism 
between the three pharmacological tools in modifying the metabolic state so that the 
network becomes hyperexcitable and produces epileptiform discharges. 
Two forms of the epileptiform discharges have been extensively described and 
discussed above in section 3.3.1. Initially, the model manifested as interictal 
discharges which gradually build up in frequency and amplitude as time progressed. 
Eventually, this would manifest in the ictal discharges, which would be followed by a 
period of no observable activity in the network, which I have called the ‘post-ictal 
126 
 
silencing’ period. Following the post-ictal silencing, the activity would re-manifest as 
interictal discharges which would then restart the cycle of interictal – ictal activity as 
above. At some point, the network activity transitioned to the late interictal recurrent 
discharges. The activity would continuously manifest as interictal discharges for a 
prolonged period of time without any ictal burst. This transition to the late recurrent 
discharges somewhat resembles the progression seen in the zero – magnesium model 
(Reddy and Kuruba, 2013). In the zero-magnesium model, this transition is associated 
with the erosion of inhibition in the tissue over time (Whittington et al., 1995). Perhaps, 
this is the same in our model as the inhibition of mitochondrial respiration has been 
associated with the selective reduction in inhibitory tone (Whittaker et al., 2011). In 
patients with mitochondrial disease, a variety of seizure semiologies can be found 
(Torbergsen et al., 1991; Bindoff and Engelsen, 2012) but the most common seizure 
types in the most common phenotype associated with epilepsy (MELAS) is generalized 
tonic-clonic seizure with focal intermittent interictal discharges (Chevallier et al., 2014). 
It can be argued that the generalized tonic-clonic seizure resembles the ictal 
discharges seen in this in vitro model and the focal interictal discharges resembles the 
interictal discharges. This further supports the face validity of this in vitro brain slice 
model of mitochondrial epilepsy.  
In section 3.3.2, it was further described that at higher concentration of the 
respiratory chain inhibitors, generalized spreading depression was induced instead of 
the epileptiform discharges. In the context of mitochondrial disease, cortical spreading 
depression was found to be associated with stroke – like episodes in patients 
presenting with MELAS (Ohno et al., 1997; Yonemura et al., 2001). This further 
supports the suggestions that this in vitro brain slice model of mitochondrial epilepsy 
does replicate the features of mitochondrial disease, particularly MELAS. Furthermore, 
cortical spreading depression is an electroencephalographic feature where there is a 
wave of neuronal and glial depolarization followed by a persistent inhibition across the 
whole cortical area (Mayevsky et al., 1996; Fabricius et al., 2008). In this model, when 
spreading depression was induced; indeed, no further local field potential was 
observed. It can be argued that this post – spreading depression silencing very closely 
resembles the phenomenon of post – ictal silencing that was observed in the model. 
Perhaps, the ictal activity seen in this model is a subtler form of cortical spreading 
depression that is induced in lower degree of respiratory chain inhibition. If so, it can 
be argued then that the cortical spreading depression represents a progression of 
electroencephalographic manifestation of metabolic failure in the tissue.   
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To further validate the model, I have examined if substitution of the respiratory 
chain inhibitors, rotenone and potassium cyanide, with other established inhibitors 
would still induce epileptiform discharges. Section 3.3.3 has outlined that the 
substitution of rotenone with MPP+-iodide or potassium cyanide with sodium azide still 
was able to induce similar epileptiform discharges in the hippocampus CA3 (see Figure 
3-5). This suggests that the mitochondrial epilepsy induction is dependent on the 
presence of mitochondrial respiratory chain complex I and IV inhibition rather than the 
specific presence of rotenone and cyanide.  
In section 3.3.4, an investigation was performed to see if the mitochondrial 
epilepsy induction protocol would similarly induce robust epileptiform discharges in 
acute brain slices from the commonly used laboratory mice, C57BL/6 mice; and from 
human patients who underwent elective neurosurgical procedures. The use of the 
mitochondrial epilepsy protocol was able to robustly produce the same interictal and 
ictal pattern of epileptiform discharges in the hippocampal brain slices from both 
species (see Figure 3-6). This further adds to the face validity of this brain slice model 
in that it is conserved across species. Furthermore, it has been discussed that the 
epileptic phenotype in mice very closely resembles that of rats, presumably due to its 
genetic similarity as members of the murine family (Consortium, 2004). The epileptic 
phenotype in human is slightly more variable and this is probably reflective of the 
genetic and clinical variety of the patients whose brain slices were obtained from (see 
Table 2-1 for patient information).  
Finally, a quantification method was described in section 3.3.5. I have argued for 
the use of seizure frequency as the initial parameter to quantify in this model of 
mitochondrial epilepsy due to its high clinical relevance (Birbeck et al., 2002). The use 
of the automated detection of epileptiform discharges represents a feasible, objective, 
and accurate measurement of the epileptic activity. The time-course experiment has 
shown a period of stable frequency of epileptiform discharges after 2 hours of 
application of rotenone and cyanide. This also coincides with the transition of the 
epileptic burst into the late recurrent interictal discharges. The presence of this time 
window is a golden opportunity to conduct pharmacological study which would require 
a stable functional system (to be discussed further below in section 4.4.1) 
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3.4.2 Neuropathological findings 
 
Since the development of this model is based on the recapitulation of 
neuropathological findings from post-mortem study on patients with mitochondrial 
epilepsy, it is imperative to show that the model does indeed recapitulate the 
mitochondrial dysfunction observed in the human neuropathology. However, it is 
important to note that the post-mortem neuropathological study represents an 
investigation into the end-stage of a disease and may not provide insights into the 
acute stage of the disease. Furthermore, the patients studied in the neuropathological 
study have genetic abnormalities that lead to their disease development. These 
genetic abnormalities manifested as the loss of expression of a subunit of the 
mitochondrial respiratory chain. Acute pharmacological manipulation would not affect 
the expression of these subunits; rather, it just reduces the activity of the relevant 
mitochondrial respiratory complexes. Therefore, it would not be accurate to conduct 
post-mortem immunohistochemistry to detect against these mitochondrial complex 
subunits as was done in the human neuropathology. Rather, I have chosen to conduct 
an initial neuropathological examination on the neuronal and astroglial population in 
the epileptic tissue; both of which have been implicated in the human 
neuropathological studies.  
 
3.4.2.1 Neuronal loss 
 
As an initial screen for the whole neuronal population, I conducted 
immunolabeling of the NeuN protein (see section 3.3.6). The NeuN protein is a nuclear 
protein that is exclusively expressed in mature post-mitotic neuronal cells 
(Gusel’nikova and Korzhevskiy, 2015). The loss of expression of NeuN is closely 
associated with neuronal damage or death (Gusel’nikova and Korzhevskiy, 2015); 
therefore its use as a marker of neuronal loss is well-justified. In rare instances, the 
loss of expression of NeuN has been associated with the loss of antigenicity (Ünal-
Çevik et al., 2004). In this study, however, antigen retrieval was also shown to reverse 
this loss of antigenicity (Ünal-Çevik et al., 2004) and since the technique I have used 
in the immunohistochemistry involved extensive antigen retrieval with heat-mediated 
sodium citrate buffer wash, I did not expect a loss of antigenicity in the assessment of 
NeuN expression in this model of mitochondrial epilepsy. Our results have 
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demonstrated a severe loss of NeuN expression across the whole brain slice and 
quantification in the CA3 region illustrated a significant reduction (see Figure 3-8). This 
strongly suggests that there is indeed neuronal loss following the mitochondrial 
epilepsy induction.  
There are many mechanisms associated with neuronal loss in the epileptic tissue. 
One mechanism that may be relevant in this model is oxidative stress and the 
subsequent activation of apoptosis (Mendez-Armenta et al., 2014).  It has been shown 
in other model of epilepsy that seizure generation results in the mitochondria – 
independent reactive oxygen species production, eventually causing apoptosis in the 
tissue (Kovac et al., 2014). Since mitochondria is a major source of the endogenous 
reactive oxygen species (Zorov et al., 2014), it would not be surprising to expect 
oxidative stress following the mitochondrial epilepsy induction. This release of the 
reactive oxygen species can create a vicious cycle that further recruits more reactive 
oxygen species release from both the mitochondrial and extramitochondrial source 
(Kovac et al., 2014; Zorov et al., 2014). All this oxidative damage would inevitably 
upregulate the apoptotic signalling and system such as the caspase system (Kannan 
and Jain, 2000; Sinha et al., 2013); leading to neuronal death and loss.   
Interestingly, in a cell culture model, it has been found that spontaneous recurrent 
interictal discharges do not result in cell death but chronic status epilepticus does 
(Deshpande et al., 2007). Indeed, acute epileptic models are rarely associated with 
neuronal loss due to the acute time course of the epileptic induction (Deshpande et al., 
2007; Deshpande et al., 2008). However, it is clear in this model that there is extensive 
neuronal loss in the epileptic tissue. This may indicate the severity of the damage 
caused by the epileptiform discharges in this model, perhaps up to the level of that of 
status epilepticus.  
To see if there is a specific subset of the neuronal population that is more 
susceptible to the mitochondrial epilepsy damage, I have conducted immunolabelling 
of the excitatory and inhibitory neuronal population through the labelling of the CaMKII 
and GABA protein respectively. Both CaMKII and GABA are well-characterized as 
specific markers of the excitatory and inhibitory neuron respectively (Benson et al., 
1992; Markram et al., 2004). There was no significant difference in the CaMKII 
expressing cell population in the epileptic hippocampus CA3 (see Figure 3-9) whereas 
there was a significant reduction of GABA expressing cell population in the epileptic 
hippocampus CA3 (see Figure 3-10). This indicates that there is a selective 
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vulnerability of the inhibitory interneuron population towards the mitochondrial epilepsy 
insult. This fits with the current theories that the inhibitory interneurons have much 
higher metabolic demand than the excitatory neurons, leading to higher mitochondrial 
capacity and subsequently higher susceptibility to mitochondrial dysfunction (Gulyás 
et al., 2006; Hazelton et al., 2009; Kann et al., 2014; Kann, 2016; Lin-Hendel et al., 
2016). Furthermore, it replicates the severe loss of inhibitory interneuron populations 
seen in the post-mortem neuropathological studies of patients with mitochondrial 
epilepsy (Lax et al., 2016). However, a note of caution is that the loss of expression of 
GABA in the epileptic tissue might not necessarily mean the loss of the GABA-ergic 
cells. Indeed, it may simply indicate that the inhibitory cells have reduced GABA 
concentration and expression and are thus undetectable through the immunolabelling 
of GABA. This is certainly a possible scenario, but, taken together with the loss of 
NeuN expression, it strongly favours the hypothesis of the selective loss of inhibitory 
interneurons in the epileptic tissue.  
To further dissect the susceptibility of the inhibitory interneuron population 
towards the mitochondrial epilepsy damage, I have screened for an initial panel of 
inhibitory interneuron markers (parvalbumin, calbindin, and calretinin) to see if there is 
a selective susceptibility of a subtype of interneurons towards the insult. Out of the 
three markers (see Figure 3-11, Figure 3-12, and Figure 3-13), all examined subtypes 
of inhibitory interneurons demonstrated a significant reduction in the epileptic 
hippocampus. This finding is surprising as immunolabeling with cytochrome c has 
revealed a strong co-localization with the parvalbumin and calbindin-expressing 
interneurons but not the calretinin-expressing interneurons of the hippocampus CA3 
(Gulyás et al., 2006). One would therefore expect that there would be a selective loss 
of the parvalbumin and calbindin-expressing interneurons due to their higher 
dependence and expression of mitochondrial cytochrome c. However, cytochrome c is 
merely a protein associated with complex IV of the respiratory chain and in this model, 
there is a concomitant inhibition of complex I and complex IV. Therefore, it would not 
be wrong to speculate that the calretinin-expressing interneuron loss may be due to 
the additional inhibition of complex I. Certainly, this finding potentially indicate that 
there is no selective susceptibility of a particular subtype of the inhibitory interneuron 
population towards the mitochondrial epilepsy insult. However, knowing that there are 
other major subtypes of interneurons that are yet to be investigated (such as the 
somatostatin, VIP, and cholecystokinin-expressing interneurons), no real conclusion 
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on the specific susceptibility of a particular subtype of interneuron can be made until 
the whole interneuron population is assessed and examined.  
Regardless, collectively, all these findings confirmed that the neuronal 
compartment is severely affected in this model of mitochondrial epilepsy. There is a 
selective vulnerability of the inhibitory interneuron population towards the mitochondrial 
epileptic damage and this closely resembles the loss of interneuron seen in the human 
neuropathological study.  
 
3.4.2.2 Astrogliosis 
 
One vital component of the mitochondrial epilepsy induction protocol is 
fluorocitrate. Fluorocitrate has been shown to be a selective astrocytic aconitase 
inhibitor (Hassel et al., 1992; Swanson and Graham, 1994; Fonnum et al., 1997). 
Therefore, it is unsurprising to expect that the astrocytic component would be severely 
affected in this model of mitochondrial epilepsy. To investigate this, I performed 
immunolabeling against the glial fibrillary acidic protein (GFAP), a protein exclusively 
expressed in the astrocytes and is also a marker of astrogliosis (Hol and Pekny, 2015). 
The expression of GFAP was found to be significantly upregulated in the epileptic 
tissue (see Figure 3-14). Severe reactive astrogliosis was apparent across the whole 
brain slice in the epileptic tissue. Furthermore, glial scar formation is seen in the 
epileptic tissue in both the neocortex and the hippocampus. This glial scar is well-
circumscribed and encapsulated an area of injury with no viable astrocytes at the core 
of the scar. According to a proposed grading system, the epileptic tissue in this model 
has exhibited feature of severe reactive astrogliosis followed by glial scar formation 
(Sofroniew and Vinters, 2010). Quantification of the proportion of gliotic area in the 
epileptic tissue has also shown a significant increase in percentage area of astrogliosis 
as compared against control. It is therefore very clear that there is extensive 
astrogliosis in this model of mitochondrial epilepsy and this closely resembles the 
astrogliosis seen in the neuropathological study of the patients with mitochondrial 
epilepsy (Lax et al., unpublished data; see Figure 3-1).  
In various other studies, reactive astrogliosis, especially the border – forming glial 
scar, is a protective mechanism to limit the extent of the brain injury to the area of 
gliosis and is closely regulated by inflammatory signals (Bush et al., 1999; Herx and 
Yong, 2001; Faulkner et al., 2004; Myer et al., 2006; Gadea et al., 2008; Voskuhl et al., 
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2009). Indeed, in studies of temporal lobe epilepsy, chronic inflammation has been 
closely implicated in the epileptic tissue (Vezzani et al., 2011; Volmering et al., 2016). 
In mitochondrial epilepsy, preliminary observations have shown in post-mortem 
neuropathological studies that indeed, signs of inflammation are seen in the neocortex 
from patients with mitochondrial epilepsy (Lax et al., personal communication and 
unpublished data). Therefore, it is not out of the realm of imagination to hypothesize 
that chronic inflammation may play a role in the seizure generation in patients with 
mitochondrial epilepsy. As a compensatory mechanism, therefore, astrocytes respond 
by activating reactive astrogliosis mechanism and forming glial scar, creating a border 
around the area of injury.  
Another possible mechanism that has been shown to modulate reactive 
astrogliosis is oxidative stress. In various studies, oxidative stress has been linked to 
the proliferation of reactive astrocytes and therefore, the initiation of astrogliosis (Bates 
et al., 2007; Borges et al., 2015; Puttachary et al., 2015). As discussed above, oxidative 
stress is closely associated with epilepsy and the major source of endogenous 
oxidative stress is mitochondria (Zorov et al., 2006; Kovac et al., 2014; Zorov et al., 
2014). Thus, oxidative stress can also be a potent modulator of reactive astrogliosis in 
this model of mitochondrial epilepsy.  
Although not directly demonstrated in this model, reactive astrogliosis has been 
closely associated with neuronal death or apoptosis (Yu et al., 2012; Livne-Bar et al., 
2016). It has been suggested that the astrocytic and the neuronal compartment is 
closely working together in the maintenance of the inhibitory – excitatory balance in 
the brain through various mechanisms. The selective induction of reactive astrogliosis 
through the use of genetically modified animals has been shown to lead to alteration 
in the potassium channel expression, causing tissue hyperexcitability and the 
subsequent development of seizure (Yu et al., 2014; Robel et al., 2015). Another 
interesting study has shown that induction of reactive astrogliosis caused an erosion 
of the inhibitory tone in the tissue through the failure of the astrocytic glutamate – 
glutamine cycle (Ortinski et al., 2010). Whatever the mechanism, it seems quite clear 
that there is an accumulative dysfunction in the astrocytic and the neuronal 
compartment that leads to the generation of seizure in this model of mitochondrial 
epilepsy. The end-stage of this dysfunction and the epileptic damage is reactive 
astrogliosis (for the astrocytic compartment) and neuronal loss (for the neuronal 
compartment).  
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3.5 Summary, strength, and weakness 
 
The findings in this chapter has presented the conceptualisation and the 
development of the novel in vitro brain slice model of mitochondrial epilepsy that will 
be investigated further throughout the remainder of this thesis. Various experiments 
have been conducted to add to the face validity of the model. Specifically, it has been 
shown that the mitochondrial epilepsy induction is dependent on the presence of all 
three components of the induction protocol; namely fluorocitrate, the astrocytic 
aconitase inhibitor, and a mitochondrial respiratory chain complex I inhibitor (either 
rotenone or MPP+-iodide) as well as a mitochondrial respiratory chain complex IV 
inhibitor (either potassium cyanide or sodium azide). Furthermore, it has been shown 
that the mitochondrial epilepsy induction is conserved across species. At higher 
concentration of the respiratory chain inhibitors, cortical spreading depression is 
induced instead, which may represent an electroencephalographic manifestation of a 
generalized metabolic failure. I have also shown that quantification of the epileptic 
activity through automated burst detection is feasible and has shown a period of stable 
epileptic system after 2 hours of induction with rotenone and cyanide. This stable 
period of activity will be the stepping stone for the conduct of pharmacological study 
(described and discussed in detail below in Chapter 4). Post-hoc 
immunohistochemistry has shown a selective loss of inhibitory interneuron population 
in the epileptic hippocampus CA3. To present, there is no selective vulnerability of a 
specific subtype of interneuron population, but more subtype of interneuron needs to 
be investigated before this can be confidently concluded. Astrogliosis is also 
demonstrated prominently in the epileptic tissue with well-defined glial scar formation.  
Overall, a novel in vitro brain slice model of mitochondrial epilepsy has been 
developed and validated through a series of control experiments presented in this 
chapter. It is quite clear that there is the implication of two cellular populations in this 
model of mitochondrial epilepsy; the neuronal and the astrocytic compartment. This 
led to the development of the ‘dual neuronal-astrocytic hit hypothesis’. This hypothesis 
postulates the requirement of both neuronal and astrocytic mechanisms to be recruited 
for the generation of seizure in mitochondrial epilepsy. These specific mechanisms are 
to be discussed and explored further in the studies presented in the remainder of this 
thesis.  
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The findings in this chapter have presented a sound approach to the development 
of an in vitro model of epilepsy. However, with any newly developed model of epilepsy, 
a certain degree of uncertainty needs to be placed in terms of what it actually is 
modelling. The development of this model is based on the recapitulation of 
neuropathological findings from human patients who have this condition. However, 
these patient populations come from a diverse genetic (m.3243A>G or m.8433A>G) 
and clinical phenotype (such as MELAS or MERRF). Therefore, whilst this model 
mimics the common pathological features in these syndromes; it does not specifically 
model any of these syndromes. It is therefore inaccurate to say that this is a model of 
MELAS or MERRF. Rather, this is a newly developed model of mitochondrial epilepsy, 
a common epileptic feature seen in all these patients; where the epilepsy is much more 
severe and pharmacoresistant than the normal epileptic phenotype. Regardless, this 
is still the first in vitro model of mitochondrial epilepsy and therefore, the merit and the 
importance of its development should not be undervalued.  
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Chapter 4 Pharmacological characterization of mitochondrial 
epilepsy 
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4.1 Introduction 
 
Mitochondrial epilepsy is particularly challenging to manage in the clinic as the 
seizures tend to respond poorly to the currently available antiepileptic drugs (Whittaker 
et al., 2015). Current practice in the management of mitochondrial disease, including 
epilepsy, remains largely supportive, symptomatic, and highly variable depending on 
the patient’s presentation and the physician’s judgment (Steele and Chinnery, 2015). 
It is this extreme pharmacoresistance that defines mitochondrial epilepsy as a unique 
subtype of epilepsy. In fact, some researchers have gone as far as postulating that 
underlying mitochondrial dysfunction may be the basis of pharmacoresistance in 
epilepsy (Yuen and Sander, 2011).  
Given the promising development of this in vitro brain slice model of mitochondrial 
epilepsy (as detailed in Chapter 3), I seized on the opportunity to conduct 
pharmacological profiling on mitochondrial epilepsy. I started by assessing the 
contribution of various common glutamatergic and GABA-ergic receptors. Then, I 
tested the response of the epileptiform activity against various currently licensed-to-
use antiepileptics from various subtypes, including sodium channel blockers, 
barbiturates, and benzodiazepines.  
Ketogenic diet is a high-fat, moderate-protein, and low-carbohydrate dietary 
intervention that has shown promising clinical efficacy in controlling intractable seizure 
in children (Branco et al., 2016). In a small study evaluating the efficacy of ketogenic 
diet in children with mitochondrial epilepsy, it was found that half of them could achieve 
seizure freedom with the undertaking of the diet (Kang et al., 2007). Furthermore, 
various case reports had reported successful treatment of various phenotypes of 
mitochondrial epilepsy with variants of the ketogenic diet (Martikainen et al., 2012; 
Steriade et al., 2014).  Although the mechanism by which ketogenic diet exerts its 
antiepileptic action is largely unknown, it has been proposed that ketogenic diet could 
have a multitude of protective effect towards the mitochondria (Branco et al., 2016), 
hence its potential use in patients with mitochondrial epilepsy.  
Despite the initial thought that the antiepileptic effect of ketogenic diet is mediated 
by the ketone bodies, it has been documented that the level of ketosis did not correlate 
with the degree of seizure control (Likhodii et al., 2000). This suggests that another 
component of the diet is responsible for its antiepileptic properties and recent studies 
have entertained the idea of these components being the fatty acids. In particular, the 
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medium-chain fatty acids such as octanoic acid and decanoic acid have been 
demonstrated to be antiepileptic (Wlaź et al., 2012; Chang et al., 2013). 
Mechanistically, decanoic acid has been shown to modulate the AMPA-R (Chang et 
al., 2015) and also upregulate mitochondrial respiratory chain complex I activity 
(Hughes et al., 2014). Together, these data show that medium-chain fatty acids, 
particularly decanoic acid, has promising potential for use in mitochondrial epilepsy 
and therefore warrants further investigation in this model.  
In spite of all the mechanisms listed above, there is no denying that the 
application of ketone bodies or fatty acids may alleviate the seizure in mitochondrial 
epilepsy simply through providing energy substrates for the system. All mechanisms 
considered, the basic scientific concept underlying mitochondrial epilepsy remains the 
‘neuronal energy crisis’ (Zsurka and Kunz, 2015). Theoretically then, any substances 
applied to the epileptic brain that could be processed metabolically by the mitochondria 
would alleviate the ‘neuronal energy crisis’ and could then silence the pathological 
seizure discharges.  
One of the most fundamental process in energy metabolism of the brain is 
glycolysis. Under physiological condition, glucose is the main obligatory substrate for 
energy metabolism in the brain (McKenna et al., 2006). The only pathway by which 
glucose can enter metabolism is through glycolysis. Glucose is converted to pyruvate, 
which can then enter the Krebs cycle in aerobic metabolism.  Glycolysis is unique to 
the other metabolic pathway in that it can occur anaerobically through the conversion 
of pyruvate to lactate, mediated by the enzyme lactate dehydrogenase. The astrocyte 
– neuron lactate shuttle hypothesis postulates that in conditions of increased network 
activity, glutamate can stimulate astrocyte to release lactate which is used by the 
neurons as a preferential energy substrate (Pellerin and Magistretti, 1994; Chih and 
Roberts, 2003; Bélanger et al., 2011) . It would, therefore, prove interesting to examine 
the effect of lactate and pyruvate application in restoring the energy crisis of the 
epileptic tissue. Modulation of brain glycolysis may prove to be an interesting avenue 
for therapeutic development in mitochondrial epilepsy.  
Another interesting substrate of the brain would have to be GABA. GABA is a 
metabolic substrate of the glutamate-glutamine cycle (Bak et al., 2006; Hertz and 
Rothman, 2016) and is also the most abundant inhibitory neurotransmitter in the brain. 
The glutamate-glutamine cycle represents one of the most important processes in 
neurotransmitter recycling and is largely mediated by the communication between two 
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distinct cellular compartments: the neuronal and astrocytic compartment (Westergaard 
et al., 1995). Of particular interest to me, with regards to this model, is that astrocytic 
impairment plays a crucial role in epileptogenesis and the glutamate-glutamine cycle 
may very well be the astrocytic process implicated in mitochondrial epilepsy.  
Having considered all these, I applied various metabolic substrates of the 
ketogenic diet, glycolysis, and the glutamate-glutamine cycle in this in vitro brain slice 
model of mitochondrial epilepsy to tease out the specific metabolic processes that 
could possibly be implicated in this epileptic model.  
 
4.2 Methods 
 
Rat hippocampal slices were prepared as described in Chapter 2. Mitochondrial 
epilepsy were induced as described in section 2.5 and inhibitors were washed in until 
it reached the period of stability as described in section 3.3.5. 
Once the epileptic activity was stable, the various pharmacological compounds 
or metabolic substrates were washed in the ACSF. For most experiments, two 
concentrations were generally used: the minimum inhibitory concentration (MIC) and 
the maximum tolerable concentration (MTC). Both concentration values were typically 
obtained through literature search. The MIC were first washed in for the first 30 minutes 
and then the MTC were washed in for the next 30 minutes. For characterization of 
receptor contribution, I used one concentration for each inhibitor, for which the 
concentration was known to adequately inhibit the target receptor selectively.  
For some novel uncharacterized interventions, a dose-response curve has been 
generated. This is typically done by washing in four increasingly higher concentration 
of the compounds for 30 minutes each. In total, the pharmacological intervention 
typically took place within 1-2 hours of the stable period of epileptic activity. Dose-
response curves were only generated when the suppressive effect appeared to be 
dose-dependent. 
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4.3 Results  
 
4.3.1 Pharmacological response towards application of vehicle 
 
In the development of any pharmacological agent, a serious consideration needs 
to be put in place for the vehicle formulations used in dissolving the compounds. Most 
pharmacological agents are water soluble, but an increasing number of new 
compounds are highly lipophilic and therefore poorly water soluble (Bittner and 
Mountfield, 2002). These compounds require an organic solvent for their dissolution 
and one of the most commonly used organic solvent is dimethyl sulfoxide (DMSO). 
Although these organic solvents are described as ‘inert’ compounds, several studies 
in various platforms have reported a ‘vehicle effect’, whereby the vehicle formulation 
used exhibited an effect on its own (Cavas et al., 2005; Nasrallah et al., 2008; Galvao 
et al., 2014). This is particularly important when evaluating the pharmacological 
response of an anticonvulsant towards epileptiform discharges. The discovery of 
valproate as an anticonvulsant started through the finding that its use as a vehicle 
formulation for a lipophilic drug exhibited antiepileptic properties on its own (Beydoun 
et al., 2008). In this study, I have used two vehicle formulations for the dissolution of 
all the pharmacological agents tested: water for the hydrophilic compounds and DMSO 
for the lipophilic compounds. Therefore, I have examined the effect of cumulative 
addition of these vehicles over four different concentrations towards the induced 
epileptiform discharges (see Figure 4-1). 
There was no significant difference (n=5, p>0.05) in the frequency of epileptiform 
discharges following cumulative application of varying percentage of dH2O (0.1 – 1 %). 
Specifically, there was no difference between baseline (14.20 ± 1.09 burst/min), 
following 0.1 % dH2O addition (14.64 ± 1.00 burst/min), 0.25% dH2O addition (13.92 ± 
0.85 burst/min), 0.5% dH2O addition (13.72 ± 0.93 burst/min), and 1% dH2O addition 
(15.34 ± 2.34 burst/min).  
Similarly, there was no statistically significant difference (n=12, p>0.05) in the 
frequency of epileptiform discharges following cumulative application of varying 
percentage of DMSO, ranging from 0.0001 – 0.1 %. Again, specifically, there was no 
difference between baseline (13.88 ± 1.85 burst/min), following 0.0001% DMSO 
addition (13.41 ± 2.28 burst/min), 0.001% DMSO addition (10.13 ± 2.70 burst/min), 
0.01% DMSO addition (11.77 ± 2.97 burst/min), and 0.1% DMSO addition (10.34 ± 
2.62 burst/min).  
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Figure 4-1 Epileptic activity does not respond towards vehicle application.  (A) Shown on the left and right hand side is the 
response of the epileptic activity towards cumulative addition of water and DMSO respectively at varying % v/v. The 
corresponding bar chart summarizing the response towards water and DMSO is shown in (B) and (C) respectively. Scale bar 
100μV and 10 seconds.  
 
 
142 
 
These results suggest that in this model of mitochondrial epilepsy, there was no 
demonstrable vehicle effect with addition of dH2O up to 1% and DMSO up to 0.1%. 
Considering this, all of the drugs used in this chapter will be dissolved using either 
dH2O or DMSO up to these concentrations. Any remaining pharmacological responses 
can then be confidently attributed to the mechanism of actions of the pharmacological 
agents tested.  
 
4.3.2 Characterization of receptor contributions in mitochondrial epilepsy 
 
Previous works on epilepsy models in acute brain slices have implicated various 
glutamatergic and GABA-ergic receptor contribution in seizure generation (Williamson 
and Wheal, 1992; Isaeva et al., 2010). The three receptors that are most frequently 
implicated in epilepsy are the glutamatergic NMDA-R and AMPA-R as well as the 
GABA-ergic GABAA receptor. I hence decided to test the response of the epileptic 
activity to selective antagonism of NMDA-Rs by the bath application of D-AP5 (50μM), 
AMPA-Rs by NBQX (20μM), and GABAA-Rs by gabazine (500nM) (see Figure 4-2.) 
These concentrations of D-AP5 and NBQX were chosen as they have been reported 
in the literature to generate a higher than 50% inhibitory effect in their respective 
inhibited receptors (Randle et al., 1992; Wu et al., 1999). On the other hand, I have 
chosen to use the IC50 of gabazine (~480nM) as a complete antagonism of inhibition 
could result in the slices progressing towards generalized spreading depression, as 
described in section 3.3.2 (Lindquist et al., 2005).  
Addition of 50μM D-AP5 for 60 minutes did not cause any significant change in 
the frequency of epileptiform discharges (9.42 ± 1.05 burst/min baseline vs 8.34 ± 2.18 
burst/min drug, p>0.05, n=5).  
In contrast, applying 20μM NBQX for 30 minutes caused a significant reduction 
in the frequency of epileptiform discharges (12.84 ± 3.37 burst/min baseline vs 0.02 ± 
0.02 burst/min drug, p<0.05, n=5).  
Applying the GABAA receptor antagonist, gabazine, at 500nM for 30 minutes 
caused an increase in the frequency of the epileptiform discharges, albeit this increase 
was not statistically significant (19.64 ± 6.00 burst/min baseline vs 25.98 ± 4.92 
burst/min drug, p>0.05, n=5).   
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Figure 4-2 Epileptic activity is dependent on the contribution of AMPA-R, but not NMDA-R.  A-C. Extracellular recordings of 
epileptic activity before (left) and after (right) addition of 50μM D-AP5 (A), 20μM NBQX (B), and 500nM gabazine (C). D-F. 
Corresponding bar charts of the burst count of each experimental condition. Asterisk indicates significance at p<0.05. Scale 
bars in (A) indicate 4 mV and 10 seconds, in (B) 0.2 mV and 10 seconds, and in (C) 0.05mV and 10 seconds. 
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4.3.3 Pharmacological responsiveness of mitochondrial epilepsy towards 
conventional antiepileptic drugs 
 
Given the novelty of our model in replicating mitochondrial epilepsy, I decided to 
assess the pharmacological response of our model towards clinically used antiepileptic 
drugs. There are currently around 28 licensed-to-use antiepileptic drugs in the UK (Sills, 
2014) for various indications. I have selected a range of antiepileptic drugs from various 
subtypes to test in this model as follow. Since the aim of this pharmacological testing 
was mainly for rapid antiepileptic drug screening, only two concentrations have been 
chosen per each antiepileptic drug; the literature – reported minimal inhibitory 
concentration (MIC) and maximal tolerable concentration (MTC).  
 
4.3.3.1 Sodium channel blockers 
 
Sodium channel blockers are one of the most commonly used and best-
characterized antiepileptic drugs. By preventing the activation of sodium channels, 
these drugs block the voltage-dependent rapid repetitive firing of action potentials 
(Macdonald and Rogawski, 2008). I chose three drugs to test from this subgroup of 
antiepileptics, namely carbamazepine, phenytoin, and lamotrigine (see Figure 4-3).  
Carbamazepine is one of the most widely prescribed ‘first generation’ 
antiepileptic drugs for partial and generalized tonic-clonic seizures (Fertig and Mattson, 
2008). The bath application of carbamazepine (50μM) did not cause any significant 
change in the frequency of epileptiform discharges (13.90 ± 4.99 burst/min baseline vs 
15.36 ± 4.83 burst/min 50μM) and increasing the drugs concentration to its MTC, 100 
μM, still did not cause any significant change (13.48 ± 1.53 burst/min, p>0.05, n=5). 
Lamotrigine, a phenyltriazine derivative, is utilized as monotherapy in paediatric 
patients and as adjunctive treatment for partial and primary and secondary generalized 
seizure in adults (Tomson et al., 2008). Application of lamotrigine (10μM) did not cause 
any significant difference in the frequency of epileptiform discharges (10.86 ± 2.14 
burst/min baseline vs 9.56 ± 1.55 burst/min 10μM) and despite the trend towards a 
decrease in frequency, increasing the concentration to 100μM still did not cause any 
significant change (7.68 ± 0.48 burst/min, p>0.05, n=5). 
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Figure 4-3 Epileptic activity exhibited pharmacoresistance against sodium channel blockers.  A-C Extracellular recordings of 
epileptic activity before (left) and after addition of MIC (middle) and MTC (right) of carbamazepine (A), lamotrigine (B), and 
phenytoin (C). D-F. Corresponding bar charts of the burst count of each experimental condition. Scale bars in (a) indicate 0.5 
mV and 10 seconds, in (b) 2 mV and 10 seconds, and in (c) 0.2mV and 10 seconds .  
 
146 
 
Phenytoin (diphenylhydantoin) is a member of the hydantoin family and is the 
most commonly prescribed agent from the family. It is indicated for partial seizures, 
with or without secondary generalization, and for primary generalized tonic-clonic 
seizures as well as being used as therapy for status epilepticus (Stern et al., 2008). 
The application of diphenylhydantoin (50μM) did not cause any significant difference 
(p>0.05, n=6) in the frequency of epileptiform discharges (12.87 ± 1.05 burst/min 
baseline vs 15.31 ± 4.06 burst/min 50μM) nor did increasing the concentration to 
100μM (13.98 ± 2.71 burst/min).   
 
4.3.3.2 Levetiracetam 
 
Levetiracetam has a unique mechanism of action among the other antiepileptic 
agents in that it binds to the synaptic vesicle SV2A receptor (Lynch et al., 2004). In 
treating patients with mitochondrial epilepsy, levetiracetam is found to be particularly 
useful in controlling myoclonus (Schaefer et al., 2010).  
Applying levetiracetam at a bath concentration of 10μM did not cause any 
significant difference in the frequency of epileptiform discharges (11.52 ± 2.13 
burst/min baseline vs 10.90 ± 1.93 burst/min 10μM). Increasing the concentration to 
100μM still did not significantly modify the frequency of the discharges (9.08 ± 1.41 
burst/min, p>0.05, n=5 – see Figure 4-4). 
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Figure 4-4 Epileptic activity is resistant against levetiracetam application. (A) shows the extracellular recordings of epileptic 
activity before (left) and after addition of 10μM levetiracetam (middle) up to 100 μM (right). (B) shows the corresponding 
bar chart of the burst count of the experimental condition. Scale bar indicate 1mV and 10 seconds.  
 
4.3.3.3 Benzodiazepines 
 
Benzodiazepines are currently used as first line treatment of status epilepticus 
due to their relatively rapid onset of action. It is well established that the primary target 
of benzodiazepines are the postsynaptic GABAA receptor and through allosteric 
binding, they increase the GABA receptor mediated current (Schmidt and Wilensky, 
2008). I chose two different types of benzodiazepines to test; lorazepam, the first-line 
treatment for early stage of status epilepticus, and midazolam, the second-line (see 
Figure 4-5).  
Lorazepam application at 50μM did not cause any significant difference in the 
frequency of epileptiform discharges (9.38 ± 1.80 burst/min baseline vs 8.70 ± 0.63 
burst/min 50μM). Increasing the concentration to 100μM did not cause any significant 
difference in the frequency of the discharges (7.10 ± 0.56 burst/min, p>0.05, n=4). 
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Figure 4-5 Epileptic activity is resistant against benzodiazepine application.  A-B Extracellular recordings of epileptic activity 
before (left) and after addition of 50μM (middle) and 100μM (right) of lorazepam (A) and midazolam (B). C-D. Corresponding 
bar charts of the burst count of each experimental condition. Scale bars in (a) indicate 1 mV and 10 seconds and in (b) 2 mV 
and 10 seconds.  
  
Similar to lorazepam, the bath application of midazolam (50μM) did not cause 
any significant difference in the frequency of epileptiform discharges (11.50 ± 1.27 
burst/min baseline vs 9.80 ± 3.52 burst/min 50μM) and similarly, increasing the 
concentration to 100 μM still did not cause any significant difference (9.16 ± 3.61 
burst/min, p>0.05, n=5). 
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4.3.3.4 Barbiturates 
 
Barbiturates are central nervous system depressants that work by modulation of 
GABAA-R, similar to benzodiazepines but at a different binding site and in a different 
manner. They are used as last-resort treatment for uncontrollable status epilepticus 
(Eadie and Kwan, 2008). Phenobarbitone is the classical anticonvulsant from the 
barbiturate subgroup; but pentobarbitone was chosen as it is much more potent than 
phenobarbitone in its modulation of GABA-R (Olsen, 2002).  
The application of sodium pentobarbital at 100μM caused a reduction in the 
frequency of the epileptiform discharges (9.28 ± 2.67 burst/min baseline vs 2.80 ± 1.42 
burst/min 100μM) but this was not statistically significant (p>0.05, n=5). Increasing the 
concentration to 200μM, however, caused a significant reduction (p<0.05, n=5) in the 
frequency of the epileptiform discharges (0.12 ± 0.12 burst/min).  
 
 
Figure 4-6 Epileptic activity is responsive to sodium pentobarbital application. (A) shows the extracellular recordings of 
epileptic activity before (left) and after addition of 100μM sodium pentobarbital (middle) up to 200 μM (right). (B) shows the 
corresponding bar chart of the burst count of the experimental condition. Scale bar indicates 0.5mV and 10 seconds. Asterisk 
indicates significance at p<0.05. 
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4.3.3.5 Valproate  
 
Valproic acid is a branched-chain fatty acid, whose discovery as an antiepileptic 
drug was a serendipitous coincidence when it was used as a lipophilic vehicle and 
found to have a strong anticonvulsant property. Valproate has multiple anticonvulsant 
properties, including potentiation of GABA-ergic mechanisms, reduction of NMDA-R 
mediated excitation, and use-dependent reduction of the sodium current. Clinically, 
valproate is often used as monotherapy and add-on therapy for partial-onset seizures 
(Beydoun et al., 2008). Available in many formulations, I chose to apply sodium 
valproate as it is water soluble and dissociates rapidly in the tissue to valproic acid.  
The addition of sodium valproate (1mM) to the circulating nACSF did not cause 
any significant change (p>0.05, n=5) to the frequency of the epileptiform discharges 
nor did increasing it up to 2mM (12.26 ± 3.53 burst/min baseline vs 12.36 ± 3.16 
burst/min 1mM vs 12.26 ± 3.90 burst/min 2mM).  
 
Figure 4-7 Epileptic activity is resistant against sodium valproate application.  (A) shows the extracellular recordings of 
epileptic activity before (left) and after addition of 1mM sodium valproate (middle) up to 2mM (right). (B) shows the 
corresponding bar chart of the burst count of the experimental condition. Scale bar indicates 2mV and 10 seconds.  
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4.3.3.6 Perampanel 
 
Perampanel is a relatively new antiepileptic drug with a novel mechanism of 
action in that it is a selective noncompetitive AMPA receptor antagonist (Hanada et al., 
2011). Clinically, perampanel is used as an adjunctive treatment for refractory partial-
onset seizures (French et al., 2013). Considering the response of the epileptiform 
discharges towards antagonism of the AMPA receptor with the competitive antagonist 
NBQX (as shown in section 4.3.2), I expected that the epileptiform discharge would 
also respond towards application of perampanel. Since perampanel is a novel 
antiepileptic drug and is not as well characterized as the other antiepileptic agents, I 
applied perampanel in an increasing cumulative concentration in its therapeutic range 
(0.1-10μM) (see Figure 4-13).   
When perampanel was applied at 0.1μM, there was approximately a 20% 
reduction in the frequency of epileptiform discharges (13.86 ± 2.74 burst/min baseline 
vs 11.00 ± 2.58 burst/min 0.1μM) but this was not statistically significant (p>0.05, n=5). 
Increasing the concentration of perampanel to 0.3μM (8.76 ± 2.56 burst/min), 1μM 
(5.94 ± 2.37 burst/min), 3μM (2.58 ± 1.30 burst/min), and 10μM (0.92 ± 0.59 burst/min) 
caused a statistically significant reduction (p<0.05, n=5) in the frequency of the 
epileptiform discharges respectively. This reduction in epileptiform discharges seems 
to be dose-dependent with an IC50 value of 0.42μM.  
 
152 
 
 
Figure 4-8 There is a dose-dependent reduction in the frequency of the epileptiform discharges following perampanel addition.  
(A) shows the extracellular recordings of epileptic activity following application of 0.1μM, 0.3μM, 1μM, 3μM, and 10μM 
perampanel respectively. (B) shows the corresponding bar chart of the burst count of the experimental condition and (C) shows 
a dose-response curve for perampanel. Scale bar indicates 1mV and 10 seconds. Asterisk indicates significance at p<0.05.  
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4.3.3.7 Summary of pharmacological responses towards antiepileptic drugs 
 
The results presented in section 4.3.3.1 to 4.3.3.6 outlined the pharmacological 
response of the induced mitochondrial epileptic activity towards clinically used 
conventional antiepileptic drugs. In most scenarios, I tested two concentrations of 
these drugs; the minimal inhibitory concentration (MIC) and the maximal tolerable 
concentration (MTC). Figure 4-9 summarizes the pharmacological responses of the 
epileptic activity towards the MIC and MTC of these conventional antiepileptic agents.  
When comparing the normalized percentage of the burst count against baseline 
following application of MIC of the drugs, there was no significant difference (p>0.05) 
between baseline and any of the pharmacological agents (100.00 ± 0.00 % baseline 
vs 116.90 ± 6.93 % carbamazepine, 90.49 ± 3.72 % lamotrigine, 116.70 ± 23.79 % 
phenytoin, 96.63 ± 10.95 % levetiracetam, 101.40 ± 12.20 % lorazepam, 78.13 ± 19.46 % 
midazolam,  53.99 ± 24.06 % pentobarbital, 105.40 ± 7.36 % valproate acid, and 76.05 
± 4.83 % perampanel).  
In contrast, when comparing the normalized percentage following application of 
MTC of the drugs, there was a significant difference (p< 0.05) between baseline 
(100.00 ± 0.00 %) and pentobarbital (13.22 ± 13.22 %), as well as perampanel (4.79 ± 
3.10 %). There was still no significant difference (p>0.05) between baseline and any 
of the remaining pharmacological agents (123.30 ± 18.67 % carbamazepine, 80.87 ± 
13.63 % lamotrigine, 105.80 ± 13.29 % phenytoin, 81.11 ± 6.70 % levetiracetam, 85.74 
± 10.15 % lorazepam, 72.27 ± 20.32 % midazolam, and 91.30 ± 9.72 % valproate acid).  
Therefore, out of all the tested conventional antiepileptic drugs, only sodium 
pentobarbital and perampanel demonstrated efficacy in this in vitro model of 
mitochondrial epilepsy. Furthermore, the higher concentration range (nearing MTC) is 
required with these two agents to demonstrate significant efficacy.   
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Figure 4-9 Summary of the response of the induced mitochondrial epileptiform discharges to the treatment with 
conventional antiepileptic agents.  (A) shows the percentage of the burst count against baseline in the various experimental 
conditions using the minimal inhibitory concentration (MIC) of the conventional antiepileptic agents whereas (B) shows the 
percentage of the burst count against baseline when using the maximal tolerable concentration (MTC) of the same 
conventional antiepileptic agents. Asterisk indicates significance at p<0.05 when compared against the baseline. CBZ – 
carbamazepine, LAM – lamotrigine, DPH – diphenylhydantoin (phenytoin), LEV – levetiracetam, LZ – lorazepam, MZ – 
midazolam, PB – sodium pentobarbital, VPA – valproate acid, PER – perampanel.  
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4.3.4 Pharmacological responses towards substrates of the ketogenic diet 
 
As mentioned above, ketogenic diet represents a form of dietary intervention that 
is commonly used in children with intractable seizures (Branco et al., 2016) and has 
shown promises in controlling pharmacoresistant seizures in children with 
mitochondrial epilepsy (Kang et al., 2007). Despite its well documented effectiveness 
in controlling intractable seizures, the mechanism whereby the ketogenic diet exerts 
its antiepileptic effect is largely unknown. Several components of the ketogenic diet 
have been identified to exhibit anticonvulsant or neuroprotective properties, including 
the ketone bodies themselves (β-hydroxybutyrate, acetone, and acetoacetate) (Rho et 
al., 2002; Minlebaev and Khazipov, 2011) and the medium-chain fatty acids (such as 
decanoic acid and octanoic acid) (Hughes et al., 2014; Chang et al., 2015; Thevenet 
et al., 2016). Considering this, I have chosen to examine the effect of acute application 
of three components of the ketogenic diet; β-hydroxybutyrate, decanoic acid, and 
octanoic acid; in this model of mitochondrial epilepsy.  
 
4.3.4.1 Βeta-hydroxybutyrate (β-HB) 
 
Beta-hydroxybutyrate, along with acetone and acetoacetate, are collectively 
called the ketone bodies. They are formed from acetyl CoA when lipolysis is the 
predominant metabolic pathway in vivo (Berg et al., 2012e). The brain preferentially 
uses the ketone bodies as metabolic fuel during chronic starvation (Berg et al., 2012e) 
and the ketogenic diet aims to simulate this through a high-fat, low-carbohydrate 
dietary intervention. Unsurprisingly, then, the ketogenic diet leads to a high presence 
of the ketone bodies in the blood, ketosis (Neal et al., 2008). To replicate this, I applied 
onto the circulating artificial cerebrospinal fluid increasing concentrations of the beta-
hydoxybutyrate to examine its acute anticonvulsant properties (see Figure 4-10). 
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Figure 4-10 There is a dose-dependent reduction in epileptiform discharges following DL-β-hydroxybutyrate acute application.  
(A) shows the extracellular recordings of epileptic activity following application of 2mM, 5mM, 10mM, and 20mM DL-β-
hydroxybutyrate respectively. (B) shows the corresponding bar chart of the burst count of the experimental condition and (C) 
shows a dose-response curve for β-hydroxybutyrate. Scale bar indicates 0.1mV and 10 seconds. Asterisk indicates significance 
at p<0.05. 
 
Application of DL-β-hydroxybutyrate at 2mM caused approximately 20% 
reduction in epileptiform discharges (16.52 ± 2.69 burst/min baseline vs 12.58 ± 1.96 
burst/min 2mM) and this was not statistically significant (p>0.05, n=5). However, 
increasing the concentration to 5mM (8.44 ± 1.36 burst/min), 10mM (3.84 ± 1.36 
burst/min), and 20mM (3.22 ± 1.24 burst/min) caused a statistically significant (p<0.05, 
n=5) reduction in epileptiform discharges respectively. There appears to be a dose-
dependent reduction in epileptiform discharges and hence, a dose-response curve was 
tabulated to obtain the IC50 value of 5.16mM.  
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4.3.4.2 Decanoic acid (C10) 
 
Although the increased production of the ketone bodies is the main goal of the 
ketogenic diet, it is not a component of the diet itself. The components of the diet, the 
medium chain fatty acids, lead to the production of the ketone bodies after undergoing 
metabolism in vivo. The two main components of the ketogenic diet, octanoic acid (C8) 
and decanoic acid (C10), are also detectable in the plasma of the children on ketogenic 
diet, in addition to the ketone bodies (Haidukewych et al., 1982). Although it has been 
shown that the level of these fatty acids in the plasma does not correlate with seizure 
control (Sills et al., 1986), more recent studies on animal models have revived the 
interest in these fatty acids.  
In particular, decanoic acid (C10) has been demonstrated to exhibit acute 
anticonvulsant properties in the pentylenetetrazol (PTZ) and low-Mg2+ model of 
epilepsy (Chang et al., 2013; Chang et al., 2015). Through works on the Xenopus 
oocytes, decanoic acid was suggested to directly inhibit the AMPA-R acutely (Chang 
et al., 2015). Hitherto, I have applied two inhibitors of the AMPA-R (NBQX in section 
4.3.2 and perampanel in section 4.3.3.6) and both of them were suppressive in this 
model of mitochondrial epilepsy. Therefore, to examine the inhibitory potential of 
decanoic acid (C10), I applied it onto the circulating NACSF in an increasing 
concentration, ranging from 100μM to 2mM (see Figure 4-11). 
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Figure 4-11 There is a dose-dependent reduction in the frequency of the epileptic activity following decanoic acid applications. 
(A) shows the extracellular recordings of epileptic activity following application of 100μM, 300μM, 1mM, and 2mM decanoic 
acid respectively. (B) shows the corresponding bar chart of the burst count of the experimental condition and (C) shows a dose-
response curve for decanoic acid. Scale bar indicates 0.1mV and 10 seconds. Asterisk indicates significance at p<0.05. 
 
Application of decanoic acid at 100μM and 300μM caused a reduction in the 
frequency of the epileptiform discharges (15.26 ± 4.22 burst/min baseline vs 12.48 ± 
4.34 burst/min 100μM vs 6.82 ± 2.39 burst/min 300μM), however, this was not 
statistically significant (p>0.05, n=5). Increasing the concentration to 1mM (1.86 ± 0.91 
burst/min) and 2mM (0.38 ± 0.38 burst/min), however, caused a statistically significant 
(p<0.05, n=5) decrease in the burst count. This reduction is dose-dependent with an 
IC50 value of 230.6μM.  
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4.3.4.3 Octanoic acid (C8) 
 
As mentioned above, not only decanoic acid but also octanoic acid was found on 
the plasma of children on ketogenic diet (Haidukewych et al., 1982). Interestingly, 
unlike decanoic acid, octanoic acid was found to have no inhibitory effect in the PTZ 
model of epilepsy (Chang et al., 2013). Furthermore, octanoic acid was also shown to 
not modulate the AMPA-R activity, unlike decanoic acid (Chang et al., 2015). Therefore, 
if the inhibitory effect of decanoic acid was truly due to its property in the AMPA-R 
modulation, then the application of octanoic acid would yield no inhibitory effect in this 
model of mitochondrial epilepsy. Hence, I added octanoic acid at a similar 
concentration range of decanoic acid to directly compare the effect of the two fatty 
acids (see Figure 4-12). 
 
 
Figure 4-12 There is a dose-dependent reduction in the frequency of the epileptic activity following octanoic acid application.  
(A) shows the extracellular recordings of epileptic activity following application of 100μM, 300μM, 1mM and 2mM octanoic 
acid respectively. (B) shows the corresponding bar chart of the burst count of the experimental condition and (C) shows a 
dose-response curve for octanoic acid. Scale bar indicates 0.1mV and 10 seconds. Asterisk indicates significance at p<0.05.  
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Similar to decanoic acid, application of octanoic acid at 100μM and 300μM 
caused a reduction in the frequency of the epileptiform discharges (12.68 ± 5.16 
burst/min baseline vs 5.95 ± 1.62 burst/min 100μM vs 4.88 ± 2.09 burst/min 300μM), 
however, this was not statistically significant (p>0.05, n=6). When I increased the 
concentration to 1mM (1.95 ± 0.87 burst/min) and 2mM (0.15 ± 0.09 burst/min), 
however, this caused a statistically significant (p<0.05, n=6) reduction in the burst 
count. This reduction is dose-dependent with an IC50 value of 134.2μM, which suggests 
that octanoic acid is more potent than decanoic acid in inhibiting the epileptiform 
discharges.  
 
4.3.5 Pharmacological responses towards substrates of glycolysis 
 
Under most physiological conditions, glucose is the obligatory main substrate for 
the brain (McKenna et al., 2006). The only pathway by which glucose enters energy 
metabolism is through the cytoplasmic process of glycolysis. In my model, I have 
inhibited both the (astrocytic) Krebs cycle and the mitochondrial respiratory chain; the 
downstream process of glucose metabolism. Since glycolysis remains uninhibited, I 
postulated that the slices would upregulate glycolysis to meet the brain’s energy 
requirement. Therefore, the addition of various substrates of glycolysis may rescue the 
epileptiform discharges induced through the restoration of the energy crisis induced by 
the mitochondrial epilepsy induction.  
 
4.3.5.1 Glucose 
 
As mentioned above, glucose is the main metabolic substrate of the brain. High 
glucose utilization has been reported during a state of seizure (Scorza et al., 2002) and 
if glycolysis is upregulated, increasing extracellular availability of glucose might be 
crucial to maximize the reserve capacity of tissue’s glycolysis. To examine this effect, 
I have applied increasing concentrations of glucose to the circulating aCSF bath, 
ranging from 2mM to 20mM (see Figure 4-13). It is important to note that the addition 
of the glucose is in addition to the pre-existing 10mM D-glucose in the aCSF 
composition.  
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Figure 4-13 There is a dose-dependent reduction in the frequency of epileptiform discharges following extra addition of glucose.  
(A) shows the extracellular recordings of epileptic activity following application of 2mM, 5mM, 10mM, and 20mM D-glucose 
respectively. (B) shows the corresponding bar chart of the burst count of the experimental condition and (C) shows the dose-
response curve for glucose. Scale bar indicates 0.05mV and 10 seconds. Asterisk indicates significance at p<0.05.  
 
Applying D-glucose at 2mM and 5mM caused an insignificant (p>0.05, n=6) 
reduction in the epileptiform discharges as compared against baseline (22.97 ± 5.61 
burst/min baseline vs 20.70 ± 5.61 burst/min 2mM vs 17.27 ± 4.20 burst/min 5mM). 
Application at 10mM and 20mM, however, caused a significant (p<0.05, n=6) reduction 
in the epileptiform discharges (14.67 ± 4.56 burst/min 10mM and 4.57 ± 2.05 burst/min 
20mM respectively). There does appear to be a dose-dependent reduction in the 
frequency of the epileptiform discharges with the addition of glucose (IC50 = 10.27mM).  
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4.3.5.2 Pyruvate 
 
Pyruvate is the end product of glycolysis. It has multiple fates following glycolysis; 
it can either enter oxidative metabolism through conversion to acetyl CoA or in 
anaerobic conditions, it can be reduced to lactate by the enzyme lactate 
dehydrogenase (Berg et al., 2012f). Knowing that the addition of glucose can suppress 
the epileptiform discharges, I decided to apply pyruvate extracellularly at the same 
concentration range in order to compare the two substrates.  
 
Figure 4-14 There is a dose-dependent reduction in the frequency of epileptiform discharges following addition of pyruvate.  
(A) shows the extracellular recordings of epileptic activity following application of 2mM, 5mM, 10mM , and 20mM sodium 
pyruvate. (B) shows the corresponding bar chart of the burst count of the experimental condition and (C) shows the dose-
response curve for pyruvate. Scale bar indicates 0.05mV and 10 seconds. Asterisk indicates significance at p<0.05.  
 
Pyruvate application at 2mM and 5mM did not cause a significant reduction 
(p>0.05, n=14) in the frequency of the epileptiform discharges as compared against 
baseline (12.69 ± 1.53 burst/min baseline vs 9.45 ± 1.53 burst/min 2mM vs 7.81 ± 1.64 
burst/min 5mM). Increasing the concentration to 10mM and 20mM, however, caused 
a significant (p<0.05, n=14) reduction in the epileptiform discharges (5.88 ± 1.48 
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burst/min 10mM and 3.36 ± 0.93 burst/min 20mM). This reduction in the frequency of 
epileptiform discharges appears to be dose-dependent with an IC50 value of 7.74mM.  
 
4.3.5.3 Lactate 
 
Lactate is generated from pyruvate by the enzyme lactate dehydrogenase in an 
anaerobic manner (Berg et al., 2012f). In the brain, it has been postulated that lactate, 
generated from astrocyte’s glycolysis, is released by the astrocyte and preferentially 
used by neurons as metabolic substrate during increased neuronal activity (Pellerin 
and Magistretti, 1994). This is also known as the ‘astrocyte-neuron lactate shuttle 
hypothesis’ (Chih and Roberts, 2003). If the ‘astrocyte-neuron lactate shuttle 
hypothesis’ is applicable in this model, then the inhibitory effect of glucose and 
pyruvate as shown above in section 4.3.5.1 and 4.3.5.2 respectively could be through 
their respective conversion to lactate in the astrocyte’s glycolytic process. To test this 
hypothesis, I applied equimolar concentration of lactate to the circulating aCSF bath 
as used with glucose and pyruvate (see Figure 4-15).  
The addition of 2mM, 5mM, or 10mM L-lactate did not cause any significant 
reduction (p>0.05, n=5) in the frequency of the epileptiform discharges (21.70 ± 7.47 
burst/min baseline vs 22.24 ± 6.71 burst/min 2mM vs 20.08 ± 5.73 burst/min 5mM vs 
20.34 ± 7.93 burst/min 10mM). Surprisingly, however, adding 20mM L-lactate caused 
a sudden significant reduction (p<0.05, n=5) in the frequency of the epileptiform 
discharges (8.44 ± 3.29 burst/min 20mM).  
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Figure 4-15 Epileptiform discharge is only suppressed by the addition of very high concentration of lactate.  (A) shows the 
extracellular recordings of epileptic activity following application of 2mM, 5mM, 10mM, and 20mM L-lactate respectively. (B) 
shows the corresponding bar chart of the burst count of the experimental condition. Scale bar indicates 0.05mV and 10 seconds. 
Asterisk indicates significance at p<0.05.  
 
4.3.5.4 Modulating glycolysis through stiripentol 
 
 
Stiripentol is a clinically used antiepileptic agent for children with Dravet 
syndrome (Chiron et al., 2000; Inoue et al., 2009). The motivation to test stiripentol in 
this model developed from recent findings that stiripentol was able to inhibit the 
glycolytic enzyme, lactate dehydrogenase (Sada et al., 2015). However, this effect was 
only seen at very high concentration of stiripentol (500μM) (Sada et al., 2015) and at 
lower concentrations, stiripentol has been shown to modulate GABAA-R mediated 
neurotransmission (Quilichini et al., 2006; Fisher, 2011). Since the metabolic 
modulation was only seen at high concentrations, I decided to apply stiripentol through 
a gradually increasing concentration, ranging from the MIC (30μM) to the 
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supraphysiological concentration (500μM), unlike the experiments with the other 
antiepileptic drugs (as conducted in section 4.3.3). 
 
 
Figure 4-16 There is a dose-dependent reduction in the frequency of the epileptiform discharges following the addition of 
stiripentol.  (A) shows the extracellular recordings of epileptic activity following application of 30μM, 100μM, 300μM, and 
500μM of stiripentol respectively. (B) shows the corresponding bar chart of the burst count of the experimental condition 
and (C) shows the dose-response curve for stiripentol. Scale bar indicates 0.2mV and 10 seconds. Asterisk indicates 
significance at p<0.05.  
 
At 30μM and 100μM, stiripentol did not cause any significant change (p>0.05, 
n=5) in the frequency of the epileptiform discharges (11.84 ± 3.85 burst/min baseline 
vs 11.32 ± 3.30 burst/min 30μM vs 9.90 ± 3.19 burst/min 100μM). Increasing the 
concentration to 300μM and 500μM caused a statistically significant reduction (p<0.05, 
n=5) in the burst count (7.52 ± 2.26 burst/min 300μM and 6.84 ± 2.85 burst/min 500μM    
respectively). This inhibition of epileptiform discharges is dose-dependent with an IC50 
of 384.10μM.  
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4.3.6 Pharmacological responses towards substrates of the glutamate-
glutamine cycle 
 
The glutamate-glutamine cycle represents an important astrocytic process that 
is involved in the recycling of neurotransmitters, including glutamate and GABA (Bak 
et al., 2006). Both neurotransmitters are recycled through the astrocytic TCA cycle and 
are regenerated through the formation of glutamine, the non-neuroactive precursor to 
both neurotransmitters. Since the astrocytic TCA cycle is directly inhibited in our model 
by the application of fluorocitrate, it can be hypothesized that downstream inhibition of 
the glutamate-glutamine cycle would occur. Therefore, the restoration of the cycle 
through external addition of the substrates of this cycle could potentially restore the 
metabolic dysfunction and suppress the epileptiform activity induced.  
 
4.3.6.1 Glutamate 
 
Glutamate is the major excitatory neurotransmitters in the brain, but in addition 
to this role in neurotransmission, glutamate is also involved in a lot of metabolic 
pathways in the nervous system, including the glutamate-glutamine cycle, the 
detoxification of ammonia, and the synthesis of peptides and glutathione (Cooper et 
al., 2003). Therefore, the effect of glutamate should not be evaluated solely on its 
metabolic role as a substrate for the glutamate-glutamine cycle.  
As described previously, the AMPA-R is implicated in the seizure generation (as 
discussed above in section 4.3.2, 4.3.3.6, and 4.3.4.2). In addition to AMPA, glutamate 
is a specific agonist for the AMPA-R (Gouaux, 2004). Therefore, since the inhibition of 
AMPA-R was able to suppress the epileptic activity significantly, the supplementation 
of agonist of this receptor is expected to increase the frequency of the epileptic activity 
instead. However, the metabolic role of glutamate, should it predominate over its role 
in neurotransmission, suggests that glutamate could suppress the epileptic activity, 
just like other metabolic substrates described above, like glucose, DL-β-
hydroxybutyrate, and pyruvate.  
Taking this into consideration, I applied glutamate at concentrations sufficient 
enough for it to be used as a metabolic substrate (see Figure 4-17).  
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Figure 4-17 Epileptic activity is not responsive towards L-glutamate application.  (A) shows the extracellular recordings of 
epileptic activity following application of 0.5mM and 2.5mM L-glutamate. (B) shows the corresponding bar chart of the 
burst count of the experimental condition. Scale bar indicates 0.2mV and 10 seconds. 
 
The application of glutamate at either 0.5mM or 2.5mM did not cause any 
significant change (p>0.05, n=6) in the frequency of the epileptiform discharges (10.83 
± 1.59 burst/min baseline vs 12.12 ± 1.55 burst/min 0.5mM vs 11.98 ± 1.56 burst/min 
2.5mM). There was, therefore, no effect whatsoever, neither metabolic nor 
neurotransmission associated, from the external supplementation of L-glutamate.  
 
4.3.6.2 GABA 
 
In contrast to glutamate, GABA is the major inhibitory neurotransmitters in the 
brain. However, similarly to glutamate, GABA is also involved as a metabolic substrate 
in the brain, including the glutamate – glutamine cycle and as precursor to many other 
substrates, including carnitine and γ-hydroxybutyrate (GHB) (Cooper et al., 2003). 
Therefore, similar to glutamate, the pharmacological effect of GABA should be 
considered from both a metabolic and a neurotransmission standpoint.  
 Again, from results presented in the previous sections (specifically section 4.3.2, 
4.3.3.3, and 4.3.3.4), the inhibition of GABAA-R (with gabazine) caused an increase in 
the frequency of the epileptiform discharges and conversely, the potentiation of 
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GABAA-R (with barbiturates) caused a significant suppression of the epileptiform 
discharges. Although GABAA-R has many potential ligands, GABA is the only 
endogenous agonist for the GABAA-R (Bergmann et al., 2013). Therefore, the addition 
of GABA, as a GABAA-R agonist, would be expected to suppress the epileptiform 
discharges. Similarly, as a metabolic substrate of the glutamate – glutamine cycle, 
GABA could also suppress the epileptiform discharges through metabolic modulation 
of the cycle. Therefore, if a suppressive effect is seen with the administration of GABA, 
it is still difficult to dissociate whether it is due to a receptor-mediated or a metabolic 
effect.  
 Putting this into consideration, I applied GABA at concentrations similar to 
glutamate where it should be at sufficient level to be used as a metabolic substrate 
(see Figure 4-18). 
 
Figure 4-18 Epileptic activity is responsive to the application of GABA.  (A) shows the extracellular recordings of epileptic 
activity following application of 0.5mM and 2.5mM GABA. (B) shows the corresponding bar chart of the burst count of the 
experimental condition. Scale bar indicates 0.05mV and 10 seconds. Asterisk indicates significance at p<0.05.  
 
Application of GABA at 0.5mM did not cause any significant change (p>0.05, 
n=8) to the frequency of the epileptiform discharges (15.79 ± 2.94 burst/min baseline 
vs 11.85 ± 3.13 burst/min 0.5mM). Increasing the concentration to 2.5mM, however, 
caused a significant (p<0.05, n=8) suppression of the epileptiform discharges (1.58 ± 
1.20 burst/min 2.5mM).  
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4.3.6.3 Glutamine 
 
Glutamine is at the core of the astrocytic glutamate – glutamine cycle, as it is 
the precursor to both glutamate and GABA. The enzyme used to produce glutamine, 
glutamine synthetase, is primarily expressed in astrocytes (Anlauf and Derouiche, 
2013). Therefore, glutamine represents an important mechanism in the interaction 
between astrocyte and neurons whereby recycling of both the excitatory and inhibitory 
neurotransmitters occur via astrocytic metabolism.  
Considering the importance of glutamine for the glutamate – glutamine cycle, I 
applied equimolar concentration of glutamine as was used in the experiments with 
glutamate and GABA (see Figure 4-19). 
 
Figure 4-19 Epileptic activity is responsive to L-glutamine addition.  (A) shows the extracellular recordings of epileptic activity 
following application of 0.5mM and 2.5mM L-glutamine. (B) shows the corresponding bar chart of the burst count of the 
experimental condition. Scale bar indicates 0.05mV and 10 seconds. Asterisk indicates significance at p<0.05. 
 
There was a similar pattern of response by the epileptic tissue to L-glutamine 
as was demonstrated with GABA. Application at 0.5mM did not cause any significant 
change (p>0.05, n=5) in the frequency of the epileptiform discharges (22.60 ± 3.17 
burst/min baseline vs 19.60 ± 1.93 burst/min 0.5mM). Increasing the concentration to 
2.5mM caused a statistically significant reduction (p<0.05, n=5) in the frequency of the 
epileptiform discharges (8.55 ± 2.42 burst/min 2.5mM).  
 
170 
 
4.3.7 Synergism between benzodiazepine and GABA 
 
Hitherto, our results have shown that the GABAergic system, involving the 
GABAA-R, is heavily implicated in the process of seizure generation. Both 
benzodiazepine and barbiturates have a well characterized binding site as the 
allosteric modulator of the GABAA-R s (Kucken et al., 2000; Greenfield Jr, 2013). It is 
well characterized, however, that barbiturates can directly activate the GABAA-R, even 
in the absence of GABA (Rho et al., 1996). In contrast, benzodiazepines cannot 
activate the GABAA-R when the tissue is devoid of GABA, even when it is administered 
at a very high concentration (Schmidt and Wilensky, 2008; Krisko et al., 2017). The 
discrepancy in the response of the epileptiform discharges in this model to 
benzodiazepines and barbiturates suggested that the tissue might be devoid of GABA, 
hence the lack of response of the benzodiazepines.  
To investigate this hypothesis, I devised an experiment to assess the synergistic 
effect in the co-application of the benzodiazepine, lorazepam, and GABA (see Figure 
4-20). I have chosen the lower concentration range of GABA (0.5mM), where it has 
been shown that there was no significant suppressive effect from this concentration of 
GABA. Similarly, I have chosen the minimal inhibitory concentration of lorazepam, 
50µM.  
The application of lorazepam at 50µM on its own caused an increase in the 
frequency of the epileptiform discharges by 1.69 ± 15.77% (n=4) whereas the 
application of GABA at 0.5mM on its own suppressed the frequency of the discharges 
by 28.69 ± 7.29 % (n=6). These two effects are significantly different (p<0.05) when 
compared with the co-application of 50µM lorazepam and 0.5mM GABA, which caused 
a 77.75 ± 8.43 % suppression in the frequency of the epileptiform discharges (n=4).  
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Figure 4-20 There is a synergistic effect with the co-application of the benzodiazepine lorazepam and GABA.  (A) shows the 
electrophysiological recordings obtained following the application of 50µM lorazepam alone (left), 0.5mM GABA alone 
(middle), and 50µM lorazepam and 0.5mM GABA together (right). (B) shows the corresponding bar chart summarizing the 
percentage change in the frequency of epileptiform discharges induced by each of the experimental conditions. Scale bar in 
(A) left indicates 0.1mV and 10 seconds and in (A) middle and right indicates 0.05mV and 10 seconds. 
 
This synergistic effect between benzodiazepine and GABA again suggested 
that the lack of response of the epileptiform discharges in this model to benzodiazepine 
administration is potentially due to the reduction in the epileptic tissue concentration of 
GABA.  
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4.3.8 The use of mitochondrial – targeting compounds 
 
At present, there is no evidence-based therapeutic intervention for 
mitochondrial disease. Most physicians have reported the use of various vitamins, 
nutritional supplements, antioxidants, and mitochondrial – targeting compounds in their 
care for patients with mitochondrial disease (Parikh et al., 2009). Various anecdotal 
evidences and small studies have reported promising effects of the use of these 
compounds (Parikh et al., 2009; Frantz and Wipf, 2010; Pfeffer et al., 2012; Avula et 
al., 2014). Although none of these compounds were specifically examined for their 
anticonvulsant properties, their modulation of mitochondrial function may represent a 
novel approach to the treatment of mitochondrial epilepsy. Therefore, I decided to 
examine some of the more promising compounds for their potential anticonvulsant 
properties in this in vitro model of mitochondrial epilepsy.  
 
4.3.8.1 Coenzyme Q10 (CoQ10) 
 
Coenzyme Q10 (CoQ10) is a natural electron acceptor in the electron transport 
chain and has been demonstrated to exhibit strong antioxidant properties (Frantz and 
Wipf, 2010). Although primarily used for mitochondrial disease with a pathogenic 
mutation resulting in primary CoQ10 deficiency, it has shown promising effects in 
patients with secondary CoQ10 deficiency as well (Hargreaves, 2014). By far, the 
prevalent expert opinion in the use of CoQ10 in patients with mitochondrial disease is 
that it is beneficial (Parikh et al., 2009). Therefore, I decided to apply CoQ10 acutely 
to the induced epileptic activity to examine its anticonvulsant activity (see Figure 4-21). 
The application of coenzyme Q10 (CoQ10) at 100μM up to 200μM did not cause 
a significant change (p>0.05, n=5) in the frequency of the epileptiform discharges (9.56 
± 1.03 burst/min baseline vs 10.08 ± 2.39 burst/min 100μM vs 10.40 ± 3.04 burst/min 
200μM). This suggests that coenzyme Q10 has exhibited no anticonvulsant properties 
and is probably not of benefit to patients with mitochondrial disease with epileptic 
component.  
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Figure 4-21 Coenzyme Q10 did not exhibit any anticonvulsant property.  (A) shows the extracellular recordings of the epileptic 
activity before (left) and after addition of 100μM of coenzyme Q10 (CoQ10) (middle) up to 200μM (right). (B) shows the 
corresponding bar chart of the burst count of the experimental condition. Scale bar indicates 0.1mV and 10 seconds.  
 
4.3.8.2 Bezafibrate 
 
Bezafibrate is a hypolipidemic drug that is commonly used for patients with 
dyslipidemia (Krisko et al., 2017). The mechanisms whereby bezafibrate exerts its 
pharmacological effect is through the activation of the peroxisome proliferator-
activated receptor α (PPARα) (Krisko et al., 2017). In the brain, PPARα is shown to be 
expressed strongly in the neurons and moderately in the astrocytes (Warden et al., 
2016) and in the hippocampus, PPARα has been shown to exhibit a role in the process 
of learning and memory, through the modulation of synaptic function (Roy et al., 2013).  
Bezafibrate, itself, has been shown to exhibit promising effects in patients with 
mitochondrial disease (Bonnefont et al., 2009). This effect is replicated in vitro through 
the demonstration that it can correct mitochondrial respiratory chain deficiency through 
stimulating mitochondrial biogenesis (Bastin et al., 2008; Johri et al., 2012; Yatsuga 
and Suomalainen, 2012). Again, similar to coenzyme Q10, bezafibrate has not been 
evaluated for its anticonvulsant properties but due to its well established effect on the 
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modulation of mitochondrial function via the PPAR system, I believe it is worthwhile to 
investigate the effect of acute application of bezafibrate in this model of mitochondrial 
epilepsy.  
 
Figure 4-22 Bezafibrate exhibited an anticonvulsant property in the in vitro model of mitochondrial epilepsy.  (A) shows the 
extracellular recordings of the epileptic activity before (left) and after addition of 10μM of bezafibrate (middle) up to 100μM 
(right). (B) shows the corresponding bar chart of the burst count of the experimental condition. Scale bar indicates 0.2mV and 
10 seconds.  
 
Applying bezafibrate at 10μM and up to 100μM caused a statistically significant 
reduction (p<0.05, n=7) in the frequency of the epileptiform discharges (17.90 ± 2.55 
burst/min baseline vs 13.03 ± 2.92 burst/min 10μM vs 10.29 ± 2.26 burst/min 100μM). 
This suggests that unlike coenzyme Q10, bezafibrate exhibited potential use as 
anticonvulsant in mitochondrial epilepsy.  
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4.4 Discussion 
 
4.4.1 Execution of an in vitro pharmacological study 
 
The process of conducting any pharmacological study requires a number of 
critical experiments to be done to verify the validity of the study. First and foremost, a 
stable system is required for the pharmacological intervention to be conducted on. One 
must be certain that the system would not fluctuate or deteriorate over time regardless 
of the drug application. In this model of mitochondrial epilepsy, a period of stability of 
the epileptiform discharges has been described previously (see section 3.3.5). 
Specifically, the epileptic network manifested as a stable interictal activity over a period 
of 2 hours after 120 minutes of incubation with the rotenone and cyanide. The natural 
progression of the frequency of the interictal activity over this 2-hour time period is 
within a 10% variation, resulting in a relatively stable system. Therefore, all of the 
pharmacological experiments discussed in this chapter is conducted over this 2-hour 
stable time period.  
Next, the ‘vehicle effect’ needs to be demonstrated and addressed before any 
conduct of a pharmacological study. A ‘vehicle effect’ is an effect whereby the vehicle 
formulation caused a change towards the system on its own, in the absence of the 
active compounds tested (Sanchez et al., 2001). This is particularly important for 
evaluating newer compounds, which tend to be highly lipophilic and poorly water 
soluble (Bittner and Mountfield, 2002). In this study, the two vehicles that I have used 
for the dissolution of all of the pharmacological compounds are distilled water (dH2O) 
for hydrophilic compounds and dimethyl sulfoxide (DMSO) for lipophilic compounds. I 
have assessed the effects of cumulative addition of increasing concentrations of dH2O 
(up to 1%) and DMSO (up to 0.1%) on the frequency of the epileptiform discharges 
over the 2 hour stable time period (see section 4.3.1). There was no significant 
difference whatsoever following the application of either dH2O or DMSO up to their 
respective highest concentration range. Therefore, the impact of ‘vehicle effect’ in this 
model of mitochondrial epilepsy can be excluded and any pharmacological responses 
described in this chapter can be confidently attributed to the pharmacological actions 
of the drugs.  
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4.4.2 Receptor contributions in mitochondrial epilepsy 
 
As mentioned above in section 4.3.2, previous works on the characterization of 
epilepsy models in acute brain slices have implicated the contribution of various 
glutamatergic and GABA-ergic receptor in the process of epileptogenesis (Williamson 
and Wheal, 1992; Isaeva et al., 2010). The receptors that are most commonly 
associated with seizure generation are the ionotropic glutamatergic receptors, N-
methyl-D-aspartate (NMDA) receptor and the α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA) receptor, as well as the ionotropic GABAergic 
receptor, the GABAA receptor.  
The NMDA, AMPA, and GABAA receptors are all ionotropic receptors. This 
means that they mediate fast synaptic responses through the facilitation of the flow of 
ions across the plasma membranes. In the case of NMDA and AMPA, they respond to 
their endogenous ligand, glutamate, and allows the flow of cations (usually Na+ or K+) 
and in the case of GABAA, it allows the flow of anions (Cl-) in response to its 
endogenous ligand, GABA (Forman et al., 2017).  
The NMDA receptor is constitutively expressed mostly in neuronal cells 
throughout the whole brain, particularly in the hippocampus, cerebellum, and the 
cerebral cortex (Moriyoshi et al., 1991). The NMDA receptor is unique to the other 
ionotropic glutamate receptors in that it requires the binding of both glutamate and 
glycine for the activation of the channel, as well as their dependence on an intense 
trains of presynaptic activity for the removal of the receptor block by the magnesium 
ion (Mg2+) (Forman et al., 2017). D-AP5 (D-(-)-2-amino-5-phosphonopentanoic acid) is 
a competitive NMDA receptor antagonist at the glutamate binding site. The application 
of D-AP5 caused no significant change in the frequency of the epileptiform discharges. 
This indicates that there is no contribution from the NMDA receptor towards the 
generation of epileptiform activity in this model of mitochondrial epilepsy. This is 
unsurprising as NMDA receptor activation in epileptic tissue is typically a secondary 
process, associated with the spread of the epileptic activity rather than seizure initiation 
(Rogawski, 2013; Forman et al., 2017).  
Unlike the NMDA receptor, the AMPA receptor mediate a larger proportion of 
excitatory neurotransmission and is expressed in an activity-dependent manner 
(Rogawski, 2013). Furthermore, functional AMPA receptor has been found to be 
expressed not only in hippocampal neurons, but also in the astrocytes (Martin et al., 
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1993; Hall and Soderling, 1997; Fan et al., 1999). NBQX (2,3-dihydroxy-6-nitro-
7sulfamoyl-benzo[f]quinoxaline-2,3-dione) is a very potent competitive AMPA/KA 
receptor antagonist (Randle et al., 1992). The complete suppression of the epileptic 
activity by application of NBQX implicated the contribution of the AMPA and potentially 
also KA receptor in this model of mitochondrial epilepsy. This corroborates previous 
reports that AMPA receptor is heavily implicated in the onset of an epileptiform activity 
(Rogawski, 2013; Forman et al., 2017). Kainate receptor activation by kainate 
produces epileptic activity in vitro as a kainate model of epilepsy but its activation is 
not usually implicated in other more commonly used epileptic models, such as the 
kindling model (Fritsch et al., 2014). It is generally less well understood than AMPA 
receptor and is more associated with the spread and severity of epileptiform 
discharges, like the NMDA receptor (Vincent and Mulle, 2009).  
The most abundant GABA receptors in the central nervous system are the 
ionotropic GABAA receptor (Forman et al., 2017). The GABAA receptor is widely 
expressed in the brain, in neurons and astrocytes alike (Fraser et al., 1994; 
Galanopoulou, 2008). GABAA receptor is a pentameric receptor with two binding sites 
for its endogenous ligand, GABA, and multiple allosteric sites. Gabazine is a selective 
GABAA receptor antagonist, at the GABA binding site (Forman et al., 2017). 
Antagonism of GABAA receptor by gabazine caused a slight increase in the frequency 
of the mitochondrial epileptiform discharges, although it is not statistically significant. 
This potentially implicates the GABAA receptor as an important modulator of the 
inhibitory neurotransmission in the mitochondrial epilepsy model. Antagonism of 
GABAA-R by addition of exogenous GABA or potentiation of GABAA-R by the allosteric 
modulators such as benzodiazepine or barbiturate may prove to be beneficial in 
controlling the epileptiform discharges in this model of mitochondrial epilepsy. 
Overall, the NMDA receptor has not contributed towards seizure generation in 
this model of mitochondrial epilepsy. The glutamatergic AMPA-R and the GABAergic 
GABAA-R, however, may play a role in the generation of epileptiform discharges in this 
model of mitochondrial epilepsy. These two receptor system may represent an 
important therapeutic target for drug development in mitochondrial epilepsy. 
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4.4.3 Use of antiepileptic drugs in mitochondrial epilepsy 
 
Mitochondrial epilepsy is characteristically known as a very pharmacoresistant 
subtype of epilepsy, with very few seizure control afforded by currently available 
conventional antiepileptics (Bindoff and Engelsen, 2012; Whittaker et al., 2015). 
Antiepileptic drug itself is a diverse family of pharmacological agents that exerts 
anticonvulsant activity through a myriad of mechanisms of actions. To screen the entire 
antiepileptic drug population is time consuming and inefficient so I have sampled some 
relevant antiepileptic drugs from the major subclasses of antiepileptic agents and 
applied the minimal inhibitory concentration (MIC) as well as the maximal tolerable 
concentration (MTC) of each drugs. The conventional drugs that I have chosen are 
sodium channel blockers (specifically carbamazepine, lamotrigine, and phenytoin), 
levetiracetam, benzodiazepines (specifically lorazepam and midazolam), barbiturates 
(specifically pentobarbitone), and valproate acid. I have also screened for two newer 
generation antiepileptic drugs that shows promising potential for use in mitochondrial 
epilepsy; the AMPA receptor antagonist, perampanel; and the metabolic modulator, 
stiripentol.  
The sodium channel blockers act by stabilizing the inactivated state of the 
sodium channel, therefore producing a use-dependent inhibition of action potentials 
(Fertig and Mattson, 2008; Stern et al., 2008; Tomson et al., 2008). The three drugs 
that I have chosen; carbamazepine, lamotrigine, and phenytoin; are clinically indicated 
for slightly different seizure syndromes but they all generally act through the 
inactivation of the sodium channel. These three drugs showed no capacity whatsoever 
in controlling the epileptic activity induced (see Figure 4-3). This corroborates previous 
finding in the low magnesium – high potassium model of epilepsy where the high – 
frequency ictal discharges respond to sodium channel blockers, but not the late 
interictal discharges (Gáll et al., 2017). Since the mechanism of action of these sodium 
channel blockers is through a use-dependent inhibition, it would not be surprising then 
to expect that only the high frequency ictal discharges would be responsive to these 
drugs and not the lower firing rate interictal discharges (Fertig and Mattson, 2008). In 
this model of mitochondrial epilepsy, the randomness of the appearance of the ictal 
discharges prevented me from being able to assess the anticonvulsant properties of 
these drugs towards the ictal discharges. As discussed in section 4.4.1, a stable 
system is required for accurate assessment of a pharmacological response and in this 
model, the stable electrophysiological system is the interictal discharges.  
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 Levetiracetam is a unique antiepileptic drug that exerts its anticonvulsant activity 
through the inhibition of exocytosis of synaptic neurotransmitters via the SV2A receptor 
(Lynch et al., 2004). Clinically, levetiracetam was suggested in existing guideline as 
one of the preferable antiepileptic drug to use for control of seizure in patients with 
mitochondrial epilepsy (Schaefer et al., 2010). The application of levetiracetam in this 
model of mitochondrial epilepsy has shown no effect towards the frequency of the 
epileptiform discharges (see Figure 4-4). This suggests that the epileptic activity in the 
mitochondrial epilepsy model is independent of the contribution of the exocytosis of 
synaptic neurotransmitters. It is very much agreed that levetiracetam binds to SV2A, 
however, very little is known on the function of the SV2A signalling. A recent study has 
suggested that unlike what was previously hypothesized, the SV2A synaptic vesicle 
selectively regulates exocytosis of GABA, rather than glutamate (Tokudome et al., 
2016). This may cast doubt on whether or not the anticonvulsant property of 
levetiracetam is indeed associated with the SV2A system and may be more 
complicated than previously thought. Very little is indeed known about the SV2A 
system and without further elucidation on the function of the SV2A protein, little can be 
speculated from a pathophysiological perspective in explaining the resistance to 
levetiracetam in my model of mitochondrial epilepsy. 
 Benzodiazepine is one of the allosteric modulator of the GABAA receptor. It has 
its own binding site on the GABAA receptor and allosterically modulate the GABA 
receptor current to increase inhibitory tone (Schmidt and Wilensky, 2008). Clinically, 
benzodiazepine is the first line drug for status epilepticus due to its rapid onset of action 
(Schmidt and Wilensky, 2008). I have chosen to evaluate two drugs from the 
benzodiazepine family; the water-soluble formulation, midazolam, and the lipophilic 
formulation, lorazepam. Both benzodiazepines did not cause any significant change in 
the frequency of the epileptiform discharges (see Figure 4-5). This lack of response to 
benzodiazepine does not necessarily exclude the implication of GABAA receptor 
system in the model of mitochondrial epilepsy. As mentioned above, the GABAA 
receptor is composed of many different subunits, and benzodiazepine selectively binds 
to the α-subunit of the GABAA receptor (Smith, 2001). The lack of response to 
benzodiazepines then suggests that the inhibitory modulation via the α-subunit of the 
GABAA receptor is not a prime therapeutic target in mitochondrial epilepsy. 
 Barbiturate is another allosteric modulator of the GABAA receptor. Similar to 
benzodiazepine, it has its own binding site on the GABAA receptor in its allosteric 
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modulation of the inhibitory tone. No specific binding site can be identified due to the 
low affinity of barbiturate towards the receptor, however, it is known to be distinct from 
the benzodiazepine binding site (Bureau and Olsen, 1993). As mentioned above, 
phenobarbitone is the classically used antiepileptic from this subgroup, but 
pentobarbitone is known to be much more potent than phenobarbitone in the 
modulation of GABAA-R (Olsen, 2002), therefore, its use is much more relevant in our 
context to evaluate the contribution of the GABAA-R. The induced mitochondrial 
epileptic activity in this model shows profound responsiveness to the application of 
pentobarbitone. This suggests that the potentiation of GABAA-R inhibitory current, as 
previously hypothesized in section 4.4.2, can indeed suppress the epileptiform 
discharges in this in vitro model of mitochondrial epilepsy. Furthermore, barbiturate is 
also well – characterized as having a dual mechanism as an AMPA-R inhibitor (Joo et 
al., 1999; Forman et al., 2017). Since inhibition of AMPA-R by NBQX was able to 
suppress the epileptiform discharges, the inhibitory effect of barbiturates could be 
mediated through its dual mechanism of actions.  
 This discrepancy between the response of the mitochondrial epileptiform 
discharges to benzodiazepine and barbiturate poses an important question in the 
modulation of the GABAA-R neurotransmission in my model of mitochondrial epilepsy. 
It has been shown in previous study that barbiturates can directly activate the      
GABAA-R at high concentrations, even in the absence of GABA (Rho et al., 1996). 
Unlike barbiturates, benzodiazepines are unable to activate GABAA-R when the tissue 
is devoid of GABA (Krisko et al., 2017). This could potentially explain the discrepancy 
of the pharmacological response in this model. To address this, I co-applied the 
benzodiazepine, lorazepam and low concentration of GABA to evaluate any synergistic 
effect. This resulted in a synergistic summation of inhibitory effect, to almost a complete 
suppression (see Figure 4-20). This experiment suggested that the epileptic tissue in 
my model of mitochondrial epilepsy could have reduced tissue concentration of GABA, 
hence the lack of response of benzodiazepine on its own. It also corroborates the 
contribution of the GABAA-R mediated inhibitory neurotransmission in the development 
of the epileptic activity in this model of mitochondrial epilepsy. 
 Valproic acid is a branched-chain fatty acid, which was surprisingly discovered 
to have a strong anticonvulsant property (Beydoun et al., 2008). Up until the present 
time, there is no single mechanism of action that valproate can be attributed to. Instead, 
it is suggested to have a broad spectrum of activity, including the potentiation of GABA-
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ergic signalling, reduction of NMDA-R mediated excitatory input, and use-dependent 
inhibition of the sodium channel (Löscher, 2002). In this model of mitochondrial 
epilepsy, valproate was found to have no inhibitory effect in the induced epileptiform 
discharges (see Figure 4-7). Mechanistically, there is perhaps no inference that can 
be made in explaining the resistance of the tissue to valproate as there is no single 
agreed mechanism that valproate was expected to act on. However, this resistance to 
valproic acid represents an interesting phenomenon when explaining the role of fatty 
acids in controlling seizure generation in this model of mitochondrial epilepsy (to be 
discussed further below in section 4.4.4). Regardless, valproic acid should be avoided 
as an antiepileptic agent for use in patients with mitochondrial epilepsy due to its well 
characterized hepatotoxicity in this subset of patient (Schaefer et al., 2010; Li et al., 
2015).  
 Hitherto, most of the conventional antiepileptic drugs exhibited little, if any, 
effects on the epileptiform discharges in this model of mitochondrial epilepsy. The only 
pharmacological agents that seemed to exhibit therapeutic potential is barbiturates. 
Even with barbiturates, significant inhibitory effect was only apparent at its reported 
maximal tolerable concentration (200µM). It is important to note that the responses of 
these conventional antiepileptic drugs have only been tested at two concentration 
points that represent the safe and recommended therapeutic range for clinical use of 
these antiepileptic drugs in conventional epileptic patient. However, current clinical 
practice in the management of mitochondrial epilepsy often involves aggressive 
treatment with very high doses of antiepileptic drugs (Schaefer et al., 2010; Whittaker 
et al., 2015), which may not be represented by the concentrations tested in this study. 
Therefore, the lack of responses to these conventional antiepileptic drugs does not 
necessarily suggest the need for immediate exclusion of these drugs in the care of 
patients with mitochondrial epilepsy. This is particularly true for drugs that seemed to 
exhibit clinical efficacy but no responses in this model, such as levetiracetam or 
lamotrigine (Schaefer et al., 2010). Perhaps, these drugs warrant further investigation 
in this model with regards to its effect on a higher than maximal tolerable concentration 
– the suprathreshold concentrations.  
By the definition of ILAE, an epileptic syndrome is classified as 
pharmacoresistant when the epileptic activity fails to respond and achieve sustained 
seizure freedom with adequate trials of two tolerated and appropriately defined 
antiepileptic drug schedules (whether as monotherapies or in combination) (Kwan et 
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al., 2010). If this is to be applied to the context of an animal model, this in vitro brain 
slice model of mitochondrial epilepsy can be classified as a pharmacoresistant 
epilepsy model. Considering the extreme pharmacoresistance that has been displayed, 
it can even be claimed that the epileptic activity in this model presents as a ‘super – 
refractory’ epilepsy. The face validity of the model and the presence of extreme 
pharmacoresistance in this model raised the opportunity to evaluate the use of the 
newer generation of antiepileptic drugs in the context of mitochondrial epilepsy.  
 One such drug is perampanel, a first-in-class antiepileptic drug, with a novel 
mechanism of action on the modulation of AMPA receptor. Unlike NBQX, however, 
perampanel is a noncompetitive selective AMPA receptor antagonist, suggesting that 
it would not be displaced even in conditions where there is a high tissue concentration 
of glutamate (Chen et al., 2014). Considering the responsiveness of the epileptic 
activity in this model to NBQX, perampanel is expected to also be able to suppress the 
induced mitochondrial epileptic activity. Indeed, the application of perampanel caused 
a dose-dependent reduction in the frequency of the epileptiform discharges with an 
almost complete suppression achievable with its MTC of 10μM (see Figure 4-8). The 
IC50 value in this model of 0.42μM is comparable with previously reported IC50 value 
of 0.56μM in the kainate model and 0.23μM in the electrical stimulation of the Schaffer 
collaterals (Ceolin et al., 2012; Rogawski and Hanada, 2013; Chen et al., 2014). This 
reaffirms the vital role that AMPA-R plays in the seizure generation in this model of 
mitochondrial epilepsy and supports the consideration of perampanel for use in 
patients with mitochondrial epilepsy.  
 Another drug that I tested in this model is stiripentol. Stiripentol is clinically only 
used in pediatric patients with Dravet syndrome (Chiron et al., 2000; Inoue et al., 2009). 
The relevance of stiripentol in this model of mitochondrial epilepsy is in the recent 
finding that stiripentol was able to inhibit the glycolytic enzyme, lactate dehydrogenase, 
and exhibited anticonvulsant activity through this mechanism (Sada et al., 2015). The 
application of stiripentol in this model of mitochondrial epilepsy did result in a dose-
dependent reduction in the frequency of epileptiform discharges, however complete 
suppression was not achievable even in the highest concentration tested of 500μM 
(see Figure 4-16). The maximum concentration of 500μM was the reported 
concentration where stiripentol inhibited the lactate dehydrogenase enzyme (Sada et 
al., 2015) and at this concentration, only around 60% of inhibition was achieved in this 
model of mitochondrial epilepsy. In human, the therapeutic range of stiripentol has 
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been fitted to the concentration range of 30 - 100μM (Quilichini et al., 2006). At this 
concentration range, stiripentol caused minimal inhibitory effect in this model of 
mitochondrial epilepsy. Furthermore, at this concentration range, stiripentol is well 
characterized to modulate GABAA receptor in a barbiturate-like manner (Quilichini et 
al., 2006; Fisher, 2011; Grosenbaugh and Mott, 2013). Therefore, it does not exclude 
the possibility that the inhibitory effect that stiripentol was able to afford in this model 
of mitochondrial epilepsy is attributed to its modulation of GABAA receptor, as 
barbiturate does. Furthermore, to achieve a 50% suppression with stiripentol, a 
relatively high concentration of 384.10μM is required, which may not be achievable in 
the clinical setting.  
 To conclude, both of the newer generation antiepileptic drugs showed inhibitory 
effects in this model of mitochondrial epilepsy. However, perampanel is clearly more 
potent and was able to achieve complete suppression at its maximal concentration. 
Stiripentol, however, needs a significantly higher concentration before it produces 
sizable inhibitory effect, hence, the use of stiripentol in mitochondrial epilepsy needs 
to be evaluated and considered further.  
 
4.4.4 Ketogenic diet in mitochondrial epilepsy 
 
As mentioned above, ketogenic diet is a form of nutritional intervention by 
employing a high-fat, moderate-protein, and low-carbohydrate diet in order to favour 
the ketone bodies production (Branco et al., 2016). Many studies have reported the 
success of ketogenic diet in controlling intractable seizures, especially in paediatric 
population (Branco et al., 2016; Martin et al., 2016; Lambrechts et al., 2017). In patients 
with mitochondrial epilepsy, ketogenic diet has also been shown in various studies to 
be effective in controlling the various phenotypes of the epilepsy (Kang et al., 2007; 
Martikainen et al., 2012; Steriade et al., 2014). As well characterized as the clinical 
efficacy of ketogenic diet is, little is known about the mechanisms whereby ketogenic 
diet is anticonvulsant. Some components of the diet have been identified to potentially 
exhibit anticonvulsant properties. I have chosen to examine the acute anticonvulsant 
activity of three components of the diet, namely the ketone body β-hydroxybutyrate 
and the medium-chain fatty acids; decanoic acid (C10) and octanoic acid (C8).  
The ketone bodies are the primary product of the ketogenic diet. Composed of 
the β-hydroxybutyrate, acetone, and acetoacetate; collectively, these products are 
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formed through the generation of acetyl CoA via the breakdown of lipids (Berg et al., 
2012e).  I have applied β-hydroxybutyrate acutely and found that there is a dose-
dependent reduction in the frequency of the epileptiform discharges with about 80% 
reduction in epileptic activity at the highest concentration tested (20mM) (see Figure 
4-10). This suggests that β-hydroxybutyrate, on its own, have an acute anticonvulsant 
property. This is consistent with previous studies reporting direct anticonvulsant 
property of β-hydroxybutyrate in the pilocarpine model of epilepsy (Yum et al., 2012b; 
Yum et al., 2012a). The mechanisms whereby β-hydroxybutyrate is directly 
anticonvulsant, however, remains largely unknown.  Within the context of mitochondrial 
epilepsy, it is possible that β-hydroxybutyrate acts as a metabolic substrate to achieve 
burst suppression. It has been shown that replacement of glucose with β-
hydroxybutyrate, can hyperpolarize the neurons; resulting in enhanced inhibition (Sada 
et al., 2015). When comparing the IC50 of glucose (10.27mM), pyruvate (7.74mM), and 
β-hydroxybutyrate (5.16mM); it is clear that β-hydroxybutyrate exhibited the highest 
potency in achieving burst suppression and perhaps reflect the shift of preferred 
metabolic fuel usage towards ketone bodies. This shift may be able to enhance general 
inhibitory tone through the hyperpolarization of the neurons; as previously reported. 
Another potential mechanism reported in previous study is through the enhancement 
of the synthesis of kynurenic acid (Chmiel-Perzyńska et al., 2011). Kynurenic acid is a 
metabolic product of L-tryptophan metabolism and has been shown to possess AMPA-
R antagonism (Weber et al., 2001). Β-hydroxybutyrate at high concentrations (15mM) 
has been shown to increase synthesis of kynurenic acid as well as upregulate the 
kynurenine aminotransferase activity in the glia (Chmiel-Perzyńska et al., 2011). 
Therefore, it is plausible that the β-hydroxybutyrate produces burst suppression 
through the antagonism of AMPA-R via upregulating the generation of kynurenic acid.   
In human studies, the role that ketone bodies play in the control of seizure 
remains controversial. On one hand, past study has shown that level of ketosis does 
not necessarily correlate with the degree of seizure control (Likhodii et al., 2000). A 
more recent study, however, has suggested relatively good correlation between blood 
ketosis level, but not urinary ketosis, and seizure reduction (van Delft et al., 2010). 
Clearly, a more direct investigation is needed into the link between ketone bodies 
generation and seizure control. This uncertainty in the role of ketone bodies production 
in seizure suppression leads to studies on the other components of the ketogenic diet 
that may also exhibit anticonvulsant properties.  
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Another interesting component of the ketogenic diet is the medium-chain fatty 
acids. The two main fatty acid components of the diet are the octanoic acid (C8) and 
the decanoic acid (C10); both of which are detectable in the plasma following 
administration of the diet (Haidukewych et al., 1982). I have demonstrated that the 
mitochondrial epilepsy in this brain slice model is responsive to both decanoic acid 
(see Figure 4-11) and octanoic acid (see Figure 4-12). This is consistent with recent 
studies that has found that decanoic acid (C10) has acute anticonvulsant properties in 
various in vitro epileptic models (Chang et al., 2013; Chang et al., 2015). This 
anticonvulsant property of C10 was suggested to be through the inhibition of AMPA-R 
currents and was, interestingly, shown to be specific to only C10 and not C8 (Chang 
et al., 2015). This same author had also demonstrated in previous study that C8 has 
no acute anticonvulsant property, unlike C10 (Chang et al., 2013). This is in direct 
contrast with our results and the results from a Polish group investigating the same 
medium chain fatty acids (Wlaź et al., 2012; Wlaź et al., 2015); both of which 
demonstrated that C8 is as effective as, if not more effective than, C10 in its acute 
anticonvulsant activity. In this model of mitochondrial epilepsy, C8 (IC50 = 134.2μM) is 
clearly more potent than C10 (IC50 = 230.6μM). This suggests that the inhibitory effect 
mediated by both C8 and C10 is unlikely through the modulation of AMPA-R. Specific 
to this model of mitochondrial epilepsy, C8 and C10 may be able to exert its inhibitory 
effect through metabolic modulation. Fatty acids and lipids are known to be the most 
efficient molecules in terms of ATP generated per molecule (Berg et al., 2012e). 
Therefore, it would be unsurprising if the application of C8 and C10, especially at the 
high concentration range (1-2mM), can provide metabolic relief in the form of ATP 
production for the epileptic tissue. However, this still does not explain the potency of 
C8 as compared against C10. A recent study has addressed this issue through an 
elegant investigation into the distinction in the metabolic fate of C8 and C10. In the 
study, it was found that C10 upregulated astrocytic glycolysis and lactate production; 
whereas C8 upregulated astrocytic ketogenesis by almost two-fold, instead of 
upregulating glycolysis (Thevenet et al., 2016). Considering that ketone bodies have 
been shown above to have an inhibitory effect on its own, it is not surprising then that 
C8 would have a more potent inhibitory effect in this scenario, as compared to C10.  
To summarize, all the three components of the ketogenic diet investigated; β-
hydroxybutyrate, octanoic acid, and decanoic acid; have been demonstrated to have 
acute anticonvulsant properties. This highly suggests that ketogenic diet may have 
efficacy in controlling mitochondrial epilepsy. However, preclinical studies on ketogenic 
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diet tend to be conducted in vivo either using animals fed on the ketogenic diet (Likhodii 
et al., 2000) or using genetically modified animals (Giménez-Cassina et al., 2012). This 
tends to be a more accurate representation of the ketogenic diet as the diet influences 
systemic metabolism in vivo and this modulation of metabolism may not be inducible 
through the acute application of a single component of the diet. However, the in vitro 
study conducted here is the only method to dissect the acute anticonvulsant property 
of each individual components of the diet. Therefore, future study should translate the 
findings from this in vitro study to in vivo animal model, as both findings should be 
complementary to each other.  
 
4.4.5 Modulating glycolysis in mitochondrial epilepsy 
 
In a physiological condition, glucose is the compulsory main substrate for brain 
energy provision and the only pathway from which glucose can enter metabolism is 
through glycolysis (McKenna et al., 2006). Since components of the mitochondrial 
epilepsy model do not directly target glycolysis, it remains the only uninhibited 
metabolic pathway and if any upregulation was necessary to compensate for the 
metabolic inhibition, glycolysis would most probably be the first pathway to be 
upregulated. To investigate this, three substrates of glycolysis were added onto the 
brain slices; glucose, pyruvate, and lactate; at similar increasing concentration range 
(2-20mM) so as to provide direct comparison between the three substrates.  
Addition of glucose was able to significantly suppress the induced epileptic 
activity with 50% suppression achieved by the addition of extra 10mM glucose into the 
nACSF bath (see Figure 4-13). This suggests that glycolysis is not saturated in the 
epileptic tissue and the upregulation of glycolysis can potentially provide metabolic 
relief for the epileptic tissue. However, the total maximal concentration of available 
glucose at 50% seizure reduction in this scenario would be 20mM (10mM already in 
the nACSF bath and extra 10mM glucose). This is potentially difficult to achieve in an 
in vivo setting as the maximal brain concentration at hyperglycemia is reported to be 
around 5mM (Silver and Erecinska, 1994). Therefore, the strategy of loading the brain 
with glucose to alleviate metabolic demand in the mitochondrial epileptic tissue may 
need to be re-evaluated.  
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Similar to glucose, the addition of pyruvate was able to significantly suppress 
the epileptiform discharges in the model of mitochondrial epilepsy (see Figure 4-14). 
This reaffirms that glucose is most likely suppressive through upregulation of glycolysis 
via the generation of pyruvate. Pyruvate, itself, has two metabolic fates; either to enter 
oxidative metabolism through conversion to acetyl CoA; or to be reduced to lactate by 
the enzyme lactate dehydrogenase (Berg et al., 2012f). To distinguish which pathway 
provides the metabolic relief, I have added lactate at a similar concentration range and 
demonstrated that lactate was not suppressive in the mitochondrial epilepsy model, 
except when it is applied at very high concentration of 20mM (see Figure 4-15). This 
suggests that pyruvate is likely to exert its inhibitory effect through entering oxidative 
metabolism; rather than through anaerobic glycolysis. It also presents empirical 
evidence that oxidative metabolism has not been completely inhibited by the 
components of the mitochondrial epilepsy protocol. The lack of response of lactate also 
directly contradicts the astrocyte – neuron lactate shuttle hypothesis; which proposes 
that lactate is preferentially used by neurons as metabolic substrate during conditions 
of increased neuronal activity (Pellerin and Magistretti, 1994). The inhibitory effect that 
was afforded by lactate at 20mM was indeed surprising as no indication of any 
inhibitory effect was seen at any of the lower concentrations. Lactate, interestingly, is 
being investigated as a  potential novel signalling molecules in the brain; found to 
interact with the HCA1 receptor, a putative G-protein coupled receptor, and the KATP 
channels (Bozzo et al., 2013; Mosienko et al., 2015). It is still unclear, however, how 
lactate acts as a signalling molecule and whether or not it affects inhibitory or excitatory 
neurotransmission.  
Metabolic modulation seems to represent an interesting approach to provide 
seizure suppression in this model of mitochondrial epilepsy. It is clear that reserve 
capacity for oxidative metabolism still persists even following all the metabolic 
inhibitions during mitochondrial epilepsy induction. Any form of therapeutic intervention 
that can upregulate or make use of this reserve capacity may be able to modulate the 
epileptic network and alleviate the metabolic stress in such tissue.  
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4.4.6 Application of substrates of glutamate – glutamine cycle in 
mitochondrial epilepsy 
 
As mentioned above, the glutamate – glutamine cycle is an important astrocytic 
process implicated in the recycling of both the excitatory neurotransmitter, glutamate 
and the inhibitory neurotransmitter, GABA; via the non-neuroactive precursor molecule, 
glutamine (Bak et al., 2006). This cycle is heavily reliant on the astrocytic TCA cycle 
as its intermediary pathway. Since fluorocitrate, as part of the protocol for mitochondrial 
epilepsy induction, inhibits astrocytic TCA cycle specifically; it would be unsurprising 
to expect a downstream inhibition of the glutamate – glutamine cycle. To examine the 
role that this cycle plays in mitochondrial epilepsy, I have added the three main 
substrates of these cycles; glutamate, GABA, and glutamine; onto the epileptic tissue 
to assess its effect on the epileptiform discharges.  
The addition of glutamate caused no effect whatsoever in the frequency of the 
epileptiform discharges (see Figure 4-17). This was starkly different to the addition of 
GABA, which caused a complete suppression at the high concentration of 2.5mM. This 
inhibitory effect of GABA is unsurprising in the context of inhibitory neurotransmission. 
Previous sections have outlined in detail the implication of GABAA-R in seizure 
generation and therefore, this inhibitory effect can easily be attributed to the agonism 
of the GABAA-R by its only known endogenous ligand, GABA (Bergmann et al., 2013). 
However, both GABA and glutamate can also enter the astrocytic TCA cycle as a 
metabolic substrate through the glutamate – glutamine cycle. In this case, one would 
expect that both GABA and glutamate would be equally inhibitory towards the 
epileptiform discharges through the alleviation of metabolic demand by the same 
pathway. This has been shown to not be the case and therefore, it can be concluded 
that the inhibitory effect afforded by GABA is more likely to be through the 
enhancement of inhibitory tone by the agonistic action on GABAA-R.  
Interestingly, the addition of glutamine was able to cause significant 
suppression at the high concentration of 2.5mM. This could be mediated through the 
increased synthesis of GABA as glutamine is the precursor molecule to both glutamate 
and GABA (Bak et al., 2006). Oral administration of glutamine has been shown to 
increase the level of GABA measured in the striatal tissue as well as in the extracellular 
fluid (Wang et al., 2007). Another possibility, however, is that glutamine can also enter 
the astrocytic TCA cycle, similar to glutamate and GABA, and enter oxidative 
metabolism to alleviate the metabolic stress. Both possibilities certainly do seem 
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feasible and possible within the context of this model. Glutamine is an interesting 
molecule as it is non-neuroactive (McKenna et al., 2006); therefore it would not affect 
neurotransmission on its own, unless it has been converted to either glutamate or 
GABA. However, recent studies have shown that glutamine is a key player in the 
neuronal – astrocytic interaction by mediating the regulation of the inhibitory 
postsynaptic current (IPSC) in a co-culture of neurons and astrocytes (Kaczor et al., 
2015). The mechanisms by which glutamine regulates this is unknown. Therefore, not 
much can be inferred still about how glutamine provides an anticonvulsant activity but 
any of the mechanisms discussed above may contribute to this effect within the context 
of this model of mitochondrial epilepsy.   
Taken together, these results have reaffirmed the importance of GABA-ergic 
neurotransmission in the process of seizure control. Glutamine represents an 
interesting therapeutic candidate as it may either modulate the inhibitory 
neurotransmission via conversion to GABA or modulate metabolism by entering the 
TCA cycle. These results warrant further investigation into the glutamate – glutamine 
cycle, specifically the role that glutamine plays in mitochondrial epilepsy. 
 
4.4.7 The use of mitochondrial – targeting compounds 
 
As mentioned above, there is no clinical guideline in an evidence-based 
therapeutic intervention in patients with mitochondrial disease. Most physicians have 
resorted to the use of mitochondrial – targeting compounds in their attempt for the 
achievement of some form of modulation of mitochondrial function (Parikh et al., 2009; 
Pfeffer et al., 2012). Out of the many mitochondrial – targeting compounds described 
in various studies, I have decided to examine the effect of two of the most promising 
compounds, coenzyme Q10 (CoQ10) and bezafibrate.  
Among all the mitochondrial – targeting compounds, CoQ10 is the most popular 
in the management of mitochondrial disease, due to its well-documented tolerability 
and safety even at high doses and its dual action as a respiratory chain component 
and antioxidant (Schon et al., 2010). In a certain subgroup of patients with mutations 
resulting in a primary CoQ10 deficiency, the administration of CoQ10 can be lifesaving 
(Hargreaves, 2014). However, evidence of its use in the other group of patients without 
the primary CoQ10 deficiency remains largely anecdotal and lacks any assessment of 
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efficacy through a rigorously controlled clinical trial (Parikh et al., 2009; Schon et al., 
2010).  
In this model of mitochondrial epilepsy, the application of coenzyme Q10 
(CoQ10) has been shown to have no anticonvulsant effect. The in vitro model of 
mitochondrial epilepsy that I have developed has a mitochondrial respiratory chain 
deficiency in complex I and IV through the administration of rotenone and potassium 
cyanide, respectively. CoQ10 is a component of the electron transport chain, as the 
mobile electron carrier from complex I and complex II to complex III (Voet and Voet, 
2011a). It does not, however, on its own upregulate the mitochondrial respiratory chain 
activity. In fact, administration of CoQ10 in a neuronal cell-line deficient of CoQ10 only 
partially rescues the mitochondrial respiratory chain activity despite its strong 
antioxidant property (Duberley et al., 2014). Indeed, CoQ10 has been shown to have 
a dual action as a potent cellular antioxidant (Leibovitz et al., 1990). This suggests that 
the metabolic modulation mediated by coenzyme Q10 through upregulation of electron 
transport and as a potent antioxidant has no direct benefit in mitochondrial epilepsy. 
Although oxidative stress is likely to occur in the epileptic tissue due to the inhibition of 
mitochondrial respiratory chain, the mere scavenging of these free radicals without any 
real effect on the mitochondrial respiratory chain activity may prove to be of no real 
benefit to the epileptic tissue.  
Bezafibrate is developing as a mitochondrial – modulating compound through 
its effect on mitochondrial biogenesis (Johri et al., 2012; Yatsuga and Suomalainen, 
2012). Unlike coenzyme Q10, bezafibrate has been shown to correct mitochondrial 
respiratory chain deficiency in a patient line deficient in complex I, III, and IV (Bastin et 
al., 2008). This effect is proposed to be through the PPARgamma coactivator-1 alpha 
(PGC1-α) mediated by the activation of the peroxisome proliferator-activated receptor 
(PPAR) system (Liang and Ward, 2006; Bastin et al., 2008; Schon et al., 2010).  
When I applied bezafibrate acutely in the model of mitochondrial epilepsy, there 
was a significant reduction in the frequency of the epileptiform discharges following the 
application of both 10μM and 100μM. This was unprecedented as bezafibrate has 
never been evaluated as a potential anticonvulsant agent. A mechanistic approach 
would suggest that the metabolic modulation afforded by bezafibrate can directly 
alleviate the metabolic stress imposed on the tissue that resulted in seizure generation. 
This could be through its correction of the mitochondrial respiratory chain deficiency, 
as described above in a previous study (Bastin et al., 2008), but this correction is 
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proposed to be through the upregulation of mitochondrial biogenesis via PGC1-α 
activation (Bastin et al., 2008; Schon et al., 2010). PGC1-α is a transcription co-
activator and its stimulation through the activation of the PPAR system upregulates 
mitochondrial biogenesis (Liang and Ward, 2006). This activation of the gene 
expression and subsequent stimulation of mitochondrial biogenesis tends to not be an 
acute effect and hence, most studies on the effect of bezafibrate has been through the 
introduction in a rodent’s diet, rather than an acute application (Johri et al., 2012; 
Chandra et al., 2016). Therefore, it is unlikely that the acute anticonvulsant effect is 
mediated through an upregulation of mitochondrial biogenesis.  
An interesting aspect of the pharmacological action of bezafibrate that tends to 
be overshadowed in recent studies is its effect on modulating lipid metabolism. As a 
hypolipidemic agent, bezafibrate is known to increase mitochondrial fatty acid oxidation 
(Krisko et al., 2017). This has been confirmed in vitro in patients’ cell line in that it shifts 
the metabolic profile of the cell towards increased beta oxidation and anaerobic 
glycolysis (Scatena et al., 2003; Li et al., 2010). Even more interesting is that in human 
studies, bezafibrate was found to be mildly ketogenic in that it increases β-
hydroxybutyrate level in the postprandial plasma (Tremblay-Mercier et al., 2010). 
When co-applied with the medium chain triglycerides, the combination of bezafibrate 
and the medium chain lipids increased initial ketone body production by twofold 
(Courchesne-Loyer et al., 2015). It is therefore highly likely that bezafibrate increases 
fatty acid oxidation to favour ketogenesis. As discussed in section 4.4.4, ketone bodies 
and fatty acids have a suppressive effect towards the induced epileptic activity. 
Perhaps, in the epileptic tissue, the underlying metabolic profile has shifted towards a 
reliance on fatty acid metabolism and the administration of bezafibrate has upregulated 
this process, particularly towards ketogenesis, resulting in the alleviation of the 
metabolic stress and the suppression of the epileptiform activity.  
Regardless of the results described above, the practice of using mitochondrial 
– targeting compounds in the care of patients with mitochondrial disease is likely to 
continue. However, it seems imperative that research is directed towards promising 
candidate compounds and evidence is collected through well designed studies and 
rigorously controlled clinical trials to support its use in patient care. According to our 
results alone, coenzyme Q10 is likely to be of no benefit for patients with mitochondrial 
epilepsy whereas bezafibrate could be of benefit. Specifically, bezafibrate might be 
useful not only for its effect towards upregulation of mitochondrial biogenesis but also 
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for its modulation of lipid metabolism. More mitochondrial – targeting compounds 
should be screened for using this model of mitochondrial epilepsy as emerging 
evidence suggests that metabolic modulation might be a novel approach in developing 
therapies for patients with mitochondrial epilepsy.  
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4.5 Summary, strength, and weakness 
 
This chapter provides a comprehensive pharmacological study and investigation 
into possible therapeutic targets for mitochondrial epilepsy. Specifically, three distinct 
systems have been identified; namely the AMPA-R system, the GABAA-R system, and 
metabolic modulation. The antagonism of the AMPA-R system by perampanel (and 
other potential modulators; like NBQX, decanoic acid (C10), and potentially β-
hydroxybutyrate via kynurenic acid) represents an interesting approach in targeting 
excitatory input in mitochondrial epilepsy. Conversely, the potentiation of the inhibitory 
transmission via the GABAA-R system is another distinct therapeutic approach 
presented in this Chapter. Barbiturate seems to be the most directly relevant 
antiepileptic drug with regards to this system; although benzodiazepine may be 
relevant if combined with a drug that can increase the tissue concentration of GABA. 
Direct agonism of GABAA-R by increasing the tissue availability of GABA may be 
another approach in targeting the GABAA-R system in terms of controlling the 
mitochondrial epileptic activity. Finally, metabolic modulation by the use of various 
substrates to alleviate metabolic demand in the epileptic tissue seems to have a 
positive effect on the epileptic network. In particular, the ketone bodies appear to be 
the most potent metabolic substrates; with various other compounds potentially 
working by modulating ketone bodies production (such as octanoic acid (C8) and 
bezafibrate). The modulation of glycolysis and the spare capacity of oxidative 
metabolism by supplementation of glucose and pyruvate may also be relevant; 
although feasibility needs to be investigated in vivo in allowing for the high 
concentrations required for a suppressive effect to be achieved in the brain.  
These pharmacological studies provide the first evidence – based suggestions 
and recommendations in term of pharmacological therapy in mitochondrial epilepsy. 
Since it is conducted on a well-validated model and on a stable system, these further 
add to the predictive validity of the results presented here. However, the efficacy or the 
lack thereof from these pharmacological agents have only been investigated in the 
context of the interictal discharges. What this translates to in the clinical setting is yet 
to be known. Empirically, there are two types of epileptiform discharges that can be 
observed in this model; the interictal and the ictal discharges. Since the ictal discharges 
appear to follow no specific pattern, it is difficult to conduct pharmacological studies on 
these activities. However, the importance of this discharge should not be overlooked 
as theoretically, some of these pharmacological interventions (such as the sodium 
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channel blockers) may work on the ictal discharges but not the interictal discharges. 
Therefore, none of the drugs presented in this Chapter should be excluded from 
therapeutic regimen without further consideration or research. Additionally, all of the 
results presented in this Chapter come from investigation using an in vitro brain slice 
model. Some of the therapeutic interventions examined in this Chapter, particularly the 
metabolic modulators, are better suited to be investigated in an in vivo context. 
Modulation of metabolism by a substrate or compound (such as the components of the 
ketogenic diet) can easily occur systematically and produce different effects in the 
neurotransmission when the systemic metabolism is accounted for. Therefore, all the 
therapeutic leads that have been instigated from the results in this Chapter should be 
furthered into an in vivo setting using an animal model. However, such an in vivo animal 
model of mitochondrial epilepsy is yet to exist. This means, however, that when such 
an animal model is inevitably to be developed in the near future, these pharmacological 
studies should be revisited and re-evaluated. Until then, the results in this Chapter still 
provides the first real evidence – based pharmacological studies in mitochondrial 
epilepsy and thus, should not be taken lightly in the development of clinical guidelines 
and pharmacological regimens for the care of patients with mitochondrial epilepsy.  
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Chapter 5 Probing the state of metabolism during mitochondrial 
epilepsy 
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5.1 Introduction 
 
Patients with mitochondrial disease normally present with varying degrees of 
oxidative phosphorylation defects, ranging from 0 to 100% of the normal activity, 
primarily due to heteroplasmy (Lightowlers et al., 1997). However, mitochondrial 
disease with an epileptic phenotype typically presents with a more severe respiratory 
chain deficiencies, particularly in complex I and IV (Lax et al., 2016). Epilepsy has been 
associated with cerebral hypometabolism (Abou-Khalil et al., 1987; Henry et al., 1993; 
Dubé et al., 2001), therefore it is no surprise that a more severe metabolic deficiency 
would be associated with the development of epilepsy in mitochondrial disease.  
In our model, I have replicated this severe metabolic deficiency through the co-
application of two mitochondrial respiratory chain inhibitors; rotenone and potassium 
cyanide; in addition to the application of a Krebs cycle inhibitor, fluorocitrate. A severe 
inhibition of metabolism from the combination of these pharmacological agents would 
therefore be expected. To observe and quantify this state of metabolism, I performed 
incubation with 13C-labelled substrates (such as 13C-glucose) to probe various 
metabolic pathways during the state of seizure. Using state-of-the-art analytical 
chemistry techniques (as described in section 2.11 - 2.13), I was able to ascertain 
which metabolic pathways are implicated in the generation of mitochondrial epilepsy 
in this model.  
A pathway of particular interest is the glutamate-glutamine cycle, which involves 
both the neuronal and astrocytic cellular compartments (Westergaard et al., 1995; 
Hertz and Zielke, 2004; Bélanger et al., 2011). The use of fluorocitrate in this model, 
which targets astrocytic aconitase specifically, would perturb astrocytic metabolism 
and the expectation would be that this results in the downstream inhibition of the 
glutamate-glutamine cycle. Through incubation with 13C-glutamate and 13C-glutamine, 
both of which were substrates of the cycle, I have probed and characterised the 
involvement of the glutamate-glutamine cycle in this model.  
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5.2 Methods 
 
All the work presented in this chapter was conducted by myself in the laboratory 
of Professor Helle Waagepetersen at the University of Copenhagen. Animal 
preparation was as described in section 2.1 and 2.2.3. Once rodent brain slices were 
obtained, they were incubated as described in section 2.11. The conditions of the 
incubation is listed in Table 5-1. Condition 1 to 4 constitutes the probing of glucose 
metabolism with the various components of the mitochondrial epilepsy protocol present. 
Condition 5 to 6 assesses the glutamate-glutamine cycle during a state of seizure with 
a low concentration of 13C-labelled glutamate. Condition 7 to 8 assesses the glutamate-
glutamine cycle during the rescue of the seizure state with a suprathreshold 
concentration of glutamine as shown in section 4.3.6.3. Analysis was conducted as 
described in section 2.12 and 2.13. 
Table 5-1 List of experimental conditions for metabolic mapping.  PI 30 min refers to time point 30 minute of the pre-incubation 
and PI 60 min refers to time point 60 minute of the pre-incubation. Rot refers to rotenone and cyan refers to potassium cyanide.  
Group PI 30 min PI 60 min Experimental medium 
1 0.9% NaCl DMSO+ddH2O 10mM [U-13C]-glucose + 0.9% NaCl + 
DMSO + ddH2O 
2 0.1mM 
fluorocitrate 
500nM rot + 
10µM cyan 
10mM [U-13C]-glucose + 0.1mM 
fluorocitrate + 500nM rot + 10µM cyan 
3 0.1mM 
fluorocitrate 
DMSO+ddH2O 10mM [U-13C]-glucose + 0.1mM 
fluorocitrate + DMSO + ddH2O 
4 0.9% NaCl 500nM rot + 
10µM cyan 
10mM [U-13C]-glucose + 0.9% NaCl + 
500nM rot + 10µM cyan 
5 0.9% NaCl DMSO+ddH2O 0.5mM [U-13C]-glutamate + 0.9% NaCl + 
DMSO + ddH2O 
6 0.1mM 
fluorocitrate 
500nM rot + 
10µM cyan 
0.5mM [U-13C]-glutamate + 0.1mM 
fluorocitrate + 500nM rot + 10µM cyan 
7 0.9% NaCl DMSO+ddH2O 2.5mM [U-13C]-glutamine + 0.9% NaCl + 
DMSO + ddH2O 
8 0.1mM 
fluorocitrate 
500nM rot + 
10µM cyan 
2.5mM [U-13C]-glutamine + 0.1mM 
fluorocitrate + 500nM rot + 10µM cyan 
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5.3 Results 
 
5.3.1 Glycolysis is significantly upregulated in epileptic tissue 
 
To measure the glycolytic activity in the tissue, I have incubated the slices with 
10mM [U-13C]-glucose and traced the13C-labelling in the two glycolytic substrates, 
lactate and alanine (see Figure 5-1).  
There was no significant difference (p>0.05, n=8) between any of the group in 
the alanine M+1 labelling. However, there was a significant reduction (p ≤ 0.001; n=8) 
in the alanine M+2 labelling in the group exposed to fluorocitrate only (7.12 ± 0.60 %), 
rotenone and cyanide only (8.04 ± 0.49 %), and to the combination of fluorocitrate, 
rotenone, and cyanide (8.19 ± 0.68 %) as compared against control (16.89 ± 1.26 %). 
There was also a significant difference (p ≤ 0.001; n=8) in the alanine M+3 labelling in 
the group exposed to fluorocitrate only (66.21 ± 1.80 %), rotenone and cyanide only 
(68.06 ± 1.43 %), and to the combination (56.95 ± 3.47 %) as compared against control 
(44.61 ± 2.29 %). A significant difference (p ≤ 0.001) was also observed between the 
fluorocitrate and the combination group as well as between the rotenone and cyanide 
only group and the combination group.  
There was no significant difference (p > 0.05, n=8) between any of the group in 
the lactate M+1 and M+2 labelling. There was, however, a significant difference (p ≤ 
0.001; n=8) in the lactate M+3 labelling between the group exposed to fluorocitrate 
only (57.07 ± 2.61 %), rotenone and cyanide only (82.18 ± 2.62 %), and to the 
combination (74.23 ± 2.90 %) as compared against control (40.90 ± 4.22 %). 
Furthermore, there was also a significant difference (p ≤ 0.001) between the 
fluorocitrate and the rotenone and cyanide group as well as the combination group; 
and also a significant difference (p ≤ 0.05) between the rotenone and cyanide and the 
combination group.  
This difference in glycolytic activity was also reflected in the amount of alanine. 
There was a significant increase (p ≤ 0.01, n=8) in the amount of alanine in the 
fluorocitrate group (12.16 ± 7.11 nmol/mg protein) and in the rotenone and cyanide 
group (p ≤ 0.05, 10.80 ± 2.84 nmol/mg protein) as compared against control (4.29 ± 
1.16 nmol/mg protein).  
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Figure 5-1 Glycolysis is significantly upregulated by the various components of the mitochondrial epilepsy protocol.  A and B 
show the 13C labelling for alanine and lactate respectively. C shows the amount of alanine and D shows the amount of lactate 
released to the media as measured by the colorimetric assay. Results are from condition 1, 2, 3, and 4. Condition 1 indicates 
control, 2 indicates FC+RC, 3 indicates FC, and 4 indicates RC.  
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As another indicator of glycolytic activity, the amount of lactate released from the 
tissue in the media was also quantified. There was a significant increase (p ≤ 0.001) in 
the amount of lactate released in the group exposed to rotenone and cyanide only 
(6838.00 ± 734.50 nmol/mg protein, n=8) and to the combination (4710.00 ± 285.7 
nmol/mg protein, n=24) as compared against control (1020.00 ± 127.90 nmol/mg 
protein, n=16) and the group exposed to fluorocitrate only (4710.00 ± 285.70 nmol/mg 
protein, n=8). Interestingly, the lactate release was also significantly lower (p ≤ 0.001) 
in the group exposed to the combination as compared against to rotenone and cyanide 
only.  
 
5.3.2 Krebs cycle activity is significantly downregulated in epileptic tissue 
 
In order to gain additional insights of the metabolic state associated with this 
model, I measured the activity of the Krebs cycle in the tissue following the incubation 
with 10mM [U-13C]-glucose (see Figure 5-2). Specifically, this can be measured by the 
incorporation of the 13C labelling in the Krebs cycle intermediates: citrate, alpha-
ketoglutarate, succinate, fumarate, and malate.  
There was a significant reduction (p ≤ 0.001; n=8) in the citrate M+1 labelling in 
the group exposed to fluorocitrate only (1.16 ± 0.07 %), rotenone and cyanide only 
(1.01 ± 0.33 %), and to the combination (0.52 ± 0.19 %) as compared against control 
(4.49 ± 0.37 %). The citrate M+2 labelling was significantly increased (p ≤ 0.01; n=8) 
in the group exposed to fluorocitrate (24.08 ± 0.45) and to rotenone and cyanide only 
(24.26 ± 1.34) as compared against the control group (21.40 ± 0.48). This increase 
was also significant (p ≤ 0.001) against the group exposed to the combination (19.59 
± 1.47). The labelling pattern for citrate M+3 and M+4 is similar in that there is a 
statistically significant difference (p ≤ 0.001; n=8) between all the group, except for 
when comparing the group exposed to rotenone and cyanide only and the group 
exposed to the combination. In the case of citrate M+3 labelling, there was a significant 
reduction in the group exposed to fluorocitrate only (4.66 ± 0.44 %), rotenone and 
cyanide only (1.37 ± 0.52 %), and to the combination (1.05 ± 0.29 %) as compared 
against control (9.76 ± 0.45 %). Similarly, with the M+4 labelling, there was a significant 
reduction in the group exposed to fluorocitrate only (9.80 ± 0.55 %), rotenone and 
cyanide only (4.38 ± 0.30 %), and to the combination (2.74 ± 0.40 %) as compared 
against control (16.01 ± 0.54 %). There was a significant difference (p ≤ 0.001; n=8) 
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between all the group in the citrate M+5 labelling. The labelling was reduced in the 
group exposed to fluorocitrate only (10.67 ± 0.63 %), rotenone and cyanide only (4.91 
± 0.60 %), and to the combination (2.16 ± 0.18 %) as compared against control (13.81 
± 0.43 %). For M+6 labelling, there was a significant reduction (p ≤ 0.001; n=8) in 
labelling in the group exposed to rotenone and cyanide only (0.69 ± 0.21 %) and to the 
combination (0.36 ± 0.09 %) as compared against control (8.76 ± 0.47 %) and to the 
fluorocitrate (7.31 ± 0.35 %).   
No significant difference (p > 0.05, n=8) was observed between any of the groups 
in the alpha-ketoglutarate M+1 and M+3 labelling. For M+2 labelling, there was a 
significant reduction (p ≤ 0.001; n=8)   in the group exposed to fluorocitrate only (6.90 
± 1.81 %), rotenone and cyanide only (2.09 ± 0.43 %), and to the combination (3.01 ± 
1.05 %) as compared against control (22.85 ± 1.31 %). Additionally, there was also a 
statistically significant difference (p < 0.05) between the group exposed to fluorocitrate 
only and to rotenone and cyanide only. Considering the M+4 labelling, there was a 
statistically significant reduction (p ≤ 0.01; n=8) in the group exposed to fluorocitrate 
(6.09 ± 0.88 %) and also (p ≤ 0.001; n=8) in the group exposed to rotenone and cyanide 
only (2.63 ± 0.75 %) as well as the group exposed to the combination (3.50 ± 0.94 %) 
as compared against control (11.83 ± 0.86 %). Regarding the M+5 labelling, there was 
a statistically significant reduction (p ≤ 0.001; n=8) in the group exposed to rotenone 
and cyanide only (2.02 ± 0.27 %) and to the combination (2.07 ± 0.60 %) as compared 
against the control group (8.60 ± 0.65 %).  
There was a significant reduction (p ≤ 0.001; n=8) in the succinate M+1 labelling 
in the group exposed to fluorocitrate only (0.32 ± 0.07 %), rotenone and cyanide only 
(0.16 ± 0.06 %), and to the combination (0.11 ± 0.06 %) as compared against control 
(2.28 ± 0.33 %). Similarly, there was a significant reduction (p ≤ 0.001; n=8) in the 
succinate M+2 labelling in the group exposed to fluorocitrate only (1.89 ± 0.39 %), 
rotenone and cyanide only (0.33 ± 0.07 %), and to the combination (0.50 ± 0.13 %) as 
compared against control (7.90 ± 0.56 %). In addition, there was a significant difference 
between the group exposed to fluorocitrate only against the group exposed to rotenone 
and cyanide only and against the group exposed to the combination. The labelling 
pattern for succinate M+3 and M+4 is similar in that there is a statistically significant 
difference (p ≤ 0.001; n=8) between all of the group, except for when comparing the 
group exposed to rotenone and cyanide only and the group exposed to the combination. 
Regarding the M+3 labelling, there was a significant reduction in the group exposed to 
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fluorocitrate only (1.81 ± 0.39 %), rotenone and cyanide only (0.14 ± 0.03 %), and to 
the combination (0.11 ± 0.02 %) as compared against control (5.14 ± 0.34 %). Similarly, 
with the M+4 labelling, there was a significant reduction in the group exposed to 
fluorocitrate only (1.98 ± 0.47 %), rotenone and cyanide only (0.24 ± 0.11 %), and to 
the combination (0.18 ± 0.07 %) as compared against control (6.46 ± 0.35 %). 
When examining the fumarate M+1 labelling, there was no significant difference 
(p > 0.05, n=8) between any of the groups. With M+2, however, there was a significant 
reduction (p ≤ 0.001; n=8) in the labelling in the group exposed to fluorocitrate only 
(3.59 ± 0.48 %), rotenone and cyanide only (2.46 ± 0.32 %), and to the combination 
(1.98 ± 0.32 %) as compared against control (7.23 ± 0.67 %). Additionally, there was 
a significant difference (p ≤ 0.01) between the group exposed to fluorocitrate only and 
the group exposed to the combination. Considering the M+3 labelling, there was a 
significant reduction (p ≤ 0.001; n=8) in the group exposed to fluorocitrate only (3.76 ± 
0.60 %), rotenone and cyanide only (4.04 ± 0.62 %), and to the combination (3.11 ± 
0.43 %) as compared against control (6.58 ± 0.58 %). With the M+4 labelling, there 
was a significant difference (p ≤ 0.05; n=8) between the group exposed to fluorocitrate 
only (3.12 ± 0.57 %) and the control group (4.89 ± 0.59 %). There was also a significant 
reduction (p ≤ 0.001) in the group exposed to rotenone and cyanide only (0.37 ± 0.06 %) 
and the group exposed to the combination (0.40 ± 0.11 %) as compared against the 
group exposed to fluorocitrate only and the control group.  
 
 
 
 
 
 
 
 
204 
 
 
 
 
 
205 
 
206 
 
 
Figure 5-2 Krebs cycle activity is significantly decreased by the various components of the mitochondrial epilepsy protocol.  A-
E shows the 13C labelling for citrate, alpha-ketoglutarate, succinate, fumarate, and malate respectively. Results are from 
condition 1, 2, 3, and 4. Condition 1 indicates control, 2 indicates FC+RC, 3 indicates FC, and 4 indicates RC. 
There was a significant reduction (p ≤ 0.001; n=8) in the malate M+1 labelling in 
the group exposed to fluorocitrate only (2.36 ± 0.41 %), rotenone and cyanide only 
(0.60 ± 0.16 %), and to the combination (0.39 ± 0.12 %) as compared against control 
(5.75 ± 0.20 %). The labelling pattern for malate M+2 showed a statistically significant 
difference (p ≤ 0.001; n=8) between all the group, except for when comparing the group 
exposed to fluorocitrate only and the control group. There was a significant reduction 
in the M+2 labelling in the group exposed to fluorocitrate only (13.09 ± 0.92 %), 
rotenone and cyanide only (5.52 ± 0.43 %), and to the combination (5.42 ± 0.59 %) as 
compared against control (22.68 ± 0.51 %). In M+3, again, there was a significant 
reduction (p ≤ 0.001; n=8) in labelling in the group exposed to fluorocitrate only (12.42 
± 1.48 %), rotenone and cyanide only (10.58 ± 1.01 %), and to the combination (8.04 
± 0.85 %) as compared against control (19.76 ± 0.52 %). Additionally, there was a 
significant difference (p ≤ 0.001) between the group exposed to fluorocitrate alone and 
the group exposed to rotenone and cyanide alone (p ≤ 0.05), as compared against the 
group exposed to the combination. With M+4, there was a significant reduction (p ≤ 
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0.001; n=8) in labelling in the group exposed to rotenone and cyanide only (0.57 ± 
0.11 %) and to the combination (0.56 ± 0.23 %) as compared against control (11.29 ± 
0.24 %) and to the fluorocitrate (9.26 ± 1.09 %). 
 
5.3.3 Aspartate labelling pattern indicates metabolic compartmentalization  
 
Aspartate is primarily synthesized and stored in the neurons and regulated by 
cycling in its second compartment in the oligodendrocytes (Baslow, 2003). To evaluate 
metabolic compartmentalization, I evaluated the incorporation of 13-C into the amino 
acid aspartate following incubation with 10 mM [U-13C]-glucose (see Figure 5-3).  
 
Figure 5-3 Aspartate labelling is significantly modified by the rotenone and cyanide component of the mitochondrial epilepsy 
protocol.  A shows the 13C labelling for aspartate and B shows the amount of tissue aspartate. Results are from condition 1, 2, 
3, and 4. Condition 1 indicates control, 2 indicates FC+RC, 3 indicates FC, and 4 indicates RC. 
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There was a significant reduction (p ≤ 0.001; n=8) in the aspartate M+1 labelling 
in the group exposed to rotenone and cyanide only (0.27 ± 0.11 %) and to the 
combination (0.17 ± 0.06 %) as compared against control (4.15 ± 0.19 %). The labelling 
pattern for aspartate M+2, M+3, and M+4 was similar in that there was a statistically 
significant difference (p ≤ 0.001; n=8) in the group exposed to rotenone and cyanide 
only and to the combination as compared against the group exposed to fluorocitrate 
only and to the control group. There was a significant reduction in M+2 labelling in the 
group exposed to rotenone and cyanide only (4.04 ± 0.29 %) and to the combination 
(3.56 ± 0.25 %) as compared against control (23.65 ± 0.26 %) and to the fluorocitrate 
(21.56 ± 0.67 %). Similarly, with M+3, there was a significant reduction in labelling in 
the group exposed to rotenone and cyanide only (8.59 ± 0.65 %) and to the 
combination (7.01 ± 0.43 %) as compared against control (18.85 ± 0.53 %) and to the 
fluorocitrate (17.52 ± 1.52 %). Again, with M+4, there was a significant reduction in 
labelling in the group exposed to rotenone and cyanide only (0.37 ± 0.05 %) and to the 
combination (0.52 ± 0.22 %) as compared against control (10.31 ± 0.35 %) and to the 
fluorocitrate (11.19 ± 1.59 %). 
There was also a statistically significant reduction (p ≤ 0.001; n=8) in the tissue 
amount of asparate in the group exposed to rotenone and cyanide only (10.31 ± 1.40 
nmol/mg protein) and the group exposed to the combination (8.79 ± 1.93 nmol/mg 
protein) as compared against the control group (32.07 ± 4.58 nmol/mg protein). To a 
lesser degree, there was also a statistically significant reduction (p ≤ 0.05) in the group 
exposed to rotenone and cyanide only as well as the group exposed to the combination 
as compared against the group exposed to fluorocitrate only (23.89 ± 3.13 nmol/mg 
protein).  
 
5.3.4 Glucose input into the glutamate – glutamine cycle is significantly 
altered in the mitochondrial epilepsy condition 
 
Glucose is the primary source of the carbon atom for glutamate, whereas the 
nitrogen is primarily sourced from the branched chain amino acid (Daikhin and Yudkoff, 
2000). Considering the significant alteration in glucose metabolism as described 
previously in section 5.3.1 to 5.3.3, I considered it worthwhile to assess the relative 
contribution of glucose into the glutamate – glutamine cycle following incubation with 
10 mM [U-13C]-glucose (see Figure 5-4).  
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Figure 5-4 The glutamate-glutamine cycle is significantly affected by the mitochondrial epilepsy protocol.  A-C shows the 13C 
labelling for glutamate, glutamine, and GABA respectively. Results are from conditions 1, 2, 3, and 4. Condition 1 indicates 
control, 2 indicates FC+RC, 3 indicates FC, and 4 indicates RC. 
 
There was a significant reduction (p ≤ 0.01; n=8) in the glutamate M+1 labelling 
in the group exposed to rotenone and cyanide only (0.47 ± 0.17 %) and to a lesser 
degree (p ≤ 0.05) the combination (0.70 ± 0.17 %) as compared against control (3.19 
± 0.27 %). The labelling pattern for glutamate M+2 and M+3 was similar in that there 
was a statistically significant difference (p ≤ 0.001; n=8) in the group exposed to 
rotenone and cyanide only and to the combination as compared against the group 
exposed to fluorocitrate only and to the control group. With M+2, there was a significant 
reduction in labelling in the group exposed to rotenone and cyanide only (8.10 ± 0.45 %) 
and to the combination (8.63 ± 0.64 %) as compared against control (28.09 ± 0.29 %) 
and to the fluorocitrate (26.10 ± 0.96 %). Similarly, with M+3, there was a significant 
reduction in labelling in the group exposed to rotenone and cyanide only (1.01 ± 0.19 %) 
and to the combination (1.21 ± 0.49 %) as compared against control (10.80 ± 0.24 %) 
and to the fluorocitrate (10.45 ± 0.60 %). There was a slightly higher M+4 labelling (p 
≤ 0.01; n=8) in the group exposed to fluorocitrate only (17.12 ± 1.31 %) as compared 
against control (14.13 ± 0.34 %). Conversely, there was a reduction in labelling in the 
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group exposed to rotenone and cyanide only (1.07 ± 0.07 %) and the combination 
group (1.21 ± 0.30 %) as compared against the control and fluorocitrate group. 
Similarly, with M+5, there was a significantly higher labelling (p ≤ 0.001; n=8) in the 
group exposed to fluorocitrate only (11.76 ± 1.59 %) as compared against control (8.13 
± 0.31 %). Additionally, there was a reduction in labelling in the group exposed to 
rotenone and cyanide only (0.55 ± 0.03 %) and the combination group (0.52 ± 0.06 %) 
as compared against the control and fluorocitrate group. 
With regards to glutamine M+1 labelling, there was a significant reduction (p ≤ 
0.001; n=8) in the group exposed to fluorocitrate alone (2.03 ± 0.71 %), rotenone and 
cyanide only (2.10 ± 1.18 %) and the combination (2.08 ± 0.94 %) as compared against 
control (10.83 ± 0.76 %). There was a significant difference (p ≤ 0.001; n=8) between 
all the group in the glutamine M+2 labelling, except for the difference between the 
group exposed to rotenone and cyanide only and to the combination which was not 
statistically significant. The M+2 labelling was reduced the most in the group exposed 
to the combination (2.86 ± 0.59 %) as compared against the group exposed to the 
rotenone and cyanide only (14.34 ± 2.50 %), to fluorocitrate only (29.07 ± 4.22 %), and 
the control group (26.08 ± 0.38 %). With M+3, there was a significant reduction (p ≤ 
0.001; n=8) in the labelling in the group exposed to fluorocitrate alone (3.95 ± 1.22 %), 
rotenone and cyanide only (0.84 ± 0.23 %) and the combination (1.24 ± 0.55 %) as 
compared against control (13.99 ± 0.39 %). Regarding the M+4 labelling, there was a 
significant reduction (p ≤ 0.001; n=8) in the group exposed to rotenone and cyanide 
only (2.36 ± 0.69 %) and to the combination (0.41 ± 0.31 %) as compared against 
control (10.00 ± 0.82 %) and to the fluorocitrate (26.10 ± 0.96 %). There was also a 
significant difference (p ≤ 0.05) between the rotenone and cyanide group as well as 
the combination group (p ≤ 0.01) when compared against control. With M+5, there was 
a significant reduction (p ≤ 0.05; n=8) in the group exposed to rotenone and cyanide 
only (1.88 ± 0.23 %) and also (p ≤ 0.01) in the group exposed to the combination (1.04 
± 0.90 %) as compared against the control group (6.43 ± 0.52 %) and the group 
exposed to fluorocitrate (7.26 ± 1.06 %).  
Taking into account the glutamate and the glutamine labelling, there was similarly 
a significant reduction (p ≤ 0.05; n=8) in the GABA M+1 labelling in the group exposed 
to rotenone and cyanide alone (0.66 ± 0.15 %) and to the combination (0.67 ± 0.13 %) 
as compared against control (5.08 ± 0.27 %). Regarding M+2 and M+4 labelling, there 
is a similar pattern of labelling in that there is a significant difference (p ≤ 0.001; n=8) 
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between all the groups, except between the group exposed to rotenone and cyanide 
alone and the group exposed to the combination. In GABA M+2, there was a significant 
reduction in the group exposed to fluorocitrate alone (22.24 ± 0.78 %) as compared 
against the control group (30.34 ± 1.21 %). Moreover, there was a significant reduction 
in the group exposed to rotenone and cyanide only (8.53 ± 0.54 %) and to the 
combination (7.30 ± 0.80 %) as compared against the control group and the group 
exposed to fluorocitrate alone. In contrast, with GABA M+4, there was a significant 
increase in the group exposed to fluorocitrate alone (19.32 ± 1.70 %) as compared 
against the control group (8.61 ± 3.19 %). However, similar to M+2, there was a 
significant reduction in the group exposed to rotenone and cyanide only (0.30 ± 0.19 %) 
and to the combination (0.33 ± 0.26 %) as compared against the control group and the 
group exposed to fluorocitrate alone. Finally, with GABA M+3, there was a significant 
reduction (p ≤ 0.05; n=8) in the group exposed to fluorocitrate alone (18.47 ± 0.99 %) 
as compared against the control group (22.88 ± 0.85 %). In addition, there was a 
significant reduction (p ≤ 0.001; n=8) in the group exposed to rotenone and cyanide 
alone (0.74 ± 0.08 %) and to the combination (0.68 ± 0.17 %) as compared against the 
control group and the group exposed to fluorocitrate alone.  
 
5.3.5 The amount of glutamine is significantly reduced in the epileptic tissue, 
despite the sustained amounts of glutamate and increased amount of 
GABA 
 
Despite the replacement of the unlabelled glucose with [U-13C]-glucose, 
conditions 1 to 4 still represents the scenario observed in the mitochondrial epileptic 
protocol in which there is equimolar amounts of glucose without any additional external 
substrates. Therefore, conditions 1 to 4 can be used to assess the level of the 
substrates of the glutamate-glutamine cycle (see Figure 5-5) in the typical 
mitochondrial epilepsy model conditions.   
 There was no significant difference (p ≥ 0.05; n= 8) across all the groups with 
regards to the amount of tissue glutamate.  
 Interestingly, there was a significant reduction (p ≤ 0.05; n=13) in the group 
exposed to the combination (0.09 ± 0.06 nmol/mg protein) as compared against the 
group exposed to fluorocitrate alone (3.34 ± 1.64 nmol/mg protein) and the control 
group (2.64 ± 0.50 nmol/mg protein).  
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 With regards to the amount of GABA, there was a significant increase (p ≤ 0.001; 
n=8) in the group exposed to rotenone and cyanide alone (33.44 ± 2.83 nmol/mg 
protein) and also (p ≤ 0.05) in the group exposed to the combination (28.03 ± 2.45 
nmol/mg protein) as compared against the control group (16.4 ± 1.23 nmol/mg protein). 
Additionally, there was also a statistically significant increase (p ≤ 0.001) in the group 
exposed to rotenone and cyanide alone as compared against the group exposed to 
fluorocitrate alone (19.03 ± 2.60 nmol/mg protein).  
 
Figure 5-5 The amounts of the substrates of the glutamate-glutamine cycle are significantly altered in the mitochondrial 
epileptic condition.  Shown in A to C are amounts of tissue glutamate, glutamine, and GABA respectively following the various 
conditions of the mitochondrial epilepsy protocol. Results are from conditions 1, 2, 3, and 4. Condition 1 indicates control, 2 
indicates FC+RC, 3 indicates FC, and 4 indicates RC. 
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5.3.6 The activity of the glutamate-glutamine cycle via the Krebs cycle is 
significantly reduced 
 
As described in section 4.3.6.3, the bath application of L-glutamate (0.5mM) did 
not cause any significant change in the electrophysiological recordings of the 
mitochondrial epileptic activity. Therefore, by adding 0.5mM [U-13C]-glutamate, I can 
probe the activity of the glutamate-glutamine cycle without interfering with the seizure 
state. The assessment of the incorporation of the 13C into the substrates of the cycle; 
glutamate, glutamine, and GABA; would give an indication of the activity of the 
glutamate – glutamine cycle (see Figure 5-6).  
 There was no significant difference (p ≥ 0.05; n= 8) between the control and the 
epileptic group with regards to glutamate M+1 labelling. There was, however, a 
significant reduction (p ≤ 0.001; n=8) in the epileptic group compared against the 
control group, with regards to the M+2 (0.01 ± 0.01 % epileptic vs 1.79 ± 0.06 % control), 
M+3 (0.98 ± 0.12 % epileptic vs 7.61 ± 0.27 % control), and M+4 (2.50 ± 0.06 % 
epileptic vs 1.33 ± 0.13 % control). In contrast, there was a significant increase (p ≤ 
0.001; n=8) in the M+5 labelling in the epileptic group (63.20 ± 1.07 %) as compared 
against the control group (39.14 ± 3.60 %).  
 Taking into account the glutamine M+1 labelling, there was a significant 
reduction (p ≤ 0.01; n=8) in the epileptic group (2.43 ± 0.55 %) as compared against 
the control group (4.84 ± 0.26 %). There was a significant reduction (p ≤ 0.001; n=8) 
in the epileptic group as compared against the control group, with regards to the M+2 
(0.13 ± 0.06 % epileptic vs 3.19 ± 0.17 % control) and M+3 (0.93 ± 0.12 % epileptic vs 
11.79 ± 0.81 % control) labelling. Conversely, there was a statistically significant 
increase (p ≤ 0.05; n=8) in the glutamine M+4 labelling in the epileptic group (1.30 ± 
0.20 %) when compared against the control group (0.69 ± 0.09 %). Moreover, there 
was a significant increase (p ≤ 0.01; n=8) in the glutamine M+5 labelling in the epileptic 
group (41.89 ± 1.51 %) when compared against the control group (30.11 ± 3.30 %). 
There was a significant reduction (p ≤ 0.001; n=8) in the epileptic group as 
compared against the control group, with regards to the GABA M+1 (0.43 ± 0.09 % 
epileptic vs 5.01 ± 0.41 % control) and M+2 (0.94 ± 0.15 % epileptic vs 7.36 ± 0.63 % 
control) labelling. In contrast, there was no statistically significant difference (p ≥ 0.05; 
n= 8) between the epileptic group and the control group, with regards to the GABA 
M+3 and M+4 labelling.  
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Figure 5-6 The immediate activity of the glutamate-glutamine cycle is sustained but recycling via the Krebs cycle is significantly 
reduced.  Shown in A to C are the 13C labelling for glutamate, glutamine, and GABA respectively. Results are from conditions 
5 and 6. Condition 5 indicates control and 6 indicates epileptic.  
 
With regards to the amounts of the substrates of the glutamate-glutamine cycle, 
the addition of 0.5mM [U-13C]-glutamate did not seem to alter the metabolic profile of 
the glutamate – glutamine cycle in the epileptic tissue (as described in section 5.3.5). 
There was still no significant difference (p ≥ 0.05; n= 8) between the control and the 
epileptic tissue in the amount of glutamate. The amount of glutamine was still 
significantly reduced (p ≤ 0.001; n=8) in the epileptic tissue (0.00 ± 0.00 nmol/mg 
protein - non detectable) as compared against the control tissue (18.05 ± 3.08 nmol/mg 
protein). Tissue amount of GABA was still significantly elevated (p ≤ 0.001; n=8) in the 
epileptic tissue (38.42 ± 1.85 nmol/mg protein) when compared against the control 
tissue (21.15 ± 1.82 nmol/mg protein).  
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Figure 5-7 The addition of glutamate did not alter the metabolic profile of the epileptic tissue.  Shown in A to C are amounts 
of glutamate, glutamine, and GABA respectively in the control and epileptic tissue following addition of 0.5mM [U-13C]-
glutamate. Results are from condition 5 and 6. Condition 5 indicates control and 6 indicates epileptic.  
 
5.3.7 Glutamate can still enter the Krebs cycle despite inhibition of 
subsequent turns of the Krebs cycle  
 
Glutamate enters the Krebs cycle via its intermediate, α-ketoglutarate (Hertz, 
2013). Considering the severe impairment of the Krebs cycle brought about by the 
model (as described in section 5.3.2), it is important to investigate if the entry of 
glutamate into the Krebs cycle is affected as well. Therefore, I measured the 
incorporation of the 13C labelling into the Krebs cycle’s intermediates following 
incubation with 0.5mM [U-13C]-glutamate (see Figure 5-8).   
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Figure 5-8 Glutamate’s entry into the Krebs cycle is not affected but subsequent turns of Krebs cycle are inhibited by the 
mitochondrial epilepsy protocol.  A-E shows the 13C labelling for alpha-ketoglutarate, succinate, fumarate, malate, and 
citrate respectively. Results are from condition 5 and 6. Condition 5 indicates control and 6 indicates epileptic.  
 
There was no significant difference (p ≥ 0.05; n= 8) between the control and the 
epileptic group with regards to the alpha-ketoglutarate M+1, M+2, and M+5 labelling. 
There was a significant reduction (p ≤ 0.001; n=8) in the epileptic group compared 
against the control group, with regards to the M+3 labelling (0.30 ± 0.19 % epileptic vs 
6.58 ± 0.14 % control). There was also a significant reduction (p ≤ 0.01; n=8) in the 
alpha-ketoglutarate M+4 labelling in the epileptic group (0.00 ± 0.00 % - non detectable) 
as compared against the control group (1.01 ± 0.28 %).  
There was a significant reduction (p ≤ 0.001; n=8) in the epileptic group 
compared against the control group, with regards to the succinate M+1 labelling (0.21 
± 0.05 % epileptic vs 1.98 ± 0.21% control) and the succinate M+2 labelling (0.34 ± 
0.07 % epileptic vs 4.04 ± 0.47 % control). In addition, there was a significant reduction 
(p ≤ 0.01; n=8) in the succinate M+3 labelling (0.35 ± 0.05 % epileptic vs 0.66 ± 0.08 % 
control) and M+4 labelling (6.14 ± 0.66 % epileptic vs 13.60 ± 1.71 % control).  
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With regards to fumarate, there was a significant reduction (p ≤ 0.001; n=8) in 
the epileptic group compared against the control group, with regards to the M+1 
labelling (0.00 ± 0.00 % - non detectable, epileptic vs 1.63 ± 0.26% control) and the 
M+2 labelling (0.24 ± 0.09 % epileptic vs 3.88 ± 0.62 % control). This was also seen in 
the fumarate M+4 labelling where there was a significant reduction (p ≤ 0.01; n=8) of 
labelling in the epileptic tissue (7.64 ± 1.24 % epileptic vs 13.64 ± 2.01 % control). In 
contrast, there was no significant difference (p ≥ 0.05; n= 8) between the control and 
the epileptic group with regards to the fumarate M+3 labelling.  
In the epileptic group, there was a significant reduction (p ≤ 0.001; n=8) in 
malate M+1 labelling when compared against the control group (0.84 ± 0.26 % epileptic 
vs 4.18 ± 0.32% control) and the malate M+2 labelling (1.44 ± 0.21 % epileptic vs 8.21 
± 0.63 % control). Interestingly, there was a significant increase (p ≤ 0.01; n=8) in the 
malate M+3 labelling in the epileptic group (4.04 ± 0.20 %) when compared against the 
control group (3.04 ± 0.31 %). There was, however, no significant difference (p ≥ 0.05; 
n= 8) between the control and the epileptic group with regards to the malate M+4 
labelling.  
Finally, a significant reduction (p ≤ 0.001; n=8) was observed in the epileptic 
group as compared against the control group, with regards to the citrate M+1 labelling 
(0.16 ± 0.07 % epileptic vs 4.84 ± 0.35 % control), M+2 labelling (0.36 ± 0.11 % epileptic 
vs 7.11 ± 0.60 % control), M+4 labelling (7.89 ± 0.38 % epileptic vs 15.39 ± 1.54 % 
control), and M+5 labelling (0.05 ± 0.03 % epileptic vs 1.69 ± 0.35 % control). This was 
also observed in the citrate M+3 labelling as a significant reduction (p ≤ 0.01; n=8), of 
labelling in the epileptic tissue (0.95 ± 0.09 % epileptic vs 2.31 ± 0.32 % control). Finally, 
there was no significant difference (p ≥ 0.05; n= 8) between the control and the epileptic 
group with regards to the citrate M+6 labelling.  
 
5.3.8 Aspartate formation is still reduced despite the addition of glutamate 
 
In astrocytes, the formation of glutamate in the glutamate – glutamine cycle from 
the Krebs cycle intermediate, α-ketoglutarate, is coupled to the formation of 
oxaloacetate from aspartate (Bak et al., 2006; Hertz, 2013).  Therefore, it is important 
to consider the aspartate compartment when evaluating the effect of glutamate 
labelling (see Figure 5-9). 
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Figure 5-9 Aspartate labelling and amount is significantly reduced in the epileptic tissue, even with the addition of glutamate. 
Shown in A is the 13C labelling for aspartate following incubation with 0.5mM [U-13C]-glutamate and concurrently in B is the 
amount of aspartate in the same condition. Results are from condition 5 and 6. Condition 5 indicates control and 6 indicates 
epileptic. 
 
There was a significant reduction (p ≤ 0.001; n=8) in the epileptic group as 
compared against the control group, with regards to the aspartate M+1 labelling (0.00 
± 0.00 % - non detectable, epileptic vs 2.75 ± 0.15 % control) and the aspartate M+2 
labelling (0.59 ± 0.12 % epileptic vs 6.76 ± 0.37 % control). Interestingly, there was no 
significant difference (p ≥ 0.05; n= 8) between the control and the epileptic group with 
regards to either the aspartate M+3 or M+4 labelling.  
This reduction in labelling was also accompanied by a significant reduction (p ≤ 
0.001; n=8) in the amount of aspartate in the epileptic group (24.52 ± 3.59 nmol/mg 
protein) when compared against the control group (73.89 ± 8.03 nmol/mg protein).  
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5.3.9 Unlike glutamate, the addition of glutamine was able to sustain GABA 
synthesis within the glutamate – glutamine cycle 
 
Glutamine is a key player in the glutamate – glutamine cycle. It is the precursor 
amino acid to both glutamate and GABA. It also presents an alternate approach to the 
trafficking of neurotransmitters as it is a non-neuroactive compound, therefore allowing 
it to be released to the extracellular fluid safely without risk of neuronal depolarization 
(unlike glutamate) (Daikhin and Yudkoff, 2000). I have applied glutamine to the 
epileptic slices and found that the application of 2.5mM L-glutamine was able to 
suppress the epileptic activity significantly (as described in section 4.3.6.3). Given all 
this, I have applied the ‘rescue’ concentration of 2.5mM [U-13C]-glutamine to trace the 
metabolic pathway that they underwent. By examining the incorporation of the 13C 
atoms in the substrates of the cycle; glutamate, glutamine, and GABA; I would have 
an indication of the activity of the glutamate – glutamine cycle following the ‘rescue’ of 
the phenotype (see Figure 5-10).  
There was a significant reduction (p ≤ 0.001; n=10) in the epileptic group as 
compared against the control group, with regards to the glutamate M+1 labelling (0.33 
± 0.13 % epileptic vs 2.79 ± 0.25 % control), glutamate M+2 labelling (0.19 ± 0.08 % 
epileptic vs 2.24 ± 0.15 % control), and glutamate M+3 labelling (1.52 ± 0.30 % epileptic 
vs 8.97 ± 0.23 % control). Conversely, there was a statistically significant increase (p 
≤ 0.001; n=10) with regards to the glutamate M+4 labelling (3.65 ± 0.10 % epileptic vs 
2.58 ± 0.13 % control) and the glutamate M+5 labelling (64.69 ± 1.58 % epileptic vs 
49.24 ± 1.40 % control).  
The labelling pattern in glutamine follows that of glutamate in these conditions. 
There was a significant reduction (p ≤ 0.001; n=10) in the epileptic group compared 
against the control group, with regards to the M+1 labelling (0.11 ± 0.03 % epileptic vs 
1.09 ± 0.06 % control), M+2 labelling (0.29 ± 0.08 % epileptic vs 1.01 ± 0.10 % control), 
and M+3 labelling (0.37 ± 0.01 % epileptic vs 4.33 ± 0.15 % control). In contrast, there 
was a significant increase (p ≤ 0.01; n=10) in the M+4 labelling (4.16 ± 0.04 % epileptic 
vs 3.81 ± 0.12 % control) and also a significant increase (p ≤ 0.001; n=10) in the M+5 
labelling (93.09 ± 0.27 % epileptic vs 82.17 ± 1.11 % control). 
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Figure 5-10 Glutamine addition did not rescue the recycling of the glutamate – glutamine cycle via the Krebs cycle but it did 
increase the synthesis of GABA.  Shown in A to C are the 13C labelling for glutamate, glutamine, and GABA respectively 
following addition of 2.5mM [U-13C]-glutamine. Results are from conditions 7 and 8. Condition 7 indicates control and 8 
indicates epileptic.  
 
In the epileptic group, there was a significant reduction (p ≤ 0.001; n=10) in 
GABA M+1 labelling when compared against the control group (0.99 ± 0.26 % epileptic 
vs 7.45 ± 0.44 % control). This was similarly seen with regards to the M+2 labelling 
(2.33 ± 0.45 % epileptic vs 10.99 ± 0.47 % control). There was, however, no significant 
difference (p ≥ 0.05; n= 10) in the GABA M+3 labelling between the control and the 
epileptic group. In contrast, there was a significant increase (p ≤ 0.001; n=10) in the 
M+4 labelling of the epileptic group compared against the control group (40.33 ± 0.96 % 
epileptic vs 26.07 ± 1.74 % control).  
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The addition of 2.5mM [U-13C]-glutamine as a ’rescue’ treatment was able to 
significantly alter the metabolic profile of the epileptic tissue (unlike the addition of 
glutamate as described in section 5.3.6). There was a significant increase (p ≤ 0.01; 
n=10) in the amount of glutamate in the epileptic tissue (420.10 ± 47.54 nmol/mg 
protein) as compared against the control tissue (259.80 ± 27.95 nmol/mg protein). The 
amount of glutamine was still significantly reduced (p ≤ 0.001; n=8) in the epileptic 
tissue (153.10 ± 13.73 nmol/mg protein) as compared against the control tissue 
(279.80 ± 18.31 nmol/mg protein), albeit now being at a detectable amount in the 
epileptic tissue unlike any of the other conditions. Tissue amount of GABA was also 
still significantly increased (p ≤ 0.001; n=8) in the epileptic tissue (35.33 ± 2.34 nmol/mg 
protein) when compared against the control tissue (17.54 ± 0.79 nmol/mg protein).  
 
Figure 5-11 The addition of glutamine significantly alter the metabolic profile of the epileptic tissue. Shown in A to C are 
amounts of glutamate, glutamine, and GABA respectively in the control and the epileptic tissue following addition of 2.5mM 
[U-13C]-glutamine. Results are from condition 7 and 8. Condition 7 indicates control and 8 indicates epileptic.  
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5.3.10 The entry of glutamine into the Krebs cycle is not impeded but 
subsequent turns of the Krebs cycle are inhibited 
 
Glutamine does not directly enter the Krebs cycle, but, both glutamate and GABA 
are recycled (or degraded) mostly in astrocytes via the Krebs cycle. Glutamate enters 
the astrocytic and neuronal Krebs cycle via its intermediate, α-ketoglutarate whereas 
GABA enters the astrocytic Krebs cycle via succinyl-semialdehyde, which eventually 
is converted into succinate (Hertz, 2013). Therefore, it is also important in the context 
of incubation with 13C-labelled glutamine to consider the incorporation of the 13C in the 
Krebs cycle intermediates (see Figure 5-12).  
There was no significant difference (p ≥ 0.05; n= 10) in the labelling of all of the 
isotopologues of alpha-ketoglutarate (M+1, M+2, M+3, M+4, and M+5) between the 
control and the epileptic group. 
In contrast, there was a significant reduction (p ≤ 0.001; n=10) in the epileptic 
group when compared against the control group, with regards to the labelling of 
succinate M+1 (0.11 ± 0.04 % epileptic vs 0.98 ± 0.13 % control), M+2 (0.20 ± 0.05 % 
epileptic vs 2.64 ± 0.29 % control), M+3 (0.30 ± 0.05 % epileptic vs 0.66 ± 0.07 % 
control), and M+4 (3.84 ± 0.53 % epileptic vs 12.87 ± 1.88 % control).  
Similarly, there was also a significant reduction (p ≤ 0.001; n=10) in the labelling 
of fumarate in the epileptic group compared against the control group, with regards to 
the M+1 (0.33 ± 0.10 % epileptic vs 2.19 ± 0.24 % control), M+2 (0.69 ± 0.14 % epileptic 
vs 4.64 ± 0.39 % control), M+3 (1.17 ± 0.11 % epileptic vs 2.31 ± 0.31 % control), and 
M+4 (9.84 ± 0.90 % epileptic vs 20.13 ± 1.43 % control) isotopologues.  
The labelling pattern of malate is unique to that of the other Krebs cycle 
intermediates in these incubation conditions. There was still a significant reduction (p 
≤ 0.001; n=10) in the epileptic group as compared against the control group, with 
regards to the M+1 (0.50 ± 0.19 % epileptic vs 4.53 ± 0.41 % control), M+2 (1.62 ± 
0.25 % epileptic vs 8.60 ± 0.29 % control) and M+4 (30.28 ± 1.71 % epileptic vs 36.76 
± 1.49 % control) labelling. However, there was no significant difference (p ≥ 0.05; n= 
10) in the M+3 labelling of malate between the control and the epileptic group.  
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Figure 5-12 The entry of glutamine into the Krebs cycle is not affected but subsequent turns of Krebs cycle is inhibited by the 
mitochondrial epilepsy protocol. A-E shows the 13C labelling for alpha-ketoglutarate, succinate, fumarate, malate, and citrate 
respectively. Results are from condition 7 and 8. Condition 7 indicates control and 8 indicates epileptic.  
 
Again, there was a statistically significant reduction (p ≤ 0.001; n=10) in the citrate 
labelling across all isotopologues in the epileptic group as compared against the 
control group. This includes the M+1 (0.30 ± 0.14 % epileptic vs 5.15 ± 0.24 % control), 
M+2 (1.53 ± 0.29 % epileptic vs 8.20 ± 0.34 % control), M+3 (1.23 ± 0.12 % epileptic 
vs 3.45 ± 0.30 % control), M+4 (16.15 ± 1.84 % epileptic vs 31.44 ± 1.36 % control), 
M+5 (0.01 ± 0.01 % epileptic vs 1.28 ± 0.35 % control), and M+6 (0.00 ± 0.00 % 
epileptic – non detectable vs 0.67 ± 0.05 % control) isotopologues.  
 
5.3.11 Addition of glutamine favours the breakdown of aspartate 
 
As described in section 5.3.8, the formation (or breakdown) of aspartate is 
coupled to the oxidative deamination of glutamate into alpha-ketoglutarate, catalysed 
by the enzyme glutamate dehydrogenase (Hertz, 2013). As such, it is important to 
examine the degree of aspartate labelling and the tissue levels of aspartate following 
this addition of the ‘rescue’ concentration of glutamine.  
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Figure 5-13 Glutamine addition favours the breakdown of aspartate.  Shown in A is the 13C labelling for aspartate following 
incubation with 2.5mM [U-13C]-glutamine and in B is the amount of aspartate in the same condition. Results are from 
conditions 7 and 8. Condition 7 indicates control and 8 indicates epileptic. 
 
There was a significant reduction (p ≤ 0.001; n=10) in the epileptic group 
compared against the control group, with regards to the aspartate M+1 (0.37 ± 0.14 % 
epileptic vs 3.83 ± 0.25 % control), M+2 (1.24 ± 0.31 % epileptic vs 8.80 ± 0.32 % 
control), and M+4 (33.20 ± 1.24 % epileptic vs 41.18 ± 1.27 % control) labelling. This 
trend was also observed in the aspartate M+3 labelling where there is significant 
reduction (p ≤ 0.01; n=10) in the epileptic group (2.70 ± 0.19 %) as compared against 
control (3.72 ± 0.23 %). 
Similar to the labelling pattern, there was a significant reduction (p ≤ 0.001; n=10) 
in the tissue level of aspartate in the epileptic group (19.00 ± 2.65 nmol/mg protein) 
when compared against the control group (56.00 ± 1.94 nmol/mg protein).  
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5.3.12 Neither glutamine nor glutamate addition decreased glycolysis in the 
epileptic tissue. 
 
Finally, to examine the impact of the addition of 0.5mM L-glutamate or the ‘rescue’ 
concentration of 2.5mM L-glutamine, the amount of lactate released to the media was 
quantified following treatment with either [U-13C]-glutamate or [U-13C]-glutamine (see 
Figure 5-14). 
 
Figure 5-14. Lactate release from the media was not affected by treatment with either glutamate or glutamine. Shown in A 
and B are amount of lactate release into the media in the control and epileptic tissue following treatment with either [U-13C]-
glutamate (A) or [U-13C]-glutamine (B). Results are from condition 5,6,7, and 8. Condition 5 indicates control + GLU, 6 indicates 
epileptic + GLU, 7 indicates control + GLN, and 8 indicates epileptic + GLN.  
 
There was a significant increase (p ≤ 0.001; n=8) in the amount of lactate release 
into the media in the epileptic tissue (5014.00 ± 350.10 nmol/mg protein) as compared 
against the control tissue (646.70 ± 83.74 nmol/mg protein) when incubated with 
0.5mM L-glutamate. Similarly seen in tissues incubated with glutamine, there was also 
a significant increase (p ≤ 0.001; n=10) in the level of lactate release in the epileptic 
tissue (4550.00 ± 509.00 nmol/mg protein) as compared against the control tissue 
(1107.0 ± 73.5 nmol/mg protein).  
 
 
 
 
 
 
233 
 
5.4 Discussion 
 
The results presented in this Chapter are comprehensive assessment of the 
metabolic state of the tissue revealed using the metabolic mapping experiments. For 
transparency, all the data has been included in the results section and presented 
accordingly but from this point onwards, only relevant labelling data will be discussed.   
 
5.4.1 Glycolysis 
 
The results presented in section 5.3.1 detail the changes in glycolysis induced 
by the various components of the mitochondrial epilepsy protocol. There was a 
significant increase in the labelling of lactate M+3 and consequently, the tissue level of 
lactate by incubation of either fluorocitrate alone, rotenone and cyanide alone, or the 
combination when incubating with [U-13C] glucose (see Figure 5-1). This indicates an 
upregulation in anaerobic glycolysis due to a change in the tissue redox state (Voet 
and Voet, 2011b). With any of the experimental conditions above, one would expect a 
severe inhibition of oxidative metabolism, hence causing a decrease in the 
NAD+/NADH ratio. In order to replenish the supply of NAD+, the excess NADH could 
be oxidized via the formation of the glycolytic by-product, lactate. In addition, under 
conditions of severe energy crisis, the formation of lactate is energetically favourable 
as it provides the NAD+ necessary to drive the process of glycolysis, the net results of 
which would produce 2 ATP for each molecule of glucose. This increased level of 
lactate release is consistent with the clinical observation of lactic acidosis characteristic 
of the various phenotypes of mitochondrial epilepsy (Pavlakis et al., 1984; Nishigaki et 
al., 2003; Robinson, 2006).  
Lactate, however, can be considered as a ‘dead end’ in metabolic terms and 
has to be converted back into pyruvate before it can be metabolized further (Berg et 
al., 2012f). There has been some suggestion that lactate could provide the primary 
source of energy for neurons during high neural activity (Pellerin and Magistretti, 1994; 
Bélanger et al., 2011) but our experiments, as described in section 4.3.5.3, have 
indicated that in this model, the induced seizure does not respond to lactate; indicating 
that lactate is not used as a metabolic substrate during the state of seizure. 
Furthermore, when comparing the value of lactate release in the control tissue (see 
Figure 5-1) against control tissue that was exposed to 0.5mM L-glutamate (see Figure 
5-14), there was a slight decrease in lactate release following exposure to glutamate, 
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which directly challenges the astrocyte – neuron lactate shuttle hypothesis (ANLSH) 
(Pellerin and Magistretti, 1994). Taken together, our results agree with the critical 
review that evidence supporting the existence of this pathway is weak (Chih and 
Roberts, 2003), at least in the context of a pathological condition such as epilepsy.  
Interestingly, there was also a trend towards an increase in the labelling of 
lactate M+2 in the group exposed to the combination (the ‘epileptic’ group) when 
compared against the control group (see Figure 5-1). This could be due to the 
upregulation of the pentose phosphate pathway. The pentose phosphate pathway 
(PPP) is an important alternate pathway to glycolysis as it is a critical source of NADPH 
and ATP in conditions of energy crisis. The NADPH generated is an important reducing 
agent against oxidative stress in the form of oxidized glutathione (GSSG) (Berg et al., 
2012b). This upregulation of PPP, therefore, suggests an ongoing process of oxidative 
stress in this model of mitochondrial epilepsy, which has been reported in other models 
and studies of mitochondrial epilepsy (Yamamoto and Tang, 1996; Liang and Patel, 
2004; Rahman, 2012).  
Interestingly, application of glutamate or glutamine to the epileptic tissue did not 
cause a reduction in lactate release (see section 5.3.12). In the case of glutamate, 
application of 0.5mM L-glutamate has been shown to not cause any change in the 
epileptic activity in the brain slices (see section 4.3.6.1), so, it is to unsurprising then 
that the addition of this concentration of glutamate did not modulate glycolytic activity. 
In the case of glutamine, application of 2.5mM L-glutamine has been shown to 
significantly suppress the epileptic activity in vitro (see section 4.3.6.3). However, 
glycolysis still seems to be significantly upregulated, even after suppression of epileptic 
activity. This suggests that even following suppression of epileptic activity, the 
underlying metabolic impairment could still be present and the tissue still heavily relies 
on glycolysis for metabolic sustainment.  
 Alanine is formed from pyruvate through a transamination reaction that is 
coupled with the deamination of glutamate into alpha-ketoglutarate (Berg et al., 2012a). 
Alanine is, therefore, another useful indicator of glycolytic activity. The significant 
increase in alanine M+3 labelling across all the groups, again, confirmed that there is 
significant upregulation of glycolysis in the epileptic tissue. Interestingly, increase in 
tissue amounts of alanine is only observed in the tissue exposed to the fluorocitrate 
alone or to rotenone and cyanide alone, but not in the epileptic tissue which was 
exposed to the combination of all three compounds. This discrepancy may be 
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explained by the dependence of alanine biosynthesis on the donor of amino group from 
glutamate. Perhaps, in the epileptic tissue, glutamate is not as actively converted into 
alpha-ketoglutarate as it is required to sustain the hyperexcitable network state.  
 
5.4.2 Krebs cycle 
 
The Krebs cycle, also known as the citric acid cycle, is the final common 
pathways for the oxidation of carbohydrates, fatty acids, and amino acids (Berg et al., 
2012d). The intermediates of the cycle that can be detected via the GCMS 
measurements are citrate, alpha-ketoglutarate, succinate, fumarate, and malate.  
The results presented in section 5.3.2 described the changes in the Krebs cycle 
as induced by the components of the mitochondrial epilepsy protocol. Citrate M+2 
represents the entry point of pyruvate via conversion to acetyl-CoA into the first turn of 
the Krebs cycle. Subsequently, citrate is converted into isocitrate by the enzyme 
aconitase (Berg et al., 2012b). Fluorocitrate, which is one of the critical components of 
the mitochondrial epilepsy protocol, is thought to be a selective astrocytic aconitase 
inhibitor (Paulsen et al., 1987; Hassel et al., 1992; Swanson and Graham, 1994).  
Accumulation of citrate M+2 in the tissue exposed to fluorocitrate only confirmed the 
inhibition of aconitase and this increase most likely reflects the contribution of the 
astrocytic Krebs cycle towards the overall labelling pattern. Interestingly, there was 
also an accumulation of citrate M+2 in the tissue exposed to rotenone and cyanide 
only. This could reflect the oxidative inactivation of mitochondrial aconitase that could 
occur during application of electron transport chain inhibitors (Cantu et al., 2009). 
Another very interesting point is that there is no significant difference in the citrate M+2 
labelling between the control group and the group exposed to the combination (the 
‘epileptic’ group). This reflects the complexity of the metabolic alterations observed 
during the epileptic state as pyruvate may still enter the Krebs cycle even in the 
presence of all the metabolic inhibitors, including an inhibitor of aconitase. To a certain 
degree, the presence of an epileptiform activity at the tissue level must place a heavy 
metabolic demand on the tissue (Zsurka and Kunz, 2015), which may be met by 
utilizing the maximal capacity of the tissue for the Krebs cycle. There was, however, a 
subsequent decrease in all the other isotopologues of citrate in all conditions and this 
may reflect the downregulation of subsequent turns of the Krebs cycle in all the 
experimental conditions.   
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To trace the first turn of the Krebs cycle, the M+2 isotopologues is the ideal 
molecular substrate of the Krebs cycle to be examined. There was consistently a 
significant decrease in all the experimental conditions in the M+2 labelling of all 
subsequent substrates of the Krebs cycle (alpha-ketoglutarate, succinate, fumarate, 
and malate). This demonstrates the severe impairment of the Krebs cycle by the 
components of the mitochondrial epilepsy protocol. Interestingly, the decrease was 
always milder in the group exposed to fluorocitrate only as compared to the group 
exposed to rotenone and cyanide only or the group exposed to the combination. This 
again reaffirms the selective inhibition of the astrocytic Krebs cycle by fluorocitrate 
(Paulsen et al., 1987; Hassel et al., 1992; Swanson and Graham, 1994).  
 
5.4.3 Aspartate 
 
Aspartate is formed from oxaloacetate through a transamination reaction 
catalysed by aspartate aminotransferase with an amino group donor from glutamate, 
as alanine is (Berg et al., 2012a). This makes aspartate a unique parameter for 
assessment of both the Krebs cycle and the glutamate – glutamine cycle.  
Fluorocitrate exposure did not cause any significant change in both the aspartate 
isotopologues labelling and the tissue level of aspartate (see Figure 5-3). This supports 
the metabolic compartmentalization of aspartate as primarily a neuronal substrate 
(Baslow, 2003) and again reaffirms the selective inhibition of the astrocytic Krebs cycle 
by fluorocitrate (Paulsen et al., 1987; Hassel et al., 1992; Swanson and Graham, 1994). 
The addition of either rotenone and cyanide or the combination (with fluorocitrate) 
caused a significant decrease in both the aspartate isotopologues labelling and the 
tissue level of aspartate. This confirms the severe inhibition of Krebs cycle as described 
previously in section 5.4.2 and reflects the recruitment of the neuronal compartment in 
the metabolic inhibition caused by the electron transport chain inhibitors, rotenone and 
cyanide.  
 
 
 
 
237 
 
5.4.4 Glutamate – glutamine cycle   
 
Since glucose is the primary source of the carbon atom required for synthesis of 
glutamate via alpha – ketoglutarate (Daikhin and Yudkoff, 2000), the results of the 
metabolic mapping with [U-13C]-glucose as described in section 5.3.4 and 5.3.5 
provides a crude assessment of the state of the glutamate – glutamine cycle although 
cycling is probably better assessed by incubation with one of the substrates of the cycle 
such as [U-13C]-glutamate or [U-13C]-glutamine. 
 Surprisingly, exposure to fluorocitrate did not cause any reduction in the M+2 
labelling of either glutamate or glutamine, despite the significant reduction in the M+2 
labelling of alpha-ketoglutarate (as described in section 5.4.2). Glutamine is primarily 
an astrocytic substrate due to the specific expression of glutamine synthetase in the 
glial family (Anlauf and Derouiche, 2013). This suggests that it is vital of the tissue to 
maintain the homeostatic balance of glutamate and glutamine by whatever Krebs cycle 
capacity is left in the astrocytes. This was confirmed by the maintained level of tissue 
glutamate and glutamine with fluorocitrate exposure (see Figure 5-5). Interestingly, 
there was a reduction in the M+2 labelling in GABA with exposure to fluorocitrate. This 
suggests that the tissue did not use the synthesized glutamate or glutamine (from 
glucose) for the synthesis of GABA in the presence of fluorocitrate. This is perhaps an 
important mechanism for the generation of mitochondrial epilepsy that is unique to 
fluorocitrate, which is to create a state of disinhibition, which has been described in 
previous study (Kaczor et al., 2015). However, overall amounts of GABA seems to be 
unaffected by the fluorocitrate exposure.  
 Exposure to rotenone and cyanide caused a significant reduction in the M+2 
labelling of glutamate, glutamine, and GABA which is concurrent with the severe 
impairment of the Krebs cycle in this group. Again, tissue amounts of glutamate and 
glutamine were sustained, which suggests the presence of a compensatory 
mechanism in the presence of these metabolic inhibitors. Interestingly, tissue amounts 
of GABA were increased with exposure to rotenone and cyanide; unlike fluorocitrate. 
This can be explained by the inhibition of GABA degradation via succinyl-coA, which 
is mediated by the enzyme succinic semialdehyde dehydrogenase. This enzyme is 
dependent on the NAD+/NADH ratio (Olsen and Betz, 2006), which would be reduced 
by inhibition of the electron transport chain. Fluorocitrate did not inhibit the electron 
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transport chain and so would not modify the NAD+/NADH ratio, hence the unaffected 
value of GABA. 
 Exposure to a combination of fluorocitrate, rotenone, and cyanide (which 
comprises the mitochondrial epilepsy protocol) caused a significant reduction in the 
M+2 labelling of glutamate, glutamine, and GABA, similar to the profile seen with 
exposure to rotenone and cyanide alone. However, there was also a significantly lower 
M+2 labelling in glutamine in this group as compared to the rotenone and cyanide 
group. This was accompanied by a concurrent significant reduction in tissue level of 
glutamine to an almost non-detectable level. This represents an interesting disparity to 
the rest of the experimental conditions. Two possibilities exist; either glutamine is 
utilized exclusively as metabolic fuel in the condition of seizure or a reflection of the 
complete shutdown of astrocyte function during a state of seizure; considering the 
exclusive localization of glutamine synthetase to the astrocytes (Anlauf and Derouiche, 
2013). Whichever mechanism it may be; it is clear that glutamine (or the lack thereof) 
plays a pivotal role in the generation of seizure. 
 An important point to note here is that in vivo, two distinct pools of glutamate 
and GABA exists: the vesicular and the non-vesicular pools (Hassel and Dingledine, 
2006; Olsen and Betz, 2006); both of which may be affected to a distinct manner by 
our treatments. Although HPLC is a very sensitive technique for detection of amino 
acids, it cannot differentiate between the two pools and so, one should be cautious in 
interpreting the glutamate and GABA readings from these measurements. Furthermore, 
this technique alone also cannot differentiate the astrocytic and neuronal origins of 
each of these substrates, although inferences can be made as demonstrated above. 
 Finally, the measured tissue GABA amount in the epileptic tissue does not 
correspond with the hypothesis presented earlier in section 4.5 that proposes a tissue 
deficiency of GABA based on the functional evidence. In addition to the technical 
limitations as discussed above, GABA-ergic inhibition is also shown to be very 
sensitive to the method of tissue preparation (Kuenzi et al., 2000). Specifically, in slices 
prepared using the perfused method, GABA-ergic inhibition was shown to be 
preserved better as compared against the decapitation method (Kuenzi et al., 2000). 
Therefore, the results in this Chapter, especially pertaining to GABA, should be taken 
with a degree of scepticism as the method of preparation used in the brain slice 
preparation (decapitation) may have significantly alter the GABA-ergic system in a 
manner unknown as of yet.  
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5.4.5 Addition of glutamate 
  
Results presented in section 5.3.6, 5.3.7, and 5.3.8 described the results of 
metabolic mapping experiments following incubation with 0.5mM [U-13C]-glutamate. As 
mentioned above in section 4.3.6.1, the application of this concentration of L-glutamate 
did not cause any change in the epileptic activity. This gives a unique opportunity for 
assessing the glutamate – glutamine cycle from the substrate’s point of view without 
causing any interference in the seizure state. 
There was an increase in glutamate M+5 and glutamine M+5 in the epileptic 
tissue as compared against control, which reflects lack of utilization of the [U-13C]-
glutamate as a metabolic substrate. Decreases in the other isotopologues of the 
glutamate and glutamine indicates the lack of recycling of glutamate via the Krebs cycle. 
As an example, if the [U-13C]-glutamate had recycled via the Krebs cycle, on the 
second turn of the glutamate cycle, M+3 labelling pattern would be expected from both 
glutamate and glutamine, which was reduced in the epileptic tissue. Level of tissue 
glutamate is unaffected by this addition of glutamate and interestingly, glutamine level 
is still depleted to a non-detectable level. As mentioned above, glutamine synthetase 
is almost exclusively expressed in astrocytes (Anlauf and Derouiche, 2013) and the 
lack of glutamine synthesis from this added glutamate supports the hypothesis of 
complete astrocyte shutdown during the epileptic state.  
Interestingly, the labelling pattern for GABA M+4 is sustained unlike glutamate or 
glutamine. This means that the glutamate is still able to be taken up by the GABA-ergic 
neurons for sustainment of the GABA pool. However, since the flux of the glutamate 
and glutamine trafficking between neurons and astrocyte is very high, glutamate is 
more likely to be taken up by the astrocytes rather than neurons (Hassel and 
Dingledine, 2006), which makes glutamate a poor choice of substrates for sustaining 
GABA synthesis. This may explain why the addition of glutamate did not cause any 
change in the epileptiform activity, as it may have been taken up by the astrocytes 
rather than the neurons in need. GABA level is still significantly increased as was 
observed in the epileptic tissue (without addition of glutamate).  
The Krebs cycle labelling results as described in section 5.3.7 also confirms the 
lack of recycling via the Krebs cycle. Interestingly, M+5 labelling of alpha-ketoglutarate 
is sustained in the epileptic tissue. This suggests that glutamate can still enter the 
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Krebs cycle via alpha-ketoglutarate but subsequent turns of the TCA cycle (into 
succinate, fumarate, malate, and citrate) are severely inhibited.  
The aspartate labelling for M+1 and M+2 are significantly decreased, which again 
reflects the inhibition of the subsequent turns of the TCA cycle. This is also reflected 
by the significant reduction in tissue level of aspartate in the epileptic slices.  
 
5.4.6 Addition of glutamine 
 
Results presented in section 5.3.9, 5.3.10, and 5.3.11 described the results of 
metabolic mapping experiments following incubation with 2.5mM [U-13C]-glutamine. As 
mentioned above in section 4.3.6.3, the application of this concentration of L-glutamine 
was able to suppress the epileptic activity, making this a ‘rescue’ concentration and 
the experiment an assessment of metabolic profile during a ‘rescue’ phenotype.  
There is, again, an increase in glutamate and glutamine M+5 labelling, which may 
reflect the lack of utilization of [U-13C]-glutamine as a metabolic substrate. This is 
supported by the decrease in other isotopologues (such as M+3), which reflects lack 
of recycling of glutamine via the Krebs cycle. Interestingly, there is now a significant 
increase in tissue glutamate amount and tissue glutamine amount is now detectable, 
albeit still lower than the control level, in the epileptic tissue. This casts doubt on the 
earlier hypothesis of the lack of utilization of [U-13C]-glutamine as a metabolic substrate. 
Instead, the increase in the M+5 labelling may reflect an upregulation of the glutamate 
– glutamine cycle (more utilization of glutamine and more synthesis of glutamate). 
Krebs cycle cycling, however, is still significantly impeded.  
Another interesting change to the metabolic profile is the significant enrichment 
in GABA M+4 in the epileptic tissue. Unlike glutamate, it seems that the addition of this 
‘rescue’ concentration of glutamine was able to upregulate GABA synthesis. As 
explained above, this may be explained by the high flux of the cycle (Hassel and 
Dingledine, 2006) that makes glutamine an excellent source for sustainment of the 
GABA pool. Tissue level of GABA is still significantly increased, which may reflect 
either increased synthesis of GABA or the lack of GABA breakdown via the redox-
dependent transamination reaction. 
The Krebs cycle labelling results as described in section 5.3.10 shows a similar 
pattern of labelling as with the incubation of [U-13C]-glutamate (detailed in section 5.3.7 
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and discussed in section 5.4.5). Glutamine can still enter the Krebs cycle via glutamate 
and alpha-ketoglutarate, as shown by the sustained M+5 alpha-ketoglutarate labelling. 
Interestingly, the addition of glutamine was able to sustain the M+3 labelling of alpha-
ketoglutarate, unlike glutamate. M+3 alpha-ketoglutarate is obtained from the cycling 
of glutamine via the second turn of the Krebs cycle (see Figure 2-4) and although the 
level of labelling of the other substrates of Krebs cycle leading to that point (i.e 
succinate M+4, fumarate M+4, malate M+4, and citrate M+4) are all significantly 
reduced, their relative level is slightly higher than the level obtained from glutamate 
incubation (for example, citrate M+4 labelling is 16.15 ± 1.84% in epileptic with 
glutamine vs 7.89 ± 0.38% in epileptic with glutamate). This suggest that following 
glutamine addition, there may be a partial rescue of the capacity of Krebs cycle, at 
least up to the second turn of the cycle. 
 Finally, aspartate labelling pattern is very much similar to the results obtained 
from glutamate incubation (as shown in section 5.3.8 and discussed in section 5.4.5), 
except for a significant reduction in M+4 and M+3 aspartate. Both M+4 and M+3 
aspartate are obtainable from recycling of glutamate or GABA via the Krebs cycle (see 
Figure 2-4). This again confirms the lack of recycling of glutamate or GABA via the 
Krebs cycle. Tissue amounts of aspartate are still significantly reduced which again 
supports this.  
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5.5 Summary, strength, and weakness 
 
Overall, the metabolic mapping experiments provided a very comprehensive 
assessment of the metabolic state of the tissue following our mitochondrial epilepsy 
protocol. The tissue’s metabolic profile is significantly modified during the epileptic 
state. There is a dependence on glycolysis for generation of energy during a state of 
seizure, which resulted in a significantly higher lactate release, consistent with what is 
observed in the patients. Krebs cycle is severely impaired, which may be reflective of 
severe inhibition of oxidative respiration. The glutamate – glutamine cycle is also 
significantly downregulated, particularly a significant loss of tissue glutamine during the 
seizure state. This, along with a series of other observations, indicates a complete 
shutdown of astrocyte’s function in mitochondrial epilepsy. Glutamine, which may 
rescue the epileptic phenotype, is shown to be capable of sustaining GABA synthesis 
in the tissue, presumably restoring the cycle’s homeostatic equilibrium. Compared to 
glutamate, glutamine is proven to be a better choice of metabolic substrate during 
mitochondrial epilepsy.  
Findings from this chapter also provided us with the exquisite evidence of the 
selectivity of fluorocitrate inhibition of the Krebs cycle in the astrocytic compartment. 
Rotenone and cyanide, as an electron transport chain inhibitor, is shown to severely 
affect neuronal metabolism. This ties in with the ‘dual neuronal – astrocytic hit 
hypothesis’ in which both the astrocytic and neuronal compartment needs to be 
affected severely before epileptic activity is seen at the network level. In fact, astrocytes’ 
metabolic function has to be completely silenced for epileptogenesis to occur.  
Although these metabolic mapping experiments is very elegantly designed and 
conducted, there are some cautions in interpreting the results. The GCMS labelling 
pattern is presented as percentage of isotopologue labelling after being adjusted for 
the natural abundance but this does not represent the absolute value of the substrates 
discussed. In the case of some substrates (such as lactate, alanine, glutamate, 
glutamine, GABA, and aspartate), the absolute value may be obtained through HPLC 
measurements. In this case, it is imperative that the GCMS labelling is interpreted 
alongside consideration of the absolute value of the substrates discussed. In most 
cases (as with the Krebs cycle intermediates), the absolute value cannot be obtained 
through HPLC and as such, only inferences can be made on the relative activity of the 
Krebs cycle. Furthermore, measurements through GCMS or HPLC cannot distinguish 
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the origin of these substrates (vesicular vs non-vesicular pool or astrocytic vs neuronal 
pool), unless the substrate is metabolically compartmentalized (such as aspartate). 
These weaknesses however do not discredit the importance of these results in 
dissecting the mechanisms of seizure generation in mitochondrial epilepsy. It has 
provided a relative assessment of the metabolic state in the tissue during mitochondrial 
epilepsy and implicated several metabolic pathways that may be important targets for 
therapeutic interventions.  
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Chapter 6 Measuring metabolic fluxes in specific cellular 
population during mitochondrial epilepsy 
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6.1 Introduction 
 
The experimental findings presented in Chapter 5 provided a comprehensive 
assessment of the state of tissue metabolism during mitochondrial epilepsy. However, 
the techniques used for this type of measurement do not directly measure 
mitochondrial respiration. One technique to address such gap is the use of Seahorse 
XF24 Flux Analyzer, which has been used extensively to measure mitochondrial 
respiration in tissues and isolated mitochondria (Beeson et al., 2010; Rogers et al., 
2011; Sauerbeck et al., 2011). This particular piece of equipment provides a live 
monitoring of oxygen consumption rates (OCR) and extracellular acidification rates 
(ECAR) as marker of mitochondrial respiration and glycolytic activity, respectively. 
However, most of the studies conducted with this technique has used cells that have 
been cultured on the Seahorse plate. It can be argued, however, that the use of ex 
vivo cell culture system would not accurately reflect the in vivo condition. As an 
example, the process of cell culture itself is known to impose oxidative stress (Halliwell 
and Whiteman, 2004), which would alter the metabolic profile of the cells. As such, this 
technique is not directly applicable for our purpose as the changes in the metabolic 
profile are due to pharmacological manipulations that may or may not induce a 
permanent change in the metabolism of the cells. Thus, a technique needs to be 
developed to be able to acutely isolate cells from fresh tissue preparation, which would 
resemble the in vivo condition as much as possible.  
Another advent in cell isolation in recent years is the magnetic-activated cell 
sorting (MACS) technique, which uses magnetic beads that recognizes specific cell 
surface antigens (Miltenyi et al., 1990). One advantage of such technique is the rapid 
cell isolation process, which does not affect cell viability (Miltenyi et al., 1990). 
Furthermore, the use of the magnetic beads allows the sorting of isolated cells based 
on their expressed cell surface markers.  
Our mitochondrial epilepsy model is heavily based on the ‘dual neuronal – 
astrocytic hit’ hypothesis (see section 3.5), which postulates the necessary recruitment 
of both the neuronal and astrocytic compartment in the generation of mitochondrial 
epilepsy. The results described in Chapter 5 have supported the involvement of both 
the neuronal and astrocytic metabolism during the epileptic state, but again, no direct 
quantification of mitochondrial respiration in these two specific cellular compartments 
have been made. 
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To address this knowledge gap, I developed a novel technique by pairing the 
acute cell isolation using magnetic-activated cell sorting with the measurement of 
metabolic fluxes in these isolated cells using Seahorse XF24 Flux Analyzer. Since the 
two distinct cell compartments critical to my model are the neurons and astrocytes, I 
chose to isolate these from acutely prepared hippocampal slices. Subsequently, I 
designed and conducted various setup of metabolic experiments using the Seahorse 
XF24 Flux Analyzer, in order to first characterize these cell populations and then test 
specific hypothesis developed in relation to the mechanisms involved in the generation 
of mitochondrial epilepsy. 
Finally, it is universally accepted that mitochondria are major source of 
endogenous reactive oxygen species and that oxidative stress is intimately linked with 
mitochondrial dysfunction (Tiwari et al., 2002; Halliwell and Whiteman, 2004; Ott et al., 
2007). Furthermore, oxidative stress has been implicated in other models of 
mitochondrial epilepsy as a core pathophysiological process (Liang and Patel, 2004; 
Cantu et al., 2009). To give an indication of the level of oxidative stress in our model 
of mitochondrial epilepsy, a measurement of carbonylated protein was performed to 
compare levels of protein peroxidation in control and epileptic tissue.  
 
6.2 Methods 
 
Animal preparation and cell isolation was as described in section 2.14. Following 
cell isolation, these cells were seeded onto the Seahorse XF24 microplate for 
measurement of metabolic fluxes as described in section 2.15. In order to test out the 
various hypothesis developed, I have used various composition of Seahorse 
experimental media as described in Table 6-1. The results of three experimental 
setups will be discussed in this chapter and the three experimental setups are as 
described in Table 6-2 and the cartridge setups are as described in Table 6-3.  
Table 6-1 Composition of media used in the Seahorse experiments 
No Media Composition 
1 Control media  Seahorse XF media + 10mM D-glucose + 
5mM pyruvate + 3% FBS 
2 Control media + glutamine As in no 1, but with 2.5mM L-glutamine 
3 Epileptogenic media As in no 1, but with 0.1mM fluorocitrate 
4 Epileptogenic media + glutamine As in no 2, but with 0.1mM fluorocitrate 
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Table 6-2 Groups in the experimental setups 
Exp cond. Group 1 Group 2 Group 3 Group 4 
1 Astrocyte in 
control media 
Astrocyte in 
control media + 
glutamine 
Neurons in 
control media 
Neurons in 
control media + 
glutamine 
2 Astrocyte in control media Neurons in control media 
3 Astrocyte in 
control media 
Astrocyte in 
epileptogenic 
media 
Neurons in 
control media 
Neurons in 
epileptogenic 
media 
4 Astrocyte in 
epileptogenic 
media 
Astrocyte in 
epileptogenic 
media + 
glutamine 
Neurons in 
epileptogenic 
media 
Neurons in 
epileptogenic 
media + 
glutamine 
 
Table 6-3 Cartridge setup in the experimental setups.  FCCP refers to the ionophore carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone and 2D-G refers to 2-deoxy-D-glucose. 
Exp cond. Port A Port B Port C Port D 
1 Oligomycin 
(1mg/ml) 
FCCP (3mM) 2D-G (10mM) Rotenone 
(500nM) and 
antimycin-A 
(2.5μM) 
2 Water (v/v) DMSO (v/v) Control media 
(v/v) 
Ethanol (v/v) 
3 Potassium 
cyanide 
(10μM) 
Rotenone 
(500nM) 
L-glutamine 
(2.5mM) 
Antimycin-A 
(2.5μM) 
4 Potassium 
cyanide 
(10μM) 
Rotenone 
(50nM) 
FCCP (3mM) Antimycin-A 
(2.5μM) 
 
Once each run in the Seahorse machine had concluded, the cells were fixed in 
4% PFA and post-hoc immunofluorescence was conducted as described in section 
2.16. The values of the Seahorse measurement were normalized against the viable 
cell count in each well. From these normalized values, various parameters were 
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quantified according to the bioenergetics profile measurement as described in other 
studies (Nicholls et al., 2010; Tan et al., 2015). Extracellular acidification rate was 
analysed using the mathematical model suggested in previous publication to account 
for the contributions of mitochondrial respiration and glycolysis to extracellular acid 
production (Mookerjee et al., 2015).  
Measurement of carbonylated protein was conducted as described in section 
2.10. All the data was tabulated and analysed as described in section 2.9. 
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6.3 Results 
 
6.3.1 Magnetic-activated cell sorting produced comparable yield and viability 
in astrocytes and neurons 
 
Neurons and astrocytes were isolated using the magnetic-activated cell sorting 
techniques. The technique has produced comparable yield and viability within the two 
cellular compartments (see Figure 6-1). These cells were deemed viable to be used 
for the measurement of metabolic fluxes using the Seahorse XF24 Analyzer system.  
 
Figure 6-1 Cells isolated through MACS have comparable yield and viability.  Shown in (A) is the total yield of cells isolated 
through the MACS protocol. The total yield of viable cells and percentage of cell viability was determined using tryptan blue 
cell viability assay and was calculated using automated cell counting, as shown in (B) and (C) respectively.  
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Overall, the total yield of the cells was significantly comparable (p ≥ 0.05, n = 9), 
with average values of 2.51 ± 0.12 (x 107 cells/ml) for astrocytes and 2.74 ± 0.14 (x 
107 cells/ml) with regards to neurons. The total yield of viable cells was also 
significantly comparable (p ≥ 0.05, n = 9), with an overall mean value of 1.30 ± 0.19 (x 
107 cells/ml) for astrocytes and 1.59 ± 0.20 (x 107 cells/ml) for neurons. Finally, the 
percentage of cell viability was not significantly different (p ≥ 0.05, n = 9), with a 
calculated mean value of 50.62 ± 4.67 % viability for astrocytes and 44.63 ± 3.78 % 
viability for neurons.  
 
6.3.2 Metabolic characterization of the isolated cellular compartments 
 
The following sub-section described the results from experimental condition 1 
(see Table 6-2 and Table 6-3). This experimental condition is designed to characterize 
the metabolic profile of the isolated cellular compartments using standard experimental 
protocol in measuring metabolic fluxes using the Seahorse XF24 Flux analyser. This 
standard protocol includes the sequential application of oligomycin, FCCP, 2-DG, and 
the co-application of rotenone and antimycin-A. Oligomycin is a well characterized 
inhibitor of ATP synthesis, by inhibiting the F0 portion of the catalytic subunit of 
mitochondrial respiratory chain complex V (ATP synthase) (Penefsky, 1985). FCCP is 
a mitochondrial uncoupler, which transports proton across the phospholipid bilayer 
membranes and uncouples mitochondrial respiration from ATP production (Benz and 
McLaughlin, 1983). This uncoupling causes the stimulation of oxygen consumption 
(mitochondrial respiration) without a concomitant increase in ATP synthesis, enabling 
the exploration of a cell’s maximum respiratory capacity. 2-DG (2-deoxy-D-glucose) is 
a potent inhibitor of glycolysis, through the inhibition of the enzyme hexokinase (TeSlaa 
and Teitell, 2014). Finally, the co-application of rotenone, a mitochondrial complex I 
inhibitor, and antimycin-A, a mitochondrial complex III inhibitor, caused a complete 
inhibition of electron transport chain. The remaining rate of respiration can then be 
attributed to non-mitochondrial respiration. These experiments have demonstrated that 
the isolated astrocytes and neurons exhibited a distinct metabolic profile (see Figure 
6-2).  
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Figure 6-2 Oxygen consumption rate of astrocytes and neurons in the absence or presence of glutamine shows a distinct 
metabolic profile. Shown in (A) is the oxygen consumption rate following the experimental sequence as described in 
experimental condition 1 (see Table 6-2, N = 3 animals). Basal respiration, shown in (B), is obtained after subtracting the non-
mitochondrial respiration rate from the baseline respiration rate. (C) and (E) shows the oxygen consumption rate that is 
attributable to ATP production and glycolysis, respectively. (D) shows the maximal respiration capacity attainable by each cell 
groups following the application of FCCP. * indicates statistical significance (p ≤ 0.05).  
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Overall, the metabolic profile of the cells is relatively similar except for a distinct 
difference in the maximal respiratory capacity in the absence or presence of glutamine 
(n = 13 for astrocytes with or without glutamine, n =15 for neurons with or without 
glutamine). There was no significant difference (p ≥ 0.05) in the basal respiration 
between all the groups (0.64 ± 0.08 nmoles/cells/min astrocytes vs 0.88 ± 0.11 
nmoles/cells/min astrocytes + glutamine vs 0.78 ± 0.08 nmoles/cells/min neurons vs 
0.73 ± 0.08 nmoles/cells/min neurons + glutamine). There was also no significant 
difference (p ≥ 0.05) in the oxygen consumption attributable to either ATP production 
(0.27 ± 0.05 nmoles/cells/min astrocytes vs 0.34 ± 0.03 nmoles/cells/min astrocytes + 
glutamine vs 0.31 ± 0.03 nmoles/cells/min neurons vs 0.30 ± 0.06 nmoles/cells/min 
neuron + glutamine) or glycolysis (0.53 ± 0.14 nmoles/cells/min astrocytes vs 0.87 ± 
0.21 nmoles/cells/min astrocytes + glutamine vs 0.89 ± 0.23 nmoles/cells/min neurons 
vs 0.92 ± 0.18 nmoles/cells/min neurons + glutamine) between all the groups. There 
was, however, a significant difference (p ≤ 0.05) in the maximal respiration, where the 
maximal respiration of astrocyte (1.38 ± 0.34 nmoles/cells/min) was significantly lower 
(p ≤ 0.05) than that of astrocyte in the presence of glutamine (3.78 ± 0.80 
nmoles/cells/min) and of neurons in the absence (3.43 ± 0.47 nmoles/cells/min) or 
presence of glutamine (3.61 ± 0.40 nmoles/cells/min). This significant increase in 
maximal respiration by glutamine appears to be selective to astrocytes and is likely to 
enable astrocytes to achieve the maximal respiration capacity similar to that of neurons.  
When analysing the ECAR data, I found that some of the cells have an ECAR 
profile that is directly correlated with the OCR measurements (see Figure 6-4.A). This 
means that 100% of the extracellular acid production is directly attributable to CO2 
generated as byproduct of mitochondrial respiration (from the TCA cycle). Specifically, 
following calculation according to the mathematical model (Mookerjee et al., 2015),          
6 out of 13 wells (46.15 %) of astrocytes had 100% of their ECAR attributable to CO2 
generated by oxidative respiration while 9 out of 14 wells (64.29 %) of neurons had 
100 % of their ECAR attributable to CO2 generated by oxidative respiration. This profile 
is slightly different when glutamine is present in the media. In the presence of glutamine, 
astrocytes become significantly more oxidative, X2(1,N=13) = 4.95, p = 0.03, with 10 
out of 13 wells (76.92 %) having 100 % of their ECAR attributable to CO2 generated 
by oxidative respiration whereas neurons become significantly less oxidative, 
X2(1,N=15) = 3.85, p = 0.05, with 6 out of 15 wells (40.00 %) having 100 % of their 
ECAR attributable to CO2 generated by oxidative respiration.  
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The relative contribution of glycolysis towards ECAR in our isolated cellular 
system appears to be very low. Specifically, there was an average of 20.94 ± 9.29 % 
and 4.64 ± 2.40 % glycolytic contribution towards ECAR in astrocytes and neuron 
respectively. This appears to be quite different but is not statistically significant (p ≥ 
0.05), perhaps due to low sample size. In the presence of glutamine, this value has 
slightly changed with a calculated mean value of 4.64 ± 2.40 % and 12.40 ± 5.12 % 
glycolytic contribution towards ECAR in astrocytes and neuron respectively. This 
profile again seems to be different from the profile in absence of glutamine, but this 
difference is yet again not statistically significant (p ≥ 0.05), possibly due to low sample 
size.  
 In general, our acutely isolated cells exhibited high oxidative respiration and in 
most cases, all of the ECAR is directly attributable to CO2 generated from oxidative 
respiration. Therefore, ECAR cannot be used as a reliable indicator of glycolytic activity 
in our isolated cells system.  However, these series of results (OCR and ECAR) truly 
demonstrated that the isolated cells are biologically viable and exhibited distinct 
metabolic profile, suggesting the relative selectivity of the isolation process. However, 
due to the inaccuracy of ECAR as a glycolytic indicator, for the remainder of this thesis, 
only OCR results will be presented and analysed.  
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Figure 6-3 ECAR is mostly attributable to CO2 generated from oxidative metabolism; yet still there exists a distinction between 
astrocytes and neurons.  Shown in (A) is the proportion of wells in each group has their ECAR 100% attributable to CO2 
generated from oxidative metabolism following mathematical adjustment. Shown in (B) is the relative contribution of 
oxidative metabolism and glycolysis to the ECAR value following adjustment.  
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6.3.3 Cell’s metabolic flux measurement is relatively stable over time 
 
To examine the stability of the cell’s metabolic flux measurement over time, I 
devised an experimental condition whereby the isolated cells were exposed to vehicle 
in accordance to the sequence of exposure in the experimental protocol (particularly 
pertaining to condition 3). The sequence of vehicle injection in the cartridge was as 
described in condition 2 in Table 6-3.  
The oxygen consumption rate is very stable over time (see Figure 6-4) and is 
unaffected (p ≥ 0.05) by exposure to the vehicle or time in both neurons (baseline 3: 
1.33 ± 0.06 nmoles/cells/min vs ethanol 2: 1.40 ± 0.09 nmoles/cells/min, n=5) and 
astrocytes (baseline 3: 1.31 ± 0.21 nmoles/cells/min vs ethanol 2: 1.40 ± 0.09 
nmoles/cells/min, n=5). These results further validate this technique for use to assess 
metabolic profile of acutely isolated neurons and astrocytes in various experimental 
conditions.  
B
a
s
e
li
n
e
 1
B
a
s
e
li
n
e
 2
B
a
s
e
li
n
e
 3
W
A
T
E
R
1
W
A
T
E
R
2
D
M
S
O
1
D
M
S
O
2
M
E
D
IA
1
M
E
D
IA
2
E
T
H
A
N
O
L
1
E
T
H
A
N
O
L
2
0 .0
0 .5
1 .0
1 .5
2 .0
O
C
R
 (
n
m
o
le
s
/c
e
ll
s
/m
in
)
A s tro c y te
N e u ro n
 
Figure 6-4 Oxygen consumption rate of astrocytes and neurons is relatively stable over time and unaffected by exposure to 
vehicle. These results are from condition 2 in Table 6-2 and Table 6-3 (N=1 animal).  
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6.3.4 Measurement of cellular mitochondrial respiration following the 
induction of mitochondrial epilepsy 
 
After demonstrating the feasibility and stability of this technique, I designed an 
experimental setup to measure the degree of mitochondrial respiration as each 
component of the mitochondrial epilepsy protocol is applied onto the isolated cells (see 
condition 3 in Table 6-2 and Table 6-3). The isolated neurons and astrocytes were 
exposed to either the control media or the epileptogenic media. The epileptogenic 
media contains 0.1mM fluorocitrate in addition to the standard composition of the 
control media. The cells were then incubated in these media for 30 minutes prior to 
being measured in the Seahorse machine. This step is reminiscent of the pre-
incubation with 0.1mM fluorocitrate in the standard mitochondrial epilepsy protocol 
(see section 2.5). Cyanide (10μM) was then injected through the cartridge first and 
rotenone (500nM) next, to see the acute impact of each of these mitochondrial 
inhibitors on oxygen consumption rate. Glutamine was then injected at the ‘rescue’ 
concentration of 2.5mM to examine if any acute rescue of the respiration is seen 
following the mitochondrial epilepsy protocol. Finally, antimycin-A was again applied to 
measure total mitochondrial respiration.  
Basal respiration is not significantly different (p ≥ 0.05) between the control and 
the epileptogenic media in both astrocytes (1.08 ± 0.12 nmol/cells/min control, n=12 
vs 1.12 ± 0.12 nmol/cells/min with fluorocitrate, n=13) and neurons (1.33 ± 0.16 
nmol/cells/min control, n=13 vs 1.15 ± 0.10 nmol/cells/min with fluorocitrate, n=15). 
Following the application of all of the components of the mitochondrial epilepsy 
protocol, mitochondrial respiration is almost completely inhibited (see Figure 6-5). 
There is no significant difference (p ≥ 0.05) in the degree of mitochondrial respiration 
inhibition by cyanide (13.17 ± 3.94 % astrocyte vs 17.17 ± 5.61 % astrocyte with 
fluorocitrate vs 10.30 ± 2.08 % neuron vs 8.07 ± 1.45 % neuron with fluorocitrate) and 
rotenone (83.87 ± 2.79 % astrocyte vs 80.09 ± 4.18 % astrocyte with fluorocitrate vs 
75.69 ± 3.37 % neuron vs 84.86 ± 3.76 % neuron with fluorocitrate) between all of the 
groups. Cyanide (10μM) inhibited an average of 12 % of mitochondrial respiration 
across all the groups while rotenone (500nM) inhibited an average of 81 % of 
mitochondrial respiration across all the groups. Glutamine did not cause any significant 
rescue in mitochondrial respiration and there was no significant difference (p ≥ 0.05) 
between the responses of any of the groups towards the acute glutamine (2.5mM) 
application (3.43 ± 1.77 % astrocyte vs 4.74 ± 1.77 % astrocyte with fluorocitrate vs 
259 
 
0.90 ± 2.37 % neuron vs 4.17 ± 1.81 % neuron with fluorocitrate). On average, there 
was only about 3 % of mitochondrial respiration that was rescued by the acute 
glutamine application.  
Overall, the pre-incubation with fluorocitrate did not inhibit mitochondrial 
respiration in both cellular compartments. The subsequent application of cyanide 
(10μM) and rotenone (500nM) inhibited most of the cells’ mitochondrial respiration 
(circa 90%). The acute application of glutamine was not able to rescue mitochondrial 
respiration in this particular scenario, perhaps due to the almost complete inhibition of 
mitochondrial respiration by the inhibitors applied.  
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Figure 6-5 There is similar degree of inhibition of mitochondrial respiration by each components of mitochondrial respiration 
in astrocytes and neurons alike.  Shown in (A) is the oxygen consumption rate following the experimental sequence as 
described in experimental condition 3 (see Table 6-2, N=3 animals). Basal respiration, shown in (B) is not different between 
the control and the epileptogenic media (for media composition, see Table 6-1). (C) and (D) shows the percentage of 
inhibition of mitochondrial respiration by the cyanide and rotenone component of the mitochondrial epilepsy induction 
protocol respectively. (E) shows the percentage of rescue of mitochondrial respiration by acute application of glutamine 
(2.5mM).  
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6.3.5 Glutamine may be able to rescue partial mitochondrial respiration 
inhibition, particularly in astrocytes 
 
Despite the strength of this technique with regard to the metabolic assessment of 
discrete cellular populations, caution is advisable when attempting to translate the 
findings on a tissue level (brain slice) to a cellular level. In addition to housing the 
neurons and glial cells, a brain tissue (or slice) is also composed of extracellular matrix 
with unique properties and compositions such as proteoglycans and glycoproteins 
(Novak and Kaye, 2000). This extracellular matrix is particularly important when 
discussing the concept of drug delivery into brain tissue as it provides a physical form 
of barrier to diffusion of active compounds (Vargová and Syková, 2014). Therefore, the 
actual cellular concentration of a drug in a tissue setting would always be lower than 
the administered drug concentration. Hence, when designing a study at ex vivo 
isolated cell system, a submaximal concentration of the drug should be applied to more 
closely resemble the cellular concentration of the drug. However, the difficulty lies in 
measuring the actual cellular concentration of the drug at a tissue setting, which cannot 
easily and accurately be determined.  
In my case, from results described in section 6.3.4, I find that exposure to both 
10μM of cyanide and 500nM of rotenone resulted in an almost complete inhibition of 
mitochondrial respiration in both cellular compartments. One can safely infer that due 
to the generation of epileptic activity with this concentration of mitochondrial respiratory 
chain inhibitors at the tissue level that this concentration would not induce complete 
inhibition of mitochondrial respiration (otherwise, generalized energy failure would 
have occurred instead). To address this, I decided to re-examine the impact of 
glutamine on a partial mitochondrial respiratory chain inhibition using a lower 
concentration of the respiratory chain inhibitors. Since cyanide at its maximal 
concentration of 10μM only inhibited about 10% of mitochondrial respiration, I did not 
feel that it is necessary to titrate the concentration even lower. Instead, I decided to 
titrate the rotenone concentration, which was the major contributor to the complete 
respiratory chain inhibition in the previous experimental condition. Therefore, I chose 
a 10 times dilution of the rotenone concentration to 50nM to ensure a still potent 
respiratory chain inhibition without eliciting its maximal inhibitory effect. To examine 
the remaining mitochondrial respiration capacity in the cells following this partial 
respiratory chain inhibition, I decided to apply FCCP (3mM) following both the cyanide 
and rotenone application. Finally, antimycin-A was again applied to examine the non-
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mitochondrial respiration. Furthermore, to properly examine the effect of glutamine on 
the metabolism, I decided to revert to pre-incubating the cells with glutamine in the 
media rather than acutely applying the glutamine through the cartridge injection. This 
allows accumulation of glutamine in the cells and the adaptation of the cellular 
metabolic machinery to the presence of glutamine prior to the respiratory chain 
inhibitions.  
Overall, this combination of concentration of respiratory chain inhibitors was able 
to produce a partial inhibition of mitochondrial respiration (see Figure 6-6). Again, there 
was no significant difference (p ≥ 0.05) in the degree of mitochondrial respiratory 
inhibition by cyanide (10μM) or the lower concentration of rotenone (50nM) across all 
of the groups. This lower concentration of rotenone (50nM) inhibited an average of 53 % 
mitochondrial respiration across all of the groups, instead of the average of 81 % 
inhibition with the maximal tissue concentration (500nM). There was, however, a trend 
where there was less inhibition of mitochondrial respiration by the 50nM rotenone in 
the astrocyte in the presence of glutamine in the media (62.85 ± 2.59 % astrocyte, n=5 
vs 43.26 ± 4.70 % astrocyte with glutamine, n=5). There was a similar trend with 
regards to the neuron, but not as apparent as astrocytes (56.50 ± 8.28 % neuron, n=5 
vs 47.88 ± 6.92 % neuron with glutamine, n=5). Due to a logistical limitation, I was 
unable to replicate this experiment, but with enough replicates, this trend would most 
probably be more apparent and reaches statistical significance. Again, there was no 
statistically significant difference (p ≥ 0.05) in the maximal respiration capacity 
following the partial respiratory chain inhibition across all the groups. There was, 
however, a trend where there is slightly higher maximal respiration capacity in both 
neurons and astrocytes in the presence of glutamine (0.25 ± 0.05 nmol/cells/min 
astrocyte vs 0.30 ± 0.06 nmol/cells/min astrocyte with glutamine vs 0.27 ± 0.04 
nmol/cells/min neuron vs 0.38 ± 0.04 nmol/cells/min neuron with glutamine). Again, 
with enough replicates of this experimental design, this trend would probably be more 
apparent and be a statistically significant difference.  
Glutamine shows a promising potential as a potent mitochondrial respiration 
modulator and future works should focus on replicating this experimental design to 
truly validate this mitochondrial protective effect of glutamine.  
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Figure 6-6 Glutamine may be able to rescue partial mitochondrial respiration inhibition, particularly in astrocytes.  Shown in 
(A) is the oxygen consumption rate following the experimental sequence as described in experimental condition 4 (see Table 
6-2, N = 1 animal). (B) and (C) shows the percentage of inhibition of mitochondrial respiration by cyanide (10μM) and a lower 
concentration of rotenone (50nM) in astrocytes and neurons in an epileptogenic media with or without glutamine (2.5mM). 
(D) shows the remaining maximal respiration capacity after the partial respiratory chain inhibition, as stimulated by the FCCP 
application.  
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6.3.6 There is significantly higher protein peroxidation in the epileptic tissue 
as compared against control tissue 
 
 Mitochondrial epilepsy has long been associated with a significant degree of 
oxidative stress in the tissue (Liang and Patel, 2004; Cantu et al., 2009). As an indicator 
of oxidative stress, I measured carbonyl concentration in the tissue, which is a direct 
measure of protein peroxidation (Levine et al., 1994; Suzuki et al., 2010).  
There is a significantly higher (p ≤ 0.05) carbonyl concentration in the epileptic 
tissue (80.98 ± 16.30 nmol/mg protein, n = 8) as compared against the control tissue 
(29.03 ± 6.07 nmol/mg protein, n = 10).  
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Figure 6-7 There is a significantly higher carbonyl concentration in the epileptic tissue as compared against the control 
tissue.  * indicates statistical significance (p ≤ 0.05).  
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6.4 Discussion 
 
6.4.1 Cell isolation 
 
As explained in section 6.1, there is a need to develop a method to acutely isolate 
specific cellular population from fresh tissue preparation to resemble the in vivo 
condition as much as possible. The method that I chose to work with was the magnetic-
activated cell sorting (MACS) technique. In order to acutely isolate cells from fresh 
tissue, I required a cell isolation technique that was rapid and capable of producing a 
pure isolate. Previous studies have indeed shown that the MACS technique is fairly 
rapid and can produce a viable pure cell population, as it is separated through the 
specific conjugation between the magnetic beads and the cell’s surface antigen 
(Miltenyi et al., 1990; Marek et al., 2008; Willasch et al., 2009).   
When I applied the MACS technique, I found that the cell isolation technique is 
relatively quick with the whole cell isolation process taking around 5 – 6 hours to 
complete for both the neuronal and astrocytic population. It also produced a relatively 
high total yield of cells with an average of around 2.6 ± 1.0 x 107 cells/ml. Viability of 
the cells was slightly lower than the previously reported viability at around 50 %. This 
is probably due to the slightly older age of animals that I have used in my study. To 
conform with our other studies (electrophysiological and metabolic mapping), I decided 
to use the standard adult 10 weeks old Wistar rats for this study as well. It is well 
established, with other cell isolation techniques such as the density gradient separation, 
that cells from aged animals tend to be less viable (Brewer, 1997). The total yield of 
viable cells, however, was relatively comparable between both neurons and astrocytes.  
Overall, the MACS technique has been able to isolate a relatively high yield of 
viable neurons and astrocytes for measurements of metabolic fluxes. The technique is 
unique to the other techniques (for example, the previously mentioned density gradient 
separation or immunopanning), in that it is relatively rapid and is quite specific in its 
separation of the cell population (to be discussed further in section 6.4.2.1). 
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6.4.2 Metabolic characterization of the cell isolates 
 
Experimental condition 1 was designed to characterize the metabolic profile of 
cell’s line by assessment of its capacity for ATP synthesis, glycolysis, and maximal 
respiration through the sequential application of various pharmacological inhibitors. 
Two parameters are continuously monitored throughout the experiment, namely the 
oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR).  
 
6.4.2.1 Oxygen consumption rate 
 
Oxygen consumption rate is used as an indicator of cellular respiration (see 
Figure 6-2). After accounting for non-mitochondrial respiration obtained from the 
remaining respiration following complete mitochondrial inhibition with rotenone and 
antimycin-A, a basal respiration value is obtained as a parameter of mitochondrial 
respiration. The basal respiration rate was not significantly different between the 
neurons and astrocytes. This suggests that there is no difference in the oxygen 
consumption rate between astrocytes and neurons under physiological condition, 
which has been reported previously in a study on isolated mitochondria (Lopez-Fabuel 
et al., 2016).  
Inhibiting ATP synthase with oligomycin is a classic method to evaluate 
mitochondrial coupling as ATP production through phosphorylating respiration is 
stopped. Only a small amount of the oxygen consumption rate is attributable to this (an 
average of 0.3 nmoles/cells/min or about 30% of the basal respiration) and it is not 
significantly different between astrocytes and neurons. This value is comparable to 
previous studies on cultured neurons (Clerc and Polster, 2012). I also inhibited 
glycolysis with 2-deoxy-D-glucose to evaluate how much oxygen consumption is 
attributable to glycolysis and again, this was not significantly different between 
astrocytes and neurons. Overall, this finding suggests that oxygen consumption under 
physiological condition, that is attributable to both glycolysis and ATP production, is 
similar between astrocytes and neurons; confirming the inference made from the basal 
respiration rate.  
Although all the other respiratory parameters are comparable between the 
neurons and the astrocytes, there is a distinct significant difference in maximal 
respiration capacity. The maximal respiration capacity is significantly higher in neurons 
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than in astrocytes. This distinction, as measured by FCCP, is comparable to previous 
observations on cultured cortical neurons and astrocytes (Divakaruni et al., 2014). It is 
well established that astrocytes and neurons have different metabolic profile when 
responding to stress. The viability of neurons under a metabolic stress depend on 
provision of oxidative phosphorylation, whereas astrocytes depend more on glycolysis 
(Almeida et al., 2001).  Furthermore, there is a structural difference in the mitochondrial 
complex I assembly that has been shown to lead to a bioenergetics distinction between 
neurons and astrocytes.  Specifically, it has been shown that in astrocytes, there is a 
higher proportion of free complex I as opposed to neurons, where most of the complex 
I is embedded into supercomplexes. This discrepancy leads to poor mitochondrial 
respiration but higher reactive oxygen species production in the astrocytes as 
compared to neurons (Lopez-Fabuel et al., 2016). Although FCCP is not a metabolic 
stressor per se, the uncoupling mechanism artificially creates a system whereby the 
mitochondria are forced to operate at its maximal capacity, which would utilize the 
reserve capacity it had to respond to metabolic stress. Therefore, it would be 
unsurprising to see that neurons have much higher reserve capacity to upregulate their 
mitochondrial respiration under this artificial modulation.  
This set of results can be viewed to add to the body of evidence that demonstrates 
that under basal physiological condition, there is no significant metabolic distinction 
between astrocytes and neurons. However, when exposed to metabolic stress or 
energetically demanding stimulus (such as electrical excitation), neurons had a much 
higher capacity for oxidative respiration than astrocytes. In addition to confirming the 
observations of other studies, this distinction also points to the selectivity of the cell 
isolation process using the MACS system to separate the cell population to the 
astrocytic and neuronal compartment.  
 
6.4.2.2 Extracellular acidification rate 
 
Extracellular acidification rate (ECAR) is a measure of the rate of proton (H+) 
production, expressed as a change in the pH of the media over time. Two major factors 
contribute to the rate of extracellular acidification, namely glycolytic turnover and CO2 
production attributable to oxidative respiration (Divakaruni et al., 2014; Mookerjee et 
al., 2015). 
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In glycolysis, the conversion of glucose into lactate, irrespective of the pathways 
it undertake, necessitates the release of two protons molecule (Voet and Voet, 2011b; 
Berg et al., 2012f), therefore acidifying the media. Another important component of 
glycolysis that can produce acidification is ATP hydrolysis. For every 2 moles of ATP 
that is hydrolysed in a system, one molecule of proton is released to the medium 
(Divakaruni et al., 2014) and within the glycolytic breakdown of a molecule of glucose, 
two ATP molecules would be hydrolysed for each glucose molecule (Berg et al., 2012f).  
Initially, it was thought that ECAR is purely attributable to glycolysis but recent 
studies have demonstrated that CO2 production from the Krebs cycle in oxidative 
metabolism may contribute towards the acidification process (Divakaruni et al., 2014; 
Mookerjee et al., 2015). The release of CO2 into the aqueous media causes its 
reversible hydration and eventual dissociation into bicarbonate and a proton (Berg et 
al., 2012c). In some systems, this may be particularly relevant as shown in a study 
using a pancreatic beta-cell line MIN6 that lacks lactate dehydrogenase expression, 
where the entire ECAR is shown to be attributable to the CO2 release due to the 
oxidative metabolism of glucose (Sakamaki et al., 2014).  
Due to the varying nature of each cell line, it is recommended that the ECAR is 
initially evaluated by accounting for both the glycolytic turnover and the oxidative 
metabolism through a proposed mathematical model (Mookerjee et al., 2015). In my 
system, a majority of the isolated cells were very oxidative (46% of astrocytes and 64% 
of neurons), meaning that 100% of the extracellular acid production is directly 
attributable to CO2 generated from oxidative metabolism. This reflects previous 
observations where glycolytic turnover is generally not as robust in primary cells as in 
immortalized cells or proliferative cell cultures (Divakaruni et al., 2014). This supports 
my view that the acutely isolated cells represent the in vivo condition better than a 
culture model, where metabolism may have significantly changed to adapt to the 
culture conditions. In vivo, it has been shown that both neurons and astrocytes are 
relatively oxidative (Hertz et al., 2006; Ivanov et al., 2013), which is what I have 
demonstrated in the isolated cells model. In addition, mitochondrial carbonic 
anhydrase, the enzyme responsible for the hydration and dissociation reaction as 
specified above, has been shown to be expressed exclusively in the neurons and 
astrocytes within the nervous system (Wong et al., 1987; Ghandour et al., 2000). 
Therefore, not surprisingly, both of our isolated neurons and astrocytes were able to 
generate substantial acidification through their oxidative metabolism.  
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When comparing the relative total contribution of glycolysis and oxidative 
metabolism towards extracellular acidification rate, a distinction exists between the 
astrocytes and neurons. Astrocytes are slightly less oxidative and more glycolytic than 
neurons. As mentioned above, the higher expression of free mitochondrial complex I 
in astrocytes suggests lower aerobic metabolism in astrocytes (Lopez-Fabuel et al., 
2016). Furthermore, astrocytes are shown to have higher capacity for glycolysis, due 
to the presence of the glycolysis-upregulating Pfkfb3 (6-phosphofructo-2-
kinase/fructose-2, 6-bisphosphatase-3) protein; which is normally absent in the 
neurons (Herrero-Mendez et al., 2009). Our observation, therefore, still supports this 
pattern and again reaffirms the selectivity of the isolation process.  
 Since the ECAR in our isolated cells is primarily reflective of the pattern of OCR, 
from this point forward, only relevant OCR data would be presented and discussed.  
 
6.4.3 Stability of metabolic flux measurement 
 
When working with primary cell isolates, the stability of the metabolic flux 
measurement over time needed to be established. Experimental condition 2 was 
designed to address this whilst also examining the presence or absence of vehicle 
effect. 
Oxygen consumption rate is very stable in both neurons and astrocytes over 
time (see Figure 6-4), which indicate the viability of the cell isolates. Furthermore, the 
addition of all the vehicles used in the experimental designs during the metabolic flux 
measurements do not cause any significant change in the oxygen consumption rate. 
Out of all the vehicle, the most concerning vehicle would be the dimethyl sulfoxide 
(DMSO). Some studies have shown that DMSO may induce behavioural, cellular, or 
metabolic change at various concentrations (Cavas et al., 2005; Nasrallah et al., 2008; 
Galvao et al., 2014). In my model, the addition of DMSO at the concentration used 
(0.1 %) did not affect the oxygen consumption rate in either neurons or astrocytes. This 
eliminates any concern for the ‘vehicle effect’ and validates further findings where 
drugs are applied using the vehicle as detailed below.  
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6.4.4 Mitochondrial respiration during mitochondrial epilepsy 
 
Experimental condition 3 was designed to characterize the amount of 
mitochondrial respiration inhibited in neurons and astrocytes by the specific 
components of the mitochondrial epilepsy protocol.  
Isolated cells were incubated in either a control or epileptogenic media (which 
contains 0.1 mM fluorocitrate). Pre-incubation with fluorocitrate did not alter the basal 
respiration of all the cells; neurons or astrocytes alike. As an inhibitor of astrocytic 
aconitase, fluorocitrate is expected to inhibit the Krebs cycle in astrocytes; which 
should bring about a subsequent reduction in oxidative metabolism. However, in this 
series of experiments, there was no change in the oxygen consumption rate in the 
astrocytes following fluorocitrate application. This supports previous finding where ATP 
level was found to be unaltered in the astrocytes following incubation with fluorocitrate; 
suggesting that fluorocitrate’s inhibitory effect in vivo results from impairment of carbon 
flux rather than impairment of oxidative metabolism (Swanson and Graham, 1994). 
Furthermore, this discredits the idea that aconitase inhibition may produce high amount 
of reactive oxygen species which would impair mitochondrial respiration (Cantu et al., 
2009; Scandroglio et al., 2014).  
Potassium cyanide (10μM) caused a relatively low inhibition of mitochondrial 
respiration (about 15 % in astrocytes and 10 % in neurons). Cyanide is a well-
established inhibitor of cytochrome-c-oxidase (complex IV) but the concentration I 
have used in this study (10μM) is relatively lower than the previously reported inhibitory 
values in other models (which is about 20μM) (Kalnenieks et al., 2000; Leavesley et 
al., 2008). Furthermore, it was suggested that mitochondrial respiration may consist of 
the cyanide-sensitive respiration and the cyanide-resistant respiration (CRR), which is 
shown to be associated with mitochondrial complex I (Esashi et al., 1981; Veiga et al., 
2003). The effect of cyanide on mitochondrial respiration has not been well 
characterized within the central nervous system setting but it is well established that 
exposure to cyanide produces extensive reactive oxygen species, which may be 
beneficial at low concentrations (Correia et al., 2012) or apoptotic-inducing at higher 
concentrations (Shou et al., 2000). Either way, in our model, it would appear that there 
is a minimal inhibitory effect on respiration by the concentration of cyanide used (10μM). 
However, the absolute requirement of cyanide as a complex IV inhibitor in inducing 
mitochondrial epilepsy in vitro suggests that cyanide may have effects other than the 
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known metabolic actions. Cyanide has been shown in a multitude of studies to alter 
the electrophysiological properties of neurons, towards hyperexcitability and 
disinhibition (Brodie, 1959; Yamamoto and Tang, 1996; Whittaker et al., 2011). In a 
study on inspiratory neuron, cyanide was found to shorten the duration of the burst and 
increase the frequency of the excitatory discharge (Brodie, 1959). In the intracellular 
recording of interneurons from the hippocampus, cyanide application reduced the firing 
rate significantly, whilst also inducing depolarization of the resting membrane potential 
(Whittaker et al., 2011).  Taken together, the effects that cyanide have on 
neurotransmission may represent an important mechanism by which cyanide, as part 
of the mitochondrial epilepsy induction protocol, modify the tissue to a state where it is 
prone to epileptogenesis. The exact mechanism, however, remains unknown. 
Rotenone (500nM) caused a significant inhibition of mitochondrial respiration 
(about 80% in both astrocytes and neurons). Rotenone is well characterized as a 
selective inhibitor of mitochondrial complex I and the concentration I have used in this 
study (500nM) is again relatively lower than the previously reported IC50 (about 2μM) 
in isolated mitochondria (Gomez et al., 2007; Frick et al., 2013). However, in this study, 
the degree of inhibition by this concentration (500nM) is almost complete (circa 80%). 
This value is comparable to results in the HL-60 cell line (Li et al., 2003) and is reflective 
of our cellular profile whereby our isolated cells rely heavily on oxidative metabolism 
(as explained above in section 6.4.2). As the largest mitochondrial complex (Janssen 
et al., 2006), complex I is essential for the process of ATP production and is also a 
major source of mitochondrial reactive oxygen species. It is well known that inhibition 
of complex I causes extensive reactive oxygen species release and induces a 
significant degree of apoptosis (Testa et al., 2005; Deng et al., 2010; Siddiqui et al., 
2013). Combined, these may be responsible for the significant degree of inhibition of 
mitochondrial respiration by rotenone in our model.  
Another interesting observation is that in the presence or absence of 
fluorocitrate, there seems to be no difference in the degree of mitochondrial respiration 
inhibition by either rotenone or cyanide. Therefore, it can be concluded that 
fluorocitrate did not increase the vulnerability of either astrocytes or neurons towards 
respiratory chain inhibition. Also, there is no significant difference in the degree of 
inhibition by both rotenone and cyanide in neurons as compared against astrocytes. 
This suggests there is no specific vulnerability of either neurons or astrocytes towards 
respiratory chain inhibition and that they are both equally inhibited by these inhibitors. 
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At this concentration, there was a much larger inhibition of mitochondrial respiration by 
the complex I inhibitor rather than the complex IV inhibitor. This reflects the original 
observation in the post-mortem neuropathological studies where there is a much larger 
complex I inhibition (~90%) and a much subtler complex IV inhibition (~40%) in the 
temporal cortex of the patients with mitochondrial epilepsy (Lax et al., 2016). 
Finally, as discussed above in section 6.3.5, when isolating neurons and 
astrocytes from their native tissue, the concentration of the drugs that these cells were 
exposed to is higher than the actual cellular concentration in vivo. This is primarily due 
to the dissociation of the extracellular matrix and other components of a tissue that 
would provide a physical barrier to the distribution of a drug onto the cells. Therefore, 
one should always be cautious in quantitatively analysing the pharmacological 
parameters (such as IC50) of these drugs as it may not be directly comparable or 
relevant to the in vivo condition. 
 
6.4.5 Effects of glutamine  
 
The effects of glutamine have been addressed in a physiological (by 
experimental condition 1) as well as in a pathological context, during the state of 
metabolic inhibition during mitochondrial epilepsy (by experimental condition 3 and 4).  
 
6.4.5.1 Physiological effects  
 
The physiological effects of glutamine were examined in experimental condition 
1, whereby the cells were either incubated in control media or media supplemented 
with 2.5mM L-glutamine. The effects of glutamine supplementation were evaluated by 
evaluating both parameters of a cell’s metabolic state; the oxygen consumption rate 
(OCR) and the extracellular acidification rate (ECAR). 
Glutamine did not alter the basal respiration of either astrocytes or neurons. The 
oxygen consumption attributable to both glycolysis and ATP production was also 
unaffected by glutamine incubation. However, glutamine significantly increased the 
maximal respiration of the astrocytes up to a level of maximal respiration value 
comparable to that observed in neurons (see Figure 6-2). This increase was only 
observed in astrocytes and was not seen in neurons exposed to the same 
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concentration of glutamine in the media. This finding suggests that glutamine can only 
be utilised by the astrocytes as metabolic fuel and not by neurons. Glutamine 
synthetase is exclusively expressed in the astrocytes (Anlauf and Derouiche, 2013); 
however, this enzyme is involved in the biosynthesis of glutamine and not in the 
utilisation (or degradation) of glutamine. The enzyme involved in the utilisation, 
glutaminase, is expressed in both neurons and astrocytes (Cardona et al., 2015). 
Some studies have interestingly suggested that glutaminase activity is much higher in 
neurons than in astrocytes (Hogstad et al., 1988). However, not much is known about 
the relative affinity of the glutaminase in neurons and astrocytes. In a study using 
tumour cell lines, it was found that during malignant transformation, there is  an 
increase in oxidative respiration which is mediated by glutamine due to an increase in 
the affinity of glutaminase (Kovačević and Morris, 1972). There is, therefore, more to 
this effect than just the simple utilization of glutamine as a metabolic substrate. There 
may be a mechanism specific to the glial biology that is regulated by glutamine, of 
which with our current understanding remains unknown.    
In terms of ECAR, glutamine altered the metabolic profile of the cells. Overall, 
the proportion of oxidative astrocytes significantly increase and the proportion of 
oxidative neurons significantly decrease. Therefore, it can be argued that glutamine 
somehow is able to upregulate oxidative respiration, as suggested by the OCR data 
as well. In recent studies, it is well characterized that glutamine is a key player in the 
growth of tumour cells. Glutamine has been shown to upregulate oxygen consumption, 
increase oxidative respiration, and to be an important carbon source for anaplerosis in 
these tumour cells (Reitzer et al., 1979; DeBerardinis et al., 2007; Weinberg et al., 
2010). The biology of glial cells is obviously very different to that of tumour cells but 
perhaps some of the insights obtained from the understanding of the role of glutamine 
in tumour cells may be applicable to the glial cells. In tumour cells, it is suggested that 
glutamine is essential for the generation of NADPH for its reductive power as well as 
for the anaplerosis of oxaloacetate for continued TCA cycle function (Kovačević and 
Morris, 1972). The study of complex I respiration in astrocytes has shown that due to 
the higher proportion of free complex I, oxidative respiration in astrocytes is 
characterized by high reactive oxygen species production and poorer mitochondrial 
respiration (Lopez-Fabuel et al., 2016). Perhaps, the limiting factor in the spare 
respiratory capacity in astrocytes is the high reactive oxygen species that it would 
produce with its upregulation of aerobic respiration. Glutamine, as a source for NADPH 
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generation, could therefore compensate for this and essentially remove the limiting 
factor, allowing the astrocytes to reach its maximum spare respiratory capacity.  
Regardless of the mechanism, the data produced in my studies has provided 
strong evidence that glutamine is a key player in astrocytic metabolism. It seems that 
glutamine has a positive effect towards modulating aerobic metabolism through 
mechanisms which remain unknown to this point. 
 
6.4.5.2 Effects during mitochondrial epilepsy 
 
Through experiments as discussed in section 4.3.6.3, glutamine was shown to 
have a suppressive effect on the induced mitochondrial epilepsy. Studies conducted 
in both Chapter 4 and Chapter 5 have suggested that one of the mechanism whereby 
glutamine has a ‘rescue’ effect is through the sustainment of GABA synthesis. To 
examine whether glutamine has a ‘rescue’ effect in terms of mitochondrial metabolism, 
I performed the metabolic flux measurement using the components of the 
mitochondrial epilepsy protocol and incorporate glutamine into the experimental design 
(see experimental condition 3 and 4). 
In experimental condition 3 (see Figure 6-5), components of the mitochondrial 
epilepsy protocol were added and glutamine (2.5mM) was injected acutely through the 
cartridge following all the other components of the protocol. As explained in section 
6.4.4, there was almost a complete inhibition of mitochondrial respiration following the 
injection of 10μM cyanide and 500nM rotenone in the presence or absence of 0.1mM 
fluorocitrate. Unsurprisingly, there was minimal effect of glutamine in terms of rescuing 
the mitochondrial respiration following this complete inhibition.  
As argued in section 6.3.5, in the in vitro brain slice scenario, the cellular 
concentration of the inhibitors is unlikely to achieve the given bath concentration due 
to the physical barrier provided by the extracellular matrix. Therefore, the concentration 
I have applied during experimental condition 3 may be too high in terms of actual 
cellular concentration and I expect there to be only partial mitochondrial respiration 
block in the in vitro brain slice condition, rather than a complete inhibition. To simulate 
this, I titrated the concentration of the rotenone, which exhibited the biggest inhibitory 
effect, to a ten times diluted concentration (50nM). This produced approximately 50% 
inhibition in mitochondrial respiration and the effect of glutamine was evaluated by its 
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direct incorporation into the media rather than acute injection via the cartridge. In the 
presence of glutamine, there was a lower percentage of inhibition of mitochondrial 
respiration by rotenone (50nM) in neurons, but this reduction in complex I inhibition 
was more apparent in the astrocytes. This was not statistically significant due to the 
low power of the study (5 wells obtained from a single animal). However, this is 
promising evidence that glutamine may be able to attenuate mitochondrial respiration 
inhibition, in particular the complex I mediated respiration. Mechanisms by which it may 
induce this are currently unknown, but may be related to the reactive oxygen species, 
as discussed previously. 
 
6.4.6 Oxidative stress during mitochondrial epilepsy 
 
As outlined earlier, mitochondrial epilepsy has been intimately associated with 
a significant oxidative stress damage in the tissue (Liang and Patel, 2004; Cantu et al., 
2009). To assess oxidative stress in the epileptic tissue, I have chosen to measure the 
carbonyl concentration in the tissue. The carbonylation of the side chains of the amino 
acids occurs mostly due to protein peroxidation but can also occur due to the 
secondary reaction of aldehydes from lipid peroxidation (Dalle-Donne et al., 2003). 
Regardless, it remains a good indicator of oxidative stress in the tissue and is the most 
commonly used biomarker due to its relative stability and ease of detection using the 
spectrophotometric assay following derivatization with DNPH (Suzuki et al., 2010).  
Unsurprisingly, there was a significantly higher concentration of carbonyl in the 
epileptic tissue as compared against the control tissue (see Figure 6-7). This confirms 
that there exists a significant degree of oxidative stress in the tissue following the 
induction of mitochondrial epilepsy. The source of this oxidative stress could be from 
any cells affected, but I postulate that this is correlated with the complete shutdown of 
the astrocyte population (as discussed in Chapter 3 to 5) during mitochondrial epilepsy. 
As discussed extensively in the previous subsections, the higher proportion of free 
complex I in the mitochondria of the astrocytes results in faster production and release 
of reactive oxygen species when compared with neurons (Lopez-Fabuel et al., 2016). 
Therefore, it would be expected that when there is complete astrocytic shutdown that 
it would be accompanied by extensive reactive oxygen species in the tissue due to the 
loss of the extensive reducing power previously provided by the astrocyte.  
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6.5 Summary, strength, and weakness 
 
In this chapter, I have presented a novel method of measuring metabolic fluxes 
in acutely isolated astrocytes and neurons by pairing the two powerful techniques of 
magnetic-activated cell sorting (MACS) and the Seahorse XF24 Metabolic Flux 
Analyzer. I have shown that the isolation process using MACS produced a relatively 
high yield of viable cells that is utilisable for the metabolic flux measurements. The 
astrocytes and neurons exhibited distinct metabolic profiles, supporting the specificity 
of the isolation process. In particular, the maximal respiratory capacity of neurons is 
much higher than that of astrocytes. In the presence of glutamine, however, the 
maximal respiratory capacity of astrocytes became similar to that of neurons. Both 
astrocytes and neurons are relatively oxidative in their respiration and most of their 
ATP production is attributable to oxidative phosphorylation. The presence of glutamine 
upregulated this oxidative metabolism in the astrocytes, but not in neurons.  
Exposure to the components of the mitochondrial epilepsy at its in vitro 
concentration caused an almost complete inhibition of mitochondrial respiration. 
Interestingly, exposure to fluorocitrate did not cause any inhibition of mitochondrial 
respiration, supporting the previously reported effect of fluorocitrate on carbon flux 
rather than respiratory inhibition. The major respiratory inhibition originates from the 
rotenone component of the protocol. This reflects the original observation from the 
post-mortem neuropathological studies of patients with mitochondrial epilepsy. To 
examine the effect of glutamine in rescuing partial respiratory chain inhibition, I titrated 
the concentration of the rotenone and found that glutamine was able to attenuate the 
mitochondrial respiratory complex I inhibition specifically in the astrocytes.  
Finally, to measure the degree of oxidative stress in the tissue, measurement of 
carbonylated protein was conducted. There was a significantly higher concentration of 
carbonylated protein in the epileptic tissue, suggesting an extensive oxidative damage 
in the epileptic tissue. I postulate that the major source of this oxidative damage is from 
the complete astrocytic shutdown during the state of epilepsy.  
The technique shown and discussed in this chapter is novel in nature. Therefore, 
it requires a lot of optimization and validation to ensure its robustness. Some of these 
have been conducted, but ideally, a lot more validation can be performed (for instance 
with the media composition or modification to the isolation process to improve yield or 
purity). However, the process has shown to be promising and produce replicable 
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measurements. Some of these measurements conform very well to previously reported 
observations or values whilst some of them also provided novel interesting observation 
that needs to be followed up. Furthermore, confirmation that the isolation produces 
pure separate isolates have yet to be performed. This can be done through various 
means such as post-hoc immunofluorescence or the use of flow cytometry. Regardless, 
the use of this technique has provided the assessment of mitochondrial respiration in 
specific cellular population isolated from the acute brain slices; an issue that was not 
addressable by the techniques and experiments conducted in Chapter 5. Together, the 
studies in both Chapter 5 and Chapter 6 provided a very comprehensive assessment 
of the state of tissue and cellular metabolism during mitochondrial epilepsy.  
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Chapter 7 Final discussion and future work 
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7.1 Conceptualisation 
 
The data presented in this thesis have focused on the development and 
understanding of a novel in vitro brain slice model of mitochondrial epilepsy. The 
rationale behind the development of this novel model has emanated from previously 
conducted neuropathological studies on patients with mitochondrial epilepsy. This 
work reported a profound loss of interneurons in the temporal neocortex of these 
patients and the remaining surviving interneurons presented with deficiency of 
mitochondrial complex I and complex IV subunit expression (Lax et al., 2016). Using 
similar technique, the authors eventually also found that similar mitochondrial 
deficiency of complex I and complex IV was also observed in the astrocytes and there 
was also extensive reactive astrogliosis in the temporal neocortex of these patients 
(Lax et al., unpublished data; see Figure 3-1). These findings provided the foundation 
to the functional modelling of mitochondrial epilepsy in vitro. Using a mitochondrial 
complex I inhibitor (rotenone), complex IV inhibitor (potassium cyanide), and a specific 
astrocytic aconitase inhibitor (fluorocitrate), I was able to robustly induce epileptiform 
discharges in the hippocampus CA3 in acutely prepared rodent brain slices. This 
induction is found to be specific to the concentrations and the incubation conditions 
used in this study (see section 3.3.1 for full details).  
I further examined the face validity of this model by putting it through a battery 
of control experiments. First, I have described that the mitochondrial epilepsy induction 
is dependent on the presence of all three pharmacological components of the protocol. 
On its own, neither of these pharmacological agents at the concentrations used was 
able to induce epileptiform discharges in the hippocampus CA3. Additionally, the dual 
combination of either of these pharmacological agents was unable to induce the 
mitochondrial epileptic activity. Next, I have demonstrated that the induction is not 
specific to the mitochondrial complex inhibitor chosen (rotenone and potassium 
cyanide). The substitution with other established mitochondrial complex I and IV 
inhibitors (MPP+-iodide and sodium azide respectively) was still able to induce 
epileptiform discharges in the hippocampus CA3 robustly. Finally, I have also shown 
that the mitochondrial epilepsy induction is not merely limited to acutely prepared brain 
slices from the Wistar rat. Using the same induction protocol, I was able to induce 
epileptiform discharges from the hippocampus CA3 of the C57BL/6 mice. Furthermore, 
using surgically resected human tissue from patients undergoing elective 
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neurosurgical procedure, I was also able to induce similar patterns of epileptiform 
discharges using the mitochondrial epilepsy induction protocol.  
As a proof of concept, I have also examined the neuropathological changes in 
the hippocampus CA3 of the rodent brain slices following the epileptic induction. I have 
found severe neuronal loss across the whole brain slice, but especially in the 
hippocampus CA3. In particular, there was a selective loss of the inhibitory interneuron 
population, while the excitatory neuron population was relatively spared. I have also 
demonstrated significant astrogliosis across the whole area of the epileptic tissue. The 
degree of gliosis in the epileptic tissue is a severe reactive astrogliosis response with 
significant glial scar formation. All of these neuropathological findings have very closely 
recapitulated the neuropathological changes that were observed in the human post-
mortem studies. This further added to the face validity of this in vitro model of 
mitochondrial epilepsy.  
In addition, I have also examined the pharmacological profile of this model of 
mitochondrial epilepsy towards conventional antiepileptic drugs. I have found that most 
of the clinically used conventional antiepileptic drugs failed to control the epileptiform 
discharges induced in this model of mitochondrial epilepsy. This reflects very well the 
severe pharmacoresistance observed in the clinical setting during the care of patients 
with mitochondrial epilepsy using conventional means of antiepileptic drugs (Bindoff 
and Engelsen, 2012; Whittaker et al., 2015). Therefore, the model not only 
recapitulates the neuropathological findings in the human study; but it also seems to 
produce epileptic phenotype that has a similar pharmacological profile to that seen in 
the clinical setting with patients suffering from mitochondrial epilepsy.  
This study, therefore, has provided the scientific community with the first ever 
in vitro brain slice model of mitochondrial epilepsy. This model has been thoroughly 
validated and seems to reflect the phenotype of mitochondrial epilepsy very closely. It 
is very difficult to develop a model of this calibre in vitro but the approach that I have 
taken in the development of the model seems to have aided in the conceptualisation 
of this model. Therefore, it might be beneficial for future studies on modelling a human 
pathological condition in vitro to follow the framework that I have laid out in order to 
increase the validity of the model. This framework has been previously published and 
takes on the approach of utilizing the observations made from post-mortem studies on 
the end-stage of a disease before taking it to an in vitro system in an animal model to 
acutely recapitulate the changes seen in the human studies (Chan et al., 2016). 
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7.2 Mechanisms 
 
All the findings presented in the previous chapters in this thesis have clearly 
implicated the role of the two major cellular compartments in the brain, the neuronal 
and astrocytic compartment. This gives rise to the ‘dual neuronal – astrocytic hit 
hypothesis’. The hypothesis focuses on the recruitment of both the neuronal and 
astrocytic compartment in the generation of epileptic activity in this in vitro model of 
mitochondrial epilepsy. Specific mechanisms have been postulated with regards to 
each cellular compartments that collectively may contribute towards the development 
of mitochondrial epilepsy.  
It has been discussed above that there is a selective loss of inhibitory 
interneurons in this model of mitochondrial epilepsy. Mitochondrial respiratory chain 
inhibitors have been reported to selectively affect the inhibitory interneurons more than 
the excitatory neurons (Whittaker et al., 2011). This selective loss of inhibitory 
interneurons would result in a generalized loss of inhibitory tone in the tissue. 
Furthermore, pharmacological studies have specifically implicated the role of GABAA-
R mediated inhibition in the generation of seizure. Any therapeutic strategy that 
upregulates or potentiate this GABAA-R mediated inhibition has been able to silence 
the epileptic activity. This further indicates that there could be a loss of the tonic 
GABAA-R mediated inhibitory tone due to the generalized loss of inhibitory 
interneurons in the epileptic tissue.  
In terms of the astrocytic compartment, the glutamate-glutamine cycle has been 
implicated as the contributing mechanism in seizure generation. Metabolic tracing has 
showed that there was significantly less metabolic flux for the recycling of the 
neurotransmitters, glutamate and GABA. Glutamine seems to be a key player in the 
generation of seizure, as there was a significant reduction in tissue level of glutamine 
that is specific only to the epileptic tissue. As glutamine is the precursor to both 
glutamate and GABA, it would be unsurprising to then expect a deficiency of GABA 
due to the downstream deficiency of glutamine. This is indeed confirmed by the 
metabolic tracing experiments that have demonstrated less utilization of glutamine in 
the synthesis of GABA following the epileptic induction. Puzzlingly, the tissue level of 
GABA is sustained or increased in the epileptic tissue. This can be explained by the 
concept of metabolic compartmentalization. As both glutamate and GABA have a dual 
role in the brain tissue as both a neurotransmitter and a metabolic substrate; it is 
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possible that there is a distinct neurotransmitter pool and metabolic pool for these 
amino acids. It is unclear if the level of GABA measured by the technique used in 
Chapter 5 measures the neurotransmitter, metabolic, or both pool of GABA. Therefore, 
this finding should be taken with a grain of salt.  
However, both the neuronal and the astrocytic mechanisms have converged on 
the mechanisms pertaining to reduced inhibition in the brain. This supports the recent 
school of thought on the ‘inhibitory energy hypothesis’ that suggests that the 
maintenance of inhibitory tone in the brain is more energetically demanding than the 
excitatory equivalent (Zsurka and Kunz, 2015; Kann, 2016; Lax et al., 2016). 
Specifically, I have also demonstrated that astrocytes have a vital role in the 
maintenance of inhibitory tone through the glutamate – glutamine cycle. Therefore, 
future discussion on the inhibitory inputs in the brain should avoid the mere focus on 
the neuronal compartment and also critically examine the astrocytic compartment.  
Metabolically, there is also a significant change in the tissue state of metabolism 
following the epileptic activity induction in this brain slice model. Particularly, glycolysis 
is significantly upregulated albeit not to the point of saturation. Lactic acid production 
is also significantly increased; which is reflective of the lactic acidosis commonly seen 
in patients with mitochondrial epilepsy (Pavlakis et al., 1984; Ohno et al., 1997; Bindoff 
and Engelsen, 2012; Steriade et al., 2014). Oxidative metabolism is severely reduced 
in the epileptic tissue, as evidenced by the severe downregulation of the Krebs cycle. 
This was again confirmed in the metabolic flux analysis of the isolated tissue; showing 
that the oxygen consumption rates of both the neurons and the astrocytes are equally 
affected by exposure to the mitochondrial respiratory chain inhibitors.  
Finally, there is also multiple evidence of the involvement of oxidative stress in 
this model of mitochondrial epilepsy. Carbonylated protein concentration is significantly 
higher in the epileptic tissue, suggesting increased reactive oxygen species damage 
of the protein (Levine et al., 1994). The upregulation of the pentose-phosphate 
pathway during the epileptic state also suggested an ongoing process of oxidative 
stress as the pathway is an important source of NADPH, a potent endogenous cellular 
antioxidant (Berg et al., 2012b). Although the use of coenzyme-Q, a potent cellular 
antioxidant, in this model of mitochondrial epilepsy showed no meaningful response; it 
does not necessarily exclude the presence of oxidative stress in the epileptic tissue. It 
may suggest, however, that oxidative stress is not the core pathogenic process in this 
in vitro model of mitochondrial epilepsy. Rather, it may be an end-stage consequence 
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of the epileptic tissue that could result in the upregulation of apoptotic cell death 
(Kannan and Jain, 2000), leading to the previously described neuronal loss in this 
model. 
Much is still not understood about the specific mechanisms of seizure 
generation in mitochondrial epilepsy. However, this study has certainly provided some 
fresh insights into the potential pathogenic mechanisms implicated. Again, I would like 
to highlight the implication of the ‘dual neuronal-astrocytic hit hypothesis’ in 
mitochondrial epilepsy. Both the specific neuronal and astrocytic mechanisms 
discussed above seem to converge towards a generalized loss of inhibitory tone in the 
tissue. These findings have enabled me to reconstruct the old hypothesized model of 
seizure generation in mitochondrial epilepsy and propose a new model in 
understanding mitochondrial epilepsy (see Figure 7-1).  
It is important to note at this point that this model has shown that an extraneous 
astrocytic dysfunction in the form of the failure of the glutamate – glutamine cycle is 
required for seizure generation. This is simulated in the model through the addition of 
fluorocitrate. However, it is currently unknown what specific mechanisms in the human 
patients with mitochondrial epilepsy led to the failure of this cycle. It is most likely not 
exclusively due to the respiratory chain deficiency through the mitochondrial DNA 
dysfunction. Therefore, it is advised that more studies are conducted on the post – 
mortem tissue of patients with mitochondrial epilepsy to better understand the nature 
of the astrocytic impairment.  
Additionally, the model is dependent on the combination of a mitochondrial 
complex I and complex IV inhibitor. Whilst both inhibitors affected the neurons and 
astrocytes equally, the majority of the energy crisis is brought about by the complex I 
inhibition. It is unclear why the complex IV inhibition (simulated either by cyanide or 
sodium azide) is necessary but it may be related to the effect of complex IV inhibitors 
on inhibitory neurotransmission. Cyanide application has been demonstrated to 
significantly suppress inhibitory interneuron firing as well as depolarize the resting 
membrane potential of these fast spiking interneurons (Whittaker et al., 2011). This 
mechanism may therefore contribute towards the generalized loss of inhibition.  
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Figure 7-1 Proposed model for the understanding of the mechanisms behind mitochondrial epilepsy. Shown are the specific 
mechanisms in the neuronal and the astrocytic compartment that contributes towards seizure generation. Red arrow indicates 
further upregulation of the target process. * Fluorocitrate is a vital component in this model which causes the failure of the 
glutamate – glutamine cycle when combined with the complex I and IV inhibition. However, in the human patients, it is 
unknown what mechanisms causes the astrocytic glutamate – glutamine cycle to fail in a manner that causes epileptic activity 
to be able to manifest.   
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7.3 Therapeutic implications 
 
The development of this novel in vitro brain slice model of epilepsy has also 
allowed me to evaluate several pharmacological approaches to the treatment of 
mitochondrial epilepsy. These findings have implicated three systems as a 
pharmacological target during the development of a pharmacological regime for 
patients with mitochondrial epilepsy. These three target systems are the AMPA-R 
system, the GABAA-R system, and metabolic modulation (summarized in Figure 7-2). 
 
7.3.1 AMPA-R  
 
Antagonism of the AMPA-R seems to be a promising and viable approach in the 
treatment of mitochondrial epilepsy. The only currently available antiepileptic drug that 
modulates the AMPA-R are barbiturates and perampanel. Both these compounds were 
able to suppress the mitochondrial epilepsy in this model, although barbiturates are 
also modulator of GABAA-R and so should be considered in its dual mechanisms of 
action. More selective to AMPA-R, perampanel is a well-characterized non-competitive 
antagonist  (Hanada et al., 2011; Ceolin et al., 2012). I have demonstrated that 
perampanel can potently suppress the epileptic activity induced in this model. This 
supports the consideration of perampanel for use in the care of patients with 
mitochondrial epilepsy. Perhaps, a proper clinical trial to look into the efficacy of 
perampanel in patients with mitochondrial epilepsy can be considered. 
Decanoic acid is a component of the ketogenic diet that has been proposed in 
the recent study as a potential antagonist of the AMPA-R (Chang et al., 2015). I have 
indeed observed that decanoic acid application was able to suppress the induced 
epileptic activity. However, I have also shown that the same is true for octanoic acid; 
which was reported to not have any AMPA-R antagonism (Chang et al., 2013; Chang 
et al., 2015). Furthermore, the concentration whereby decanoic acid exhibits significant 
suppressive effect in this model is relatively higher than the usual concentration where 
it is indicated as an AMPA-R antagonist. Therefore, the effects by which decanoic acid 
and octanoic acid may suppress the epileptic activity are more likely attributable to 
other mechanism such as through metabolic modulation (discussed further below). 
In addition, as described in detail in Chapter 4, many other compounds may also 
have an indirect effect in AMPA-R modulation which could contribute to their 
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pharmacological effect on this model of mitochondrial epilepsy. One such compound 
is β-hydroxybutyrate. At high concentration of β-hydroxybutyrate, it has been reported 
that it can upregulate the synthesis of kynurenic acid, an antagonist of AMPA-R (Weber 
et al., 2001). Both octanoic acid and bezafibrate has also been reported to increase 
the production of β-hydroxybutyrate (Courchesne-Loyer et al., 2015; Thevenet et al., 
2016); therefore, these compounds may also indirectly modulate the AMPA-R through 
the kynurenic acid production.  
Regardless, it is inevitably clear that the antagonism of AMPA-R is a fruitful 
target in mitochondrial epilepsy. Should more compounds be developed in the future 
that modulate the AMPA-R, these compounds should be looked into for their 
effectiveness in mitochondrial epilepsy, both in pre-clinical studies and clinical trials.  
 
7.3.2 GABAA-R 
 
The modulation of GABAA-R is another recurring system in its implication in 
mitochondrial epilepsy. It has been discussed above that the converging mechanisms 
in the seizure generation in mitochondrial epilepsy seems to be through the loss of 
inhibition. Therefore, unsurprisingly the enhancement of inhibition through the 
modulation of the GABAA-R system would be a viable approach for therapy in this 
condition.  
The two antiepileptic drugs that modulate the GABAA-R are benzodiazepines 
and barbiturates. Barbiturates have been shown to have a potent effect in suppressing 
the induced mitochondrial epilepsy. Benzodiazepines, however, do not suppress the 
epileptic activity, unless applied concomitantly with GABA. This discrepancy in 
pharmacological response is explained by the capacity of barbiturate to directly 
activate the GABAA-R even in the absence of GABA (Rho et al., 1996). 
Benzodiazepines, on the other hand, cannot modulate the GABAA-R in the absence of 
GABA (Krisko et al., 2017). Since the epileptic tissue is most likely devoid of GABA (as 
discussed above in section 7.2), the use of benzodiazepine clinically should be paired 
with other agents that can increase tissue concentration of GABA (such as gabapentin). 
Barbiturates, on the other hand, seems to be readily used as an antiepileptic of choice 
for the care of patients with mitochondrial epilepsy.  
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Another therapeutic strategy that can modulate the GABAA-R is by increasing 
the level of the endogenous agonist of the receptor, GABA. I have demonstrated that 
the direct administration of GABA onto the epileptic tissue can suppress the induced 
mitochondrial epilepsy. Therefore, theoretically, the external supplementation of GABA 
should prove to be beneficial for these patients. GABA is indeed available as a 
nutritional supplement; however, its clinical efficacy and whether or not it crosses the 
blood-brain barrier is controversial and not well understood (Boonstra et al., 2015). 
Analogues of GABA have been developed that crosses the blood-brain barrier, such 
as the infamous gamma-hydroxybutyrate (GHB) or baclofen (van Bree et al., 1991; 
Bhattacharya and Boje, 2004). The use of these GABA analogues should be 
considered and examined in this model of mitochondrial epilepsy.  
Taking a different approach to increase the tissue concentration of GABA is 
through the modulation of the glutamate – glutamine cycle. Glutamine has been 
discussed extensively as a promising therapeutic candidate due to its capacity to 
suppress the mitochondrial epileptic activity. This is thought to be due to a dual 
mechanisms of action; by increasing the production of GABA and by upregulating 
astrocytic oxidative respiration. Unlike GABA, glutamine readily crosses the blood – 
brain barrier (Ennis et al., 1998; Xiang et al., 2003). This makes glutamine a favourable 
candidate for therapeutic use as it can increase the bioavailability of GABA in the brain. 
Its use can therefore be potentially paired with other GABAA modulators such as 
benzodiazepine or barbiturate.  
Nevertheless, again, the modulation of GABAA-R is clearly a viable therapeutic 
approach in caring for patients with mitochondrial epilepsy. Recommendations can be 
made based on evidence presented in this study to support the use of barbiturates in 
this subset of epileptic patient. Benzodiazepine can be considered for use as a 
combination with other antiepileptic that can increase the bioavailability of GABA in the 
brain tissue. The direct supplementation of GABA through nutritional means or through 
the use of the GABA analogues should be examined further in this model or potentially 
in a clinical context. Finally, glutamine should seriously be considered as a novel 
therapeutic approach and strategy for its use in the clinical context should be 
developed.  
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7.3.3 Metabolic modulation 
 
Inevitably, there is a severe change in the tissue metabolism following the 
mitochondrial epilepsy induction. I have found that metabolic modulation through 
alleviating the tissue’s metabolic demand by the application of various substrates was 
also able to suppress the induced epileptiform discharges.  
In this model, a significant upregulation of glycolysis, specifically anaerobic 
glycolysis resulting in lactate production, has been well – described. I have 
demonstrated that the extraneous addition of glucose and pyruvate was able to 
suppress the epileptiform discharges. This suggests that glycolysis is very much 
upregulated, but not to the point of saturation. Furthermore, it seems that there remains 
some degree of oxidative metabolism to accommodate the external pyruvate as an 
additional metabolic substrate. However, this suppressive effect was only achieved at 
very high concentrations (10-20mM). Although glucose and pyruvate are readily 
transported across the blood – brain barrier (Witt et al., 2001), achieving such level of 
bioavailability in the brain tissue may be impractical or verging on impossible. 
Therefore, its use as a metabolic modulator should be considered in combination with 
other metabolic substrates to achieve a synergistic metabolic modulation.  
As mentioned above, the modulation of glutamate – glutamine cycle is another 
approach in the treatment of mitochondrial epilepsy. Out of the three compounds 
tested, glutamine appears to be the most effective modulator of the glutamate – 
glutamine cycle. Application of glutamine has a dual effect in the modulation of 
metabolism; through the increased production of GABA as well as through the 
upregulation of astrocytic oxidative respiration. Therefore, as discussed above, 
glutamine should seriously be considered as a promising therapeutic intervention for 
patients with mitochondrial epilepsy. In rats, at least, it has been shown that oral 
glutamine administration was able to increase the level of GABA measured in the 
striatal tissue and the extracellular fluid (Wang et al., 2007). Therefore, the concern of 
its distribution through the blood – brain barrier has somewhat been addressed and 
shows promises.  
Interestingly, all three components of the ketogenic diet tested in this model (β-
hydroxybutyrate, octanoic acid, and decanoic acid) exhibited an acute anticonvulsant 
effect. This strongly supports the consideration of ketogenic diet use in patients with 
mitochondrial epilepsy. Indeed, preliminary reports have shown that there is clinical 
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benefit to the use of ketogenic diet in these patients; although it is almost never used 
in isolation (Kang et al., 2007; Martikainen et al., 2012; Steriade et al., 2014). It should 
be understood, however, that ketogenic diet is a systemic metabolic modulator and so 
further studies should look into the efficacy of ketogenic diet in mitochondrial epilepsy 
in an in vivo model.  
An exciting observation that came about from the experiments on the 
components of ketogenic diet is that the modulation of lipid metabolism was also able 
to control the epileptiform discharges. Both octanoic and decanoic acid are fatty acids 
that are readily broken down as energy source through mitochondrial β-oxidation. 
Furthermore, bezafibrate, an agent shown to increase mitochondrial fatty acid β-
oxidation (Krisko et al., 2017), was also able to significantly suppress the epileptiform 
discharges. Therefore, the upregulation of fatty acid metabolism via mitochondrial β-
oxidation may also be a viable therapeutic approach for intervention in patients with 
mitochondrial epilepsy.  
To conclude, various forms of metabolic modulation is potentially beneficial for 
patients suffering from mitochondrial epilepsy. Out of all the metabolic substrates 
discussed, the most straightforward to be applied directly in clinical care of these 
patients is perhaps ketogenic diet. The role of fatty acid metabolism in this context 
should be evaluated further and may represent an entirely novel approach in metabolic 
modulation on these patients. Finally, the modulation of glycolysis as well as the 
glutamate – glutamine cycle should also be considered in the clinical setting.  
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Figure 7-2 Therapeutic target in mitochondrial epilepsy.  Shown is the proposed model of mechanisms underlying seizure 
generation in mitochondrial epilepsy along with the therapeutic interventions shown to have efficacy in this model and their 
respective therapeutic target. These therapeutic interventions fall into one of three categories: those working on the AMPA-R 
system (blue), GABAA-R system (green), and metabolic modulators (orange). Each respective therapeutic intervention either 
inhibits (shown with the negative symbol) or upregulates / rescues (shown with the positive symbol) the respective system it 
targets. 
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7.4 Future work 
 
This thesis has described the development of a novel in vitro brain slice model 
of mitochondrial epilepsy. Various mechanisms have been investigated in the context 
of understanding seizure generation in mitochondrial epilepsy. Extensive 
pharmacological studies have also been conducted to provide recommendations for 
creating a therapeutic regimen for patients with mitochondrial epilepsy.  
Future studies should firstly try to further develop the model to another platform. 
As discussed above, despite the close resemblance of the in vitro rodent brain slice 
model to the human phenotype; some experimental design requires the use of an in 
vivo platform for scientifically accurate exploration (for instance, the examination of the 
effect of ketogenic diet). Therefore, efforts should be made, where possible, to try and 
extrapolate the findings from this model to developing an in vivo model of mitochondrial 
epilepsy. Furthermore, as discussed, this model is not a genetic model of mitochondrial 
disease per se, rather it is a model of the phenotypic manifestation of mitochondrial 
disease; the mitochondrial epilepsy. Hence, it is not by leaps and bounds to expect the 
development of a genetically modified animal model of mitochondrial epilepsy based 
on the findings from this study.  
This model has also provided the opportunity of doing a pharmacological screen 
of various potential therapeutic interventions in mitochondrial epilepsy. Several of 
these interventions have shown very promising anticonvulsant effects that it should be 
further considered for use in a clinical setting. More pharmacological interventions can 
be screened for using this model and any leads from this initial screen can then be 
followed up through small clinical studies assessing efficacy of the treatment.  
Finally, discussion on mechanisms that could potentially contribute towards 
seizure generation in mitochondrial epilepsy has been extensively argued for in the 
context of the model. These findings should be reassessed in the human patient study 
(such as using the post-mortem neuropathological study) to confirm that the 
mechanisms truly do contribute towards seizure generation in these patients. As 
discussed, mechanisms behind seizure generation may differ between an animal 
model and a human patient system. Therefore, as much as possible, a mechanistic 
investigation in an in vitro model, such as this, should be correlated with a human 
mechanistic study to ensure conservation of the pathogenic mechanisms across 
species. 
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